

Georgina V. Long AO

Melanoma Institute Australia and The University of Sydney
40 Rocklands Road, North Sydney NSW 2060
+61 2 9911 7336 | georgina.long@sydney.edu.au

PROFILE

Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal 2021 and was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor's Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is also Clarivate highly-cited Researcher for 2017-2022. Her H index is 139 and in May 2024 she was ranked the world's equal 1st melanoma expert in all fields and discipline (<http://expertscape.com/ex/melanoma>)

Professor Long is the author of over 500 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 250 occasions. She is Past President for the prestigious international Society for Melanoma Research (2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024) she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

QUALIFICATIONS

Fellow of the Royal Australasian College of Physicians, Sydney NSW, Australia **From 2008**

Sub-specialty Medical Oncology

University of Sydney, School of Medicine, Sydney NSW, Australia **2000**

Bachelor of Medicine, Bachelor of Surgery (MB BS Hons)

Scripps Biomedical Research Institute, La Jolla CA, United States of America **1996-1997**

Fulbright Postdoctoral Fellow

Principal Investigator: Dr M R Ghadiri, Department of Chemistry

Study Title Self-Assembling Cyclic Peptides in Biological Systems

University of Sydney, School of Chemistry, Sydney NSW, Australia

1993-1996

Doctor of Philosophy

Supervisor Dr M. M. Harding, Division of Organic Chemistry

Thesis Title Interactions of Streptonigrin with Metal Ions and DNA

University of Sydney, Sydney NSW, Australia

1992

Bachelor of Science (Hons 1), University Medal

MEDICAL LICENSING

Medical Board of Australia (Registration Number MED0001186892) **From 2010**

Medical Board of NSW (inactive, Registration Number MPO 338589) **2001-2009**

United Kingdom General Medical Council, Registered Medical Practitioner (inactive) **2004-2010**

CURRENT POSITION

Co-Medical Director, Melanoma Institute Australia (MIA) **From 2017**

Professor of Melanoma Medical Oncology and Translational Research **From 2016**

Medical Oncologist and Translational Researcher

Melanoma Institute Australia and The University of Sydney, Mater and Royal North Shore Hospitals

Clinical Responsibilities

Outpatient Duties

Clinical Trials Group, Melanoma Institute Australia

Inpatient and On-Call Duties

Clinical Supervision of Medical Oncology Team, including

Weekly Melanoma Multi-disciplinary meeting

Research

Clinical Trials (See section Clinical Trials for detail)

Investigator for Phase 1, 2 and 3 Clinical Trials of Systemic Therapy for Adjuvant & Metastatic Melanoma

- 45 sponsored trials (22 currently open)
- 12 current investigator-led trials; I wrote the protocols and obtained funding for the conduct of 6 of these trials, including international clinical trials

Translational and Clinical Research Projects

- Currently lead over 20 clinical and translational research projects
- At the centre of this research activity is the TEAM (Treat Excise Analyse Melanoma) study
- Established and lead this investigator-led translational project that aims to examine clinical and biomarker correlates of melanoma drug sensitivity and resistance. This is a large collaboration across Melanoma Institute Australia involving clinicians (surgery, medical oncology and

pathology), cell biologists and molecular biologists, and has had and continues to have a major impact on future therapies.

International and National Research Collaborations

- Have established collaborations with scientists and clinicians within Australia, USA, Europe and New Zealand. See my publications list for outputs due to collaborations.
- Collaborating centers include (note these collaborations are separate from international sponsored clinical trials): Harvard, Dana-Faber, University of California LA, Vanderbilt-Ingram Cancer Centre, University of California San Francisco, MD Anderson, John Wayne Cancer Centre, University of Washington, University of North Carolina, University of Pennsylvania, Oxford University, University of Duisburg-Essen, Eberhard Karls University, University of Heidelberg, The Netherlands Cancer Institute, Peter MacCallum Cancer Centre, University of Western Australia, Olivia Newton John Cancer Research Institute, and Auckland University.

Teaching and Supervision (See section Teaching, Mentorship and Supervision for detail)

- To 2022; 21 Fellows
- Each year 4 Advanced Trainees rotate through Melanoma Institute Australia and Royal North Shore Hospital.
- As at 2019; 8 completed PhDs, 1 Masters.
- Observership and Sabbaticals

AWARDS AND DISTINCTIONS

Fulbright U.S. Mission Australia Award for Leadership Excellence	2024
The Best of the USCAP Journals	2024
peer reviewed manuscript published in Modern Pathology featured in “The Best of the USCAP Journals” session at United States and Canadian Academy of Pathology 113th Annual Meeting in Baltimore, MD, USA March 2024. “Vergara IA*, Aivazian K*, et Genomic profiling of metastatic basal cell carcinoma reveals candidate drivers of disease and therapeutic targets. Mod Pathol. 2023 Apr;3 PMID: 36788083”	
2024 Australian of the Year	2024
Co-Awardee – Prof Richard Scolyer AO	
2024 NSW Australians of the Year	2024
Co-Awardee – Prof Richard Scolyer AO	
Clarivate Analytics 2023 – Highly Cited Researcher – Clinical Medicine	2023
Medical Oncology Group of Australia – Novartis Oncology Cancer Achievement Award	2023
Top 10% of article published in The Journal of Clinical Endocrinology & Metabolism	2023
Muir CA, Long GV et al, J Clin Endocrinol Metab, Aug 2021	
The Australian Newspaper – Research Magazine’s Top 250 researchers – Oncology	2022
Clarivate Analytics 2022 – Highly Cited Researcher – Clinical Medicine	2022
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2019	2022
Gide TN, Quek C (Awardee Tuba Nur Gide – 1 st Author) et al, Cancer Cell 2019, 35 238-255	
Sydney Local Health District/Sydney Research 2022 Research Excellence Award	2022
Co-awardees Professor Richard Scolyer & Assoc Professor Alexander Menzies in recognition of the best publication in a high impact journal for “Menzies, A.M., et al. Nat Med 27, 301–309 (2021)	

Ramaciotti Medal for Excellence in Biomedical Research	2021
Vice Chancellor's Award for Excellence Award for Outstanding Research, University of Sydney	2021
Co-awardee Professor Richard Scolyer	
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2018	2021
Long GV, Scolyer RA, Menzies AM, et al, Lancet Oncology 2018, (5):672–to 681	
The Australian Newspaper – Research Magazine's Top 250 researchers – Oncology	2021
AAHMS 2021 Medal for Outstanding Female Researcher	2021
Clarivate Analytics 2021 – Highly Cited Researcher – Clinical Medicine	2021
Clarivate Analytics 2020 – Highly Cited Researcher – Clinical Medicine	2020
Order of Australia	2020
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2017	2020
Hayward NK, Wilmott JW (Awardee J Wilmott – snr author) et al, Nature 2017, 545(7653):175-180	
The Australian Newspaper – 2019 Research Magazine Named as Field Leader (Oncology)	2019
Clarivate Analytics 2019 Highly Cited Researcher – Clinical Medicine	2019
Australian Financial Review – 100 Women of Influence Award Finalist	2019
Clarivate Analytics 2018 Highly Cited Researcher – Clinical Medicine	2018
GSK Award for Research Excellence, Research Australia Health & Medical Research Awards	2018
Co-awardee Professor Richard Scolyer	
Cancer Institute NSW Premiers Awards: Outstanding Cancer Researcher of the Year	2018
Clarivate Analytics 2017 Highly Cited Researcher – Clinical Medicine	2017
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2014	2017
Rizos H, Long GV (Awardee H Rizos – senior author) et al, Clinical Cancer Res 2014, 20(7): 1965–1977	
Cancer Institute NSW Premiers Awards: Excellence in Translational Cancer Research Award	2017
Co-awardees Professor Richard Scolyer and the Melanoma Institute Australia Translational Team	
Fellowship of the Australian Academy of Health and Medical Sciences	2017
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2013	2016
Long GV, Wilmott JS (Awardee JSW - shared 1 st authorship) et al, Am J Surg Pathol 2013, 37:61.	
Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research	2016
For extensive contributions to the field of melanoma research and clinical services	
Society for Melanoma Research, Young Investigator Award	2016
Society for Melanoma Research 2015 International Congress, 18-21 November, San Francisco, USA	
Amgen Australia, Award for the Best Consultant Poster, Medical Oncology Group of	2015
Australia's Annual Scientific Meeting in Hobart	
Thomson Reuters Citation and Innovation Award for Outstanding Research	2015
For research in BRAF-mutated melanoma. Co-awardees Professor Richard Scolyer, Professor Richard Kefford, Professor Grant McArthur	
INSTYLE award for Women in Science and Technology	2015
Finalist, Pride of Australia Award for contribution to the community (Telegraph Newspaper)	2015

Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2011	2014
Long GV et al J Clin Oncol 2011, 29:1239-46	
Top 5 most highly cited article 2012 for Clinical Cancer Research (IF 7.837)	2014
Long GV, Wilmott J (shared first authorship) Clin Can Res, 2012, 18:1386-94	
Top 50 most highly cited article 2011 for Journal Clinical Oncology (IF18.97)	2013
Long GV et al J Clin Oncol 2011, 29:1239-46	
Cancer Institute NSW Premiers award for Outstanding Cancer Research Fellow	2013
Nominated for Australian of the Year 2013	2013
Sir Roy McCaughey Fellowship, RACP	2013
Melanoma Research Alliance Young Investigator	2013-2016
Marjorie Hooper Scholarship, RACP	2012
Best published manuscript, Westmead Millennium Institute	2011
Development Fellowship, Cancer Institute NSW	2011
Career Development Grant, Cancer Institute NSW	2011
Australia Post Melanoma Fellowship, Cancer Institute NSW	2010
Cancer Institute NSW, Conference Grant	2010
ANZATAX, Advanced Trainee Travel Grant	2007
Amgen Australia, Advanced Trainee Grant, for best oral presentation MOGA	2006
DK Baird Bicentennial Travelling Fellowship, Royal Prince Alfred Hospital	2006
Esma May Harris Scholarship, Sydney University	1998, 1999
J B Watt Travelling Scholarship, Sydney University	1996, 1997
C G and R J W Le Fevre Postgraduate Student Lecture, Sydney University	1995
George Harris Postgraduate Prize, Sydney University	1995
James Kentley Memorial Scholarship, Sydney University	1994
G H S and I R Lightoller Scholarship, Sydney University	1994
R J W Le Fevre Travelling Scholarship, Sydney University	1994
Henry Bertie Florence Mable Gritton Postgraduate Scholarship	1993-1996
Australian Post Graduate Research Award, Sydney University	1993
University Medal for Organic Chemistry, Sydney University	1992
Janet Elspeth Crawford Prize, Chemistry, Sydney University	1992
Inglis Hudson Scholarship (major), Chemistry, Sydney University	1991
Vacation Scholarship, Research School of Chemistry, ANU,	1991-1992
Prof. D Evans – Molecular Dynamics	

MAJOR GRANTS AWARDED

Funding	Project title	Role	Start	End	Amount (AUD)
NHMRC 2023 Ideas Grants APP2029584	Microbe-immune interactions shape immune checkpoint inhibitor immunotherapy outcomes	AI	01.01.2024	31.12.2027	\$1,150,614.00
Australian Cancer Research Foundation	The ACRF Centre for Advanced Cancer Modelling	CI	01.11.2023	01.11.2026	\$2,000,000.00
Australian Government, Department of Health and Aged Care	Cancer Screening and Management Services, National Melanoma Nurses Program		01.07.2023	30.06.2028	\$14,800,000.00
NHMRC Ideas Grant APP2020569	Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers	AI	01.01.2023	31.12.2026	\$852,280.00
NHMRC Clinical Trials and Cohorts Studies Grant APP2023996	A Phase II, open label, single arm clinical trial of neoadjuvant nivolumab and ipilimumab in stage I to III resectable merkel cell carcinoma	CI	01.01.2023	31.12.2028	\$2,053,040.00
NHMRC MRFF Early to Mid-Career Researchers Grant APP2022808	Unveiling organ-specific mechanisms of resistance to standard immunotherapy in melanoma and matching optimal drug therapy for these resistant patients	AI	01.01.2023	31.12.2025	\$783,935.00
Sydney Cancer Partners	Identifying the immune populations driving response to immune checkpoint blockade therapies	CI	15.04.2023	15.04.2024	\$116,000.00
Department of Defense W81XWH-22-1-0732	Multimodal Precision Liquid Biopsy to Predict Risk of Melanoma Recurrence	PI	01.09.2022	30.09.2025	\$769,864.00 (USD)
The University of Sydney Equipment Grant	PAVONE - transformative, automated high-throughput testing platform for nanomedicine, mechanopharmacology, mechanobiology, and precision medicine		01.06.2022	31.12.2022	\$217,115.00
NHMRC Ideas Grant APP2012860	Restoring Anti-Tumour Immunity in Melanoma	AI	01.01.2022	31.12.2025	\$1,134,001.00
Cancer Institute NSW APP2021/TPG2114	Personalised Immunotherapy Program - Precision immunotherapies for multiple solid tumours using a biomarker driven	CI	01.01.2022	31.12.2026	\$3,748,551.00

Funding	Project title	Role	Start	End	Amount (AUD)
	adaptive enrichment clinical trials platform				
Cancer Institute NSW Premiers Award	Wildfire Award, most cited article published in 2018		01.01.2021	31.12.2021	\$10,000.00
NHMRC Investigator Grant APP2007839	Towards Zero Deaths from Melanoma Innovative Clinical Trials with -Multi-omics Analysis	CI	01.01.2022	31.12.2026	\$3,927,015.00
NHMRC Project Grant APP2009057	Integrated Multimodel precision liquid biopsy to enhance melanoma and NSCLC Treatment (IMPLEMENT)	CID	01.06.2021	31.05.2025	\$2,031,178.80
NHMRC Project Grant APP2007157	NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab	CIA	01.06.2021	31.05.2025	\$2,023,376.40
NHMRC Project Grant APP2006415	Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study	CIA	01.07.2021	30.06.2026	\$1,010,141.60
Friends of the Mater Foundation		CI	01.01.2021	31.12.2021	\$80,000.00
Investigator-led trial grant NCT04207086	Merck Sharpe & Dohme A Phase II study of Neoadjuvant Pembrolizumab & Lenvatinib for resectable Stage III Melanoma (NeoPele)	CI	01.01.2020	31.12.2025	\$635,937.60
MRFF International Clinical Trial Collaborations grant program 2019 MRFF MRF1192497	Circulating Tumours DNA guided therapy for Stage IIB/C BRAF mutant positive melanoma after surgical resection (Detection)	CI	01.06.2020	30.11.2025	\$3,230,670.00
USYD & NHMRC Equipment Grant	Economic and versatile single-cell preparation system for shared use, in the Multi-Disciplinary Sydney Cytometry Faculty, from Cancer to COVID-19	CI	01.01.2020	31.12.2020	\$55,000.00
Tour de Cure	Improving survival in melanoma by matching optimal drug therapy for individual patients	CI	01.01.2019	31.12.2019	\$199,526.00

Funding	Project title	Role	Start	End	Amount (AUD)
Bristol-Myers Squibb Investigator-led Trial Grant	Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X)	CI	01.01.2019	31.12.2024	\$2,400,000
Cancer Institute NSW Premiers Awards	Outstanding Cancer Researcher of the Year	CI	01.01.2018	31.12.2018	\$60,000.00
NHMRC Project Grant	A randomized Phase III study of the duration of the Anti PD-1 – therapy in metastatic melanoma (STOP-GAP)	CI	01.01.2018	31.12.2023	\$2,276,726.60
The Council of the Queensland Institute of Medical Research	Overcoming resistance to cancer immunotherapy by targeting MET-signalling in Neutrophils		01.01.2018	31.12.2020	\$447,375.00
The Council of the Queensland Institute of Medical Research	Immunotherapy in cancer and virus infection		01.01.2018	31.12.2022	\$9,312,735.00
GSK Award	GSK Award for Research Excellence (co-awardee Richard Scolyer)	CI	01.01.2018	31.12.2018	\$80,000.00
NHMRC Program Grant	Melanotransferrin: A “missing link” and a novel pharmacological target for treatment		01.01.2018	31.12.2022	\$613,848.00
NHMRC Project Grant	Acquired resistance to PD1 inhibition in melanoma		01.01.2017	31.12.2021	\$986,348,00
Cancer Institute NSW Premiers Award	Wildfire Award, most cited article published in 2014		01.01.2017	31.12.2017	\$20,000.00
NHMRC	Centre of Research Excellence in Melanoma: person, tumour and system-focused knowledge to drive better outcomes in melanoma		01.11.2017	31.10.2022	\$2,486,945.00
Merck Sharpe Dohme Investigator-led Trial Grant	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF mutant resectable Stage III Melanoma (NeoTrio)	CI	01.01.2017	31.12.2022	\$1,301,730.00
USYD & NHRMC Equipment Grant	Dolomite Bio Single Cell RNAseq system	CI	01.01.2017	31.12.2022	\$138,000.00
The Council of the Queensland Institute of Medical Research	Towards better treatments for acral melanoma through function genomics	CI	01.01.2017	31.12.2020	\$1,456,823.00

Funding	Project title	Role	Start	End	Amount (AUD)
NHMRC Practitioner Fellowship Grant	Development of systemic therapies to improve response and prevent resistance in the treatment of Melanoma	CI	01.01.2017	31.12.2021	\$569,219.00
NHMRC Project Grant	Determinants of response to immune checkpoint inhibitors in melanoma	CI	01.01.2017	31.12.2020	\$1,021,486,50
	The combination of CDK4 and MAPK-ERK pathway inhibitor therapy in Melanoma: defining melanoma cell intrinsic and immune mediated responses		01.01.2016	31.12.2019	\$824,288.00
NHMRC Program Grant	Molecular determinants of risk, progression and treatment response in melanoma	Co-PI	01.01.2016	31.12.2021	\$14,663,120.00
Sir Zelman Cowan Universities Fund Prize for Discovery in Medical Research	Prize for Discovery in Medical Research		01.01.2006	31.12.2006	\$20,000.00
NHMRC Equipment Grant	NanoString Counter SPRINT Profiler System for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility		2016		\$199,000.00
NHMRC Project Grant	Alpha-actinin-4 as an oncogenic driver and therapeutic target in melanoma		01.01.2016	31.12.2019	\$401,786.40
CINSW Equipment Grant	Biacore T200 Molecular interaction analysis system for the open access, multi-disciplinary Sydney Cancer Research Core Facility		01.01.2015	31.12.2017	\$354,048.00
NHMRC Project Grant	Significance of soluble PD-L1 in melanoma patients	CI	01.03.2015	28.02.2019	\$542,974.00
Cancer Research Institute Clinical Trial Team Grant	Targeting adenosine in the tumour microenvironment	CI	01.01.2015	31.12.2015	\$15,050.00
CINSW Research Infrastructure Grant	Advanced Technical Support for the open access, multi-disciplinary Sydney Cancer Research Core Facility		01.01.2016	31.12.2018	\$272,876.00
NSW Government Health, Office for Health and Medical	Genetic factors in outcome of new therapies for metastatic melanoma	CI	01.01.2015	31.12.2015	\$811,150.00

Funding	Project title	Role	Start	End	Amount (AUD)
Research Genomics Collaborative Grants Program					
Society for Melanoma Research	Young Investigator Award		01.01.2015	31.12.2015	\$5,000.00
USYD Collaborative Research Equipment Grant	Automated high throughput hypoxic live cell imaging system for shared use in open access, multi-user Bosch, Blackburn Molecular Biology Facility	AI	01.01.2014	31.12.2014	\$170,573.00
Novartis – Investigator-led trial grant	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 Mutation positive melanoma: a single arm, open label single-centre phase 2 trial (Neocombi)	CI	01.01.2014		\$981,755.00
Cancer Institute NSW Premier's Award	Wildfire Award		01.01.2014	31.12.2014	\$20,000.00
Bristol-Myers Squibb Investigator-led Trial Grant	Anti-PD1 Brain Collaboration for patients with Melanoma Brain Metastases (ABC)	CI	01.01.2014		\$1,876,980.00
NHMRC	MAPK reactivation drives melanoma resistance to MAPK inhibition		01.01.2014	31.12.2016	\$720,558.00
Melanoma Research Alliance Award	Targeting BRAF-mutant melanoma brain metastases		01.06.2013	31.05.2018	USD\$900,000.00
Cancer Institute NSW	Premier's award for Outstanding Cancer Research Fellow		01.01.2013	31.12.2013	\$20,000.00
Sir Roy McCaughey Fellowship RACP	Enhancing response to MAP kinase inhibition in melanoma		01.01.2013	31.12.2013	\$75,000.00
Marjorie Hooper Scholarship RACP	Mechanisms of Response and Resistance to Targeted Drugs in Melanoma		01.01.2012	31.12.2012	\$20,000.00
Cancer Institute NSW, Career Development Grant	Determining mechanisms of resistance and heterogeneity of response to novel targeted drugs in metastatic melanoma to improve survival and prevent metastatic disease		01.01.2011	31.12.2014	\$599,895.00
ACRF	Completion and expansion of the ACRF Melanoma Research		01.01.2011	31.12.2011	\$5,000,000.00

Funding	Project title	Role	Start	End	Amount (AUD)
	Laboratories at Westmead Millennium Institute for Cancer Research				
NHMRC Project Grant	Manipulating the MAPK pathway in Melanoma		01.01.2011	31.12.2013	\$543,390.00
NHMRC Project Grant	Manipulating the B-RAF/MEK pathway in the genesis and treatment of melanoma		01.01.2011	31.12.2013	\$652,815.75
Cancer Institute NSW	Clinical and biomarker correlates of melanoma chemosensitivity		01.01.2009	31.12.2009	\$174,852.00
Australia Post, Medical Research Fellowship RACP	Clinical and biomarker correlates of melanoma chemosensitivity and epidemiological studies of outcomes in Stage IV melanoma		01.01.2009	30.12.2010	\$100,000.00
Scripps Research Institute	Fulbright Postdoctoral Fellow Award		01.01.1996	31.12.1996	\$25,000.00
British Ramsay Fellowship	Offer declined		01.01.1995	31.12.1998	
Australian Postgraduate Research Award			01.01.1993	31.12.1996	\$60,000.00

PUBLICATIONS (Key Contributions to Field Bolded)

- Albrecht, L. J., Dimitriou, F., Grover, P., Hassel, J. C., Erdmann, M., Forschner, A., Johnson, D. B., Varaljai, R., Lodde, G., Placke, J. M., Krefting, F., Zaremba, A., Ugurel, S., Roesch, A., Schulz, C., Berking, C., Pottgen, C., Menzies, A. M., **Long, G. V.**, Dummer, R., Livingstone, E., Schadendorf, D., Zimmer, L., Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma, *Eur J Cancer*, **2024 May;20** 2:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. PMID 38484692
- Stassen, R. C., Maas, C., van der Veldt, A. A. M., Lo, S. N., Saw, R. P. M., Varey, A. H. R., Scolyer, R. A., **Long, G. V.**, Thompson, J. F., Rutkowski, P., Keilholz, U., van Akkooi, A. C. J., Verhoef, C., van Klaveren, D., Grunhagen, D. J., Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis, *Lancet Oncol*, **2024 Apr;25** (4):509-517. doi: 10.1016/S1470-2045(24)00076-7. PMID 38547894
- Luke, J. J., Davar, D., Andtbacka, R. H., Bhardwaj, N., Brody, J. D., Chesney, J., Coffin, R., de Baere, T., de Gruijl, T. D., Fury, M., Goldmacher, G., Harrington, K. J., Kaufman, H., Kelly, C. M., Khilnani, A. D., Liu, K., Loi, S., **Long, G. V.**, Melero, I., Middleton, M., Neyns, B., Pinato, D. J., Sheth, R. A., Solomon, S. B., Szapary, P., Marabelle, A., Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease, *J Immunother Cancer*, **2024 Apr 18**; 12(4):e008378. doi: 10.1136/jitc-2023-008378. PMID 38641350
- Bai, X., Attrill, G. H., Gide, T. N., Ferguson, P. M., Nahar, K. J., Shang, P., Vergara, I. A., Palendira, U., da Silva, I. P., Carlino, M. S., Menzies, A. M., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., Quek, C.,

- Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma, *Nat Commun.* **2024 Apr 8**;15(1):3014. doi: 10.1038/s41467-024-47301-9. PMID 38589406
5. Gjorup, C. A., Woodford, R., Li, I., Carlino, M. S., Ch'ng, S., Chung, D., Hsiao, E., Lo, S. N., London, K., **Long, G. V.**, Menzies, A. M., Nieweg, O. E., Pennington, T. E., Rtshiladze, M. A., Saw, R. P. M., Scolyer, R. A., Shannon, K. F., Spillane, A. J., Stretch, J. R., Thompson, J. F., Varey, A. H. R., van Akkooi, A. C. J., Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging, *Ann Surg Oncol.* **2024 Mar**;31 (3):1857-1864. doi: 10.1245/s10434-023-14526-9. Epub 2023 Nov 15. PMID 37966706
 6. Jacques, S. K., McKeown, J., Grover, P., Johnson, D. B., Zaremba, A., Dimitriou, F., Weiser, R., Farid, M., Namikawa, K., Sullivan, R. J., Rutkowski, P., Lebbe, C., Hamid, O., Zager, J. S., Michielin, O., Neyns, B., Nakamura, Y., Robert, C., Mehnert, J., Ascierto, P. A., Bhave, P., Park, B., Zimmer, L., Mangana, J., Mooradian, M., Placzke, J., Allayous, C., Glitza Oliva, I. C., Mehmi, I., Depalo, D., Wicky, A., Schwarze, J. K., Roy, S., Boatwright, C., Vanella, V., **Long, G. V.**, Menzies, A. M., Lo, S. N., Carlino, M. S., Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy, *Eur J Cancer.* **2024 Mar**;19 9:113563. doi: 10.1016/j.ejca.2024.113563. Epub 2024 Jan 22. PMID 38278007
 7. Ertl, C., Ruf, T., Mentzer, D., Kong, M., Kramer, R., Bergwelt-Baildon, M. V., Subklewe, M., Tomsitz, D., Ascierto, P. A., Dummer, R., Gogas, H., Lebbe, C., **Long, G. V.**, McArthur, G., Neilan, T. G., Ribas, A., Robert, C., Schadendorf, D., Zimmer, L., Eigentler, T., Grabbe, S., Forschner, A., Kahler, K. C., Milani, V., Pfohler, C., Hassel, J., Gutzmer, R., Loquai, C., Routy, B., Furness, A. J. S., Blank, C., Wolchok, J. D., French, L. E., Hauschild, A., Heinzerling, L., The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects, *Eur J Cancer.* **2024 Mar**;19 9:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. PMID 38262306
 8. Schadendorf, D., Luke, J. J., Ascierto, P. A., **Long, G. V.**, Rutkowski, P., Khattak, A., Del Vecchio, M., de la Cruz-Merino, L., Mackiewicz, J., Sileni, V. C., Kirkwood, J. M., Robert, C., Grob, J. J., Dummer, R., Carlino, M. S., Zhao, Y., Kalabis, M., Krepler, C., Eggermont, A., Scolyer, R. A., Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial, *J Immunother Cancer.* **2024 Mar 13**;12(3):e007501. doi: 10.1136/jitc-2023-007501. PMID 38485189
 9. Maher, N. G., Vergara, I. A., **Long, G. V.**, Scolyer, R. A. Prognostic and predictive biomarkers in melanoma, *Pathology.* **2024 Mar**;5 6(2):259-273. doi: 10.1016/j.pathol.2023.11.004. PMID 38245478
 10. Kirkwood, J. M., Vecchio, M. D., Weber, J., Hoeller, C., Grob, J. J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., Rutkowski, P., Arenberger, P., Quereux, G., Meniawy, T. M., Ascierto, P. A., Menzies, A. M., Durani, P., Lobo, M., Campigotto, F., Gastman, B., **Long, G. V.**, Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery, *Future Oncol.* **2024 Feb 23**. doi: 10.2217/fo-2023-0977. Online ahead of print. PMID 38390818
 11. Rogiers, A., Dimitriou, F., Lobon, I., Harvey, C., Vergara, I. A., Pires da Silva, I., Lo, S. N., Scolyer, R. A., Carlino, M. S., Menzies, A. M., **Long, G. V.**, Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy, *Eur J Cancer.* **2024 Feb**;19 8:113506. doi: 10.1016/j.ejca.2023.113506. Epub 2023 Dec 26. PMID 38184928
 12. Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Anstas, G., Taylor, M. H., Kim, K. B., McKean, M., **Long, G. V.**, Sullivan, R. J., Faries, M., Tran, T. T., Cowey, C. L., Pecora, A., Shaheen, M., Segar, J., Medina, T., Atkinson, V., Gibney, G. T., Luke, J. J., Thomas, S., Buchbinder, E. I., Healy, J. A., Huang, M., Morrissey, M., Feldman, I., Sehgal, V., Robert-Tissot, C., Hou, P., Zhu, L., Brown, M., Aanur, P., Meehan, R. S., Zaks, T., Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study, *Lancet.* **2024 Feb 17**;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. PMID 38246194
 13. **Long, G. V.**, Durante, J., Browne, M., Scolyer, R. A., Affecting change as a clinical academic, *Trends Cancer.* **2024 Feb**;10(2):93-96. doi: 10.1016/j.trecan.2023.10.003. Epub 2023 Nov 10. PMID 37951732

14. Varey, A. H. R., Li, I., El Sharouni, M. A., Simon, J., Dedeilia, A., Ch'ng, S., Saw, R. P. M., Spillane, A. J., Shannon, K. F., Pennington, T. E., Rtshiladze, M., Stretch, J. R., Nieweg, O. E., van Akkooi, A., Sullivan, R. J., Boland, G. M., Gershenwald, J. E., van Diest, P. J., Scolyer, R. A., **Long, G. V.**, Thompson, J. F., Lo, S. N., Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator, *J Clin Oncol.* **2024 Feb 5** :jco2301020. doi: 10.1200/JCO.23.01020. Online ahead of print, PMID 38315961
15. Maul, L. V., Jamiolkowski, D., Lapidus, R. A., Mueller, A. M., Hauschild, A., Garbe, C., Lorigan, P., Gershenwald, J. E., Ascierto, P. A., **Long, G. V.**, Wang-Evers, M., Scolyer, R. A., Saravi, B., Augustin, M., Navarini, A. A., Legge, S., Nemeth, I. B., Janosi, A. J., Mocellin, S., Feller, A., Manstein, D., Zink, A., Maul, J. T., Buja, A., Adhikari, K., Roider, E., Health Economic Consequences of Delayed Melanoma Diagnosis due to the COVID-19 Pandemic in Europe, *JAMA Netw Open.* **2024 Feb 5**;7(2):e2356479. doi: 10.1001/jamanetworkopen.2023.56479, PMID 38363565
16. Kennedy, O. J., Glassee, N., Kicinski, M., Blank, C. U., **Long, G. V.**, Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M., Giacomo, A. M. D., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Gandini, S., Buhner, E., Suci, S., Robert, C., Eggermont, A. M. M., Mandala, M., Lorigan, P., Valpione, S., Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma, *Eur J Cancer.* **2024 Feb 1** :201:113585. doi: 10.1016/j.ejca.2024.113585. Online ahead of print. PMID 38402687
17. Harvey, C., Nahar, K. J., McKeown, J., Lo, S. N., Farag, S., Yousaf, N., Young, K., Tas, L., Meerveld-Eggink, A., Blank, C., Thomas, A., McQuade, J., Schilling, B., Johnson, D. B., Huertas, R. M., Arance, A., Lee, J., Zimmer, L., **Long, G. V.**, Carlino, M. S., Wang, Y., Menzies, A. M., Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series, *J Immunother Cancer.* **2024 Jan 31**; 12(1):e008232. doi: 10.1136/jitc-2023-008232. PMID 38296594
18. Bai, X., Lawless, A. R., Czapl, J. A., Gerstberger, S. C., Park, B. C., Jung, S., Johnson, R., Yamazaki, N., Ogata, D., Umeda, Y., Li, C., Guo, J., Flaherty, K. T., Nakamura, Y., Namikawa, K., **Long, G. V.**, Menzies, A. M., Johnson, D. B., Sullivan, R. J., Boland, G. M., Si, L., Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study, *JAAD Int.* **2024 Jan 19**:15:105-114. doi: 10.1016/j.jdin.2023.11.014. eCollection 2024 Jun. PMID 38500872
19. Brahmer, J. R., **Long, G. V.**, Hamid, O., Garon, E. B., Herbst, R. S., Andre, T., Armand, P., Bajorin, D., Bellmunt, J., Burtness, B., Choueiri, T. K., Cohen, E. E. W., Diaz, L. A., Jr., Shitara, K., Kulkarni, G., McDermott, D., Shah, M., Taberner, J., Vogel, A., Zinzani, P. L., Jafari, N., Bird, S., Snyder, E., Gause, C., Bracco, O. L., Pietanza, M. C., Gruber, T., Ribas, A., Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients, *Eur J Cancer.* **2024 Jan 11** :199:113530. doi: 10.1016/j.ejca.2024.113530. Online ahead of print. PMID: 8295556
20. Hepner, A., Versluis, J. M., Wallace, R., Allayous, C., Brown, L. J., Trojaniello, C., Gerard, C. L., Jansen, Y. J., Bhave, P., Neyns, B., Haydon, A., Michielin, O., Mangana, J., Klein, O., Shoushtari, A. N., Warner, A. B., Ascierto, P. A., McQuade, J. L., Carlino, M. S., Zimmer, L., Lebbe, C., Johnson, D. B., Sandhu, S., Atkinson, V., Blank, C. U., Lo, S. N., **Long, G. V.**, Menzies, A. M., The features and management of acquired resistance to PD1-based therapy in metastatic melanoma, *Eur J Cancer.* **2024 Jan**:1 96:113441. doi: 10.1016/j.ejca.2023.113441. Epub 2023 Nov 20. PMID 37988842
21. Fraterman, I., Reijers, I. L. M., Dimitriadis, P., Broeks, A., Gonzalez, M., Menzies, A. M. M., Lopez-Yurda, M., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Hospers, G. A. P., **Long, G. V.**, Blank, C. U., van de Poll-Franse, L. V., Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma, *Nat Med.* **2023 Dec**;29 (12):3090-3099. doi: 10.1038/s41591-023-02631-x. Epub 2023 Nov 13. PMID 37957378
22. Soon, J. A., To, Y. H., Alexander, M., Trapani, K., Ascierto, P. A., Athan, S., Brown, M. P., Burge, M., Haydon, A., Hughes, B., Itchins, M., John, T., Kao, S., Koopman, M., Li, B. T., **Long, G. V.**, Loree, J. M., Markman, B., Meniawy, T. M., Menzies, A. M., Nott, L., Pavlakis, N., Petrella, T. M., Popat, S., Tie, J., Xu, W., Yip, D., Zalberg, J., Solomon, B. J., Gibbs, P., McArthur, G. A., Franchini, F., I. Jzerman M, A tailored approach to horizon scanning for cancer medicines, *J Cancer Policy.* **2023 Dec**:3 8:100441. doi: 10.1016/j.jcpc.2023.100441. Epub 2023 Nov 20., PMID 38008488

23. Lian, B., Li, Z., Wu, N., Li, M., Chen, X., Zheng, H., Gao, M., Wang, D., Sheng, X., Tian, H., Si, L., Chi, Z., Wang, X., Lai, Y., Sun, T., Zhang, Q., Kong, Y., **Long, G. V.**, Guo, J., Cui, C., Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma, *Ann Oncol.* **2023 Nov 11** :S0923-7534(23)05061-5. doi: 10.1016/j.annonc.2023.10.793. Online ahead of print. PMID 37956739
24. Dharan, N. J., Sasson, S. C., Ahlenstiel, G., Andersen, C. R., Bloch, M., Buckland, G., Hamad, N., Han, W. M., Kelleher, A. D., **Long, G. V.**, Matthews, G. V., Mina, M. M., Papot, E., Petoumenos, K., Swaminathan, S., Withers, B., Yun, J., Polizzotto, M. N., Coria Study Group, Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia, *PLoS One.* **2023 Nov 1**;18(11):e0289907. doi: 10.1371/journal.pone.0289907. eCollection 2023., PMID 37910527
25. Schmitt, C., Hoefsmit, E. P., Fangmeier, T., Kramer, N., Kabakci, C., Vera Gonzalez, J., Versluis, J. M., Compter, A., Harrer, T., Mijocovic, H., Schubert, S., Hundsberger, T., Menzies, A. M., Scolyer, R. A., **Long, G. V.**, French, L. E., Blank, C. U., Heinzerling, L. M., Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections, *Cancer Immunol Immunother.* **2023 Nov**;72(11):3475-3489. doi: 10.1007/s00262-023-03498-0. Epub 2023 Aug 22. PMID 37606856
26. Bai, X., Shaheen, A., Grieco, C., d'Arienzo, P. D., Mina, F., Czaplak, J. A., Lawless, A. R., Bongiovanni, E., Santaniello, U., Zappi, H., Dulak, D., Williamson, A., Lee, R., Gupta, A., Li, C., Si, L., Ubaldi, M., Yamazaki, N., Ogata, D., Johnson, R., Park, B. C., Jung, S., Madonna, G., Hochherz, J., Umeda, Y., Nakamura, Y., Gebhardt, C., Festino, L., Capone, M., Ascierto, P. A., Johnson, D. B., Lo, S. N., **Long, G. V.**, Menzies, A. M., Namikawa, K., Mandala, M., Guo, J., Lorigan, P., Najjar, Y. G., Haydon, A., Quaglino, P., Boland, G. M., Sullivan, R. J., Furness, A. J. S., Plummer, R., Flaherty, K. T., Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study, *EClinicalMedicine.* **2023 Oct 31**;65:102290. doi: 10.1016/j.eclinm.2023.102290. eCollection 2023 Nov. PMID 37965433
27. Handelsman, D. J., Idan, A., Sleiman, S., Bacha, F., **Long, G. V.**, Menzies, A. M., Vaishnav, T., Litkouhi, N., Volckmar, X., Ledger, W., Anazodo, A., Testicular function after non-cytotoxic and immunotherapy drug treatment, *Andrology.* **2023 Oct 27**. doi: 10.1111/andr.13546. Online ahead of print. PMID 37889046
28. Mallardo, D., Woodford, R., Menzies, A. M., Zimmer, L., Williamson, A., Ramelyte, E., Dimitriou, F., Wicky, A., Wallace, R., Mallardo, M., Cortellini, A., Budillon, A., Atkinson, V., Sandhu, S., Olivier, M., Dummer, R., Lorigan, P., Schadendorf, D., **Long, G. V.**, Simeone, E., Ascierto, P. A., The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab, *J Transl Med.* **2023 Oct 25**;21(1):753. doi: 10.1186/s12967-023-04607-4. PMID 37880788
29. Simpson, R. C., Shanahan, E. R., Scolyer, R. A., **Long, G. V.**, Towards modulating the gut microbiome to enhance the efficacy of immune-checkpoint inhibitors, *Nat Rev Clin Oncol.* **2023 Oct**;20(10):697-715. doi: 10.1038/s41571-023-00803-9. Epub 2023 Jul 24. PMID 37488231
30. Conway, J. W., Braden, J., Lo, S. N., Scolyer, R. A., Carlino, M. S., Menzies, A. M., **Long, G. V.**, Silva, I. P. D., VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-Analysis, *Cancers (Basel).* **2023 Oct 16**; 15(20):5012. doi: 10.3390/cancers15205012. PMID 37894379
31. Kirkwood, J., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J. J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., Rutkowski, P., Arenberger, P., Quereux, G., Meniawy, T. M., Ascierto, P. A., Menzies, A. M., Durani, P., Lobo, M., Campigotto, F., Gastman, B., **Long, G. V.**, Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial, *Nat Med.* **2023 Oct 16**. doi: 10.1038/s41591-023-02583-2. Online ahead of print. PMID 37845511
32. Adegoke, N. A., Gide, T. N., Mao, Y., Quek, C., Patrick, E., Carlino, M. S., Lo, S. N., Menzies, A. M., Pires da Silva, I., Vergara, I. A., Scolyer, R. A.*, Wilmott, J. S.*, **Long, G.***, Classification of the tumour immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies, *J Immunother Cancer.* **2023 Oct**;11(10):e007144. doi: 10.1136/jitc-2023-007144. PMID 37865395
33. Gide, T. N., Paver, E. C., Yaseen, Z., Maher, N., Adegoke, N., Menzies, A. M., Pires da Silva, I., Wilmott, J. S.*, Scolyer, R. A.* **Long, G. V.***, Lag-3 expression and clinical outcomes in metastatic melanoma

- patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies, *Oncoimmunology*. **2023 Oct 4**;12(1):2261248. doi: 10.1080/2162402X.2023.2261248. eCollection 2023. PMID 37808404
34. Ong, J. S., Seviiri, M., Dusingize, J. C., Wu, Y., Han, X., Shi, J., Olsen, C. M., Neale, R. E., Thompson, J. F., Saw, R. P. M., Shannon, K. F., Mann, G. J., Martin, N. G., Medland, S. E., Gordon, S. D., Scolyer, R. A., **Long, G. V.**, Iles, M. M., Landi, M. T., Whiteman, D. C., MacGregor, S., Law, M. H., Uncovering the complex relationship between balding, testosterone and skin cancers in men, *Nat Commun*. **2023 Oct 3**; 14(1):5962. doi: 10.1038/s41467-023-41231-8., PMID 37789011
 35. Gjorup, C. A., Pires da Silva, I., Martin, L., Stretch, J. R., Scolyer, R. A., **Long, G. V.**, Hong, A., Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose, *Melanoma Res*, **2023 Oct 1**; 33(5):422-424. doi: 10.1097/CMR.0000000000000905. Epub 2023 Aug 3. PMID 37534694
 36. Goodman, R. S., Di Guardo, L., Maurichi, A., Kirwin, B., Khattak, A., Vanella, V., Lee, J., Lawless, A., Czaplá, J., Spagnoletti, A., Ambrosini, M., Livingstone, E., **Long, G. V.**, Sullivan, R. J., Carlino, M. S., Atkinson, V., Trojanello, C., Ascierto, P. A., Schadendorf, D., Warburton, L., Menzies, A. M., Santinami, M., Johnson, D. B., Long-Term Outcomes and Persistent Toxicities Following BRAF/MEK Inhibitor Therapy for Advanced Melanoma, *Eur J Cancer*, **2023 Sept 22**:194:113354. doi: 10.1016/j.ejca.2023.113354. Online ahead of print. PMID 37827067
 37. van Akkooi, A. C., Hauschild, A., **Long, G. V.**, Mandala, M., Kicinski, M., Govaerts, A. S., Klauk, I., Ouali, M., Lorigan, P. C., Eggermont, A. M., COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma, *Future Oncol*. **2023 Sep 4**. doi: 10.2217/fon-2023-0414. Online ahead of print. PMID 37665297
 38. Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M. S., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G., Hampel, P. J., **Long, G. V.**, Wargo, J. A., Ferrajoli, A., Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia, *Ann Oncol*. **2023 Sep;34**(9):796-805. doi: 10.1016/j.annonc.2023.06.007. Epub 2023 Jul 4. PMID 37414216
 39. Diab, A., Gogas, H., Sandhu, S., **Long, G. V.**, Ascierto, P. A., Larkin, J., Sznol, M., Franke, F., Ciuleanu, T. E., Pereira, C., Munoz Couselo, E., Bronzon Damian, F., Schenker, M., Perfetti, A., Lebbe, C., Quereux, G., Meier, F., Curti, B. D., Rojas, C., Arriaga, Y., Yang, H., Zhou, M., Ravimohan, S., Statkevich, P., Tagliaferri, M. A., Khushalani, N. I., Bimpegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results, *J Clin Oncol*. **2023 Aug 31**;JCO2300172. doi: 10.1200/JCO.23.00172. Online ahead of print. PMID 37651676
 40. Robert, C., Carlino, M. S., McNeil, C., Ribas, A., Grob, J. J., Schachter, J., Nyakas, M., Kee, D., Petrella, T. M., Blaustein, A., Lotem, M., Arance, A., Daud, A. I., Hamid, O., Larkin, J., Anderson, J., Krepler, C., Grebennik, D., **Long, G. V.**, Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma, *J Clin Oncol*. **2023 Aug 20**; 41(24):3998-4003. doi: 10.1200/JCO.22.01599. Epub 2023 Jun 22. PMID 37348035
 41. Lee, R., Mandala, M., **Long, G. V.**, Eggermont, A. M. M., van Akkooi, A. C. J., Sandhu, S., Garbe, C., Lorigan, P., Adjuvant therapy for stage II melanoma: the need for further studies, *Adjuvant therapy for stage II melanoma: the need for further studies*, *Eur J Cancer*. **2023 Aug;18** 9:112914. doi: 10.1016/j.ejca.2023.05.003. Epub 2023 May 8. PMID 37301717
 42. **Long, G. V.**, Swetter, S. M., Menzies, A. M., Gershenwald, J. E., Scolyer, R. A., Cutaneous Melanoma, *Lancet*. **2023 Aug 5**; 402(10400):485-502. doi: 10.1016/S0140-6736(23)00821-8. Epub 2023 Jul 24. PMID 37499671
 43. Goodman, R. S., Lawless, A., Woodford, R., Fa'ak, F., Tipirneni, A., Patrinely, J. R., Yeoh, H. L., Rapisuwon, S., Haydon, A., Osman, I., Mehnert, J. M., **Long, G. V.**, Sullivan, R. J., Carlino, M. S., Menzies, A. M., Johnson, D. B., Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma, *JAMA Netw Open*. **2023 Aug 1**; 6(8):e2327145. doi: 10.1001/jamanetworkopen.2023.27145. PMID 37535354
 44. Schadendorf, D., Tawbi, H., Lipson, E. J., Stephen Hodi, F., Rutkowski, P., Gogas, H., Lao, C. D., Grob, J. J., Moshyk, A., Lord-Bessen, J., Hamilton, M., Guo, S., Shi, L., Keidel, S., **Long, G. V.**, Health-

- related quality of life with nivolumab and relatlimab versus nivolumab alone in patients with previously untreated metastatic or unresectable melanoma: RELATIVITY-047 trial, *Eur J Cancer*. **2023 Jul;18** 7:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. PMID 37167764
45. Ming, Z., Lim, S. Y., Stewart, A., Pedersen, B., Shklovskaya, E., Menzies, A. M., Carlino, M. S., Kefford, R. F., Lee, J. H., Scolyer, R. A., **Long, G. V.**, Rizos, H., IFN-gamma Signaling Sensitizes Melanoma Cells to BH3 Mimetics, *J Invest Dermatol*, . **2023 Jul;14** 3(7):1246-1256.e8. doi: 10.1016/j.jid.2023.01.017. Epub 2023 Feb 1. PMID 36736995
 46. Garbe, C., Dummer, R., Amaral, T., Amaria, R. N., Ascierto, P. A., Burton, E. M., Dreno, B., Eggermont, A. M. M., Hauschild, A., Hoeller, C., Kaufmann, R., Lebbe, C., Mandala, M., Menzies, A. M., Moreno, D., Michielin, O., Nathan, P., Patel, S. P., Robert, C., Schadendorf, D., Lorigan, P. C., Scolyer, R. A., Tawbi, H. A., van de Wiel, B. A., Blank, C., **Long, G. V.**, Neoadjuvant immunotherapy for melanoma is now ready for clinical practice., *Nat Med*. **2023 Jun;29**(6):1310-1312. doi: 10.1038/s41591-023-02336-1, PMID37193799
 47. Livingstone A, Howard K, Menzies AM, **Long GV**, Stockler MR, Morton RL., Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment, *Patient*. **2023 Jun 23**. doi: 10.1007/s40271-023-00635-w. Online ahead of print, PMID 37351797
 48. Thompson, J. R., Lai-Kwon, J., Morton, R. L., Guminski, A. D., Gonzalez, M., Atkinson, V., Sandhu, S., Brown, M. P., Menzies, A. M., McArthur, G. A., Lo, S. N., **Long, G. V.**, Bartula, I., Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy, *Immunotherapy*. **2023 Jun;15** (8):593-610. doi: 10.2217/imt-2022-0262. Epub 2023 May 2. PMID 37132182
 49. El Zarif, T., Nassar, A. H., Adib, E., Fitzgerald, B. G., Huang, J., Mouhieddine, T. H., Rubinstein, P. G., Nonato, T., McKay, R. R., Li, M., Mittra, A., Owen, D. H., Baiocchi, R. A., Lorentsen, M., Dittus, C., Dizman, N., Falohun, A., Abdel-Wahab, N., Diab, A., Bankapur, A., Reed, A., Kim, C., Arora, A., Shah, N. J., El-Am, E., Kozaily, E., Abdallah, W., Al-Hader, A., Abu Ghazal, B., Saeed, A., Drolen, C., Lechner, M. G., Drakaki, A., Baena, J., Nebhan, C. A., Haykal, T., Morse, M. A., Cortellini, A., Pinato, D. J., Dalla Pria, A., Hall, E., Bakalov, V., Bahary, N., Rajkumar, A., Mangla, A., Shah, V., Singh, P., Aboubakar Nana, F., Lopetegui-Lia, N., Dima, D., Dobbs, R. W., Funchain, P., Saleem, R., Woodford, R., **Long, G. V.**, Menzies, A. M., Genova, C., Barletta, G., Puri, S., Florou, V., Idossa, D., Saponara, M., Queirolo, P., Lamberti, G., Addeo, A., Bersanelli, M., Freeman, D., Xie, W., Reid, E. G., Chiao, E. Y., Sharon, E., Johnson, D. B., Ramaswami, R., Bower, M., Emu, B., Marron, T. U., Choueiri, T. K., Baden, L. R., Lurain, K., Sonpavde, G. P., Naqash, A. R., Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium, *J Clin Oncol*. **2023 May 16**; JCO2202459. doi: 10.1200/JCO.22.02459. Online ahead of print. PMID 37192435
 50. Shteinman, E. R., Vergara, I. A., Rawson, R. V., Lo, S. N., Maeda, N., Koyama, K., da Silva, I. P., Long, G. V., Scolyer, R. A., Wilmott, J. S., Menzies, A. M., Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma, *Pathology*. **2023 May 16**; S0031-3025(23)00121-6. doi: 10.1016/j.pathol.2023.03.007. Online ahead of print. PMID 37286471
 51. Reijers ILM*, Rao D*, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Griepink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, **Long GV**, Blank CU, IFN- γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma, *J Exp Med*. **2023 May 1**; 220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID 36920329
 52. **Long, G. V.**, Menzies, A. M., Scolyer, R. A., Neoadjuvant checkpoint inhibitor immunotherapy and melanoma: the time is now, *J Clin Oncol*. **2023 Apr 27**; JCO2202575. doi: 10.1200/JCO.22.02575. Online ahead of print. PMID 37104746
 53. Hoefsmit, E. P., Vollmy, F., Rozeman, E. A., Reijers, I. L. M., Versluis, J. M., Hoekman, L., van Akkooi, A.C. J., **Long, G. V.**, Schadendorf, D., Dummer, R., Altelaar, M., Blank, C. U., Systemic LRG1 expression in melanoma is associated with disease progression and recurrence, *Cancer Res Commun*. **2023 Apr 20**;3(4):672-683. doi: 10.1158/2767-9764.CRC-23-0015. eCollection 2023 Apr. PMID 37089863
 54. Kennedy, O. J., Kicinski, M., Valpione, S., Gandini, S., Suci, S., Blank, C. U., **Long, G. V.**, Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J.,

- Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Robert, C., Eggermont, A. M. M., Lorigan, P., Mandala, M., Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma, *Eur J Cancer*. **2022 Apr**;16 5:97-112. doi: 10.1016/j.ejca.2022.01.017. Epub 2022 Feb 24. PMID 35220182
55. Mao, Y., Gide, T. N., Adegoke, N. A., Quek, C., Maher, N., Potter, A., Patrick, E., Saw, R. P. M., Thompson, J. F., Spillane, A. J., Shannon, K. F., Carlino, M. S., Lo, S. N., Menzies, A. M., da Silva, I. P., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach, *J Transl Med*. **2023 Apr 13**;21(1):257. doi: 10.1186/s12967-023-04092-9. PMID 37055772
56. Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch'ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Griepink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen JBAG, Schumacher TN, van Akkooi ACJ, **Long GV**, Blank CU, Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials, *Ann Oncol*. **2023 Apr**;3 4(4):420-430. doi: 10.1016/j.annonc.2023.01.004. Epub 2023 Jan 18. PMID 36681299
57. Schadendorf, D., Tawbi, H., Lipson, E. J., Stephen Hodi, F., Rutkowski, P., Gogas, H., Lao, C. D., Grob, J. J., Moshyk, A., Lord-Bessen, J., Hamilton, M., Guo, S., Shi, L., Keidel, S., **Long, G. V.**, Health-related quality of life with nivolumab and relatlimab versus nivolumab alone in patients with previously untreated metastatic or unresectable melanoma: RELATIVITY-047 trial, *Eur J Cancer*. **2023 Jul**;18 7:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. PMID 37167764
58. **Georgina V. Long**, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi, Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma, **March 22, 2023**, *NEJM Evidence*, 2023 Apr;2(4):EVIDoA2200239, PMID 38320023
59. Lai-Kwon, J., Jacques, S., Carlino, M., Benannoune, N., Robert, C., Allayous, C., Baroudjian, B., Lebbe, C., Zimmer, L., Eroglu, Z., Topcu, T. O., Dimitriou, F., Haydon, A., Lo, S. N., Menzies, A. M., **Long, G. V.**, Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma, *Eur J Cancer*. **2023 Mar 11**;186:12-21. doi: 10.1016/j.ejca.2023.03.006. Online ahead of print. PMID 37018924
60. Bhave, P., Hong, A., Lo, S. N., Johnson, R., Mangana, J., Johnson, D. B., Dulgar, O., Eroglu, Z., Yeoh, H. L., Haydon, A., Lodde, G. C., Livingstone, E., Khattak, A., Kahler, K., Hausschild, A., McArthur, G. A., Menzies, A. M., **Long, G.**, Wang, W., Carlino, M. S., Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy, *J Immunother Cancer*. **2023 Mar**;11 (3):e006629. doi: 10.1136/jitc-2022-006629. PMID 36889810
61. Lim, S. Y., Shklovskaya, E., Lee, J. H., Pedersen, B., Stewart, A., Ming, Z., Irvine, M., Shivalingam, B., Saw, R. P. M., Menzies, A. M., Carlino, M. S., Scolyer, R. A., **Long, G. V.**, Rizos, H., The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma, *Nat Commun*. **2023 Mar 18**;14(1):1516. doi: 10.1038/s41467-023-36979-y. PMID 36934113
62. Park, B. C., Narayanan, S., Gavraldis, A., Ye, F., Fan, R., Sullivan, R. J., Boland, G., Reynolds, K. L., Balko, J. M., Carlino, M. S., **Long, G. V.**, Zubiri, L., Menzies, A. M., Johnson, D. B., Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations, *Oncoimmunology*. **2023 Mar 8**;12(1):2188719. doi: 10.1080/2162402X.2023.2188719. eCollection 2023. PMID 36926262
63. Chatterton, S., Xi, S., Jia, J. X., Krause, M., **Long, G. V.**, Atkinson, V., Menzies, A. M., Fernando, S. L., Boyle, T., Kwok, S., Duggins, A., Karikios, D., Parratt, J. D. E., Case series: Immune checkpoint inhibitor-induced transverse myelitis, *Front Neurol*. **2023 Feb 21**;14:1130313. doi: 10.3389/fneur.2023.1130313. eCollection 2023. PMID 36895912
64. Lee, H., Ferguson, A. L., Quek, C., Vergara, I. A., Pires daSilva, I., Allen, R., Gide, T. N., Conway, J. W., Koufariotis, L. T., Hayward, N. K., Waddell, N., Carlino, M. S., Menzies, A. M., Saw, R. P. M.,

- Shklovskaya, E., Rizos, H., Lo, S., Scolyer, R. A., **Long, G. V.**, Palendira, U., Wilmott, J. S., Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy, *Clin Cancer Res.* **2023 Feb 15**;CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657. Online ahead of print. PMID 36790412
65. Ascierto, P. A., Lipson, E. J., Dummer, R., Larkin, J., **Long, G. V.**, Sanborn, R. E., Chiarion-Sileni, V., Dreno, B., Dalle, S., Schadendorf, D., Callahan, M. K., Nyakas, M., Atkinson, V., Gomez-Roca, C. A., Yamazaki, N., Tawbi, H. A., Sarkis, N., Warad, D., Dolfi, S., Mitra, P., Suryawanshi, S., Grob, J. J., Nivolumab and Relatlimab In Patients With Advanced Melanoma Who Had Prior Pd-1/Pd-L1 Therapy: Results From The Phase 1/2 Relativity-020 Trial, *J Clin Oncol.* **2023 Feb 13**;JCO2202072. doi: 10.1200/JCO.22.02072. Online ahead of print. PMID 36780608
 66. Wilmott, J. S., Tawbi, H., Engh, J. A., Amankulor, N. M., Shivalingam, B., Banerjee, H., Vergara, I. A., Lee, H., Johansson, P. A., Ferguson, P. M., Saiag, P., Robert, C., Grob, J. J., Butterfield, L. H., Scolyer, R. A., Kirkwood, J. M., **Long, G. V.**, Davies, M. A., Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases, *Clin Cancer Res.* **2023 Feb 1**;29(3):521-531. doi: 10.1158/1078-0432.CCR-22-2581, PMID 36477181
 67. Wepler, A. M., Da Meda, L., Pires da Silva, I., Xu, W., Grignani, G., Menzies, A. M., Carlino, M. S., **Long, G. V.**, Lo, S. N., Nordman, I., Steer, C. B., Lyle, M., Trojaniello, C., Ascierto, P. A., Lebbe, C., Sandhu, S., Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation, *Eur J Cancer.* **2023 Jan 30**;183:109-118. doi: 10.1016/j.ejca.2023.01.016. Online ahead of print. PMID 36842413
 68. Sandhu, S., Atkinson, V., Cao, M. G., Medina, T., Rivas, A. S., Menzies, A. M., Caro, I., Roberts, L., Song, Y., Yan, Y., Guo, Y., Xue, C., **Long, G. V.**, Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy, *Eur J Cancer.* **2023 Jan**;17 8:180-190. doi: 10.1016/j.ejca.2022.10.019. Epub 2022 Nov 2. PMID 36455412
 69. Vergara, I. A., Aivazian, K., Carlino, M. S., Guminski, A. D., Maher, N. G., Shannon, K. F., Ch'ng, S., Saw, R. P. M., **Long, G. V.**, Wilmott, J. S., Scolyer, R. A., Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets, *Mod Pathol.* **2023 Jan 10**;36(4):100099. doi: 10.1016/j.modpat.2023.100099. Online ahead of print. PMID 36788083
 70. Wong, S. K., Blum, S. M., Sun, X., Da Silva, I. P., Zubiri, L., Ye, F., Bai, K., Zhang, K., Ugurel, S., Zimmer L., Livingstone, E., Schadendorf, D., Serra-Bellver, P., Munoz-Couselo, E., Ortiz, C., Lostes, J., Huertas, R. M., Arance, A., Pickering, L., **Long, G. V.**, Carlino, M. S., Buchbinder, E. I., Vazquez-Cortes, L., Jara-Casas, D., Marquez-Rodas, I., Gonzalez-Espinoza, I. R., Balko, J. M., Menzies, A. M., Sullivan, R. J., Johnson, D. B., Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma, *Eur J Cancer.* **2022 Dec 27**;181:188-197. doi: 10.1016/j.ejca.2022.12.013. Online ahead of print. PMID 36680880
 71. Smith, J. L., Menzies, A. M., Cohen, J. V., Mut-Lloret, M., Ozgun, A., Spain, L., Park, J., Quach, H. T., Pallan L., McQuade, J., Feng, S., Sandhu, S., Atkinson, V., Tsai, K., **Long, G. V.**, Larkin, J., Eroglu, Z., Johnson, D. B., Sullivan, R., Herkes, G. K., Henderson, A., Carlino, M. S., Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series, *Melanoma Res.* **2022 Dec 1**; 32(6):451-459. doi: 10.1097/CMR.0000000000000825. Epub 2022 Sep 23. PMID 36164923
 72. Lai-Kwon, J., Kelly, B., Lane, S., Biviano, R., Bartula, I., Brennan, F., Kivikoski, I., Thompson, J., Dhillon, H. M., Menzies, A., **Long, G. V.**, Feasibility, acceptability and utility of a pilot nurse-led survivorship program for people with metastatic melanoma (MELCARE), *Support Care Cancer.* **2022 Nov**;30 (11):9587-9596. doi: 10.1007/s00520-022-07360-4. Epub 2022 Sep 22. PMID 36136246
 73. Conway, J. W., Braden, J., Wilmott, J. S., Scolyer, R. A., **Long, G. V.**, Pires da Silva, I., The effect of organ-specific tumor microenvironments on response patterns to immunotherapy, *Front Immunol.* **2022 Nov 17**; 13:1030147. doi: 10.3389/fimmu.2022.1030147. eCollection 2022. PMID 36466910
 74. Lee, J., Ahmed, T., Maurichi, A., Di Guardo, L., Stagno, A. M., Warburton, L., Taylor, A. M., Livingstone, E., Rehman, S., Khattak, A., Kahler, K. C., Vanella, V., Atkinson, V., Millward, M., Schadendorf, D., Johnson, D. B., Ascierto, P. A., Hauschild, A., Lo, S. N., **Long, G. V.**, Menzies, A. M., Carlino, M. S., BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-

- term outcomes, *Eur J Cancer*. **2022 Nov 12**; 179:87-97. doi: 10.1016/j.ejca.2022.11.009. Online ahead of print. PMID 35609002
75. Paver, E., Aivazian, K., Maclean, F., **Long, G. V.**, Spillane, A. J., Wilmott, J. S., Scolyer, R. A., Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma, *Pathology*. **2022 Oct 29**; S0031-3025(22)00277-X. doi: 10.1016/j.pathol.2022.08.011. Online ahead of print. PMID 36400594
 76. Meric-Bernstam, F., Sweis, R. F., Kasper, S., Hamid, O., Bhatia, S., Dummer, R., Stradella, A., **Long, G. V.**, Spreafico, A., Shimizu, T., Steeghs, N., Luke, J. J., McWhirter, S. M., Muller, T., Nair, N., Lewis, N., Chen, X., Bean, A., Kattenhorn, L., Pelletier, M., Sandhu, S., Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study, *Clin Cancer Res*. **2022 Oct 25**; CCR-22-2235. doi: 10.1158/1078-0432.CCR-22-2235. Online ahead of print. PMID 36285874
 77. Serra-Bellver, P., Versluis, J. M., Oberoi, H. K., Zhou, C., Slattery, T. D., Khan, Y., Patrinely, J. R., Pires da Silva, I., Martinez-Vila, C., Cook, N., Graham, D. M., Carlino, M. S., Menzies, A. M., Arance, A. M., Johnson, D. B., **Long, G. V.**, Pickering, L., Larkin, J. M. G., Blank, C. U., Lorigan, P., Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study, *Eur J Cancer*. **2022 Oct 7**; 176:121-132. doi: 10.1016/j.ejca.2022.09.004. Online ahead of print. PMID 36215945
 78. Shteinman, E. R., Wilmott, J. S., da Silva, I. P., **Long, G. V.**, Scolyer, R. A., Vergara, I. A., Causes, consequences and clinical significance of aneuploidy across melanoma subtypes, *Front Oncol*. **2022 Oct 6**; 12:988691. doi: 10.3389/fonc.2022.988691. eCollection 2022. PMID 36276131
 79. Moschos, S. J., Sandhu, S., Lewis, K. D., Sullivan, R. J., Puzanov, I., Johnson, D. B., Henary, H. A., Wong, H., Upreti, V. V., **Long, G. V.**, Flaherty, K. T., Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study, *Invest New Drugs*. **2022 Oct**; 40(5):1051-1065. doi: 10.1007/s10637-022-01253-3. Epub 2022 May 30. PMID 35635631
 80. Shklovskaya, E., Pedersen, B., Stewart, A., Simpson, J. O. G., Ming, Z., Irvine, M., Scolyer, R. A., **Long, G. V.**, Rizos, H. Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers, *Cancers (Basel)*. **2022 Oct 3**; 14(19):4830. doi: 10.3390/cancers14194830, PMID 36230753
 81. Khattak, M. A., Luke, J. J., **Long, G. V.**, Ascierto, P. A., Rutkowski, P., Schadendorf, D., Robert, C., Grob, J. J., de la Cruz Merino, L., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Carlino, M. S., Mohr, P., De Galitiis, F., Ross, M. I., Eroglu, Z., Chen, K., Jiang, R., Fukunaga-Kalabis, M., Krepler, C., Eggermont, A. M. M., Kirkwood, J. M., Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study, *Eur J Cancer*. **2022 Oct 3**; S0959-8049(22)00477-4. doi: 10.1016/j.ejca.2022.08.004. Online ahead of print. PMID 36202690
 82. Smith, A. L., Watts, C. G., Henderson, M., **Long, G. V.**, Rapport, F., Saw, R. P. M., Scolyer, R. A., Spillane, A. J., Thompson, J. F., Cust, A. E., Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework *Implement Sci Commun*. **2022 Oct 1**; 3(1):103. doi: 10.1186/s43058-022-00351-w. PMID 36183121
 83. Nahar, K. J., Marsh-Wakefield, F., Rawson, R. V., Gide, T. N., Ferguson, A. L., Allen, R. O., Quek, C., Pires da Silva, I., Tattersall, S., Kiely, C. J., Sandanayake, N., Carlino, M. S., McCaughan, G., Wilmott, J. S., Scolyer, R. A., **Long, G. V.**, Menzies, A. M., Palendira, U., Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie immunotherapy-induced colitis, *JCI Insight*. **2022 Sep 29**; e157839. doi: 10.1172/jci.insight.157839. Online ahead of print. PMID 36173679
 84. Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., Ascierto, P. A., Sandhu, S., Eigentler, T., Gutzmer, R., Hassel, J. C., Robert, C., Carlino, M. S., Di Giacomo, A. M., Butler, M. O., Munoz-Couselo, E., Brown, M. P., Rutkowski, P., Haydon, A., Grob, J. J., Schachter, J., Queirolo, P., de la Cruz-Merino, L., van der Westhuizen, A., Menzies, A. M., Re, S., Bas, T., de Pril, V., Braverman, J., Tenney, D. J., Tang, H., **Long, G. V.**, Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915), *J Clin Oncol*. **2022 Sep 26**; JCO2200533. doi: 10.1200/JCO.22.00533. PMID 36162037

85. Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., Adhikari, C., Menzies, A. M., Saw, R. P. M., Gonzalez, M., Shannon, K. F., Spillane, A. J., Velickovic, R., Lazar, A. J., Damania, A. V., Mishra, A. K., Chelvanambi, M., Banerjee, A., Ajami, N. J., Wargo, J. A., Macia, L., Holmes, A. J., Wilmott, J. S., Blank, C. U., Scolyer, R. A., **Long, G. V.**, Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome, *Nat Med.* **2022 Sep 22**. doi: 10.1038/s41591-022-01965-2. Online ahead of print. PMID 36138151
86. Muller-Jensen, L., Zierold, S., Versluis, J. M., Boehmerle, W., Huehnchen, P., Endres, M., Mohr, R., Compter, A., Blank, C. U., Hagenacker, T., Meier, F., Reinhardt, L., Gesierich, A., Salzmann, M., Hassel, J. C., Ugurel, S., Zimmer, L., Banks, P., Spain, L., Soon, J. A., Enokida, T., Tahara, M., Kahler, K. C., Seggewiss-Bernhardt, R., Harvey, C., **Long, G. V.**, Schoberl, F., von Baumgarten, L., Hundsberger, T., Schlaak, M., French, L. E., Knauss, S., Heinzerling, L. M., Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study, *Eur J Cancer.* **2022 Sep 22**; 175:224-235. doi: 10.1016/j.ejca.2022.08.009. Online ahead of print. PMID 36155116
87. Newell, F., Johansson, P. A., Wilmott, J. S., Nones, K., Lakis, V., Pritchard, A. L., Lo, S. N., Rawson, R. V., Kazakoff, S. H., Colebatch, A. J., Koufariotis, L. T., Ferguson, P. M., Wood, S., Leonard, C., Law, M. H., Brooks, K. M., Broit, N., Palmer, J. M., Coutts, K. L., Vergara, I. A., **Long, G. V.**, Barbour, A. P., Nieweg, O. E., Shivalingam, B., Robinson, W. A., Stretch, J. R., Spillane, A. J., Saw, R. P. M., Shannon, K. F., Thompson, J. F., Mann, G. J., Pearson, J. V., Scolyer, R. A., Waddell, N., Hayward, N. K., Comparative genomics provides etiological and biological insights into melanoma subtypes, *Cancer Discov.* **2022 Sep 13**; CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Online ahead of print. PMID 36098958
88. Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw R. P. M., Thompson, J. F., Spillane, A. J., Shannon, K. F., Shivalingam, B., Menzies, A. M., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A., Pires da Silva, I., Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites, *J Immunother Cancer.* **2022 Sep**;10(9):e004884. doi: 10.1136/jitc-2022-004884. PMID 36096531
89. Alexander MM Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, **Georgina V Long**, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, MD, , Susana Puig MD, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus JM van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Nageatte Ibrahim, Sandrine Marreaud, Stefan Suciu, Caroline Robert, Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma, *NEJM Evidence*, **Sept 10 2022**, <https://doi.org/10.1056/EVIDoa2200214>
90. Seviiri, M., Scolyer, R. A., Bishop, D. T., Newton-Bishop, J. A., Iles, M. M., Lo, S. N., Stretch, J. R., Saw, R. P. M., Nieweg, O. E., Shannon, K. F., Spillane, A. J., Gordon, S. D., Olsen, C. M., Whiteman, D. C., Landi, M. T., Thompson, J. F., **Long, G. V.**, MacGregor, S., Law, M. H., Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting, *J Transl Med.* **2022 Sep 5**;20(1):403. doi: 10.1186/s12967-022-03613-2, PMID 36064556
91. **Long, G. V.**, Ferrucci, P. F., Khattak, A., Meniawy, T. M., Ott, P. A., Chisamore, M., Trolle, T., Hyseni, A., Heegaard, E., KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma, *Future Oncol.* **2022 Sep 1**. doi: 10.2217/fo-2022-0694. Online ahead of print. PMID 36047545
92. Chesney, J. A., Ribas, A., **Long, G. V.**, Kirkwood, J. M., Dummer, R., Puzanov, I., Hoeller, C., Gajewski, T. F., Gutzmer, R., Rutkowski, P., Demidov, L., Arenberger, P., Shin, S. J., Ferrucci, P. F., Haydon, A., Hynngstrom, J., van Thienen, J. V., Haferkamp, S., Guilera, J. M., Rapoport, B. L., VanderWalde, A., Diede, S. J., Anderson, J. R., Treichel, S., Chan, E. L., Bhatta, S., Gansert, J., Hodi, F. S., Gogas, H., Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma, *J Clin Oncol.* **2022 Aug 23**; JCO2200343. doi: 10.1200/JCO.22.00343. Online ahead of print. PMID 35998300
93. Larkin, J., Weber, J., Del Vecchio, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J. J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., De la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A., Fecher, L. A., Millward, M.,

- Khushalani, N. I., Queirolo, P., **Long, G. V.**, Lobo, M., Askelson, M., Ascierto, P. A., Mandala M., Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C/IV melanoma: reassessment of 4 year CheckMate 238 efficacy outcomes per AJCC-8 staging criteria, *EJC*, June 26 2022, accepted for publication *Eur J Cancer*. **2022 Aug 11** ;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Online ahead of print. PMID 35964471
94. Attrill, G. H., Lee, H., Tasker, A. T., Adegoke, N. A., Ferguson, A. L., da Silva, I. P., Saw, R. P. M., Thompson, J. F., Palendira, U., **Long, G. V.**, Ferguson, P. M., Scolyer, R. A., Wilmott, J. S., Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome, *Front Immunol*. **2022 Aug 8**; 13:979993. doi: 10.3389/fimmu.2022.979993. eCollection 2022. PMID 36003398
95. Arance, A., de la Cruz-Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Marquez-Rodas, I., Spreafico, A., Atkinson, V., Costa Svedman, F., Mant, A., Khattak, M. A., Mihalciou, C., Jang, S., Cowey, C. L., Smith, A. D., Hawk, N., Chen, K., Diede, S. J., Krepler, C., **Long, G. V.**, Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination, *J Clin Oncol*, **2022 Jul 22**; JCO2200221. doi: 10.1200/JCO.22.00221. Online ahead of print.
96. Rawson RV, Shteinman ER, Ansar S, Vergara IA, Thompson JF, **Long GV**, Rcolyer RA, Wilmott JS, Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics, *Pathology*. **2022 Jul 31**; S0031-3025(22)00215-X. doi: 10.1016/j.pathol.2022.05.012. Online ahead of print. PMID 35987723
97. Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., Robert, C., Trojanello, C., Wicky, A., Heywood, R., Tran, L., Batty, K., Dimitriou, F., Stansfeld, A., Allayous, C., Schwarze, J. K., Mooradian, M. J., Klein, O., Mehmi, I., Roberts-Thomson, R., Maurichi, A., Yeoh, H. L., Khattak, A., Zimmer, L., Blank, C. U., Ramelyte, E., Kahler, K. C., Roy, S., Ascierto, P. A., Michielin, O., Lorigan, P. C., Johnson, D. B., Plummer, R., Lebbe, C., Neyns, B., Sullivan, R., Hamid, O., Santinami, M., McArthur, G. A., Haydon, A. M., **Long, G. V.**, Menzies, A. M., Carlino, M. S., Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma, *J Immunother Cancer*. **2022 Jul 10** (7):e004668. doi: 10.1136/jitc-2022-004668, PMID 35793872
98. Holmberg, C. J., Ny, L., Hieken, T. J., Block, M. S., Carr, M. J., Sondak, V. K., Ortenwall, C., Katsarelias, D., Dimitriou, F., Menzies, A. M., Saw, R. P., Rogiers, A., Straker, R. J., 3rd, Karakousis, G., Applewaite, R., Pallan, L., Han, D., Vetto, J. T., Gyorki, E., Tie, E. N., Vitale, M. G., Ascierto, P. A., Dummer, R., Cohen, J., Hui, J. Y., Schachter, J., Asher, N., Helgadottir, H., Chai, H., Kroon, H., Coventry, B., Rothermel, L. D., Sun, J., Carlino, M. S., Duncan, Z., Broman, K., Weber, J., Lee, A. Y., Berman, R. S., Teras, J., Ollila, D. W., **Long, G. V.**, Zager, J. S., van Akkooi, A., Olofsson Bagge, R., The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study, *Eur J Cancer*. **2022 Jul;16** 9:210-222. doi: 10.1016/j.ejca.2022.03.041. Epub 2022 May 26. PMID 35644725
99. Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Lebbe, C., Mangana, J., Ascierto, P. A., Johnson, D. B., Carlino, M., Menzies, A., **Long, GV.**, Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma, *J Immunother Cancer*. **2022 Jul;10** (7):e004610. doi: 10.1136/jitc-2022-004610. PMID 35798536
100. Reijers, I. L. M., Menzies, A. M., van Akkooi, A. C. J., Versluis, J. M., van den Heuvel, N. M. J., Saw, R. P. M., Pennington, T. E., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Hospers, G. A. P., Rozeman, E. A., Klop, W. M. C., van Houdt, W. J., Sikorska, K., van der Hage, J. A., Grunhagen, D. J., Wouters, M. W., Witkamp, A. J., Zuur, C. L., Lijnsvelt, J. M., Torres Acosta, A., Griepink-Ongering, L. G., Gonzalez, M., Jozwiak, K., Bierman, C., Shannon, K. F., Ch'ng, S., Colebatch, A. J., Spillane, A. J., Haanen, Jbag, Rawson, R. V., van de Wiel, B. A., van de Poll-Franse, L. V., Scolyer, R. A., Boekhout, A. H., **Long, G. V.**, Blank, C. U., Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial, *Nat Med*. **2022 Jun;28** (6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. PMID 35661157
101. Garbe, C., Keim, U., Amaral, T., Berking, C., Eigentler, T. K., Flatz, L., Gesierich, A., Leiter, U., Stadler, R., Sunderkotter, C., Tuting, T., Utikal, J., Wollina, U., Zimmer, L., Zouboulis, C. C., Ascierto, P. A., Eggermont, A. M. M., Grob, J. J., Hauschild, A., Sekulovic, L. K., **Long, G. V.**, Luke, J. J., Michielin,

- O., Peris, K., Schadendorf, D., Kirkwood, J. M., Lorigan, P. C., Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment, *J Clin Oncol.* **2022 Jun 16** ;jco2200202. doi: 10.1200/JCO.22.00202. Online ahead of print. PMID 35709414
102. Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhawe, P., Farid, M., Kahler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M. S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D. B., Ascierto, P. A., Shoushtari, A. N., Sullivan, R. J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C. U., Lo, S. N., Menzies, A. M., **Long, G. V.**, Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study, *Ann Oncol.* **2022 Jun 16**; s0923-7534(22)01731-8. doi: 10.1016/j.annonc.2022.06.004. Online ahead of print, PMID 35716907
 103. Tawbi, H. A., Robert, C., Brase, J. C., Gusenleitner, D., Gasal, E., Garrett, J., Savchenko, A., Gorgun, G., Flaherty, K. T., Ribas, A., Dummer, R., Schadendorf, D., **Long, G. V.**, Nathan, P. D., Ascierto, P. A., Spatalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i), *J Immunother Cancer.* **2022 Jun**;10 (6):e004226. doi: 10.1136/jitc-2021-004226. PMID 35728875
 104. Attrill, G. H., Owen, C. N., Ahmed, T., Vergara, I. A., Colebatch, A. J., Conway, J. W., Nahar, K. J., Thompson, J. F., Pires da Silva, I., Carlino, M. S., Menzies, A. M., Lo, S., Palendira, U., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy, *J Immunother Cancer.* **2022 Jun**;10 (6):e004771. doi: 10.1136/jitc-2022-004771. PMID 35688560
 105. Vellano, C. P., White, M. G., Andrews, M. C., Chelvanambi, M., Witt, R. G., Daniele, J. R., Titus, M., McQuade, J. L., Conforti, F., Burton, E. M., Lastrapes, M. J., Ologun, G., Cogdill, A. P., Morad, G., Prieto, P., Lazar, A. J., Chu, Y., Han, G., Khan, M. A. W., Helmink, B., Davies, M. A., Amaria, R. N., Kovacs, J. J., Woodman, S. E., Patel, S., Hwu, P., Peoples, M., Lee, J. E., Cooper, Z. A., Zhu, H., Gao, G., Banerjee, H., Lau, M., Gershenwald, J. E., Lucci, A., Keung, E. Z., Ross, M. I., Pala, L., Pagan, E., Segura, R. L., Liu, Q., Borthwick, M. S., Lau, E., Yates, M. S., Westin, S. N., Wani, K., Tetzlaff, M. T., Haydu, L. E., Mahendra, M., Ma, X., Logothetis, C., Kulstad, Z., Johnson, S., Hudgens, C. W., Feng, N., Federico, L., **Long, G. V.**, Futreal, P. A., Arur, S., Tawbi, H. A., Moran, A. E., Wang, L., Heffernan, T. P., Marszalek, J. R., Wargo, J. A., Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy, *Nature.* **2022 Jun 6** 06(7915):797-803. doi: 10.1038/s41586-022-04833-8. Epub 2022 Jun 15. PMID 35705814
 106. Schwartz, R. J., Ho, G., Smith, A., Collgros, H., Regio Pereira, A., Gouveia, B., **Long, G. V.**, Menzies, A. M., Potter, A. J., Paver, E., Star, P., Scolyer, R. A., Martin, L. K., Successful treatment of eruptive keratoacanthomas with actitrein for patients on checkpoint inhibitor immunotherapy, *J Eur Acad Dermatol Venereol.* **2022 Jun**;3 6(6):e445-e448. doi: 10.1111/jdv.17940. Epub 2022 Jan 28 PMID 35043483
 107. Yaseen, Z., Gide, T. N., Conway, J. W., Potter, A. J., Quek, C., Hong, A. M., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma, *Front Mol Biosci.* **2022 May 19**; 9:810858. doi: 10.3389/fmolb.2022.810858. eCollection 2022.
 108. Li, A. T., Miin Yip, J., Choksi, H., London, K., Potter, A. J., Lo, S. N., Saw, R. P. M., Shannon, K. F., Pires da Silva, I., Varey, A. H. R., Menzies, A. M., **Long, G. V.**, Shivalingam, B., Scolyer, R. A., Thompson, J. F., Ch'ng, S., Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread, *Melanoma Res.* **2022 May 13**. doi: 10.1097/CMR.0000000000000827. Online ahead of print. PMID 35579680
 109. Ascierto, P. A., Warner, A. B., Blank, C., Caraco, C., Demaria, S., Gershenwald, J. E., Khushalani, N. I., **Long, G. V.**, Luke, J. J., Mehnert, J. M., Robert, C., Rutkowski, P., Tawbi, H. A., Osman, I., Puzanov, I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021, *J Transl Med.* **2022 May 10** ;20(1):200. doi: 10.1186/s12967-022-03406-7. PMID 35538491
 110. Luke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz, Merino, L., Khattak, M. A., Schadendorf, D., **Long, G. V.**, Ascierto, P. A., Mandala, M., De Galitiis, F.,

- Haydon, A., Dummer, R., Grob, J. J., Robert, C., Carlino, M. S., Mohr, P., Poklepovic, A., Sondak, V. K., Scolyer, R. A., Kirkwood, J. M., Chen, K., Diede, S. J., Ahsan, S., Ibrahim, N., Eggermont, A. M. M., Keynote- Investigators, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial, *Lancet*, **2022 Apr 30**;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. PMID 35367007
111. Jobson, D., Roffey, B., Arnold, C., Azzi, A., Button-Sloan, A., Dawson, T., Fernandez-Penas, P., Fishburn, P., Gyorki, D. E., Hiscutt, E. L., Jakrot, V., Lilleyman, A., Lochhead, A., **Long, G. V.**, Mailer, S., Mann, G., McCormack, C. J., Muir, J., Pratt, G. F., Scolyer, R. A., Shackelton, M., Shumack, S., Soyer, H. P., Tan, C. G., Webb, A., Zalberg, J., Morton, R., Mar, V., Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study, *Australas J Dermatol*. **2022 Apr 29**. doi: 10.1111/ajd.13848. Online ahead of print.
112. Kaptein, P., Jacobberger-Foissac, C., Dimitriadis, P., Voabil, P., de Bruijn, M., Brokamp, S., Reijers, I., Versluis, J., Nallan, G., Triscott, H., McDonald, E., Tay, J., **Long, G. V.**, Blank, C. U., Thommen, D. S., Teng, M. W. L., Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade, *Sci Transl Med*. **2022 Apr 27** ;14(642):eabj9779. doi: 10.1126/scitranslmed.abj9779. Epub 2022 Apr 27 PMID 35476594
113. Eggermont, A. M. M., Hamid, O., **Long, G. V.**, Luke, J. J., Optimal systemic therapy for high-risk resectable melanoma, *Nat Rev Clin Oncol*. **2022 Apr 25**. doi: 10.1038/s41571-022-00630-4. Online ahead of print. PMID 35468949
114. Colebatch, A. J., Adhikari, C., Diefenbach, R. J., Rawson, R. V., Ferguson, P. M., Rizos, H., **Long, G. V.**, McCarthy, S. W., Thompson, J. F., Wilmott, J. S., Scolyer, R. A., Comprehensive clinical, histopathological and molecular analysis and long-term follow-up of patients with nodal blue nevi, *Am J Surg Pathol*, **2022 Apr 20**. doi: 10.1097/PAS.0000000000001902. Online ahead of print. PMID35439782
115. Hanna S, Marinos E, Bryan D, Ahmed T, Lo SN, Carlino MS, Smith A, Cairns G, Shannon K, **Long GV**, Scolyer RA, Saw RPM, Effect of the SunSafe Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. *Clin Exp Dermatol*. **2022 Apr 18**. doi: 10.1111/ced.15220. Online ahead of print. PMID: 35434843
116. Diefenbach, R. J., Lee, J. H., Stewart, A., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Stretch, J. R., **Long, G. V.**, Scolyer, R. A., Rizos, H., Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA, *Front Oncol*. **2022 Apr 12**;12:820510. doi: 10.3389/fonc.2022.820510. eCollection 2022. PMID 35494035
117. Wang, M., Zadeh, S., Pizzolla, A., Thia, K., Gyorki, D. E., McArthur, G. A., Scolyer, R. A., **Long, G.**, Wilmott, J. S., Andrews, M. C., Au-Yeung, G., Weppler, A., Sandhu, S., Trapani, J. A., Davis, M. J., Neeson, P. J., Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation, *J Immunother Cancer*. **2022 Apr**;10 (4):e004095. doi: 10.1136/jitc-2021-004095, PMID 35383113
118. Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggiolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N. R., Newell, F., Wilmott, J. S., Johansson, P. A., Thompson, J. F., **Long, G. V.**, Pearson, J. V., Mann, G. J., Scolyer, R. A., Waddell, N., Montal, E. D., Huang, T. H., Jonsson, P., Donoghue, M. T. A., Harris, C. C., Taylor, B. S., Xu, T., Chaligne, R., Shliha, P. V., Hendrickson, R., Jungbluth, A. A., Lezcano, C., Koche, R., Studer, L., Ariyan, C. E., Solit, D. B., Wolchok, J. D., Merghoub, T., Rosen, N., Hayward, N. K., White, R. M., Anatomic position determines oncogenic specificity in melanoma, *Nature*. **2022 Apr 6**, 04(7905):354-361. doi: 10.1038/s41586-022-04584-6. Epub 2022 Mar 30. PMID 35355015
119. Luke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M. A., Schadendorf, D., **Long, G. V.**, Ascierto, P. A., Mandala, M., De Galitiis, F., Haydon, A., Dummer, R., Grob, J. J., Robert, C., Carlino, M. S., Mohr, P., Poklepovic, A., Sondak, V. K., Scolyer, R. A., Kirkwood, J. M., Chen, K., Diede, S. J., Ahsan, S., Ibrahim, N., Eggermont, A. M. M., Keynote- Investigators, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial, *Lancet*. **2022 Apr 30**;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. PMID 35367007
120. Star, P., Jackett, L. A., Cheung, K., Wilmott, J. S., Ho, G., Smith, A., **Long, G. V.**, Scolyer, R. A., Martin, L. K., Multiple eruptive squamoproliferative lesions during immunotherapy for metastatic melanoma:

- an exploration of pathogenesis with immunohistochemical analysis, *Dermatol Ther.* **2022 Mar 29** ;e15472. doi: 10.1111/dth.15472. Online ahead of print. PMID 35347815
121. Bai, X., Shoushtari, A. N., Betof Warner, A., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Quach, H. T., Cann, C. G., Zhang, M. Z., Pallan, L., Harvey, C., Kim, M. S., Kasumova, G., Sharova, T., Cohen, J. V., Lawrence, D. P., Freedman, C., Fadden, R. M., Rubin, K. M., Frederick, D. T., Flaherty, K. T., **Long, G. V.**, Menzies, A. M., Sullivan, R. J., Boland, G. M., Johnson, D. B., Guo, J., Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study, *Br J Dermatol.* **2022 Mar 16.** doi: 10.1111/bjd.21241. Online ahead of print. PMID 35293617
 122. Ho, G., Schwartz, R. J., Regio Pereira, A., Dimitrou, F., Paver, E., McKenzie, C., Saw, R. P. M., Scolyer, R. A., **Long, G. V.**, Guitera, P., Reflectance confocal microscopy as a non-invasive tool for monitoring systemic treatment response on a primary unresected scalp melanoma, *J Eur Acad Dermatol Venereol.* **2022 Mar 14.** doi: 10.1111/jdv.18076. Online ahead of print. PMID 35285090
 123. Potter, A. J., Colebatch, A. J., Rawson, R. V., Ferguson, P. M., Cooper, W. A., Gupta, R., O'Toole, S., Saw, R. P. M., Ch'ng, S., Menzies, A. M., **Long, G. V.**, Scolyer, R. A., Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre, *Pathology.* **2022 Mar 3** ;S0031-3025(22)00062-9. doi: 10.1016/j.pathol.2021.12.290. Online ahead of print.
 124. Colebatch, A. J., Paver, E. C., Vergara, I. A., Thompson, J. F., **Long, G. V.**, Wilmott, J. S., Scolyer, R. A., Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma, *Pathology.* **2022 Mar 2** ;S0031-3025(22)00061-7. doi: 10.1016/j.pathol.2021.12.289. Online ahead of print. PMID 35248370
 125. Kennedy, O. J., Kicinski, M., Valpione, S., Gandini, S., Suci, S., Blank, C. U., **Long, G. V.**, Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Robert, C., Eggermont, A. M. M., Lorigan, P., Mandala, M., Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma, *Eur J Cancer.* **2022 Feb 24** ;165:97-112. doi: 10.1016/j.ejca.2022.01.017. Online ahead of print. PMID 35220182
 126. Pennington, T. E., Zhao, C. Y., Colebatch, A. J., Fernandez-Penas, P., Guitera, P., Burke, H., Scolyer, R. A., Menzies, A. M., Carlino, M. S., Lo, S., **Long, G. V.**, Saw, R. P., Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma, *Australas J Dermatol.* **2022 Feb 21.** doi: 10.1111/ajd.13807. Online ahead of print. PMID 35188271
 127. Goldinger, S. M., Buder-Bakhaya, K., Lo, S. N., Forschner, A., McKean, M., Zimmer, L., Khoo, C., Dummer, R., Eroglu, Z., Buchbinder, E. I., Ascierto, P. A., Gutzmer, R., Rozeman, E. A., Hoeller, C., Johnson, D. B., Gesierich, A., Kolblinger, P., Bennannoune, N., Cohen, J. V., Kahler, K. C., Wilson, M. A., Cebon, J., Atkinson, V., Smith, J. L., Michielin, O., **Long, G. V.**, Hassel, J. C., Weide, B., Haydu, L. E., Schadendorf, D., McArthur, G., Ott, P. A., Blank, C., Robert, C., Sullivan, R., Hauschild, A., Carlino, M. S., Garbe, C., Davies, M. A., Menzies, A. M., Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis, *Eur J Cancer.* **2022 Feb;16** 2:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21. PMID 34952480
 128. Pires da Silva, I., Ahmed, T., McQuade, J. L., Nebhan, C. A., Park, J. J., Versluis, J. M., Serra-Bellver, P., Khan, Y., Slattery, T., Oberoi, H. K., Ugurel, S., Haydu, L. E., Herbst, R., Utikal, J., Pfohler, C., Terheyden, P., Weichenthal, M., Gutzmer, R., Mohr, P., Rai, R., Smith, J. L., Scolyer, R. A., Arance, A. M., Pickering, L., Larkin, J., Lorigan, P., Blank, C. U., Schadendorf, D., Davies, M. A., Carlino, M. S., Johnson, D. B., **Long, G. V.**, Lo, S. N., Menzies, A. M., Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma, *J Clin Oncol.* **2022 Feb 10** ;JCO2101701. doi: 10.1200/JCO.21.01701. Online ahead of print. PMID 35143285
 129. Reijers, I. L. M., Rawson, R. V., Colebatch, A. J., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Wouters, M. W., Saw, R. P. M., van Houdt, W. J., Zuur, C. L., Nieweg, O. E., Ch'ng, S., Klop, W. M. C., Spillane, A. J., **Long, G. V.**, Scolyer, R. A., van de Wiel, B. A., Blank, C. U., Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma, *JAMA Surg.* **2022 Feb 9.** doi: 10.1001/jamasurg.2021.7554. Online ahead of print. PMID 35138335

130. **Long, G. V.**, Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., Schachter, J., Grob, J. J., Lotem, M., Middleton, M. R., Neyns, B., Steven, N., Ribas, A., Walpole, E., Carlino, M. S., Lebbe, C., Sznol, M., Jensen, E., Leiby, M. A., Ibrahim, N., Robert, C., Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma Enrolled in KEYNOTE-006, *Ann Oncol.* **2022 Feb 3** 3(2):204-215 doi:10.1016/j.annonc.2021.10.010. Epub 2021 Oct 25. PMID 34710571
131. Muir, C. A., Wood, C. C. G., Clifton-Bligh, R. J., **Long, G. V.**, Scolyer, R. A., Carlino, M. S., Menzies, A. M., Tsang, V. H. M., Association of anti-thyroid antibodies in checkpoint inhibitor associated thyroid immune related adverse events, *J Clin Endocrinol Metab.* **2022 Feb 1**; dgac059. doi: 10.1210/clinem/dgac059. Online ahead of print, PMID 35104870
132. van Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C., Ascierto, P. A., Asero, Svma, Blank, C. U., Block, M. S., Boland, G. M., Caraco, C., Chng, S., Davidson, B. S., Duprat Neto, J. P., Faries, M. B., Gershenwald, J. E., Grunhagen, D. J., Gyorki, D. E., Han, D., Hayes, A. J., van Houdt, W. J., Karakousis, G. C., Klop, W. M. C., **Long, G. V.**, Lowe, M. C., Menzies, A. M., Olofsson Bagge, R., Pennington, T. E., Rutkowski, P., Saw, R. P. M., Scolyer, R. A., Shannon, K. F., Sondak, V. K., Tawbi, H., Testori, A. A. E., Tetzlaff, M. T., Thompson, J. F., Zager, J. S., Zuur, C. L., Wargo, J. A., Spillane, A. J., Ross, M. I., International Neoadjuvant Melanoma Consortium, Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC), *Ann Surg Oncol.* **2022 Jan 28.** doi: 10.1245/s10434-021-11236-y. Online ahead of print. PMID 35089452
133. Eggermont, A. M., Ascierto, P. A., Khushalani, N. I., Schadendorf, D., Boland, G., Weber, J., Lewis, K. D., Johnson, D., Rivalland, G., Khattak, A., Majem, M., Gogas, H., **Long, G. V.**, Currie, S. L., Chien, D., Tagliaferri, M. A., Carlino, M. S., Diab, A., PIVOT-12: a Phase III study of adjuvant bempedaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence, *Future Oncol.* **2022 Jan 25.** doi: 10.2217/fo-2021-1286. Online ahead of print, PMID 35073733
134. Dummer, R.*, **Long, G. V.***, Robert, C., Tawbi, H. A., Flaherty, K. T., Ascierto, P. A., Nathan, P. D., Rutkowski, P., Leonov, O., Dutriaux, C., Mandala, M., Lorigan, P., Ferrucci, P. F., Grob, J. J., Meyer, N., Gogas, H., Stroyakovskiy, D., Arance, A., Brase, J. C., Green, S., Haas, T., Masood, A., Gasal, E., Ribas, A., Schadendorf, D., Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma, *J Clin Oncol.* **2022 Jan 14**; JCO2101601. doi: 10.1200/JCO.21.01601. Online ahead of print. PMID 35030011
135. Newell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., Lakis, V., Kazakoff, S. H., Mukhopadhyay, P., Ferguson, P. M., Leonard, C., Koufariotis, L. T., Wood, S., Blank, C. U., Thompson, J. F., Spillane, A. J., Saw, R. P. M., Shannon, K. F., Pearson, J. V., Mann, G. J., Hayward, N. K., Scolyer, R. A., Waddell, N., **Long, G. V.**, Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance, *Cancer Cell.* **2022 Jan 10**;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012. Epub 2021 Dec 23. PMID34951955
136. Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutierrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., Dalle, S., Arance, A., Grob, J. J., Srivastava, S., Abaskharoun, M., Hamilton, M., Keidel, S., Simonsen, K. L., Sobiesk, A. M., Li, B., Hodi, F. S., **Long, G. V.**, Relativity- Investigators, Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma, *N Engl J Med.* **2022 Jan 6**; 386(1):24-34. doi: 10.1056/NEJMoa2109970, PMID 34986285
137. Dimitriou, F., Lo, S. N., Tan, A. C., Emmett, L., Kapoor, R., Carlino, M. S., **Long, G. V.**, Menzies, A. M., FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma, *Ann Oncol.* **2022 Jan 3**, 3(1):99-106. doi: 10.1016/j.annonc.2021.10.003. Epub 2021 Oct 21. PMID 34687894
138. Scolyer, R. A., Atkinson, V., Gyorki, D. E., Lambie, D., O'Toole, S., Saw, R. P. M., Amanuel, B., Angel, C. M., Button-Sloan, A. E., Carlino, M. S., Ch'ng, S., Colebatch, A. J., Daneshvar, D., Pires da Silva, I., Dawson, T., Ferguson, P. M., Foster-Smith, E., Fox, S. B., Gill, A. J., Gupta, R., Henderson, M. A., Hong, A. M., Howle, J. R., Jackett, L. A., James, C., Lee, C. S., Lochhead, A., Loh, D., McArthur, G. A., McLean, C. A., Menzies, A. M., Nieweg, O. E., O'Brien, B. H., Pennington, T. E., Potter, A. J., Prakash, S., Rawson, R. V., Read, R. L., Rtshiladze, M. A., Shannon, K. F., Smithers, B. M., Spillane, A. J., Stretch, J. R., Thompson, J. F., Tucker, P., Varey, A. H. R., Vilain, R. E., Wood, B. A., **Long, G. V.**, BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance

- for the Australian setting, *Pathology*. **2021 Dec 19** ;S0031-3025(21)00533-X. doi: 10.1016/j.pathol.2021.11.002. Online ahead of print. PMID34937664
139. Choi, S., Hong, A., Wang, T., Lo, S., Chen, B., Silva, I., Kapoor, R., Hsiao, E., Fogarty, G. B., Carlino, M. S., Menzies, A. M., **Long, G. V.**, Shivalingam, B. S., Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location, *Strahlenther Onkol*. **2021 Dec;197(12):1104-1112**. doi: 10.1007/s00066-021-01798-x. Epub 2021 Jun 10. PMID 34114045
 140. Gallagher, S. J., Bailey, T., Rawson, R. V., Mahar, A. M., Thompson, J. F., **Long, G. V.**, Wilmott, J. S., Scolyer, R. A., Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis *Pathology*. **2021 Dec 5** 3(7):830-835. doi: 10.1016/j.pathol.2021.02.012. Epub 2021 Jun 2 PMID 34090666
 141. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Marquez-Rodas, I., Haanen, Jbag, Guidoboni, M., Maio, M., Schoffski, P., Carlino, M. S., Lebbe, C., McArthur, G., Ascierto, P. A., Daniels, G. A., **Long, G. V.**, Bas, T., Ritchings, C., Larkin, J., Hodi, F. S., Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, *J Clin Oncol*. **2021 Nov 24**;JCO2102229. doi: 10.1200/JCO.21.02229. Online ahead of print. PMID 34818112
 142. Liyanage, U., MacGregor, S., Bishop, D. T., Shi, J., An, J., Ong, J. S., Han, X., Scolyer, R. A., Martin, N. G., Medland, S. E., Byrne, E. M., Green, A. C., Saw, R. P. M., Thompson, J. F., Stretch, J., Spillane, A., Jiang, Y., Tian, C., andMe Research, Team, Gordon, S. G., Duffy, D. L., Olsen, C. M., Whiteman, D. C., **Long, G. V.**, Iles, M. M., Landi, M. T., Law, M. H., Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma, *J Invest Dermatol*, **2021 Nov 20**; S0022-202X(21)02513-6. doi: 10.1016/j.jid.2021.08.449. Online ahead of print PMID 34813871
 143. Hamid, O., Robert, C., Daud, A., Carlino, M. S., Mitchell, T. C., Hersey, P., Schachter, J., **Long, G. V.**, Hodi, F. S., Wolchok, J. D., Arance, A., Grob, J. J., Joshua, A. M., Weber, J. S., Mortier, L., Jensen, E., Diede, S. J., Moreno, B. H., Ribas, A., Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006, *Eur J Cancer*, **2021 Nov;15** 7:391-402. doi: 10.1016/j.ejca.2021.08.013. Epub 2021 Sep 25. PMID 34571336
 144. Dimitriou F, Hogan S, Cheng PF, Menzies AMM, Dummer R, **Long GV**, Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy, *Eur J Cancer*, . **2021 Nov;15** 7:214-224. doi: 10.1016/j.ejca.2021.08.031. Epub 2021 Sep 15. PMID: 34536945
 145. Bai, X., Hu, J., Betof Warner, A., Quach, H. T., Cann, C. G., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Pallan, L., Harvey, C., Manos, M. P., Ouyang, O., Kim, M. S., Kasumova, G., Cohen, J. V., Lawrence, D. P., Freedman, C., Fadden, R. M., Rubin, K. M., Sharova, T., Frederick, D. T., Flaherty, K. T., Rahma, O. E., **Long, G. V.**, Menzies, A. M., Guo, J., Shoushtari N., , Johnson, D. B., Sullivan, R. J., Boland, G. M., Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy, *Clin Cancer Res*. **2021 Nov 1**; 27(21):5993-6000. doi: 10.1158/1078-0432.CCR-21-1283. Epub 2021 Aug 10. PMID 34376536
 146. Zaremba, A., Kramer, R., De Temple, V., Bertram, S., Salzmann, M., Gesierich, A., Reinhardt, L., Baroudjian, B., Sachse, M. M., Mechtersheimer, G., Johnson, D. B., Weppler, A. M., Spain, L., Loquai, C., Dudda, M., Pfohler, C., Hepner, A., **Long, G. V.**, Menzies, A. M., Carlino, M. S., Lebbe, C., Enokida, T., Tahara, M., Brockelmann, P. J., Eigentler, T., Kahler, K. C., Gutzmer, R., Berking, C., Ugurel, S., Stadler, N., Sucker, A., Becker, J. C., Livingstone, E., Meier, F., Hassel, J. C., Schadendorf, D., Hanoun, M., Heinzerling, L., Zimmer, L., Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis, *Front Oncol*. **2021 Oct 21**; 11:765608. doi: 10.3389/fonc.2021.765608. eCollection 2021, PMID 34746007
 147. Srinivasan, M., Taylor, A. M., **Long, G. V.**, Herkes, G., King, G. G., Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy, *Respir Med Case Rep*. **2021 Oct 21**; 34:101533. doi: 10.1016/j.rmcr.2021.101533. eCollection 2021. PMID 34745870
 148. Eggermont, A. M., Meshcheryakov, A., Atkinson, V., Blank, C. U., Mandala, M., **Long, G. V.**, Barrow, C., Di Giacomo, A. M., Fisher, R., Sandhu, S., Kudchadkar, R., Ortiz Romero, P. L., Svane, I. M., Larkin, J., Puig, S., Hersey, P., Quaglino, P., Stroyakovskiy, D., Bastholt, L., Mohr, P., Hernberg, M.,

- Chiarion-Sileni, V., Strother, M., Hauschild, A., Yamazaki, N., van Akkooi, A. C., Lorigan, P., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, *Eur J Cancer*. **2021 Oct 18**;158:156-168. doi: 10.1016/j.ejca.2021.09.023. Online ahead of print. PMID 34678677
149. Quek, C., Bai, X., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy, *Genes (Basel)*. **2021 Oct 16**; 12(10):1629. doi: 10.3390/genes12101629. PMID 34681023
 150. Halle, B. R., Betof Warner, A., Zaman, F. Y., Haydon, A., Bhave, P., Dewan, A. K., Ye, F., Irlmeier, R., Mehta, P., Kurtansky, N. R., Lacouture, M. E., Hassel, J. C., Choi, J. S., Sosman, J. A., Chandra, S., Otto, T. S., Sullivan, R., Mooradian, M. J., Chen, S. T., Dimitriou, F., **Long, G.**, Carlino, M., Menzies, A., Johnson, D. B., Rotemberg, V. M., Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy, *J Immunother Cancer*. **2021 Oct**;9(10):e003066. doi: 10.1136/jitc-2021-003066. PMID 34635495
 151. Cho, K. K., Cust, A. E., Foo, Y. M., **Long, G. V.**, Menzies, A. M., Eslick, G. D., Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis, *Melanoma Res*. **2021 Oct 1**; 31(5):482-486. doi: 10.1097/CMR.0000000000000764. PMID 34433196
 152. Waldstein C, Wanga W, Lo S, Shivalingam B, Fogarty GB, Carlino MS, Menzies AM, **Long GV**, Hong AM, Melanoma brain metastasis: The outcome of whole brain radiation therapy in the era of effective systemic therapy. *Therapeutic Radiology and Oncology*, **Sept 20 2021**, doi.org/10.21037/tro-21-6
 153. Dey, A, Rogiers A, **Long GV**, Schrieber L, Immunotherapy for Cancer and immune related-adverse events (irAEs), *Medicine Today*, **Sept 2021**
 154. A. Zaremba, A.M.M. Eggermont, C. Robert, R. Dummer, S. Ugure, L. Livingstone, P. Ascierto, **G. Long**, D. Schadendorf, L. Zimmer, The concepts of rechallenge and retreatment in melanoma treated with immune checkpoint blockade, *Eur J Cancer*. **2021 Sep 15** 5:268-280. doi: 10.1016/j.ejca.2021.07.002. Epub 2021 Aug 12. PMID 34392069
 155. Carlino, M. S., Larkin, J., **Long, G. V.**, Immune checkpoint inhibitors in melanoma, *Lancet*, **2021 Sep 11**; 398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. PMID 34509219
 156. Livingstone, A, Dempsey, K, Stockler, M. R, Howard, K, **Long, G. V**, Carlino, M. S, Menzies, A. M., Morton, R. L, Adjuvant immunotherapy recommendations for stage III melanoma: Physician and Nurse interviews, *BMC Cancer* **2021 Sep 10**; 21(1):1014. doi: 10.1186/s12885-021-08752-1. PMID 34507552
 157. Potter, A. J., Dimitriou, F., Karim, R. Z., Mahar, A., Chan, C., **Long, G. V.**, Scolyer, R. A., Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma, *Pathology*. **2021 Aug 19**; S0031-3025(21)00423-2. doi: 10.1016/j.pathol.2021.05.097. Online ahead of print. PMID 34420793
 158. Dearden, H., Au, L. Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Cuvietto, M., Khoo, C., Atkinson, V., Lo, S., **Long, G. V.**, Sandhu, S., Ascierto, P. A., Carlino, M. S., Johnson, D. B., Larkin, J., Menzies, A. M., Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy, *Eur J Cancer*, **2021 Aug**;15 3:168-178. doi: 10.1016/j.ejca.2021.04.045. Epub 2021 Jun 25. PMID 34182268
 159. Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., **Long, G. V.**, Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., Tang, H., Wind-Rotolo, M., Rizzo, J. I., Jackson, D. G., Ascierto, P. A., TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma, *Cancer Immunol Res*, **2021 Aug 13**; canimm.0983.2020. doi: 10.1158/2326-6066.CIR-20-0983. Online ahead of print. PMID 34389558
 160. Li, A. T., Vakharia, K., Lo, S. N., Varey, A. H. R., Carlino, M. S., Saw, R. P. M., Shannon, K. F., Howle, J. R., Pennington, T. E., Stretch, J. R., Nieweg, O. E., Spillane, A. J., **Long, G. V.**, Menzies, A. M., Scolyer, R. A., Thompson, J. F., Ch'ng, S., Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma, *Ann Surg Oncol*. **2021 Aug 4**. doi: 10.1245/s10434-021-10489-x. Online ahead of print. PMID 34347220
 161. Schadendorf, D., Robert, C., Dummer, R., Flaherty, K. T., Tawbi, H. A., Menzies, A. M., Banerjee, H., Lau, M., **Long, G. V.**, Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in

- BRAF-mutant cancers, *Eur J Cancer*. **2021 Jul 2**; 153:234-241. doi: 10.1016/j.ejca.2021.05.005. Online ahead of print. PMID 34225229
162. Haas, L., Elewaut, A., Gerard, C. L., Umkehrer, C., Leiendecker, L., Pedersen, M., Krecioch, I., Hoffmann, D., Novatchkova, M., Kuttke, M., Neumann, T., da Silva, I. P., Witthock, H., Cuendet, M. A., Carotta, S., Harrington, K. J., Zuber, J., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Michielin, O., Vanharanta, S., Wiesner, T., Obenaus, A. C., Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma *Nat Cancer*. **2021 Jul;2** (7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15. PMID 35121945
 163. **Long, G. V.**, Robert, C., Butler, M. O., Couture, F., Carlino, M. S., O'Day, S., Atkinson, V., Cebon, J. S., Brown, M. P., Dalle, S., Hill, A. G., Gibney, G. T., McCune, S., Menzies, A. M., Niu, C., Ibrahim, N., Homet Moreno, B., Diab, A., Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules, *Clin Cancer Res*. **2021 Jul 1**; clincanres.0793.2021. doi: 10.1158/1078-0432.CCR-21-0793. Online ahead of print. PMID 34210681
 164. Hepner, A., Atkinson, V. G., Larkin, J., Burrell, R. A., Carlino, M. S., Johnson, D. B., Zimmer, L., Tsai, K. K., Klein, O., Lo, S. N., Haydon, A., Bhave, P., Lyle, M., Pallan, L., Pires da Silva, I., Gerard, C., Michielin, O., **Long, G. V.**, Menzies, A. M., Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy, *Eur J Cancer*, **2021 Jun 28**; 153:213-222. doi: 10.1016/j.ejca.2021.04.021. Online ahead of print, PMID 34214936
 165. Gide, T. N., Pires da Silva, I., Quek, C., Ferguson, P. M., Batten, M., Shang, P., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets, *Cancers (Basel)*. **2021 Jun 25**; 13(13):3186. doi: 10.3390/cancers13133186. PMID 34202352
 166. Pires da Silva, I., Ahmed, T., Reijers, I. L. M., Weppeler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., Zimmer, L., Trojaniello, C., Stout, D., Lyle, M., Klein, O., Gerard, C. L., Michielin, O., Haydon, A., Ascierto, P. A., Carlino, M. S., Lebbe, C., Lorigan, P., Johnson, D. B., Sandhu, S., Lo, S. N., Blank, C. U., Menzies, A. M., **Long, G. V.**, Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study, *Lancet Oncol*. **2021 Jun;22** (6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. PMID: 33989557
 167. Li, A. T., Maw, A. M., Hsiao, E., Ch'ng, S., **Long, G. V.**, Shannon, K. F., Morrison, E. J., Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma, *ANZ J Surg*. **2021 Jun 14**. doi: 10.1111/ans.16992. Online ahead of print. PMID 34124833
 168. Ch'ng, S., Uyulmaz, S., Carlino, M. S., Pennington, T. E., Shannon, K. F., Rtshiladze, M., Stretch, J. R., Nieweg, O. E., Varey, A. H. R., Hsiao, E., Kapoor, R., Pires da Silva, I., Lo, S. N., Spillane, A. J., Scolyer, R. A., **Long, G. V.**, Hong, A. M., Saw, R. P. M., Thompson, J. F., Menzies, A. M., Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies, *Eur J Cancer*. **2021 Jun 11**; 153:8-15. doi: 10.1016/j.ejca.2021.04.037. Online ahead of print. PMID 34126335
 169. Parakh, S., Mosafer, A., Paessler, S., Witkowski, T., Suen, Csnlw, Tutuka, C. S. A., Carlino, M. S., Menzies, A. M., Scolyer, R. A., Cebon, J., Dobrovic, A., **Long, G. V.**, Klein, O., Behren, A., PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma, *Front Immunol*. **2021 Jun 9**; 12:672521. doi: 10.3389/fimmu.2021.672521. eCollection 2021, PMID 34177913
 170. Brase, J. C., Walter, R. F. H., Savchenko, A., Gusenleitner, D., Garrett, J., Schimming, T. T., Varaljai, R., Castelletti, D., Kim, J. Y., Dakappagari, N. K., Schultz, K., Robert, C., **Long, G. V.**, Nathan, P. D., Ribas, A., Flaherty, K. T., Karaszewska, B., Schachter, J., Sucker, A., Schmid, K. W., Zimmer, L., Livingstone, E., Gasal, E., Schadendorf, D., Roesch, A., Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib, *Clin Cancer Res*. **2021 Jun 9**; clincanres.3586.2020. doi: 10.1158/1078-0432.CCR-20-3586. Online ahead of print, PMID 34108180
 171. Menzies, A. M., Scolyer, R. A., **Long, G. V.**, Neoadjuvant immunotherapy in melanoma - the new frontier, *Clin Cancer Res*. **2021 Jun 3**; clincanres.1236.2021. doi: 10.1158/1078-0432.CCR-21-1236. Online ahead of print, PMID 34083235

172. Rawson, R. V., Adhikari, C., Bierman, C., Lo, S. N., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., Guminski, A. D., Tetzlaff, M. T., Stretch, J. R., Eriksson, H., van Thienen, J. V., Wouters, M. W., Haanen, Jbag, Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Nieweg, O. E., Ch'ng, S., Rizos, H., Saw, R. P. M., Spillane, A. J., Wilmott, J. S., Blank, C. U., **Long, G. V.**, van de Wiel, B. A., Scolyer, R. A., Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma, *Ann Oncol.* **2021 Jun;3** 2(6):766-777. doi: 10.1016/j.annonc.2021.03.006. Epub 2021 Mar 17, PMID: 33744385
173. Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandala, M., **Long, G. V.**, Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khatkhat, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suci, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial, *Lancet Oncol.* **2021 May 22** (5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. PMID 33857414
174. Knispel, S., Gassenmaier, M., Menzies, A. M., Loquai, C., Johnson, D. B., Franklin, C., Gutzmer, R., Hassel, J. C., Weishaupt, C., Eigentler, T., Schilling, B., Schummer, P., Sirokay, J., Kiecker, F., Owen, C. N., Fleischer, M. I., Cann, C., Kahler, K. C., Mohr, P., Bluhm, L., Niebel, D., Thoms, K. M., Goldinger, S. M., Reinhardt, L., Meier, F., Berking, C., Reinhard, R., Susok, L., Ascierto, P. A., Drexler, K., Pfohler, C., Tietze, J., Heinzerling, L., Livingstone, E., Ugurel, S., **Long, G. V.**, Stang, A., Schadendorf, D., Zimmer, L., Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition, *Eur J Cancer.* **2021 May;14** 8:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub 2021 Mar 15, PMID 33735811
175. Wu, S. Z., Roden, D. L., Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A. S., Chan, C. L., Junankar, S., Hui, M. N., Millar, E. A., Beretov, J., Horvath, L., Joshua, A. M., Stricker, P., Wilmott, J. S., Quek, C., **Long, G. V.**, Scolyer, R. A., Yeung, B. Z., Segara, D., Mak, C., Warriar, S., Powell, J. E., O'Toole, S., Lim, E., Swarbrick, A., Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis, *Genome Med.* **2021 May 10**;13(1):81. doi: 10.1186/s13073-021-00888-z, PMID 33971952
176. Brown, L. J., Weppler, A., Bhawe, P., Allayous, C., Patrinely, J. R., Jr., Ott, P., Sandhu, S., Haydon, A., Lebbe, C., Johnson, D. B., **Long, G. V.**, Menzies, A. A., Carlino, M. S., Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders, *J Immunother Cancer.* **2021 May;9** (5):e002121. doi: 10.1136/jitc-2020-002121, PMID 33963010
177. Versluis, J. M., Hendriks, A. M., Weppler, A. M., Brown, L. J., de Joode, K., Suijkerbuijk, K. P. M., Zimmer, L., Kapiteijn, E. W., Allayous, C., Johnson, D. B., Hepner, A., Mangana, J., Bhawe, P., Jansen, Y. J. L., Trojaniello, C., Atkinson, V., Storey, L., Lorigan, P., Ascierto, P. A., Neyns, B., Haydon, A., Menzies, A. M., **Long, G. V.**, Lebbe, C., van der Veldt, A. A. M., Carlino, M. S., Sandhu, S., van Tinteren, H., de Vries, E. G. E., Blank, C. U., Jalving, M., The Role of Local Therapy in the Treatment of Solitary Melanoma Progression upon Immune Checkpoint Inhibition: A Multicenter Retrospective Analysis; *Eur J Cancer.* **2021 May 7**;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Online ahead of print. PMID 33971447
178. Muir, C. A., Clifton-Bligh, R. J., **Long, G. V.**, Scolyer, R. A., Lo, S. N., Carlino, M. S., Tsang, V. H. M., Menzies, A. M., Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment, *J Clin Endocrinol Metab.* **2021 Apr 20**; dgab263. doi: 10.1210/clinem/dgab263. Online ahead of print. PMID 33878162
179. Park, J. J., Diefenbach, R. J., Byrne, N., **Long, G. V.**, Scolyer, R. A., Gray, E. S., Carlino, M. S., Rizos, H., Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition, *Cancers (Basel).* **2021 Apr 6**; 13(7):1740. doi: 10.3390/cancers13071740, PMID 33917514
180. Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martinez-Vila, C., Wallace, R., Bhawe, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A.,

- Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C. U., Welsh, S. J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J. L., Ascierto, P. A., Zimmer, L., Johnson, D. B., Arance, A., Lorigan, P., Lebbe, C., Carlino, M. S., Sullivan, R. J., **Long, G. V.**, Menzies, A. M., Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma, *Ann Oncol.* **2021 Mar 30**; S0923-7534(21)01101-7. doi: 10.1016/j.annonc.2021.03.204. Online ahead of print, PMID 33798657
181. Patrinely, J. R., Jr., Johnson, R., Lawless, A. R., Bhawe, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., **Long, G. V.**, Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., Johnson, D. B., Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma, *JAMA Oncol.* **2021 Mar 25**. doi: 10.1001/jamaoncol.2021.0051. Online ahead of print. PMID: 33764387
182. F. Dimitriou, **G.V. Long**, A.M. Menzies, Novel adjuvant options for cutaneous melanoma, *Ann Oncol.* **2021 Mar 24**; S0923-7534(21)01077-2. doi: 10.1016/j.annonc.2021.03.198. Online ahead of print, PMID: 33771664
183. Lee, H., Da Silva, I. P., Palendira, U., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Targeting NK Cells to Enhance Melanoma Response to Immunotherapies, *Cancers (Basel)*. **2021 Mar 17**; 13(6):1363. doi: 10.3390/cancers13061363, PMID 33802954
184. Versluis, J. M., Reijers, I. L. M., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Wouters, M. W., Ch'ng, S., Saw, R. P. M., Scolyer, R. A., van de Wiel, B. A., Schilling, B., **Long, G. V.**, Blank, C. U., Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma, *Eur J Cancer.* **2021 Mar 15**;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Online ahead of print, PMID: 33735809
185. Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppner, A., Spain, L., Loquai, C., Dudda, M., Pfohler, C., Hepner, A., **Long, G. V.**, Menzies, A. M., Carlino, M. S., Sachse, M. M., Lebbe, C., Baroudjian, B., Enokida, T., Tahara, M., Schlaak, M., Hayani, K., Brockelmann, P. J., Meier, F., Reinhardt, L., Friedlander, P., Eigentler, T., Kahler, K. C., Berking, C., Zimmer, L., Heinzerling, L., Hematological immune related adverse events after treatment with immune checkpoint inhibitors, *Eur J Cancer.* **2021 Mar 8**;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Online ahead of print. PMID: 33706206
186. Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., Saw, R. P. M., Xu, X., Karakousis, G. C., Ascierto, P. A., Spillane, A. J., van Akkooi, A. C. J., Davies, M. A., Mitchell, T. C., Tawbi, H. A., Scolyer, R. A., Wargo, J. A., Blank, C. U., **Long, G. V.**, Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) *Nat Med.* **2021 Feb**;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. PMID 33558722
187. Garg, M., Couturier, D. L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jonsson, G. B., Newton-Bishop, J., Parkinson, C., Middleton, M. R., Bishop, D. T., McDonald, S., Stefanos, N., Tadross, J., Vergara, I. A., Lo, S., Newell, F., Wilmott, J. S., Thompson, J. F., **Long, G. V.**, Scolyer, R. A., Corrie, P., Adams, D. J., Brazza, A., Rabbie, R., Tumour gene expression signature in primary melanoma predicts long-term outcomes, *Nat Commun.* **2021 Feb 18**;12(1):1137. doi: 10.1038/s41467-021-21207-2, PMID 33602918
188. Olofsson Bagge, R., Ny, L., Ascierto, P. A., Hodi, F. S., Larkin, J., Robert, C., Schachter, J., Weber, J. S., **Long, G. V.**, van Akkooi, A. C. J., The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials, *Melanoma Res.* **2021 Feb 18**. doi: 10.1097/CMR.0000000000000719. Online ahead of print, PMID: 33625104
189. Kelly, G. M., Al-Ejeh, F., McCuaig, R., Casciello, F., Ahmad Kamal, N., Ferguson, B., Pritchard, A. L., Ali, S., Silva, I. P., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A., Rao, S., Hayward, N. K., Gannon, F., Lee, J. S., G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma, *Clin Cancer Res.* **2021 Feb 15**. doi: 10.1158/1078-0432.CCR-20-3463. Online ahead of print. PMID: 33589432
190. Syeda, M. M., Wiggins, J. M., Corless, B. C., **Long, G. V.**, Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., Grob, J. J., Gasal, E., Squires, M., Marker, M., Garrett, J., Brase, J. C., & Polsky, D. (2021). Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study, *Lancet Oncol.* **2021 Feb 12**;S1470-2045(20)30726-9. doi: 10.1016/S1470-2045(20)30726-9. Online ahead of print, PMID: 33587894
191. Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A.,

- Grijpink-Ongering, L. G., Shannon, K., Haanen, J., Stretch, J., Ch'ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., **Long, G. V.**, & Blank, C. U. (2021). Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma, *Nat Med.* **2021 Feb 8**. doi: 10.1038/s41591-020-01211-7. Online ahead of print. PMID 33558721
192. Patrinely, J. R., Jr., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., Scoville, E. A., **Long, G. V.**, Shi, C., Mehnert, J. M., Sullivan, R. J., Salama, A. K., Sosman, J. A., Menzies, A. M., Johnson, D. B., A multicenter characterization of hepatitis associated with immune checkpoint inhibitors, *Oncoimmunology*, . **2021 Feb 8**;10(1):1875639. doi: 10.1080/2162402X.2021.1875639. PMID 33628621
 193. Simpson, R. C., Shanahan, E., Scolyer, R. A., & **Long, G. V.** Targeting the Microbiome to Overcome Resistance, *Cancer Cell.* **2021 Feb 8**;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016 PMID 33561397
 194. Vergara, I. A., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape, *Exp Dermatol.* **2021 Jan 17**. doi: 10.1111/exd.14287. Online ahead of print. PMID: 33455025
 195. Rabbie, R., Ferguson, P., Wong, K., Couturier, D. L., Moran, U., Turner, C., Emanuel, P., Haas, K., Saunus, J. M., Davidson, M. R., Lakhani, S. R., Shivalingam, B., **Long, G. V.**, Parkinson, C., Osman, I., Scolyer, R. A., Corrie, P., & Adams, D. J. (2020). The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence, *Br J Cancer.* **2021 Jan**;124(1):156-160. doi: 10.1038/s41416-020-01090-2. Epub 2020 Oct 7 PMID 33024263
 196. Rogiers, A., Pires da Silva, I., Tentori, C., Tondini, C. A., Grimes, J. M., Trager, M. H., Nahm, S., Zubiri, L., Manos, M., Bowling, P., Elkrief, A., Papneja, N., Vitale, M. G., Rose, A. A. N., Borgers, J. S. W., Roy, S., Mangana, J., Pimentel Muniz, T., Cooksley, T., Lupu, J., Vaisman, A., Saibil, S. D., Butler, M. O., Menzies, A. M., Carlino, M. S., Erdmann, M., Berking, C., Zimmer, L., Schadendorf, D., Pala, L., Queirolo, P., Posch, C., Hauschild, A., Dummer, R., Haanen, J., Blank, C. U., Robert, C., Sullivan, R. J., Ascierto, P. A., Miller, W. H., Jr., Stephen Hodi, F., Suijkerbuijk, K. P. M., Reynolds, K. L., Rahma, O. E., Lorigan, P. C., Carvajal, R. D., Lo, S., Mandala, M., & **Long, G. V.** (2021). Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition, *J Immunother Cancer.* **2021 Jan**;9(1):e001931. doi: 10.1136/jitc-2020-001931, PMID 33468556
 197. Mangantig, E., MacGregor, S., Iles, M. M., Scolyer, R. A., Cust, A. E., Hayward, N. K., Montgomery, G. W., Duffy, D. L., Thompson, J. F., Henders, A., Bowdler, L., Rowe, C., Cadby, G., Mann, G. J., Whiteman, D. C., **Long, G. V.**, Ward, S. V., Khosrotehrani, K., Barrett, J. H., & Law, M. H. (2021). Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. *Hum Mol Genet.* **2021 Jan 6**;29(21):3578-3587. doi: 10.1093/hmg/ddaa222, PMID 33410475
 198. Robert, C., Hwu, W. J., Hamid, O., Ribas, A., Weber, J. S., Daud, A. I., Hodi, F. S., Wolchok, J. D., Mitchell, T. C., Hersey, P., Dronca, R., Joseph, R. W., Boutros, C., Min, L., **Long, G. V.**, Schachter, J., Puzanov, I., Dummer, R., Lin, J., Ibrahim, N., Diede, S. J., Carlino, M. S., & Joshua, A. M. (2020). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma, *Eur J Cancer.* **2020 Dec 23**;144:182-191. doi: 10.1016/j.ejca.2020.11.010. Online ahead of print. PMID 33360855
 199. Papadopoulos, K. P., Autio, K. A., Golan, T., Dobrenkov, K., Chartash, E., Chen, Q., Wnek, R., & **Long, G. V.** (2020). Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors, *Clin Cancer Res.* **2020 Dec 21**;clincanres.2886.2020. doi: 10.1158/1078-0432.CCR-20-2886. Online ahead of print, PMID 33355238
 200. Ferrucci, P. F., Di Giacomo, A. M., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., **Long, G. V.**, Stephens, R., Svane, I. M., Lotem, M., Abu-Amna, M., Gasal, E., Ghorri, R., Diede, S. J., Croydon, E. S., Ribas, A., Ascierto, P. A., & team, K.-i. (2020). KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. *J Immunother Cancer,* **2020 Dec**;8(2):e001806. doi: 10.1136/jitc-2020-001806 PMID: 33361337
 201. Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P,

- Scolyer RA, Kapiteijn EW, Peeper DS, **Long GV**, Schumacher TNM, Blank CU, Comprehensive analysis of cutaneous and uveal melanoma live metastases, *J Immunother Cancer*. **2020 Dec**;8(2):e001501. doi: 10.1136/jitc-2020-00150, PMID: 33262254
202. Smith AL, Watts CG, Robinson S, Schmid H, Goumas C, Mar VJ, Thompson JF, Rapport F, Australian Melanoma Centre of Research Excellence Study Group*, *Braithwaite J, *Gyorki DE, *Henderson M *Hong AM, *Kelly JW, ***Long GV**, *Menzies A, *Morton RL, *Saw RPM, *Scolyer RA, *Spillane AJ, *Mann GJ Cust AE, Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study, *Australas J Dermatol*. **2020 Dec 5**. doi: 10.1111/ajd.13518. Online ahead of print. PMID: 33277693
203. Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., Vu, K. A., Ma, J., Ning, J., Haydu, L. E., Saw, R. P. M., Wargo, J. A., Tawbi, H. A., Gershenwald, J. E., **Long, G. V.**, Davies, M. A., & Scolyer, R. A. Histopathologic features of complete pathologic response predict recurrence free survival following neoadjuvant targeted therapy for metastatic melanoma, *Ann Oncol*. **2020 Nov**;30(11):1569-1579. doi: 10.1016/j.annonc.2020.07.016. Epub 2020 Jul 31 PMID: 32739408
204. Eggermont AMM, Blank CU, Mandala M, **Long GV**, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciú S, Robert C, Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: new results from the EORTC1325-MG/Keynote 054 trial, *J Clin Oncol*. **2020 Nov 20**;38(33):3925-3936. doi: 10.1200/JCO.20.02110. Epub 2020 Sep 18, PMID32946353
205. Hong, A. M., Waldstein, C., Shivalingam, B., Carlino, M. S., Atkinson, V., Kefford, R. F., McArthur, G. A., Menzies, A. M., Thompson, J. F., & **Long, G. V.** (2020). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia, *Eur J Cancer*, **2020 Nov 15**;142:10-17. doi: 10.1016/j.ejca.2020.10.013. Online ahead of print PMID: 33207293
206. Geva, R., Voskoboynik, M., Dobrenkov, K., Mayawala, K., Gwo, J., Wnek, R., Chartash, E., & **Long, G. V.** (2020). First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors, *Cancer*. **2020 Nov 15**; 126(22):4926-4935. doi: 10.1002/cncr.33133. Epub 2020 Aug 18, PMID 32809217
207. Marsavela, G. Lee, J., Calapre, L., Wong, S. Q., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Abed, A., Khattak, M. A., Meniawy, T. M., Dawson, S. J., Sandhu, S., Carlino, M. S., Menzies, A. M., Scolyer, R. A., **Long, G. V.**, Amanuel, B., Millward, M., Ziman, M. R., Rizos, H., Gray, E. S., Circulating Tumor DNA Predicts Outcome from First, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy, *Clin Cancer Res*. **2020 Nov 15**; 26(22):5926-5933. doi: 10.1158/1078-0432.CCR-20-2251. Epub 2020 Oct 16. PMID 33067256
208. Shklovskaya, E., Lee, J. H., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P., Saw, R. P., Thompson, J. F., Shivalingam, B., Carlino, M. S., Scolyer, R. A., Menzies, A. M., **Long, G. V.**, Kefford, R. F., & Rizos, H. (2020). Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma, *Cancers*, **2020 Nov 14**, doi.org/10.3390/cancers12113374 PMID 33202676
209. Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino, Palendira U, Scolyer RA, **Long GV**, Menzies AM, Clinicopathological characteristics and management of colitis with anti- PD1 immunotherapy alone or in combination with ipilimumab, *J Immunother Cancer*. **2020 Nov**;8(2):e001488. doi: 10.1136/jitc-2020-001488 PMID 33234603
210. Clarke ME, Rizos H, Pereira MR, McEvoy AC, Marsavela G, Calapre L, Mehan K, Ruhen O, Khattak MA, Meiniawy TM, **Long GV**, Carlino MS, Menzies AM, Millward M, Ziman M, Gray ES, Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies, *Oncotarget* **2020 Nov 3**;11(44):4016-4027. doi: 10.18632/oncotarget.27790, PMID: 33216826

211. Dey, A., Manolios, N., **Long, G. V.**, Carlino, M. S., Kefford, R., & Schrieber, L. (2020). Musculoskeletal immune-related adverse events with use of checkpoint inhibitors in malignancy, *Intern Med J.* **2020 Nov 2**. doi: 10.1111/imj.15123. Online ahead of print. PMID: 33135853
212. Dummer, R., Lebbe, C., Atkinson, V., Mandala, M., Nathan, P. D., Arance, A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., Tawbi, H. A., Ascierto, P. A., Ribas, A., Flaherty, K. T., Pakhle, N., Campbell, C. D., Gusenleitner, D., Masood, A., Brase, J. C., Gasal, E., & **Long, G. V.** (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i, *Nat Med.* **2020 Oct;26**(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5. PMID 33020648
213. Bhave, P., Pallan, L., **Long, G. V.**, Menzies, A. M., Atkinson, V., Cohen, J. V., Sullivan, R. J., Chiarion-Sileni, V., Nyakas, M., Kahler, K., Hauschild, A., Plummer, R., Trojaniello, C., Ascierto, P. A., Zimmer, L., Schadendorf, D., Allayous, C., Lebbe, C., Maurichi, A., Santinami, M., Roy, S., Robert, C., Lesimple, T., Patel, S., Versluis, J. M., Blank, C. U., Khattak, A., Van der Westhuizen, A., Carlino, M. S., Shackleton, M., & Haydon, A. (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis, *Br J Cancer*, **2020 Oct 22**. doi: 10.1038/s41416-020-01121-y. Online ahead of print. PMID 33087895
214. Newell, F., Wilmott, J. S., Johansson, P. A., Nones, K., Addala, V., Mukhopadhyay, P., Broit, N., Amato, C. M., Van Gulick, R., Kazakoff, S. H., Patch, A. M., Koufariotis, L. T., Lakis, V., Leonard, C., Wood, S., Holmes, O., Xu, Q., Lewis, K., Medina, T., Gonzalez, R., Saw, R. P. M., Spillane, A. J., Stretch, J. R., Rawson, R. V., Ferguson, P. M., Dodds, T. J., Thompson, J. F., **Long, G. V.**, Levesque, M. P., Robinson, W. A., Pearson, J. V., Mann, G. J., Scolyer, R. A., Waddell, N., & Hayward, N. K. (2020). Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. *Nat Commun.* **2020 Oct 16**;11(1):5259. doi: 10.1038/s41467-020-18988-3. PMID: 33067454
215. Braun, M., Aguilera, A. R., Sundarajan, A., Corvino, D., Stannard, K., Krumeich, S., Das, I., Lima, L. G., Meza Guzman, L. G., Li, K., Li, R., Salim, N., Jorge, M. V., Ham, S., Kelly, G., Vari, F., Lepletier, A., Raghavendra, A., Pearson, S., Madore, J., Jacquelin, S., Effern, M., Quine, B., Koufariotis, L. T., Casey, M., Nakamura, K., Seo, E. Y., Holzel, M., Geyer, M., Kristiansen, G., Taheri, T., Ahern, E., Hughes, B. G. M., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A., Batstone, M. D., Landsberg, J., Dietrich, D., Pop, O. T., Flatz, L., Dougall, W. C., Veillette, A., Nicholson, S. E., Moller, A., Johnston, R. J., Martinet, L., Smyth, M. J., & Bald, T. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells, *Immunity*, **2020 Oct 13**, 53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010 PMID33053330
216. Fischer, G. M., Carapeto, F. C. L., Joon, A. Y., Haydu, L. E., Chen, H., Wang, F., Van Arnem, J. S., McQuade, J. L., Wani, K., Kirkwood, J. M., Thompson, J. F., Tetzlaff, M. T., Lazar, A. J., Tawbi, H. A., Gershenwald, J. E., Scolyer, R. A., **Long, G. V.**, & Davies, M. A. (2020). Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker, *Cancer Med.* **2020 Oct 5**. doi: 10.1002/cam4.3474. Online ahead of print. PMID 33016647
217. Carlino, M. S., Menzies, A. M., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., Hwu, W. J., Hodi, F. S., Guminski, A. D., Kefford, R., Wu, H., Ibrahim, N., Homet Moreno, B., & **Long, G. V.** (2020). Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B *Clin Cancer Res.* **2020 Oct 1;26**(19):5086-5091. doi: 10.1158/1078-0432.CCR-20-0177. Epub 2020 Jun 30.
218. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, **Long GV**. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. *J Clin Oncol.* **2020 Sep 30**;JCO2000995. doi: 10.1200/JCO.20.00995. Online ahead of print. PMID 32997575
219. Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Gasal, E., Tan, M., **Long, G. V***, & Schadendorf, D*. (2020). Five-Year

- Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma., *N Engl J Med.* **2020 Sep 17**;383(12):1139-1148. doi: 10.1056/NEJMoa2005493. Epub 2020 Sep 2. PMID: 32877599
220. Attrill, G. H., Ferguson, P. M., Palendira, U., **Long, G. V.**, Wilmott, J. S., & Scolyer, R. A. (2020). The tumour immune landscape and its implications in cutaneous melanoma a, *Pigment Cell Melanoma Res.* **2020 Sep 16**. doi: 0.1111/pcmr.12926 Online ahead of print. PMID 32939993
 221. Edwards, J., Ferguson, P. M., Lo, S. N., Pires da Silva, I., Colebatch, A. J., Lee, H., Saw, R. P. M., Thompson, J. F., Menzies, A. M., **Long, G. V.**, Newell, F., Pearson, J. V., Waddell, N., Hayward, N. K., Johansson, P. A., Mann, G. J., Scolyer, R. A., Palendira, U., & Wilmott, J. S. (2020). Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas, *Cancer Immunol Res.* **2020 Sep 11**; canimm.0835.2019. doi: 10.1158/2326-6066.CIR-19-0835. Online ahead of print PMID: 32917657
 222. Ascierto, P. A., Puzanov, I., Agarwala, S. S., Blank, C., Carvajal, R. D., Demaria, S., Dummer, R., Ernstoff, M., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Hwu, P., Lo, R. S., **Long, G. V.**, Luke, J. J., Osman, I., Postow, M. A., Sullivan, R. J., Taube, J. M., Trinchieri, G., Zarour, H. M., Caraco, C., & Thurin, M. (2020). Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy), **7 Sept 2020**, published, DOI: 10.1186/s12967-020-02482-x, PMID: 32894202
 223. Hultin, S., Nahar, K., Menzies, A. M., **Long, G. V.**, Fernando, S. L., Atkinson, V., Cebon, J., & Wong, M. G. (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report, *BMC Nephrology*, **7 Sept 2020**, DOI: 10.1186/s12882-020-02044-9, PMID: 32894101
 224. Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM*, **Long GV*** Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy, *Ann Oncol* **2020 Aug**;31(8):1075-1082. doi: 10.1016/j.annonc.2020.04.471. Epub 2020 May 6. PMID: 32387454
 225. Diefenbach, R. J., Lee, J. H., Menzies, A. M., Carlino, M. S., **Long, G. V.**, Saw, R. P. M., Howle, J. R., Spillane, A. J., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2020). Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA, *Cancers (Basel)* **2020 Aug 10**;12(8):E2228. doi: 10.3390/cancers12082228, PMID 32785074
 226. Puzanov I, Ribas A, Robert C, Schachter J, Nyakas N, Daud A, Blank CU, Arance A, Carlino MS, O'Day SJ, **Long GV**, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Moreno BH, Ibrahim N. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. *JAMA Oncol.* **2020 Aug 1**;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288. PMID 32672795
 227. Menzies AM, Carlino MS, McEvoy AC, Sandhu A, Weppeler AM, Diefenback RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili S, Tra T, Gray ES, Wong SQ, Scolyer RA, **Long GV**, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. *Clin Cancer Res.* **2020 Aug 1**;26(15):4064-4071. doi: 10.1158/1078-0432.CCR-19-3926. Epub 2020 Apr 22. PMID 3231716
 228. Puzanov, I., Ribas, A., Robert, C., Schachter, J., Nyakas, M., Daud, A., Arance, A., Carlino, M. S., O'Day, S. J., **Long, G. V.**, Margolin, K. A., Dummer, R., Schadendorf, D., Lutzky, J., Ascierto, P. A., Tarhini, A., Lin, J., Mogg, R., Homet Moreno, B., Ibrahim, N., & Hamid, O. (2020). Association of BRAFV600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of Three Clinical Trials *JAMA Oncol.* **2020 Aug 1**;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288, PMID: 32672795
 229. SC. Sasson*, JJ. Zaunders, K. Nahar, C. Mee-Ling Munier, BP. Fairfax, S. Danielli, A. Olsson-Brown, Cc Jolly, SA. Read, G. Ahlenstiel, U. Palendira, RA. Scolyer, MS. Carlino, MJ. Payne, VTF. Cheung, T. Gupta, P Klenerman, **GV. Long**, O. Brain#, AM. Menzies, AD. Kelleher# Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis, *Clin Exp Immunol.* **2020 Jul 31**. doi: 10.1111/cei.13502. Online ahead of print PMID: 32734627

230. Khushalani, N. I., Diab, A., Ascierto, P. A., Larkin, J., Sandhu, S., Sznol, M., Koon, H. B., Jarkowski, A., Zhou, M., Statkevich, P., Geese, W. J., & **Long, G. V.** (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design, *Future Oncol.* **2020 Jul 29**. doi: 10.2217/fon-2020-0351. Online ahead of print. PMID: 32723187
231. Grossman D, Bar-Eli M., Bartlett EK, Berry E, Berwick M, Bowen GM, Bowles T, Buchbinder EI, Burton E, Chu EY., Coit DG, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon D, Ferris LK, Gershenwald JE, Grossmann KF, Hartman RI, Hu-Lieskovan S, Hyingstrom J, Jeter JM, Judson-Torres R, Karakousis GC, Kendra KL, Korde L, Lawson DH, Leachman SA, Lee S, Leming PD, **Long GV**, Kim CC, Kirkwood JM, Marchetti MA, Mehnert JM, Ming ME, Nelson KC, Okwundu N, Othus M, Polsky D, Scolyer RA, Smith EA, Sondak V, Stark M, Thompson JA, Thompson JF, Wei ML, Swetter SM. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. *JAMA Dermatology* **29 July 2020** DOI: 10.1001/jamadermatol.2020.1729 PMID: 32725204
232. MH Law, LG Aoude, DL Duffy, **GV Long**, PA Johannson, AL Pritchard, K Khosrotehani, GJ Mann, GW Montgomery, MM Iles, AE Cust, J Palmer, Melanoma GWAS Consortium, KF Shannon, AJ Spillane, JR Stretch, JF Thompson, RPM Saw, RA Scolyer, NG Martin, NK Hayward, S MacGregor Multiplex melanoma families are enriched for polygenic risk colour figures : Yes, *Hum Mol Genet.* **2020 Jul 27**;ddaa156. doi: 10.1093/hmg/ddaa156. Online ahead of print
233. Barnhill R, van Dam PJ, Vermeulen P, Champenois G, Nicolas A, Rawson RV, Wilmott JS, Thompson JF, **Long GV**, Cassoux N, Roman-Roman S, Busam KJ, Scolyer RA, Lazar AJ, Lugassy C. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value, *J Pathol Clin Research*, **2020 Jul**;6 (3):195-206. doi: 10.1002/cjp2.161. Epub 2020 Apr 18, PMID: 32304183
234. Gide T, Silva IP, Quek C, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Batten M, **Long GV**, Scolyer RA, Wilmott JS. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. *Oncoimmunology.* **2019 Oct 16**;9(1):1659093. doi: 10.1080/2162402X.2019.1659093. PMID32002281
235. **GV Long** and RA Scolyer. Translating Basic Cancer Discoveries to the Clinic. Feature Article: A Critical Nexus. *Cancer cell*, **8 June 2020**, Vol.37(6), pp.735-737. DOI:https://doi.org/10.1016/j.ccell.2020.05.017. PMID: 32516583
236. Cipponi A, Goode DL, Bedo J, Croucher DR, McCabe MJ, Rajal AG, Saunders DN, Lobachevsky P, Junanakar SR, Papenfuss AT, Pajic M, Nessen D, Nobis M, Warren SC, Timpson P, Cowley M, Vargas AC, Qiu MR, Generali DG, Keerthikumar S, Nguyen U, Corcoran NM, **Long GV**, Blay LY, Thomas DM. MTOR Signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancers. *Science.* **2020 Jun 5**;368(6495):1127-1131. doi: 10.1126/science.aau8768. PMID 32499442
237. Watts, C. G., Smith, A. L., Robinson, S., Chang, C. S., Goumas, C., Schmid, H., Kelly, J. W., Hong, A. M., Scolyer, R. A., **Long, G. V.**, Spillane, A. J., Henderson, M., Gyorki, D. E., Mar, V. J., Morton, R. L., Saw, R. P., Varey, A. H., Mann, G. J., Thompson, J. F., Cust, A. E., Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management, *Aust J Gen Pract*, **2020 Jun**;4 9(6):355-362. doi: 10.31128/AJGP-10-19-5138. PMID: 32464734
238. Tsang V, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, **Long GV**, Menzies AM, Response to Letter to the Editor for “Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes”. *J Clin Endocrinol Metab.* **2020 Jun 1**;105(6). pii: dgaa144. doi: 10.1210/clinem/dgaa144. PMID 32188993.
239. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Jakrot V, Scolyer RA, Guminski AD, **Long GV**, Menzies AM. Response to Letter to the Editor: “Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes”.. *J Clin Endocrinol Metab.* **2020 Jun 1**;105(6). pii: dgaa144. doi: 10.1210/clinem/dgaa144. PMID32188993
240. Johannson, P. A., Brooks, K., Newell, F., Palmer, J. M., Wilmott, J. S., Pritchard, A. L., Broit, N., Wood, S., Carlino, M. S., Leonard, C., Koufariotis, L. T., Nathan, V., Beasley, A. B., Howlie, M., Dawson, R., Rizos, H., Schmidt, C. W., **Long, G. V.**, Hamilton, H., Kiilgaard, J. F., Isaacs, T., Gray, E. S., Rolfe, O. J., Park, J. J., Stark, A., Mann, G. J., Scolyer, R. A., Pearson, J. V., van Baren, N., Waddell, N., Wadt, K. W., McGrath, L. A., Warriar, S. K., Glasson, W., & Hayward, N. K. (2020). Whole genome landscapes

- of uveal melanoma show a role for ultraviolet radiation in iris tumours, *Nature Communications*, **2020 May 15**;11(1):2408. doi: 10.1038/s41467-020-16276-8, PMID: 32415113
241. Siemys A, Kim MS, Menzies A, Willmott J, **Long GV**, Scolyer RA, Kwong LN, Holder AM, Boland GM. Integration of Digital Pathologic and Transcriptomic Analyses Connect Tumor-Infiltrating Lymphocyte Spatial Density with Clinical Response to BRAF Inhibitors. *Frontiers in Oncology* **2020 May 14**;10:757. doi: 10.3389/fonc.2020.00757. eCollection 2020, PMID: 32528881
242. Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, **Long GV**, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition – Update 2019 - *Eur J Cancer*. **2020 May**;13 0:126-138. doi: 10.1016/j.ejca.2020.02.021. Epub 2020 Mar 13, PMID 32179447
243. Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočevár M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, **Long GV**, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA; GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; 23andMe; SDH Study Group; IBD Investigators; Essen-Heidelberg Investigators; AMFS Investigators; MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH. Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility. *Nat Genet*. **2020 May**;52(5):494-504. doi: 10.1038/s41588-020-0611-8. Epub 2020 Apr 27 PMID:32341527
244. Haydu LE, Lo S, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza I, Tawbi H, Carlino MS, Menzies AM, **Long GV**, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma *J Clin Oncol*. **2020 May 1**;38(13):1429-1441. doi: 10.1200/JCO.19.01508. Epub 2020 Jan 28, PMID31990608
245. Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Willmott JS, Menzies AM, Leduc C, Stagg J, Routy B, **Long GV**, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. *Clin Cancer Res*. **28 Apr 2020**. pii: clincanres.3925.2019. doi: 10.1158/1078-0432.CCR-19-3925. PMID: 32345648
246. Versluis JM, **Long GV**, Blank CU. Learning from Clinical Trials of neoadjuvant checkpoint blockade. *Nature Medicine* Published **26 April 2020**. 10.1038/s41591-020-0829-0. PMID 32273608
247. Lee JH, Menzies AM, Carlino MS, Mcevoy AC, Sandhu S, Wepler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili S, Tra T, Gray ES, Wong SQ, Scolyer RS, **Long GV**, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. **22 April 2020** *Clin Cancer Res*. doi: 10.1158/1078-0432.CCR-19-3926 PMID 32321716

248. Lee J, Shklovskaya E, Yin Lim S, Carlino M, Menzies A, Stewart A, Pedersen B, Irvine M, Alavi S, Yang J, Strbenac D, Saw R, Thompson J, Wilmott J, Scolyer R, **Long GV**, Kefford R, Rizos H. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. *Nat Commun.* **2020 Apr 20**;11(1):1897. doi: 10.1038/s41467-020-15726-7. PMID 32312968
249. McKelvey, K. J., Hudson, A. L., Prasanna Kumar, R., Wilmott, J. S., Attrill, G. H., **Long, G. V.**, Scolyer, R. A., Clarke, S. J., Wheeler, H. R., Diakos, C. I., & Howell, V. M. (2020). Temporal and spatial modulation of the tumor and systemic immune response in the murine G1261 glioma model. *PLoS One.* **2020 Apr 2**;15(4):e0226444. doi: 10.1371/journal.pone.0226444. PMID 32240177
250. Wang DY, McQuade JL; Rai RR, Park JJ, Zhao S, Ye F, Beckermann KE, Rubinstein SM; Johnpulle RA, **Long GV**, Carlino MS, Menzies AM, Davies MA, Johnson DB. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. *The Oncologist* **2020 Mar**;25(3):e602-e605. doi: 10.1634/theoncologist.2019-0518. Epub 2019 Nov 29 PMID: 32162820
251. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, **Long GV**. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. *Lancet Onc. Lancet Oncol.* **2020 Mar**;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. PMID32007138
252. Pirozyan MR, McGuire HM, Al Emran A, Tseng H, Tiffen JC, Lee JH, Carlino MS, Menzies AM, **Long GV**, Scolyer RA, Fazekas de St Groth B, Hersey P. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. *Front Immunol.* **2020 Mar 10**; 11:372. doi: 10.3389/fimmu.2020.00372. PMID 32210968
253. Rapport F, Smith AL, Cust AE, Mann GJ, Watts CG, Gyorki DE, Henderson M, Hong AM, Kelly JW, **Long GV**, Mar VJ, Morton RL, Saw RP, Scolyer RA, Spillane AJ, Thompson JF, Braithwaite J. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. **27 Feb 2020** *BMJ Open.* doi: 10.1136/bmjopen-2019-032636. PMID 32111612
254. Eggermont AMM; Kicinski M; Blank CU; Mandala M; **Long GV** Atkinson V, Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial, *JAMA Oncol*, **2 Jan 2020** doi: 10.1001/jamaoncol.2019.5570. PMID 31895407
255. Luke J, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, **Long GV**, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, Eggermont AMM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. *Future Oncol.* E-published **24 December 2019**, 16(3), 4429–4438. DOI: 10.2217/fo-2019-0666, PMID: 31870188
256. Diefenbach, R. J., Lee, J. H., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., **Long, G. V.**, Spillane, A. J., Stretch, J. R., Saw, R. P. M., Thompson, J. F., Ch'ng, S., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2019). Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. *Cancers (Basel).* **2019 Nov 29**;11(12). pii: E1905. doi: 10.3390/cancers11121905. PMID 31795494
257. Atkinson V, Sandhu S, Hospers G, **Long GV**, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Sayed Ali, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). *Epub ahead of print. Melanoma Res.* **2020 Jun**;30, doi: 10.1097/CMR.0000000000000654. PMID31895752
258. Diefenbach RJ, Lee JH, Chandler D, Wang Y, Pflueger C, **Long GV**, Scolyer RA, Carlino MS, Menzies AMM, Kefford RF, Rizos H. Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. *Applied sciences.* **2019**,

259. Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, **Long GV**, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. *J Clin Oncol*. **2019 Nov 20**;37(33):3132-3141. doi: 10.1200/JCO.19.01414. PMID31553661
260. Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, **Long GV**, Menzies AM. Site-Specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti-PD-1 Therapy. *Cancer*. **2020 Jan 1**;126(1):86-97. doi: 10.1002/cncr.32522. PMID31584722
261. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, **Long GV**, Wilmott JS, Loi S, Darcy PK, Beavis PA. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clin Cancer Res*. **2020 Jan 15**;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. PMID31636098
262. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms K, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, **Long GV**, Kefford R, Enk A, Blank CU, Hassel JC. Targeted therapy in advanced melanoma with rare BRAF mutations. *J Clin Oncol*. **2019 Nov 20**;37(33):3142-3151. doi: 10.1200/JCO.19.0048. PMID31580757.
263. Mason R, Dearden HC, Nguyen B, Oon JS, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, **Long GV**, Carlino MS, Millward M, Atkinson VG, Menzies AM. Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. *Pigment Cell Melanoma Res*. **2020 Mar**;33(2):358-365. doi: 10.1111/pcmr.12831. PMID31587511.
264. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao CD, Cowey L, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, **Long GV**, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi S, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med*. **2019 Oct 17**;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. PMID31562797.
265. **Long GV**, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. *Lancet Oncol*. **2019 Jul**;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. PMID31171444
266. **Long GV**, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncol*. **2019 Aug**;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. PMID31221619
267. Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., Gogas, H., Mandala, M., Haanen, J., Lebbe, C., Mackiewicz, A., Rutkowski, P., Nathan, P. D., Ribas, A., Davies, M. A., Flaherty, K. T., Burgess, P., Tan, M., Gasal, E., Voi, M., Schadendorf, D., & **Long, G. V.** (2019). Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, *N Engl J Med*. **2019 Aug 15**;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4, PMID: 31166680
268. Colebatch AJ, Ferguson P, Newell F, Kazakoff S, Witkowski T, Dobrovic A, Johansson PA, Menzies AM, Saw R, Stretch J, McArthur G, **Long GV**, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS. Molecular genomic profiling of melanocytic nevi. *J Invest Dermatol*. **2019 Aug**;13. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14. PMID 30772300

269. Newel F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Liang Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane A, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. *Nat Commun.* 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107. PMID31320640
270. Zhang X, Zhong Tang J, Vergara I, Fang Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell K, Shaw E, Rizos H, Long GV, Hayward N, McArthur G, Papenfuss A, Harvey K, Shackleton M. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. *Mol Cancer Res* 2018. *Mol Cancer Res.* 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4. PMID 30833299
271. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suci S, Robert C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *Eur J Cancer.* 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. PMID31200321
272. Ascierto PA, Ferrucci PF, Fisher R Del Vecchio, M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat Med.* 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6 PMID: 31171878
273. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol* 2019; 20(9):1239-1251
274. Johnson DB, McDonnell WJ, Ericsson-Gonzalez PI, Al-Rohil R, Mobley BC, Salem J-E, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem J, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger S, Rushing E, Buchbinder E, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. *Nature Med* 2019; 25(8):1243-1250.
275. Ipenburg NA, Nieweg O, Ahmed T, van Doorn R, Scolyer RA, Long GV, Thompson JF, Lo S. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. *Br J Surg.* 2019 Sep;106(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16, PMID: 31310333
276. Amaria RN, Menzies A, Burton EM, Van Akkooi A, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty K, Gershenwald JE, Hamid O, Hong A, Kirkwood J, Lo S, Margolin K, Messina J, Postow M, Rizos H, Ross MI, Rozeman L, Saw R, Scolyer R, Sondak V, Spillane A, Sullivan RJ, Taube J, Tetzlaff MT, Thompson J, Van de Weil B, Davies JMA, Wargo JA, Blank CU, Tawbi H, Long GV. Shaping the Future of Neoadjuvant Systemic Therapy in Melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol.* 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8 PMID 31267972
277. Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A. Reply to E. Hindicé and K.R. Hess. *J Clin Oncol.* 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. PMID 30939092

278. Gide, T. N., Allanson, B. M., Menzies, A. M., Ferguson, P. M., Madore, J., Saw, R. P. M., Thompson, J. F., **Long, G. V.**, Wilmott, J. S., & Scolyer, R. A. (2019). Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. *Histopathology*. **2019 May**;74(6):817-828. doi: 10.1111/his.13814, PMID: 30589949
279. **Long GV**. Making a difference to many. *Nat Med*. March **2019**;25(3):356.
280. **Long GV**, Gasal E, Hauschild A. Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply. *N Engl J Med*. April **2019**;380(14):1376-7.
281. Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hojbjergs L, Schmidt H, van Thiene JV, Haanen Jbag, Tiainen L, Svane IM, Makela S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, **Long GV**, Atkinson V, Blank CU, Neyns B. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. *Ann Oncol*. March **2019**.
282. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall, V L J, Liu C, Bettington M. L, Takeda K, **Long GV**, Scolyer R. A, Lan R, Siemers N, Korman A, Teng MWL, Johnston R. J, Dougall WC, Smyth, M J. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. *Cancer Immunol Res*. **2019 Apr**;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20. PMID: 30894377
283. Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., Broeks, A., van Thienen, J. V., Guminski, A. D., Acosta, A. T., Ter Meulen, S., Koenen, A. M., Bosch, L. J. W., Shannon, K., Pronk, L. M., Gonzalez, M., Ch'ng, S., Grijpink-Ongering, L. G., Stretch, J., Heijmink, S., van Tinteren, H., Haanen, J., Nieweg, O. E., Klop, W. M. C., Zuur, C. L., Saw, R. P. M., van Houdt, W. J., Peeper, D. S., Spillane, A. J., Hansson, J., Schumacher, T. N., **Long, G. V.**, & Blank, C. U. (2019). Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol*. **2019 Jul**;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. PMID: 31160251
284. Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, **Long GV**, Mann GJ, Scolyer RA, Wilmott JS. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. *Oncotarget*. Jan **2019**;10(9):930-41.
285. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SM, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM., **Long GV**, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. *Pigment Cell Melanoma Res*. **2019**. 32(4):553-563
286. Heinzerling L, Ascierto PA; Dummer R, GogasH, Grob JJ, Lebbe C, **Long GV**, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0- Let's get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology. *Eur J Cancer*. **2019 May**;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. PMID: 30903870
287. Edwards J, Batten M, Ferguson A, Palendira U, Wilmott JS, **Long GV**, Scolyer RA. Novel immune targets in melanoma – Response. *Clin Cancer Res* Sept **2019**. 25:5254-5425.
288. Edwards JJ, Tasker A, Silva I, Quek C, Batten M, Ferguson AL, Allen R, Allanson BM, Saw RP, Thompson JF, Menzies AM, Palendira U, Wilmott JS, **Long GV**, Scolyer RA. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials. *Clin Cancer Res*. June **2019**. 25:3247-3258.
289. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Jr, Carlino MS, Fisher R, **Long GV**, Hodi SF, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Homet Moreno B, Ibrahim N, Hamid O. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. **2019** *Nature Medicine*. 25:936-940

290. Lee JH, Saw RPM, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch J, Howle J, Menzies AM, Carlino MS, Kefford RF, **Long GV**, Scolyer RA, Rizos. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients *Annals of Oncology*. **2018** 30:815-822.
291. Kim H, Duong JK, Gonzalez M, **Long GV**, Menzies AM, Rizos H, Yin Lim S, Lee J, Boddy AV. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. *Cancer Chemother Pharmacol* April **2019**. 83:693-704.
292. Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M., & **Long, G. V.** (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. **2019 May**;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27, PMID: 30928620
293. Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RP, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva I, Batten M, Scolyer RA, Wilmott JS* **Long GV***, Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. *Cancer Cell* Feb **2019**. 35: 238-255.
294. Ascierto PA, **Long GV**, Robert C, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles , Mihalciou C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Marie Svane I, Schadendorf D, Gogas H, Sagi A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Onc* **2018**. [Epub ahead of print].
295. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood J, **Long GV**. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. *J Clin Oncol* **2018**. [Epub ahead of print].
296. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminski A, **Long GV**, Menzies AM. Leptomeningeal melanoma-A case series in the era of modern systemic therapy. *Pigment Cell Melanoma Res* **2018**; 31: 120-124.
297. Lim S, Lee J, Gide T, Menzies A, Guminski A, Carlino M, Breen E, Yang J, Ghazanfar S, Kefford R, Scolyer R, **Long GV**, Rizos H. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. *Clin Cancer Res*. **2019 Mar** 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8. 3, PMID: 30409824
298. Pires da Silva I, Wang K, Wilmott J, Holst J, Carlino M, Park J, Quek C, Wongchenko M, Yan Y, Mann G, Johnson D, McQuade J, Rai R, Kefford R, Rizos H, Scolyer R, Yang J, **Long GV**, Menzies A. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. *Clin Cancer Res* **2019**; 25: 1272-1279
299. Lee H, Quek C, Edwards J, Madore J, Palendira M, Menzies A, Carlino M, Guminski A, Saw R, Thompson J, Silva I, Ferguson P, **Long GV**, Scolyer R, Wilmott J. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncoimmunology* **2019**, 8: e1537581
300. Tio M, Rai R, Ezeoke OM, McQuade J, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson B, Rizvi H, Joshua AM, Hellmann MD, **Long GV**, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. *Eur J Cancer* **2018**; 104: 137-144.
301. Orozco J, Knijnenburg J, Manughian-Peter A, Salomon M, Barkhoudarian G, Jalas J, Wilmott J, Hothi, Xiaowen Wang R, Takasumi Y, Buckland M, Thompson J, **Long GV**, Cobbs C, Shmulevich I, Kelly

- D, Scolyer R, Hoon D, Marzese D. Epigenetic profiling for the molecular classification of metastatic brain tumors. *Nature Communications* **2018**; 9: 4627.
302. Wang D, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell K, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, **Long GV**, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan R, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis *JAMA Oncol.* **2018 Dec 1**;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923, PMID: 30242316
303. Dodds T, Wilmott J, Jackett L, Lo S, **Long GV**, Thompson J, Scolyer R. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. *Pathology* **2019**. Epub; 51: 39-45.
304. Silva da I, Battem M, **Long GV**. Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. *Br J Cancer* **2018**; 119: 661-662.
305. **Long GV**, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. *Ann Oncol* **2018**. 29:2208-2213.
306. Wang K, Menzies AM, Silva IP, Wilmott J, Yan Y, Wongchenko M, Kefford R, Scolyer RA, **Long GV**, Tarr G, Mueller S, Yang JYH. bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. *Bioinformatics.* **2019 Apr 15**;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783. PMID: 30215668
307. Allanson B, Weber M, Jackett L, Chan C, Lau L, Ziegler D, Warby M, **Long GV**, Maher A, Tucker K, Anazodo A, Scolyer RA. Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. *Pathology* **2018**. 50: 648-653.
308. Wilmott J, Johansson P, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard A, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RP, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, **Long GV**, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. *Int J Cancer* **2019**; 144: 1049-1060.
309. Strub T, Ghiraldini F, Carcamo S, Wroblewska A, Li M, Wang Z, Singh R, Goldberg M, Hasson D, Gallagher S, Hersey P, Ma'ayan A, **Long GV**, Scolyer R, Zheng B, Brown B, Bernstein E. SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signaling. *Nat Commun* **2018**; 9:3440.
310. Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann G, **Long GV**, Scolyer R, Molloy M. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. *Br J Cancer* **2018**; 119: 713-723.
311. Tetzlaff M, Messina J, Stein J, Xu X, Amaria R, Blank C, Van De Wiel B, Ferguson P, Rawson R, Ross M, Spillane A, Gershenwald J, Saw R, Mitchell T, Menzies A, **Long GV**, Wargo J, Davies M, Prieto V, Taube J, Scolyer R. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol* **2018**; 29: 1861-1868.
312. Carlino MS, **Long GV**, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blan C, Hoeller C, Bar-Selat G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomized clinical trial. *Eur J Cancer* **2018**; 101: 236-243.
313. **Long GV**, Atkinson V, Hong A, McArthur G, Menzies AM. Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply. *Lancet Oncol* **2018**; 19: e367.
314. Eggermont A, Blank C, Mandala M, **Long GV**, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto P, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh A, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi A, Suci S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med* **2018**; 378: 1789-1801.

315. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, S, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea G, Ecker BL, Allegrrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich DI, Stone EL, Nowicki TS, Sosman JA, Rai R, Carlino MS, **Long GV**, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling MA, Schadendorf D, Menzies AM, McQuade JL, Johnson DB, Osman, Weeraratna AT. Age correlates with response to anti-PD1, reflecting age-related differences in intra-tumoral effector and regulatory T cell populations. *Clinical Cancer Res.* **2018**; 24: 5347-5356.
316. **Long GV**, Hauschild A, Kirkwood M. Adjuvant Therapy in Resected Melanoma. *N Engl J Med* **2018**; 19:1813-1823.
317. Edwards J, Wilmott J, Madore J, Gide T, Quek C, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton W, Saw R, Thompson J, Menzies A, **Long GV**, Scolyer R, Palendira U. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and response to anti-PD1 immunotherapy. *Clin Cancer Res* **2018**; 24: 3036-3045.
318. Borcoman E, Nandikolla A, **Long GV**, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. *American Society for Clinical Oncology Education Book* **2018**. 38:169-178.
319. **Long GV, Atkinson V, Lo S, Guminski AS, Sandhu S, Brown MP, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol** **2018**; **19**:672-681.
320. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Guminski AD, **Long GV**, Tonks KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. *Pituitary* **2018**; 21: 274-282.
321. Star P, Goodwin A, Kapoor R, Conway RM, **Long GV**, Scolyer R, Guitera P. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. *Eur J Cancer* **2018**; 92: 48-53.
322. Tio M, Xuan W, Carlino, Shivalingam B, Fogarty G, Guminski A, Lo S, Hong A, Menzies A, **Long GV**. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. *Pig Cell Mel Res* **2017**; 31:509-515.
323. Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger S, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, **Long GV**, Lorigan P. Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" *Eur J Cancer* **2018**; 91: 116-124.
324. Lee J, **Long GV**, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford K, Rizos H, Carlino M. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. *JAMA Oncol* **2018**; 4: 717-721.
325. Scott E, **Long GV**, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang V. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma *Eur J Endocrinol* **2018**; 178: 175-182.
326. Tan A, Emmett L, Lo S, Liu V, Kapoor R, Carlino M, Guminski A, **Long GV**, Menzies A. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. *Ann Oncol* **2018**; 29: 2115-2120.
327. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JP, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki T, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, **Long GV**, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. *Lancet Oncol* **2018**; 19: 310-322.

328. Lee J, Lyle M, Menzies A, Chan M, Lo S, Clements A, Carlino M, Kefford R, **Long GV**. Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. *Pigment Cell Melanoma Res* **2018**; 31: 404-410.
329. **Long GV**. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. *Clin Adv Hematol Oncol* **2018**; 16(1):25-27.
330. Ferguson P, **Long GV**, Scolyer RA, Thompson JF. Impact of genomics on the surgical management of melanoma. *Br J Surg* **2018**; 105: e31-e47.
331. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, **Long GV**, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. *Ann Oncol* **2018**; 29: 250-255.
332. Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, **Long GV**, Ward R, Menzies A, Harris-Wai J, Kaur R. Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. *Eur J Cancer Care (Engl)*. **2017 Nov**;26(6). doi: 10.1111/ecc.12600. Epub 2016 Oct 11
333. Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., **Long, G. V.**, Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual, *CA Cancer J Clin*. **2017 Nov**;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13, PMID: 29028110
334. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminski A, **Long GV**, Menzies AM. Leptomeningeal melanoma – a case series in the era of modern systemic therapy. *Pig Cell Mel Res* **2017**; 31:120-124.
335. Davies MA, Saiag P, **Long GV**. Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply. *Lancet Oncol* **2017**; 18:509.
336. Gu YF, Menzies AM, **Long GV**, Fernando SL, Herkes G. Immune mediated neuropathy following combined checkpoint immunotherapy. *J Clin Neurosci* **2017**; 45:14-17.
337. Gide TN, Wilmott J, Scolyer R, **Long GV**. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. *Clin Cancer Res* **2018**; 24: 1260-1270.
338. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Won Kim D, Algazi A, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku P, Wei C, Sosman JA, Joseph R, Postow MA, Carlino MS, Hwu W-J, Scolyer RA, Messina J, Cochran AJ, **Long GV**, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. *Nature* **2018**; 553: 347-350.
339. **Long GV**, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. *J Clin Oncol* **2018**; 36: 667-673.
340. **Long GV**, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood J. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med* **2017**; 19:1813-1823.
341. Lim SY, Lee J, Welsh S, Ahn SB, Breen E, Khan A, Carlino M, Menzies A, Kefford R, Scolyer RA, **Long GV**, Rizos H. Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. *Biomark Res*. **2017 Nov** 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017, PMID 29152306
342. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AN, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, **Long GV**, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Min Kim T, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA., Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV melanoma. *N Engl J Med* **2017**. 377(19):1824-1835.

343. Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey L, Lao C, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino M, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, **Long GV**, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhole R, Hodi S, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med* **2017**; 377:1345-1356.
344. Glodde N, Bald T, Boorn-Konijnenberg D, Nakamura K, O'Donnell J, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, Van der Sluis T, Ruotsalainen J, Gaffal E, Landsberg J, Ludwig K, Wilhelm C, Riek-Burchardt M, Müller A, Gebhardt C, Scoyler R, **Long GV**, Janzen V, Teng M, Kastenmüller W, Mazzone M, Smyth M, Tüting T, Hölzel M. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity* **2017**; 47:789-802.
345. Sidhu P, Menzies AM, Carlino MS, **Long GV**, Kapoor R. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. *J Med Imaging Radiat Oncol* **2017**. 61(6):759-766.
346. Gershenwald J, Scolyer RA, Hess K, Sondak V, **Long GV**, Ross M, Lazar A, Faries M, Kirkwood J, McArthur G, Haydu L, Eggermont A, Flaherty K, Balch C, Thompson J, and members of the AJCC Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA* **2017**. 67(6):472-492.
347. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka R, Michielin O, Olszanski AJ, Malvey J, Cebon J, Fernandez E, Kirkwood J, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman M, Gansert J, Hodi FS, **Long GV**. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell* **2018**; 174: 1031-1032.
348. Aivazian K, **Long GV**, Sinclair E, Kench JG, McKenzie CA. Histopathology of Pembrolizumab-Induced Hepatitis: a case report. *Pathology* **2017**. 49(7): 789-792 [Epub ahead of print].
349. Rawson R, Robbins E, Kapoor R, Scoyler RA, **Long GV**. Recurrent bowel obstruction: unusual presentation of Pembrolizumab-induced pancreatitis in annular pancreas. *Eur J Cancer* **2017**; 82:167-170.
350. Silvam IP, **Long GV**. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. *Curr Opin Oncol.* **2017 Nov**;29(6):484-492. doi: 10.1097/CCO.0000000000000405.
351. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, **Long GV**, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies – Update 2017. *Eur J Cancer* **2017**; 83:247-257.
352. Somasundaram R, Wagner SN, Zhang G, Perego M, Wagner C, Hristova D, Garg K, Hards R, Wei Z, Wu L, Frederick DT, Flaherty K, Scolyer RA, **Long GV**, Maurer M, Fukunaga-Kalabis M, Krepler C, Damle M, Ellingsworth C, Grinman L, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Liu Q, Bennett K, Griss J, Schaidler H, Czerniecki BJ, Schuchter L, Herlyn D, Herlyn M. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. *Nat Commun* **2017**; 8:607.
353. Reinhardt J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiew SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, **Long GV**, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. *Cancer Res* **2017**; 77:4697-4709.
354. Mar VJ, Scolyer RA, **Long GV**. Computer-assisted diagnosis for skin cancer: have we been outsmarted? *Lancet* **2017**; 389:1962-1964.
355. Kakavand H, Rawson R, Pupo G, Yang J, Menzies A, Carlino M, Kefford R, Howle J, Saw R, Thompson J, Wilmott J, **Long GV**, Scolyer R, Rizos H. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. *Clin Can Res* **2017**; 23:6054-6061.

356. Kakavand H, Jakkett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, **Long GV**, Scolyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. *Mod Pathol* **2017**; 30(12): 1666-1676.
357. Schadendorf D, Larkin J, Wolchok J, Hodi S, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey L, Lao C, Wagstaff J, Callahan M, Postow M, Smylie M, Ferrucci P, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, **Long GV**. Health-related quality of life results from the phase III CheckMate 067 Study. *Eur J Cancer* **2017**; 82: 80-91.
358. Schadendorf D, **Long GV**, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen J, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies M, Zhang Y, Kaper M, Mookerjee B, Legos J, Flaherty K, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. *Eur J Cancer* **2017**; 82: 45-55.
359. Young A, Ngiew SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas D, Ahern E, Huntington N, Schadendorf D, **Long GV**, Boyle G, Hölzel M, Scolyer RA, Smyth MJ. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. *Cancer Res* **2017**; 77:4684-4696.
360. **Long GV**, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C, Hill A, Ribas A, Atkins M, Thompson J, Hwu W-J, Hodi S, Menzies A, Guminski A, Kefford R, Kong B, Tamjid B, Srivastava A, Lomax A, Islam Shu X, Ebbinghaus S, Ibrahim N, Carlino M. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma: the open-label, phase 1b KEYNOTE-029 study. *Lancet Onc* **2017**; 18:1202-1210.
361. Vilain R, Menzies A, Wilmott J, Kakavand H, Madore J, Guminski A, Liniker E, Kong B, Cooper A, Howle J, Saw R, Jakrot V, Lo S, Thompson J, Carlino M, Kefford R, **Long GV** (shared senior author), Scolyer R. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. *Clin Cancer Res* **2017**; 23:5024-33.
362. Schachter J, Ribas A, **Long GV**, Arance A, Grob J-J, Mortier L, Daud A, Carlino M, Catriona McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella T, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* **2017**; 390:1853-1862.
363. **Long GV**, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol* **2017**; 28:1631-1639.
364. Davies M, Saiag P, Robert C, Grob J-J, Flaherty K, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos S, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, MD, Zhang Y, Huang Y, Mookerjee B, **Long GV**. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* **2017**; 18(7):863-873.
365. Wilmott J, Rizos H, Scolyer RA, **Long GV**. The "tricky business" of identifying mechanisms of resistance to anti-PD-1. *Clin Cancer Res* **2017**; 23:2921-2923.
366. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch A-M, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, de Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm S-J, Pritchard A, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, **Long GV**, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ. Whole-genome landscapes of major melanoma subtypes. *Nature* **2017**; 545:175-180.

367. **Long GV**, Weber JS, Larkin J, Atkinson V, Grob J-J, Schadendorf D, Dummer R, Robert C, Marquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain J-F, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials. *JAMA Onc* **2017**; 3:1511-1519.
368. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozon V, **Long GV**, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* **2017**; 18:435-445.
369. Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, **Long GV**, Scolyer RA. Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. *Lab Invest.* **2017 Feb**;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24 PMID 27775961
370. Lee JH, **Long GV**, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. *Ann Oncol* **2017**; 28:1130-1136.
371. Pupo G, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen, B, Johannson P, Hayward NK, Kefford RF, Scolyer RA, **Long GV**, Rizos H. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. *Biomark Res* **2017**; 5:17.
372. Luke JJ, Flaherty KT, Ribas A, **Long GV**. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol.* **2017**;14:463-482.
373. Menzies AM, **Long GV**. Optimum dosing of ipilimumab in melanoma: too little, too late? *Lancet Oncol* **2017**; 18:558-559.
374. Eskioçak B, McMillan E, Mendiratta S, Kollipara R, Zhang H, Humphries C, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales T, Eskioçak U, Smith MP, Sudderth J, Komurov K, DeBerardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, **Long GV**, Kittler R, White M. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. *Cancer Discov* **2017**; 7(8); 832–51.
375. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, **Long GV** (shared senior author), Hellmann MD. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. *J Clin Oncol.* **2017 Mar**;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30 PMID: 27646942
376. O'Donnell JS, **Long GV**, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. *Cancer treatment reviews* **2017**; 52:71-81.
377. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, **Long GV**, Menzies AM, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. *Br J Cancer*, **2017**; 116:1558-1563.
378. Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, **Long GV**, Hong AM. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. *Eur J Cancer* **2017**; 75:169-178.
379. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoustari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, **Long GV**. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol* **2017**; 28:368-376.
380. Atkinson V, **Long GV**, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. *Asia Pac J Clin Oncol* **2016**; 7:5-12

381. **Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA.** Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. *Lancet Oncol* **2016**; 17:1743-1754.
382. Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, **Long GV**, Ascierto PA. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. *Br J Cancer* **2016**; 115:1280-1284.
383. Arnheiter H, **Long G**, Aplin A, Harris J, Kelsh R. Triple jeopardy for people with albinism. *Pigment Cell Melanoma Res* **2016**; 29(5):48.
384. Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, **Long GV**, Blank CU. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. *Oncoimmunology* **2016**. [Epub ahead of print]5(12): e1238557.
385. Menzies AM, **Long GV**. Recent Developments in Melanoma Therapy. *JAMA Oncol* **2016**; 2:1259-1260.
386. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, **Long GV**, Li H, Waxman IM, Jiang J, Caroline Robert C. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma. *J Clin Oncol* **2017**; 35:785-792.
387. **Long G**, Hoadley A, Sandanayake N. Atrophic Exocrine Pancreatic Insufficiency Associated with Anti-PD1 Therapy. *Ann Oncol* **2017**; 28(2):434-435.
388. Thompson, JF, Shivalingam, B, Hong AM, Lyle, M, **Long, GV**, Chapter 5 – Brain Metastases from Melanoma, *Brain Metastases from Primary Tumours, Volume 3, 2016 October 21*
389. Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, **Long GV**. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. *Oncoimmunology* **2016**. 5(9): e1214788.
390. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, **Long GV**, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. *Pigment Cell Melanoma Res* **2016**; 29:404-416.
391. **Long GV**, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. *Ann Oncol* **2016**; 27:1940-1946.
392. Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, Kefford RF, **Long GV**, Carlino MS. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. *Pigment Cell Melanoma Res* **2016**; 29:572-577.
393. Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, **Long GV**, O'Toole SA, Scolyer RA. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. *Histopathology* **2016**; 69:680-686.
394. Carlino MS, **Long GV**. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? *Clin Cancer Res* **2016**; 22:3992-3998.
395. Ascierto PA, **Long GV**. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. *Lancet Oncol* **2016**; 17:1037-1039
396. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, OConnell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA,

- Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, **Long GV**, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature* **2016**; 537:254.
397. De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, **Long GV**, Scolyer RA. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. *Pathology* **2016**; 48:261-266.
398. Welsh SJ, Rizos H, Scolyer RA, **Long GV**. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? *Eur J Cancer* **2016**; 62:76-85.
399. Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, **Long GV**, Carlino MS, Klein O. Reply to Comment on Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. *Br J Cancer* **2017**; 116:e15.
400. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, **Long GV**, Mann GJ, Scolyer RA, Wilmott JS. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. *Clin Cancer Res* **2016**; 22:3915-3923.
401. Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, **Long GV**. The molecular profile of metastatic melanoma in Australia. *Pathology* **2016**; 48:188-193.
402. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, **Long GV**, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. *Eur J Cancer* **2016**; 53:125-134.
403. Pulvirenti T, Hong A, Clements A, Forstner D, Suchowersky A, Guminski A, McNeil C, Hersey P, Fogarty G, Kefford R, **Long GV**, Wang W. Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. *J Clin Oncol* **2016 Jan 20**;34(3):e17-20. doi: 10.1200/JCO.2013.49.0565. Epub 2014 May 2.
404. Kakavand H, Wilmott JS, **Long GV**, Scolyer RA. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. *Pathology* **2016**; 48:194-202.
405. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, **Long GV**, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. *JAMA Oncol* **2016**; 2:234-240.
406. **Long GV**, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. *J Clin Oncol* **2016**; 34:871-878.
407. Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, **Long GV**, McArthur G, McNeil CM, Millward M, Sandhu S. Sentinel node biopsy for melanoma: The medical oncology perspective. *Aust Fam Physician* **2015**; 44(12):875-876.
408. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, **Long GV**, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, OHagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. *Clin Cancer Res* **2016**; 22:567-574.
409. Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, **Long GV**, Ward R, Menzies AM, Guminski A, Harris-Wai J, Kaur R. Oncology patients attitudes toward, and experiences with, somatic mutation tumour testing. *Asia Pac J Clin Oncol* **2015**; 11:144.

410. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, **Long GV**, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, Opatt McDowell D, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. *Lancet Oncol* **2015**; Oct: 16(13):1389-1398.
411. Grob JJ, **Long GV**, Schadendorf D, Flaherty K. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. *Lancet Oncol* **2015**; Oct: 16(13):e522–e526.
412. Carlino MS, **Long GV**, Kefford RF, Rizos H. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. *Crit Rev Oncol Hematol* **2015**; Dec: 96(3):385-398.
413. Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H., Scolyer, R. A., Siew, K., Lomma, C., Cooper, A., Khattak, M. A., Meniawy, T. M., **Long, G. V.**, Carlino, M. S., Millward, M., & Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma, *Oncotarget*. **2015 Dec 8**;6(39):42008-18. doi: 10.18632/oncotarget.5788, PMID: 26524482
414. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, **Long GV**, Scolyer RA. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. *Mod Pathol* **2015**; Dec: 28:1535-1544.
415. Arnheiter H, **Long GV**, Aplin A, Harris J, Kelsh, Welcome to the New Year!, (Editorial) *Pigment Cell & Melanoma Research*, **2015 Dec 15**, doi.org/10.1111/pcmr.12446
416. Johnson DB, Menzies AM, Zimmer L, Eroglud Z, Yea F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer J, Gogas H, Kefford RF, Thompson JT, Becker JC, Berking C, Egberts F, Loquai C, Goldinger S, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, **Long GV**, Schadendorf D. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms. *Eur J Cancer* **2015**; Dec: 51(18):2792-2799.
417. Carlino MS, **Long GV**. Is chemotherapy still an option in the treatment of melanoma? *Ann Oncol* **2015**; Nov: 26(11):2203-4.
418. Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, **Long GV**, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferraro PT. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. *Sci Signal* **2015**; Aug: 18:8(390):ra82.
419. **Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* **2015**; Aug; **1:386(9992):444-51.****
420. Theodosakis N, Meeth K, Micevic G, Scolyer RA, **Long GV**, Marzuka A, Stern D, Bosenberg M. BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume. *Mol Cancer Ther* **2015**; Jul: 14(7):1680-92.
421. Amaravadi RK, Hamilton KE, Ma X, Piao S, Del Portillo A, Nathanson KL, Carlino MS, **Long GV**, Puzanov I, Xu X, Morrissette JJD, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. *Clin Cancer Res* **2015**; Dec: 21(23):5215-21
422. Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MMK, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, **Long GV**. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. *Cancer* **2015**; Nov: 121(21):3826-35.

423. Ramanujam S, Schadendorf D, **Long GV**. Systemic therapies for melanoma brain metastases: which drug for whom and when? *Chin Clin Oncol* **2015**; Jun: 4(2):25. doi: 10.3978/j.issn.2304-3865.2015.06.06.
424. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, Bartlett P, Bastian BC, Baylin SB, Behera M, Belyaev D, Benz C, Bernard B, Beroukhi R, Bir N, Black AD, Bodenheimer T, Boice L, Boland G, Bono R, Bootwalla MS, Bosenberg M, Bowen J, Bowlby R, Bristow CA, Brockway-Lunardi L, Brooks D, Brzezinski J, Bshara W, Buda E, Burns WR, Butterfield YSN, Button M, Calderone T, Cappellini GA, Carter C, Carter SL, Cherney L, Cherniack AD, Chevalier A, Chin L, Cho J, Cho RJ, Choi YL, Chu A, Chudamani S, Cibulskis K, Ciriello G, Clarke A, Coons S, Cope L, Crain D, Curley E, Danilova L, D'Atri S, Davidsen T, Davies MA, Delman KA, Demchok JA, Deng QA, Deribe YL, Dhalla N, Dhir R, DiCara D, Dinikin M, Dubina M, Ebrom JS, Egea S, Eley G, Engel J, Eschbacher JM, Fedosenko KV, Felau I, Fennell T, Ferguson ML, Fisher S, Flaherty KT, Frazer S, Frick J, Fulidou V, Gabriel SB, Gao J, Gardner J, Garraway LA, Gastier-Foster JM, Gaudioso C, Gehlenborg N, Genovese G, Gerken M, Gershenwald JE, Getz G, Gomez-Fernandez C, Gribbin T, Grimsby J, Gross B, Guin R, Gutschner T, Hadjipanayis A, Halaban R, Hanf B, Haussler D, Haydu LE, Hayes DN, Hayward NK, Heiman DI, Herbert L, Herman JG, Hersey P, Hoadley KA, Hodis E, Holt RA, Hoon DSB, Hoppough S, Hoyle AP, Huang FW, Huang M, Huang S, Hutter CM, Ibbes M, Iype L, Jacobsen A, Jakrot A, Janning A, Jeck WR, Jefferys SR, Jensen MA, Jones CD, Jones SJM, Ju Z, Kakavand H, Kang H, Kefford RF, Khuri FR, Kim J, Kirkwood JM, Klode J, Korkut A, Korski K, Krauthammer M, Kucherlapati R, Kwong LN, Kycler W, Ladanyi M, Lai PH, Laird PW, Lander E, Lawrence MS, Lazar AJ, Łażniak R, Lee D, Lee JE, Lee J, Lee K, Lee S, Lee S, Leporowska E, Leraas KM, Li HI, Lichtenberg TM, Lichtenstein L, Lin P, Ling S, Liu J, Liu O, Liu W, Long GV, Lu Y, Ma S, Ma Y, Mackiewicz A, Mahadeshwar HS, Malke J, Mallery D, Manikhas GM, Mann GJ, Marra MA, Matejka B, Mayo M, Mehrabi S, Meng S, Meyerson M, Mieczkowski PA, Miller JP, Miller ML, Mills GB, Moiseenko F, Moore RA, Morris M, Morrison C, Morton D, Moschos S, Mose LE, Muller FL, Mungall AJ, Murawa D, Murawa P, Murray PA, Nezi L, Ng S, Nicholson D, Noble MS, Osunkoya A, Owonikoko TK, Ozenberger BA, Pagani E, Paklina OV, Pantazi A, Parfenov M, Parfitt J, Park PJ, Park WY, Parker JS, Passarelli F, Penny R, Perou CM, Pihl TD, Potapova O, Prieto VG, Protopopov A, Quinn MJ, Radenbaugh A, Rai K, Ramalingam SS, Raman AT, Ramirez NC, Ramirez R, Rao U, Rathmell WK, Ren X, Reynolds SM, Roach J, Robertson AG, Ross MI, Roszik J, Russo G, Saksena G, Saller C, Samuels Y, Sander C, Sander C, Sandusky G, Santoso N, Saul M, Saw RPM, Schadendorf D, Schein JE, Schultz N, Schumacher SE, Schwallier C, Scolyer RA, Seidman J, Sekhar PC, Sekhon HS, Senbabaoglu Y, Seth S, Shannon KF, Sharpe S, Sharpless NE, Mills Shaw KR, Shelton C, Shelton T, Shen R, Sheth M, Shi Y, Shiao YJ, Shmulevich I, Sica GL, Simons JV, Sinha R, Sipahimalani P, Sofia HJ, Soloway MG, Song X, Sougnez C, Spillane AJ, Spychala A, Stretch JR, Stuart J, Suchorska WM, Sucker A, Sumer So, Sun Y, Synott M, Tabak B, Tabler TR, Tam A, Tan D, Tang J, Tarnuzzer R, Tarvin K, Tatka H, Taylor BS, Teresiak M, Thiessen N, Thompson JF, Thorne L, Thorsson V, Trent JM, Triche Jr TJ, Tsai KY, Tsou P, Van Den Berg DJ, Van Allen Em, Veluvolu U, Verhaak RG, Voet D, Voronina O, Walter V, Walton JS, Wan Y, Wang Y, Wang Z, Waring S, Watson IR, Weinhold N, Weinstein JN, Weisenberger DJ, White P, Wilkerson MD, Wilmott JS, Wise L, Wiznerowicz M, Woodman SE, Wu CJ, Wu CC, Wu J, Wu Y, Xi R, Xu AW, Yang D, Yang L, Yang L, Zack TI, Zenklusen JC, Zhang H, Zhang J, Zhang W, Zhao X, Zhu J, Zhu K, Zimmer L, Zmuda E, Zou L Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. *2015 Jun* 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044 PMID: 26091043
425. Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, **Long GV**. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. *Pigment Cell Melanoma Res* **2015**; Sep: 28(5):607-10.
426. Stark M, Klein K, Weide B, Haydu L, Pflugfelder A, Tang YH, Palmer J, Whiteman D, Scolyer RA, Mann GJ, Thompson JF, **Long GV**, Barbour A, Soyer HP, Garbe C, Herington A, Pollock P, Hayward N. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. *EBioMedicine* **2015**; May: 12;2(7):671-80.

427. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Cowey L, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, **Long GV**, Callahan MK, Postow MA, Grossman K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* **2015**; Jul; 2;373(1):23-34.
428. Lam T, Chan MMK, Sweeting AN, De Sousa SMC, Clements A, Carlino MS, **Long GV**, Tonks K, Chua E, Kefford RF, Chipps DR. Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. *Intern Med J* **2015**; Oct; 45(10):1066-73.
429. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, **Long GV**. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. *Eur J Cancer* **2015**; May; 51(7):833-40.
430. **Robert C, Schachter J, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; Jun: 25;372(26):2521-32**
431. Anforth R, Menzies AM, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford RF, **Long GV**, Fernandez-Penas P. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. *J Am Acad Dermatol* **2015**; May; 72(5):809-15.e1.
432. Wilmott JS, Hersey P, **Long GV**, Scolyer RA. Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? *Melanoma Manag* **2015**; 2(1):15-19.
433. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, **Long GV**, Scolyer RA. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. *Clin Cancer Res* **2015**; 21(14):3140-48.
434. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, **Long GV**, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncol* **2015**; Jan; 16(1):15-17.
435. Phan TG, **Long GV**, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. *Immunol Cell Biol* **2015**; Apr; 93(4):323-5.
436. Wilmott JS, Colebatch A, Kakavand H, Shang P, Carlino MS, Thompson JF, **Long GV**, Scolyer RA, Hersey P. Expression of the Class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. *Mod Pathol* **2015**; Jul; 28(7):884-94.
437. Madore J, Vilain R, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, **Long GV**, Hersey P, Scolyer RA. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. *Pigment Cell Melanoma Res* **2015**; May; 28(3):245-53.
438. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, **Long GV**, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. *Ann Oncol* **2015**; Feb; 26(2):415-21.
439. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, **Long GV**, Flaherty K, Nathan P, Ribas A, Martin A-M, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. *N Engl J Med* **2015**; Jan; 1;372(1):30-9.
440. **Long GV, Fung C, Menzies AM, Pupo G, Carlino M, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward N, Johansson P, Scolyer RA, Kefford RF, Rizos H.**

- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. Nat Commun 2014; Dec: 2:5:5694**
441. Carlino MS, Fung C, Shahheydari H, Todd JR, Nagrial, AM, Scolyer RA, Kefford RF, **Long GV**, Rizos, H. Pre-existing MEK1^{P124} mutations diminish response to BRAF inhibitors in metastatic melanoma patients. *Clin Cancer Res* **2015**; Jan: 1;21(1):98-105
442. **Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassell JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalciou C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in Previously Untreated Melanoma without BRAF mutation. N Engl J Med 2015; Jan: 22;372(4):320-30**
443. **Long GV**. From dismal prognosis to rising star: melanoma leading the way with new generation cancer therapies. *Med J Aust* **2015**; Feb: 16:202(3):115-6.
444. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, **Long GV**, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients with BRAFV600-Mutant Melanoma Experiencing Progression with Single-Agent BRAF Inhibitor. *J Clin Oncol* **2014**; **Nov: 20:32(33):3697-704**.
445. Gopal VNV, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, **Long GV**, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 α and Oxidative Phosphorylation in melanoma. *Cancer Res* **2014**; Dec: 1:74(23):7037-47.
446. Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, **Long GV**, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM. TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. *Oncotarget* **2014**; Oct: 30:5(20):10127-39.
447. **Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin A-M, Le N, Patel K, Flaherty K. Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma. N Engl J Med 2014; Nov: 13:371(20):1877-88.**
448. Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., **Long, G. V.**, Menzies, A. M., Scolyer, R. A., Izraely, S., Sagi-Assif, O., Witz, I. P., & Hoon, D. S. B. (2015). Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. *J Invest Dermatol* . **2015 Feb;135(2):532-541**. doi: 10.1038/jid.2014.418. Epub 2014 Sep 22 PMID: 25243790
449. De Sousa, S, **Long GV**, Tonks K. Ipilimumab-induced hypophysitis: early Australian experience. *Med J Aust* **2014**; Aug: 18:201(4):198-9.
450. **Long GV**, Falchook GS, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin M, ODay SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436). *Clin Cancer Res* **2014**; Sept: 1:20(17):4449-58.
451. Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, **Long GV**. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. *Mel Res* **2014**; Oct: 24(5):468-74.
452. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, **Long GV**. Reply to M. Perier-Muzet et al. *J Clin Oncol* **2014**; Oct: 1:32(28):3203-4.

453. Bowyer SE, Rao A, Lyle M, Sandhu S, **Long GV**, McArthur G, Raleigh J, Hicks R, Millward M Activity of Trametinib in K601E and L597Q BRAF Mutation-Positive Metastatic Melanoma. *Mel Res* **2014**; Oct: 24(5):504-8.
454. Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, NG CC, Cooper W, Thompson JF, Kefford RF, OToole SO, Scolyer RA, **Long GV**. Correlation of BRAF and NRAS mutation status with outcome, organ involvement and response to chemotherapy in metastatic melanoma. *Br J Cancer* **2014**; Jul: 15:111(2):292-9.
455. Chan, M. M., Haydu, L. E., Menzies, A. M., Azer, M. W., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R. F., & **Long, G. V.** (2014). The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition, *Cancer*. **2014 Oct 15**;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1, PMID: 24985732
456. Chien A, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, **Long GV**. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. *PlosOne* **2014**; Apr: 14:9(4):e94748.
457. Brown MP, **Long GV**. The Use of Vemurafenib in Australian Patients with Unresectable or Metastatic Melanoma Containing the V600 *BRAF* Gene Mutation. *Asia-Pac J Clin Oncol* **2014**; Apr: (10):suppl S3:1-15.
458. Menzies AM, **Long GV**. Systemic treatment for BRAF-mutant melanoma: Where do we go next? Invited Review. *Lancet Oncol* **2014**; Aug: 15(9):e371-81.
459. Menzies AM, **Long GV**. Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Invited review. *Clin Cancer Res* **2014**; Apr: 15:20(8):2035-43.
460. Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AMM, Hauschild A, Kefford R, Kirkwood JM, **Long GV**, Lorigan P, Mackensen A, McArthur G, ODay S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *Lancet Oncol*. **2014**; Mar: 15(3):297-304.
461. Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, **Long GV**. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF- mutant melanoma patients during BRAF inhibitor treatment. *Journal Immun* **2014**; Mar: 1:192(5):2505-2513.
462. **Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. Clin Cancer Res** **2014**; Apr: **1:20(7):1965-77.**
463. Carlino M, Todd J, Gowrishankar K, Mijatov B, Pupo G, Snoyman S, Hersey P, **Long GV**, Kefford RF, Rizos H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. *Mol Oncol* **2014**; May: 8(3):544-54.
464. Anastas JN, Tamir T, Kulikauskas RM, Rizos H, **Long GV**, Euw EM, Chen H-W, Haydu L, Yang P-T, Toroni RA, Lucero OM, Chien AJ, Moon RT. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors and promotes cell growth and survival through activation of AKT signaling. *J Clin Inv* **2014**; Jul: 1:124(7):2877-90.
465. Parmenter T, Kleinschmidt M, Kinross K, Bond S, Li J, Kaadige M, Sheppard K, Hugo W, Pupo G, Pearson R, McGee S, **Long GV**, Scolyer R, Rizos H, Lo R, Cullinane C, Ayer D, Ribas A, Johnstone R, Hicks R, McArthur G. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. *Cancer Discov* **2014**; Apr: 4(4):423-33.
466. Shi H, Hong A, Kong X, Koya R, Song C, Moriceau G, Hugo W, Yu C, Ng C, Chodon T, Scolyer R, Kefford R, Ribas A, **Long GV**, Lo R, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discov* **2014**; 4(1):69-79.
467. Shi H, Willy H, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson D, Dahlman KB, Kelley M, Kefford RF, Chmielowski B, Glaspy J, Sosman JA, **Long GV**, Ribas A, Lo R, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov* **2014**; 4(1):80-93.

468. Lyle M, **Long GV**. The Role of Systemic Therapies in the Management of Melanoma Brain Metastases. *Current Opin Onc* **2014**; 26(2):222-9.
469. Menzies AM, Haydu LE, Carlino M, Azer MF, Carr PJA, Kefford RF, **Long GV**. Inter- and inpatient heterogeneity of response and progression to targeted therapy in metastatic melanoma. *PlosOne* **2014**; 9(1):e85004.
470. Carlino MS, Kwan V, Miller DK, Saunders CAB, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, **Long GV**. New *RAS*-mutant Pancreatic Adenocarcinoma with Combined BRAF and MEK inhibition for Metastatic Melanoma. *J Clin Oncol* **2014**; Apr: 10:33(11).
471. Kakavand H, Crainic O, O'Toole S, Kefford RF, Thompson JF, Wilmott JS, **Long GV**, Scolyer RA. Concordant BRAF^{V600E} mutation status in primary melanomas and associated nevi: implications for mutation testing of primary melanomas. *Pathol* **2014**; 46(3):193-198.
472. Lezcano C, Lee C-W, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC, Ogino S, **Long GV**, Scolyer RA, Murphy GF Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. *Mod Pathol* **2014**; Sep: 27(9):1193-202.
473. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi SF, Kefford RF, Menzies AM, Atkins MB, Cho DC, Sullivan RJ, **Long GV** (shared senior author). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after targeted therapy. *Cancer* **2014**; Jun: 1:120(11):1695-1701
474. Azer MWF, Menzies AM, Haydu LE, Kefford RF, **Long GV**. Patterns of Response and Progression in Patients with BRAF-mutant Melanoma Metastatic to the Brain treated with Dabrafenib. *Cancer* **2014**; 120:530-6.
475. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Richard F. Kefford RF, John F. Thompson JF, Schadendorf D, **Long GV**. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. *J Clin Oncol* **2014**; Mar: 10;32(8):816-23.
476. Menzies AM, Wilmott JS, **Long GV**, Scolyer RA. Intra-patient heterogeneity of BRAF mutation status: fact or fiction? *Br J Cancer* **2014**; Mar: 38(3):377-82.
477. Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, O'Toole S, **Long GV**, Scolyer RA. Inpatient homogeneity of BRAFV600E expression in melanoma. *Am J Surg Path* **2014**; Mar: 38(3):377-82.
478. Hu W, Jin L, Jiang CC, **Long GV**, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. *Cell Death Dis.* **2013**; 4:e914.
479. Lyle M, **Long GV**. Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. Invited review *J Clin Oncol* **2013**; 31:3176-81.
480. Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, **Long GV**, Fernandez-Peñas P. Acneiform Eruptions: A Common Cutaneous Toxicity of the MEK Inhibitor Trametinib. *Australas J Derm* **2014**; Nov: 55(4):250-4 .
481. Menzies AM, **Long GV**. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. *Eur J Cancer* **2013**; 49(15):3229-41.
482. Anforth R, Blumetti TCMP, Clements A, Kefford R, **Long GV**, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. *Br J Dermatol.* **2013**; 169:1310-3.
483. Menzies AM, Kefford RF, **Long GV**. Paradoxical oncogenesis: are all BRAF inhibitors equal? *Pigment Cell Melanoma Res* **2013**; 26(5):611-5.
484. Nathanson KL, Martin A-M, Wubbenhorst B, Greshock J, Letrero R, DAndrea K, ODay S, Infante JR, Falchook GS, Arkenau H-T, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis M, Lebowitz PF, Kefford RF, **Long GV**. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). *Clinical Cancer Res* **2013**; 19(17):4868-4878.

485. Menzies AM, **Long GV**. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Invited review *Ther Adv Med Oncol* **2013**; 5:278-85.
486. Ascierto PA, Minor D, Ribas A, Lebbe C, OHagan A, Arya N, Guckert M, Schadendorf D, Kefford R, Grob J-J, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, **Long GV**, Martin A-M, Mazumdar J, V Goodman V, Trefzer U. A Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. *J Clin Oncol* **2013**; 31:3205-3211.
487. **Long, G. V.**, Wilmott, J. S., Haydu, L. E., Tembe, V., Sharma, R., Rizos, H., Thompson, J. F., Howle, J., Scolyer, R. A., & Kefford, R. F. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. *Pigment Cell Melanoma Res.* **2013 Jul**;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3, PMID 23557327
488. Carlino, M. S., Gowrishankar, K., Saunders, C. A., Pupo, G. M., Snoyman, S., Zhang, X. D., Saw, R., Becker, T. M., Kefford, R. F., **Long, G. V.**, & Rizos, H. (2013). Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma, *Mol Cancer Ther.* **2013 Jul**;12(7):1332-42. doi: 10.1158/1535-7163.MCT-13-0011. Epub 2013 May 3, PMID: 23645591
489. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Peter Hersey P, **Long GV**, Lawrence D, Ott PA, Amaravadi R K, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spliss O, Schell-Steven A, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients with Metastatic Melanoma. *J Clin Oncol* **2013**; 31:1767-74.
490. **Long GV**, Margolin KA. Multidisciplinary Approach to Brain Metastasis from Melanoma; Systemic Targeted Therapies for CNS Metastases. Invited review *American Society of Clinical Oncology Educational Book*, **2013**; 393-8.
491. Wilmott, J. S., Menzies, A. M., Haydu, L. E., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., von Deimling, A., Scolyer, R. A., & **Long, G. V.** (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, *Br J Cancer.* **2013 Mar** 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12 PMID 23403819.
492. Lo RS, A. Ribas A, **Long GV**, Ballotti R, Berger M, Hugo W, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KSM. Meeting report from the Society for Melanoma Research **2012** Congress, Hollywood, California. *Pigment Cell Melanoma Res* **2013**; 26:E1-7.
493. Anforth RM, Fernandez-Penas P, **Long GV**. Cutaneous Toxicities of RAF Inhibitors. Invited review *Lancet Onc* **2013**; 14:e11-8.
494. Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., Gonzalez, R., Ott, P. A., **Long, G. V.**, Gardner, O. S., Ouellet, D., Xu, Y., DeMarini, D. J., Le, N. T., Patel, K., & Lewis, K. D. (2013). Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor, *J Clin Oncol.* **2013 Feb** 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 1 PMID: 23248257
495. Klein O, Clements A, Menzies A, Kefford R, **Long GV**. BRAF inhibitor activity in V600R metastatic melanoma. *Eur J Cancer* **2013**; 49:1797-8.
496. **Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford R. Sosman JA, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi AP, Lewis KD, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber JS. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med** **2012**; 367:1694-703.
497. Menzies AM, **Long GV**, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Invited review *Drug Des Develop Ther* **2012**; 6:391-40.
498. Klein O, Ribas A, Chmielowski B, Walker G, Clements A, **Long GV**, Kefford K. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. *J Clin Oncol* **2013**; 31:e215-7.

499. Carlino, M. S., Saunders, C. A., Haydu, L. E., Menzies, A. M., Martin Curtis, C., Jr., Lebowitz, P. F., Kefford, R. F., & **Long, G. V.** (2013). (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma, *Eur J Cancer*. **2013 Jan**;49(2):395-402. doi: 10.1016/j.ejca.2012.08.018. Epub 2012 Sep 1, PMID: 22981500
500. **Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. *Am J of Surg Path* 2013; 37:61-5.**
501. **Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., Mortier, L., Tawbi, H., Wilhelm, T., Zimmer, L., Switzky, J., Swann, S., Martin, A. M., Guckert, M., Goodman, V., Streit, M., Kirkwood, J. M., & Schadendorf, D. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, *Lancet Oncol*. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8, PMID 23051966**
502. Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, **Long GV**, Fernandez-Penas, P. Cutaneous Manifestations of GSK2118436, A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. *Br J Dermatol* **2012**; 167:1153-60.
503. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, **Long GV**. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. *Mole Can Therap* **2012**; 12:2704-8.
504. Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, **Long GV**. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. *Cancer* **2012**; 118:4519-29.
505. Menzies AM, **Long GV**. Clinicopathologic Features of V600E and V600K Melanoma—Response. *Clin Cancer Res*. **2012**; 18(24):6793.
506. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, **Long GV**. Distinguishing Clinicopathologic Correlates of BRAF mutant V600E and V600K Metastatic Melanoma. *Clin Can Res* **2012**; 18:3242-9.
507. **Long GV, Falchook G (shared first authorship), Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, ODay SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. *Lancet*, 2012; 379:1893-90.**
508. Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., Busam, K., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S. M., Dummer, R., **Long, G. V.**, McArthur, G., Scherag, A., Sucker, A., & Schadendorf, D. (2012). Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, *J Clin Oncol*. **2012 Jul 1**;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21, PMID: 22614973
509. Wilmott JS, Scolyer RA, **Long GV**, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Invited review *OncoImmunology*, **2012**; 1:997-999.
510. Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchicocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., Halaban, R., Kefford, R. F., **Long, G. V.**, Ribas, A., & Lo, R. S. (2012). Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors, *Cancer Discov*. **2012 May**;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1, PMID 22588879
511. Carlino M S, Fogarty GB, **Long GV**. Treatment of melanoma brain metastases: A new paradigm. Invited review *The Cancer J* **2012**; 18:208-12.

512. Murali R, Haydu LE, Quinn MJ, Saw RPM, Shannon K, Spillane AJ, Stretch JR, Thompson JF, **Long GV**, Scolyer RA. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. *Ann Surg Oncol* **2012**; 19:1782-9.
513. Shi H, Moriceau G, Kong X, Lee M, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman J, Kefford R, **Long GV**, Nelson SF, Ribas A, Lo R. Melanoma exome sequencing identifies V600E BRAF amplification driving acquired resistance to vemurafenib. *Nat Commun* **2012**; 3:724.
514. **Long GV, Wilmott J (shared first authorship), Sharma RN, Howle JR, Thompson J, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce Marked T cell Infiltration into Human Melanoma. Clin Cancer Res, 2012, 18:1386-94.**
515. Scolyer R, **Long GV**, Thompson JF. Evolving Concepts in Melanoma Classification and Their Relevance to Multidisciplinary Melanoma Patient Care. Invited review *Mol Oncol* **2011**; 5:124-136.
516. **Long GV, Menzies AM, Nagrial AM, Haydu L, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford, RF. Prognostic and clinico-pathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-46.**
517. Arkenau H-T, Kefford R, **Long GV**. Targeting B-RAF for patients with melanoma. Invited review *Br J Cancer* **2011**; 104:392-398.
518. **Long GV**. Book Review of The molecular biology of the cell Eds. Pelengaris and Khan, **2007**. *Cancer Forum* **2007**; 31:121.
519. **Long GV**, Tattersall MH. Lung encasement by metastatic osteoblastic sarcoma. *Med J Aust* **2007**; 186:100.
520. Fernandez-Lopez S, Kim H-S, Choi E, Delgado M, Granja J, Khasanov K, **Long GV**, Weinberger D, Wilcoxon K, Ghadiri MR. Antibacterial Agents based on the Cyclic D,L- α -Peptide Architecture. *Nature* **2001**; 412:452-55.
521. **Long GV**, Harding MM, Turner P. X-ray Structure of the Zinc Complex of the Central Metal Chelation site of the Antitumour Drug Streptonigrin. *Polyhedron* **2000**; 19:1067-1071.
522. Harding MM, **Long GV**. Interaction of the Antitumour Antibiotic Streptonigrin with Metal Ions and DNA. *Curr Med Chem* **1997**; 4:405-420.
523. **Long GV**, Harding MM, Fan J-Y, Denny WA. Interaction of the Antitumour Antibiotic Streptonigrin with DNA and Oligonucleotides. *Anti-cancer Drug Des* **1997**; 12:453-472.
524. **Long, G.V.**, Harding, M.M., A proton nuclear magnetic resonance study of the interaction of zinc(II) with the antitumour drug streptonigrin, *Journal of Chemical Society*, **1996**
525. **Long GV**, Harding MM, Turner P, Hambley TW. Copper(II) Bipyridyl and Iminopyridyl Analogues of Streptonigrin. *J Chem Soc, Dalton Trans* **1995**; 3905-3910.
526. **Long GV**, Harding MM, Xie MCL, Buys IE, Hambley TW. 3- Amino-6,6-bis(methoxycarbonyl)-2,2-bipyridine, a Model for the Central Chelation Unit of Streptonigrin. *J Chem Soc, Dalton Trans* **1995**; 951-955.
527. **Long GV**, Boyd SE, Harding MM, Buys IE, Hambley TW. Synthesis, Properties and Complexation Studies of 3-Amino-6,6-dimethyl-2,2-bipyridine. *J Chem Soc, Dalton Trans* **1993**; 3175-3180.
528. Harding MM, **Long GV**, Brown CL. Solution Conformation of the Antitumour Drug Streptonigrin. *J Med Chem* **1993**; 36:3056-3060.

PAPERS ACCEPTED FOR PUBLICATION (awaiting publication)

- 1.
2. Ines Pires da Silva, Isabel Li, Selma Ugurel, Patricio Serra-Bellver, Avanti Andhale, Hannah Burnette, Francisco Aya, Jordan W. Conway, Matteo S. Carlino, Alexander M. Menzies, Michael Weichenthal, Peter Mohr, Ralf Gutzmer, Ana M. Arance, Douglas B. Johnson, Paul Lorigan, Dirk Schadendorf, Serigne Lo, **Georgina V. Long**, Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases, **May 4 2024**, *EJC*, *accepted for publication*

3. **Georgina V. Long**, Matteo S. Carlino, George Au-Yeung, Andrew J. Spillane, Kerwin F. Shannon, David E. Gyorki, Edward Hsiao, Rony Kapoor, Jake R. Thompson, Iris Batula, Julie Howle, Sydney Ch'ng, Maria Gonzalez, Robyn P. M. Saw, Thomas E. Pennington, Serigne N. Lo, Richard A. Scolyer, Alexander M. Menzies, Neoadjuvant combinations of pembrolizumab, dabrafenib, and trametinib in BRAFV600-mutant resectable melanoma: the randomised phase II NeoTrio trial, **April 25 2024**, *Nature Med*, *accepted for publication*
4. Florentia Dimitriou, Phil F. Cheng, Annalisa Saltari, Katrin Schaper-Gerhardt, Ramon Staeger, Veronika Haunerding, Federica Sella, Aizhan Tastanova, Daniela Mihic-Probst, Olivier Michielin, Ralf Gutzmer, Mitchell P. Levesque, **Georgina V. Long**, Burkhard Becher, Reinhard Dummer, Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targets, *Nat Cancer*, April 9 2024, *accepted for publication*
5. Lianne. P. Zijlker, Henry Chen, **Georgina V. Long**, Alexander M. Menzies, Serigne Lo, Maria Gonzalez, Peter Ferguson, Robert Rawson, Richard A. Scolyer, Andrew Colebatch, Thomas E. Pennington, Andrew J. Spillane, Sydney Ch'ng, Kerwin F. Shannon, Robyn P.M. Saw, Alexander C.J. van Akkooi, The effect of neoadjuvant systemic therapy on surgical outcomes following lymph node dissections for stage III melanoma; an Australian cohort, **Mar 30 2023**, *Annals of Surgical Oncology*, *accepted for publication*
6. Kelly M. Hotchkiss; Philipp Karschnia; Karisa C. Schreck; Marjolein Geurts; Timothy F. Cloughesy; Jason Huse; Elizabeth S. Duke; Justin Lathia; David M. Ashley; Edjah K. Nduom; **Georgina Long**; Kirit Singh; Anthony Chalmers; Manmeet S. Ahluwalia; Amy Heimberger; Stephen Bagley; Tomoki Todo; Roel Verhaak; Patrick D. Kelly; Shawn Hervey-Jumper; John de Groot; Anoop Patel; Peter Fecci; Ian Parney; Victoria Wykes; Colin Watts; Terry Burns; Nader Sanai; Matthias Preusser; Joerg Christian Tonn; Katharine J. Drummond; Michael Platten; Sunit Das; Kirk Tanner; Michael A. Vogelbaum; Michael Weller; James R. Whittle; Mitchel Berger; Mustafa Khasraw, A Brave New Paradigm for Glioma Drug Development, **Mar 28, 2024**, *Lancet Onc*, *accepted for publication*
7. Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, **Georgina V. Long**, Willem Joost Lesterhuis, Exploiting temporal aspects of cancer immunotherapy, **Mar 26 2024**, *Nature Reviews Cancer*, *accepted for publication*
8. Judith M. Versluis*, Stephanie A. Blankenstein*, Petros Dimitriadis, Robert Elens, Willeke Blokk, Winan J. van Houdt, Yvonne M. Schrage, Michel W.J.M. Wouters, Joyce Sanders, Annegien Broeks, Karijn P.M. Suijkerbuijk, **Georgina V. Long**, Alexander C.J. van Akkooi#, Christian U Blank,#, Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma, **Mar 25 2024**, *JITC*, *accepted for publication*
9. Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus Butler, Anna Marie Di Giacomo, Mark Middleton, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil Khushalani, Paola Queirolo, **Georgina Long**, Maurice Lobo, Margarita Askelson, Paolo Ascierto*, James Larkin*, Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238, **Mar 21 2024**, *JCO*, *accepted for publication*
10. Luke, J. J., Ascierto, P. A., Khattak, M. A., de la Cruz Merino, L., Del Vecchio, M., Rutkowski, P., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Kirkwood, J. M., Robert, C., Grob, J. J., de Galitiis, F., Schadendorf, D., Carlino, M. S., Wu, X. L., Fukunaga-Kalabis, M., Krepler, C., Eggermont, A. M. M., **Long, G. V.**, Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study, *J Clin Oncol*. **2024 Mar 7**:JCO2302355. doi: 10.1200/JCO.23.02355. Online ahead of print. PMID 38452313
11. Alexander M Menzies, **Georgina V Long**, Amice Kohn, Hussein Tawbi, Jeffrey Weber, Keith Flaherty, Grant McArthur, Paolo Ascierto, Yanina Pfluger, Karl Lewis, Katy Tsai, Omid Hamid, Hans Prenen, Luis Fein, Erjian Wang, Carolin Guenzel, Fan Zhang, Joseph F Kleha, Alessandra di Pietro, Michael Davies, A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis, *Neuro-Oncology Advances*, **Mar 5 2024**, *accepted for publication*

12. Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo Davide d'Arienzo, Florentia Mina, Juliane A. Czapl, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Madonna Gabriele, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Paolo Ascierto, Douglas B Johnson, **Georgina V. Long**, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana Najjar, Andrew Haydon, Pietro Quaglino, Genevieve Boland, Ryan J. Sullivan, Andrew Furness, Ruth Plummer, Keith Flaherty, Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study, *eClinicalMedicine*, **October 14 2023**, *accepted for publication*

PUBLISHED AND PRESENTED ABSTRACTS FOR MAJOR INTERNATIONAL CONFERENCES FROM 2016 ONWARDS

Conference	Presented abstracts	Year
American Society for Clinical Oncology	15	2024
American Association for Cancer Research	2	2024
Society for Melanoma Research	7	2023
European Society for Medical Oncology	6	2023
American Society of Clinical Oncology	17	2023
American Association of Clinical Oncology	10	2023
Society for Melanoma Research	14	2022
European Society for Medical Oncology	20	2022
American Association of Clinical Oncology	24	2022
Society for Melanoma Research	16	2021
European Society for Medical Oncology	11	2021
American Association for Cancer Research	2	2021
American Society of Clinical Oncology	13	2021
European Society for Medical Oncology	7	2020
American Association for Cancer Research	5	2020
American Society of Clinical Oncology	17	2020
American Society of Clinical Oncology	21	2019
European Society for Medical Oncology	15	2019
Society for Melanoma Research	11	2019

American Society of Clinical Oncology	15	2018
European Society for Medical Oncology	17	2018
Society for Melanoma Research	14	2018
American Society of Clinical Oncology	16	2017
European Society for Medical Oncology	8	2017
Society for Melanoma Research	7	2017
American Society of Clinical Oncology	16	2016

FULL LIST OF ABSTRACTS FROM 2020 ONWARDS

Conference

American Society of Clinical Oncology (ASCO)

1. Ana Arance; Steven J. O'Day; Luis de la Cruz Merino; Teresa M. Petrella; Jamal Rahima; Lars Ny; Ana Carneiro; Alfonso Berrocal; Ivan Márquez-Rodas; Anna Spreafico; Victoria Atkinson; Fernanda Costa Svedman; Chinyere Okpara; Kevin Lawlor; Scott J. Diede; Tobias Neff; **Georgina V. Long**, Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti-PD-1/L1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study
2. Reinhard Dummer; Jean-Jacques Grob; Caroline Robert; Ronnie Shapira-Frommer, Celeste Lebbe; Paolo Ascierto; Stephane Dalle; Omid Hamid; Nicolas Meyer; Muhammad Khattak; Andrew Hill; Jonathan Cohen; Giuseppe Curigliano; Anna Maria Di Giacomo; Michele Del Vecchio; Sekwon Jang; Rohini Singh; Xuan Peng, Scott J. Diede; **Georgina V. Long** – oral presentation
3. **Georgina V. Long**, Robert Haddad, Caroline Robert, Laurent Mortier, Dirk Schadendorf, Ravindra Uppaluri, Inge-Marie Svane, Philippe Saiag, Annette M. Lim, Ainara Soria Rivas, Richard A. Scolyer, Marya Chaney, Cecilie Abildgaard, Qasim Ahmad, Francois Ringeisen, Diane Opatt McDowell, Barbara Burtness, A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors
4. Axel Hauschild, Reinhard Dummer, Mario Santinami, Paul Chapman, Victoria Atkinson, Mario Mandala, Barbara Merelli, Vanna Chiarion Sileni, Andrew Haydon, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Elizabeth Plummer, James Larkin, Monique Tan, Sachin Bajirao Adnaik, Paul Burgess, Tarveen Jandoo, **Georgina V. Long**, Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study – oral presentation
5. Anstas, George; Buchbinder Elizabeth, Luke Jason, Jeffrey Weber, Theresa Medina, Huang Mo, Gibney Geoffrey, Manju Morrissey, Healy Jane Anne, Sullivan Ryan J, Michelle Brown, Tran Thuy, Vasudha Sehgal, Tarek Meniawy, Segar Jennifer, Zaks Tal, Huzhang Mao, Taylor Matthew, Faries Mark, Atkinson Victoria, Cowey Charles, Kim, Kevin, Igor Feldman, Jia Guo, **Georgina Long**, Carlino Matteo, Robert Meehan, Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected

melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial - **oral presentation**

6. **Georgina Long**, Victoria Atkinson, Paolo Ascierto, Diwakar Davar, Omid Hamid, Caroline Robert, Marcus Butler, Reinhard Dummer, Christine Hafner, Muhammad Adnan Khattak, James Larkin, Paul Lorigan, Meredith McKean, Rino Seedor, Heather Shaw, Joseph Stephenson, Yuan Yuan, Roma Patel, Piruntha Thiyagarajah, Dirk Schadendorf, A Phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301)
7. Li Zhou, Ed Hsiao, Serigne Lo, Matteo Carlino, George Au-Yeung, Maria Gonzalez, Andrew Spillane, Tom Pennington, Julie Howle, Kerwin Shannon, Rony Kapoor, Jonathan Stretch, David Gyorki, Robyn Saw, Sydney Ch'Ng, Richard Scolyer, **Georgina Long**, Alexander Menzies, FDG-PET Associations with Pathological Response and Survival with Neoadjuvant Immunotherapy for Melanoma
8. Maria Gonzalez, Alexander Van Akkooi, Sydney Ch'ng, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, Michael Rtshiladze, Thomas Pennington, David Coker, Robyn P.M. Saw, Rony Kapor, Edward Hasio, Robert V. Rawson, Monica Osorio, Alexander M. Menzies, Serigne N. Lo, Richard A. Scolyer, Angela Hong, **Georgina V. Long**, Ines Silva, A Phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel Cell Carcinoma (Neo-MCC)
9. Paolo Antonio Ascierto, Reinhard Dummer, Caroline Gaudy, Samantha Bowyer, Evan J. Lipson, Eleonora Ghisoni, Mark Middleton, Barbara Ratto, Will Jackson, Alicia Cheong, Sourav Mukherjee, Jenny Wu, **Georgina V. Long**, Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: results from RELATIVITY-048 – **Oral presentation**
10. C.U. Blank, M.W. Lucas, R.A. Scolyer, B.A. van de Wiel, A.M. Menzies, M. Lopez-Yurda, A.C.J. van Akkooi, W.J. van Houdt, R.P.M. Saw, A. Torres-Acosta, S.N. Lo, G.A.P. Hospers, M.S. Carlino, J.W.B. de Groot, E. Kapiteijn, K.P.M. Suijkerbuijk, P. Rutkowski, S. Sandhu, A.A.M. van der Veldt, **G.V. Long**, Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: the phase 3 NADINA trial – **Oral presentation**
11. Jeffrey S. Weber; Jason J. Luke; Matteo S. Carlino; Muhammad A. Khattak; Robert Meehan; Michelle Brown; Jinchun Zhang; Clemens Krepler; J. Paul Duic; **Georgina V. Long**, INTerpath-001 trial in progress: pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma
12. Ines Pires da Silva, Jordan Conway, Akshaya Ramanathan, Laura Smith, Robert Rawson, Piyush Grover, Nigel Maher, Jorja Braden, Maria Gonzalez, Umaimainthan Palendira, Alexander Menzies, Richard A Scolyer, **Georgina Long**, Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (NeoPele); analysis of tumor microenvironment (TME) and pathological response
13. Eleanor Handel, Janet McKeown, Joe Wei, Roma Kanaria, Hannah Burnette, Aleigha Lawless, Juliane Czapla, Lea J Albrecht, Johanna Mangana, Jolien Kessels, Clara Allayous, Christina Boatwright, Margaret Ottaviano, Anna M Czarnecka, Serigne Lo, **Georgina Long**, Alexander Menzies, Matteo Carlino, Outcomes following long-term disease control with checkpoint inhibitors in patients with advanced melanoma
14. Davies, MA; Simon, JM; Menzies, A; Milton, DR; Wilmott, JS; Ledesma, DA; Burton, EM; Ferguson, SD; Tawbi, HA; Glitza, IC; Gershenwald, JE; Torres-Cabala, CA; Lazar, AJ; Saw, RPM; Spillane, A; Carlino, M; Scolyer, RA; Long, GV, Incidence and risk factors for central nervous system (CNS)

metastasis (met) in stage III melanoma patients (pts) treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT)

15. Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma

American Association of Cancer Research (AACR)

1. Michael Abadier, Ryan Sullivan, Jacky Chow, Vasudha Sehgal, Randy Sweis, Adil Daud, Ronnie Shapira-Frommer, Ruth Perets, Shivaani Kumar, Meredith McKean, Ravit Geva, Manish R. Patel, Adnan Khattak, Pablo Fernandez- Peñas, Sima Zacharek, Natalia Wahl, Russell Walker, Linh Van, Jim Ward, Khanh T. Do, **Georgina V. Long**, Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36 γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors – **oral presentation** April 2024

Society Melanoma Research (SMR)

1. **Georgina V. Long**, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, John M. Kirkwood, Adjuvant nivolumab (NIVO) versus placebo (PBO) in stage IIB/C melanoma: longer follow-up from CheckMate 76K – **oral presentation** Nov 2023
2. Jeffrey S. Weber, Jason J. Luke, Matteo S. Carlino, Robert Meehan, Michelle Brown, Jinchun Zhang, Clemens Krepler, J. Paul Duic, **Georgina V. Long**, Adjuvant V940 (mRBA-4157) with pembrolizumab versus placebo in patients with high-risk stage II-IV melanoma: trial in progress
3. John M. Kirkwood, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Tarek Meniawy, Stephane Dalle, Mario Mandala, Alexander van Akkooi, Ayman Nassar, Jasmin Ashour, Federico Campigotto, **Georgina V. Long**, Michele Del Vecchio, Adjuvant nivolumab (NIVO) v placebo (PBO) in stage IIB/C melanoma: longer follow-up from CheckMate 76K – **oral presentation**
4. **Georgina V. Long**, Michael A. Davis, Jean Jacques Grob, Axel Hauschild, John M Kirkwood, Mario Mandalà, Paul D. Nathan, Caroline Robert, Jie Yang, Lang Ho Lee, da Silva ABP, Dirk Schadendorf, Reinhard Dummer, An exploratory analysis of predictive biomarkers for treatment outcomes in patients (pts) with metastatic melanoma from phase III COMBI-i trial
5. Lenvatinib plus pembrolizumab (len + pembro) versus pembro alone for unresectable or metastatic melanoma (MEL): results of LEAP-003 -**Oral presentation**
6. John M. Kirkwood,* Peter Mohr, Christoph Hoeller, Jean-Jacques Grob, Michele Del Vecchio, Jennifer Lord-Bessen, Swetha Srinivasan, Ayman Nassar, Jasmin Ashour, Federico Campigotto, Hannah Fairbanks, Fiona Taylor, Christine Yip, **Georgina V. Long**, Jeffrey Weber, Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) after complete resection of stage IIB/C melanoma in the phase 3 CheckMate 76K trial
7. Xinyu Bai, Camelia Quek, Ghamdan Al-Eryani, Kate Harvey, Ines Pires da Silva, Alexander M. Menzies, Alex Swarbrick, **Georgina V. Long**, Richard A. Scolyer, James S. Wilmott, Single-cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy

European Society of Medical Oncology (ESMO)

1. M.W. Lucas, E.A. Rozeman, J.M. Versluis, A.M. Menzies, H. Eriksson, BA van de Wiel, RA Scolyer, J van Thienen, H Mallo, M. Gonzalez, L. Landman, A. Torres Acosta, L.G. Grijpink-Ongering, JBAG Haanen, ACJ van Akkooi, **GV Long**, CU Blank, Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma Oct 2023
2. Ines Pires da Silva, Isabel Li, Selma Ugurel, Patricio Serra-Bellver, Avanti Andhale, Hannah Burnette, Francisco Aya, Jordan W. Conway, Matteo S. Carlino, Alexander A. Menzies, Michael Weichenthal, Peter Mohr, Ralf Gutzmer, Ana M. Arance, Douglas B. Johnson, Paul Lorigan, Dirk Schadendorf, Serigne N. Lo, **Georgina V. Long**, Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma patients with liver metastases
3. Jeffrey S. Weber, Adnan Khattak, Matteo S. Carlino, Ryan J. Sullivan, Jason J. Luke, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, Mark B Faries, Thuy Tran, Charles Lance Cowey, Theresa Michelle Medina, Victoria Atkinson, Geoffrey Thomas Gibney, Elizabeth Iannotti Buchbinder, Moderna Author's Group, Robert S. Meehan, **Georgina V. Long**, mRNA-4157 individualized neoantigen therapy plus pembrolizumab in resected melanoma clinical efficacy and correlates of response, – oral presentation
4. **Georgina V. Long**, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Francisco Medina-Soto, Michele Maio, Micaela Hernberg, Jacek Mackiewicz, Sorilla Prey, Karnele Mujika, Victoria Atkinson, Jessica Hassel, Gabriela Cinat, Barbara Ratto, Saima Rodriguez, Peter Wang, Sonia Dolfi, Hussein A. Tawbi, Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047 – Oral presentation
5. ILM Reijers, P Dimitriadis, AM Menzies, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, WJ van Houdt, RPM Saw, A Broeks, S Cornelissen, L Grijpink-Ongering, Thomas Pennigton, A Colebatch, BA van de Wiel, RA Scolyer, ACJ van Akkooi and **GV Long** and CU Blank, Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
6. Evan J. Lipson, Sonia Dolfi, Tracy Tang, Helen Gogas, Hussein Tawbi, F. Stephen Hodi, Paolo A. Ascierto, Erika Gutierrez, , Dirk Schadendorf, Francisco Medino-Soto, Piotr Rudkowski, Emilio Murillo, Michele Maio, Yuanfang Xu, Keyur Desai, Annie Yu, Korey Demers, Sarah Keidel, **Georgina Long**, Charlie Garnett-Benson, Comprehensive analyses of tumor microenvironment (TME) factors and on-treatment changes in peripheral blood in patients with advanced melanoma treated with nivolumab+ relatlimab (NIVO+RELA) and NIVO alone within RELATIVITY-047 trial

American Society of Clinical Oncology (ASCO)

1. Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Barbara Ratto,15 Saima Rodriguez, Yuanfang Xu, Peter Wang, Sonia Dolfi, **Georgina V. Long**, Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047 - oral presentation June 2023
2. Jason J Luke; Paolo A Ascierto; Muhammad A Khattak; Luis de la Cruz Merino; Michele Del Vecchio; Piotr Rutkowski; Francesco Spagnolo; Jacek Mackiewicz; Vanna Chiarion-Sileni; John M Kirkwood; Caroline Robert; Jean-Jacques Grob; Federica de Galitiis; Dirk Schadendorf; Matteo S Carlino; Xi Lawrence Wu; Mizuho Fukunaga-Kalabis; Clemens Krepler; Alexander M M Eggermont; **Georgina V. Long**, Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of

- distant-metastasis free survival in the phase 3 KEYNOTE-716 study - **oral presentation**
3. Matteo S. Carlino, Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy, Ryan J. Sullivan, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Mark B Faries, Charles Lance Cowey, Geoffrey Thomas Gibney, Jason J. Luke, Sajeve Samuel Thomas, Vasudha Sehgal, Igor Feldman, Praveen Aanur, Michelle Brown, Robert S. Meehan, Celine Robert-Tissot, **Georgina V. Long**, Minimal residual disease as a predictive biomarker of recurrence free survival in high-risk melanoma patients treated with a combination of mRNA-4157 and pembrolizumab
 4. Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, **Georgina V. Long**, Ryan J. Sullivan, Mark B Faries, Thuy Tran, Charles Lance Cowey, Theresa Michelle Medina, Jennifer Margaret Segar, Victoria Atkinson, Geoffrey Thomas Gibney, Jason J. Luke, Elizabeth Iannotti Buchbinder, Robert S. Meehan, Matteo S. Carlino, Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial – **Oral Presentation**
 5. **Georgina V. Long**; Alexander M. M. Eggermont; Jeffrey E. Gershenwald; Dirk Schadendorf; Paolo A. Ascierto; Reinhard Dummer; Axel Hauschild; Matteo S. Carlino; Antoni Ribas; Caroline Robert; Richard A. Scolyer; Vernon K. Sondak; Jonathan E. Cohen; Jinchun Zhang; Dmitri Grebennik; Clemens Krepler; Jason J. Luke, KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma
 6. **Georgina V. Long**, John M. Kirkwood, Christoph Hoeller, Jean-Jacques Grob, Jeffrey Weber, Janis Taube, Peter Mohr, Alexander van Akkooi, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Daniel Tenney, Sonia Dolfi, Tracy Tang, Corey Ritchings, Maurice Lobo, Federico Campigotto, Wenjia Wang, Brian R. Gastman,* Michele Del Vecchio, Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K) – **oral presentation**
 7. Piyush Grover, Isabel Li, Lydia Warburton, Alexander M. Menzies, **Georgina V. Long**, Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID)
 8. Maria Gonzalez, Alexander Christopher Jonathan Van Akkooi, Andrew John Spillane, Sydney Ch'ng, Kerwin Frank Shannon, Jonathan Stretch, Michael Alexander Rtshiladze, Thomas Pennington, Robyn P.M. Saw, Alexander M. Menzies, Robert V Rawson, Linda Martin, Pascale Guitera, Kevin London, Edward Hsiao, Rony Kapoor, Serigne N. Lo, Richard A. Scolyer, **Georgina V. Long**, A phase 2 study to determine the pathological response to neoadjuvant nivolumab (nivo) & relatlimab (rela) in high risk stage II cutaneous melanoma (NeoReNi II)
 9. Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy, Rachel Woodford, Janet McKeown, Lotte Hoeijmakers, Joanna Mangana, Celeste Lebbe, Farzana Yasmin Zaman, Francisco Aya Sr., John Marsiglio, Rachel S Goodman, Victoria Rayson, Joanna Placzke, Jolien Isabel Kessels, Egle Ramelyte, Waqas Haque, Isabella Wilson, Claudia Trojaniello, Rachel Roberts-Thomson, Caroline Robert, **Georgina V. Long**, Alexander M. Menzies
 10. Dirk Schadendorf,* Hussein Tawbi, Evan Lipson, F Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiquiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Leon A. Sakkal, **Georgina V. Long**, Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO+RELA) versus nivolumab plus

ipilimumab (NIVO+IPI) in advanced melanoma: an indirect treatment comparison (ITC) using patient-level data (PLD)

11. ILM Reijers, AM Menzies, JM Versluis, RPM Saw, W van Houdt, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, H Eriksson, GAP Hospers, WMC Klop, M Lopez-Yurda, L Grijpink-Ongering, M Gonzalez, A Spillane, RA Scolyer, BA van de Wiel, ACJ van Akkooi, **GV Long** and CU Blank, The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma – 3-year data of PRADO and OpACIN-neo – **oral presentation**
12. Rachel S. Goodman, Aleigha Lawless, Rachel Woodford, MPhil; Faisal Fa'ak, Asha Tipirneni, J. Randall Patrinely, Hui Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Janice Mehnert, **Georgina Long**, Ryan Sullivan, Matteo S. Carlino, Alexander M. Menzies, Douglas B. Johnson, Long-Term Outcomes of Chronic Immune-Related Adverse Events (irAEs) from Adjuvant Anti-PD1 for High-Risk Resected Melanoma
13. ILM Reijers, I Fraterman, Petros Dimitriadis, Annegien Broeks, M Gonzalez, Alexander M Menzies, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, GV Long, CU Blank and LV Van de Poll-Franse, The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma
14. Alexander Christopher Jonathan Van Akkooi, Axel Hauschild, **Georgina V. Long**, Mario Mandalà, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul Lorigan, Alexander M. Eggermont, Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
15. Tamar Melkadze, Miranda Gogishvili, Tamta Makharadze, David Giorgadze, Mariam Zhvania, Khatuna Vacharadze, John Crown, Ana Baramidze, Omid Hamid, **Georgina Long**, Caroline Robert, Mario Sznol, Michael Smylie, Hector Martínez-Said, Jayakumar Mani, Usman Choudhary, Mark Salvati, Israel Lowy, Matthew Fury, Giuseppe Gullo, A phase 3 trial evaluating the superiority of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) compared to pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma
16. M.W. Lucas, P. Dimitriadis, I.L.M. Reijers, A.M. Menzies, E.A. Rozeman, J.M. Versluis, A.C. Huang, S. Cornelissen, A. Broeks, R.A. Scolyer, T.C. Mitchell, **G.V. Long** and C.U. Blank, Revisiting the Optimal Neoadjuvant Immunotherapy Regimen in Resectable Stage III Melanoma based on the Interferon Gamma Signature: a Pooled Analysis
17. Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Johnson Douglas, Elisabeth Livingstone Alexander Roesch, Selma Ugurel, Carsten Schulz, Carola Berking, Alexander M. Menzies, **Georgina V. Long**, Reinhold Dummer, Dirk Schadendorf, Lisa Zimmer, Anti-PD-1 plus BRAF/MEK inhibitors (Triplet Therapy) after failure of standard therapy in advanced melanoma

19th EADO Congress

1. Michele Del Vecchio, John M. Kirkwood, Brian Gastman, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo, Federico Campigotto, **Georgina V. Long**, Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K) Apr 2023
2. Florentia Dimitriou, Phil F. Cheng, Annalisa Saltari, Katrin Schaper-Gerhardt, Ramon Staeger, Veronika Haunerding, Federica Sella, Aizhan Tastanova,

Daniela Mihic-Probst, Olivier Michielin, Ralf Gutzmer, Burkhard Becher, **Georgina V. Long**, Mitchell P. Levesque, Reinhard Dummer, Multiomics analysis of immune-related adverse events in melanoma patients treated with anti-PD1-based immune checkpoint inhibitors – **oral presentation**

American Association of Cancer Research (AACR)

1. Tuba N. Gide*, Nurudeen Adegoke*, Yizhe Mao, Monica Lennox, Saurab Raj, Camelia Quek, Ismael A. Vergara,, Nigel Maher, Alison Potter, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Maria Gonzalez , Serigne E. Lo, Alexander M. Menzies, Inês Pires da Silva, Richard A. Scolyer*, **Georgina V. Long*** , James S. Wilmott*, Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: Genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP) – **Oral presentation** Apr 2023
2. Ismael A. Vergara, Serigne N. Lo, Isabel Li, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, **Georgina V. Long**, Inês Pires da Silva, Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients
3. Jordan W. Conway, Felix Marsh-Wakefield, Kazi J Nahar, Serigne N.Lo, Ismael A. Vergara, Tuba N. Gide, Grace H.Attrill, Jorja Braden, Matteo S.Carlino, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Brindha Shivalingam, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, **Georgina V. Long**, Richard A. Scolyer, Inês Pires da Silva, The association between melanoma liver metastases (mets) and the systemic anti-tumour immune profile
4. Grace H. Attrill, Eva R. Shteinman, Xinyu Bai, Camelia Quek, Umaimainthan Palendira, Ismael A. Vergara, **Georgina V. Long**, Richard A. Scolyer, James S. Wilmott, The spatial organization of the Tumour Immune Microenvironment (TIME) in primary and metastatic melanoma organisation is associated with patient outcome in primary and metastatic melanoma
5. C. Quek*, A. Pratapa*, I. Silva*, G. Al-Eryani*, A. Mayer*, N. Bartonicek, K. Harvey, C. Buckley, O. Braubach, R. Saw, J. Stretch, K. Shannon, A. Menzies, R. Scolyer*, G. Long*, A. Swarbrick*, J. Wilmott*, Distinct spatial and molecular maps in the tumour microenvironment of resistant melanoma patients treated with checkpoint inhibitor immunotherapy
6. Spira A, Gambardella V, Kato S, Perez CB, McKean M, Gonzalez-Cao M, Kim R, Chen CT, Italiano A, Cassier P, Mehnert J, Chmielowski B, Lee G, Williams R, Severson P, Unger C, Guan X, **Long GV**, Trials in Progress: A Global Phase 1/1b Clinical Trial Evaluating Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in adult patients with BRAF-Altered Solid Tumors and NRAS Mutant Melanoma – **oral presentation**
7. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Ines P. Silva, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Maria Gonzalez, Umaimainthan Palendira, Andrew Holmes, James S. Wilmott, Christian U. Blank, Richard A. Scolyer, **Georgina V. Long**, Longitudinal microbiome-immune dynamics in melanoma patients treated with immune checkpoint inhibitor immunotherapy - **oral presentation**
8. Ismael A. Vergara, Serigne N. Lo, Isabel Li, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, **Georgina V. Long**, Inês Pires da Silva, Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients
9. Srikanth Manda, Adel Aref, Erin K. Sykes, Steven G Williams, Jennifer M. Koh, Erin M Humphries, Daniel Bucio-Noble, Daniela Lee-Smith, Natasha Lucas, Dylan Xavier, Ines Da Silva, **Georgina, V. Long**, Alexander Menzies, Felicity Newell, Rosemary Balleine, Peter Hains, Graham Mann, Phil Robinson, James Wilmott, Qing Zhong, Roger Reddel, Richard A. Scolyer,

A six-protein-based risk score that predicts response and survival in patients with advanced cutaneous melanoma treated with immunotherapy

10. Reinhard Dummer, Caroline Robert, Richard Scolyer, Janis M. Taube, Michael T. Tetzlaff, Andrew Hill, Jean-Jacques Grob, David Portnoy, Celeste Lebbe, Muhammad A. Khattak, Jonathan Cohen, Gil Bar-Sela, Omid Hamid, Ronnie Shapira Frommer, Nicolas Meyer, Yixin Ren, Mizuho Fukunaga-Kalabis, Clemens Krepler, **Georgina V. Long**, KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma – **oral presentation**

Melanoma Research Alliance

1. Alexander MM Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, **Georgina V Long**, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, Susana Puig, Paolo A Ascierto, Paul Lorigan, Dmitri Grebennik, Nageatte Ibrahim, Sandrine Marreaud, Stefan Suciu, Caroline Robert, Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/KEYNOTE-054 double-blinded phase 3 trial Mar 2023
2. **Georgina V. Long**; Alexander M. M. Eggermont; Jeffrey E. Gershenwald; Dirk Schadendorf; Paolo A. Ascierto; Reinhard Dummer; Axel Hauschild; Matteo S. Carlino; Antoni Ribas; Caroline Robert; Richard A. Scolyer; Vernon K. Sondak; Jinchun Zhang; Dmitri Grebennik; Clemens Krepler; Jason J. Luke, A study of adjuvant MK-7684A (vibostolimab with pembrolizumab) versus adjuvant pembrolizumab in participants with high-risk stage II-IV melanoma (KEYVIBE-010): trial in progress

Australasian Melanoma Congress (AMC)

1. Caroline Asirvatham Gjorup, Ines Pires da Silva, Linda Martin, Jonathan Stretch, Richard Scolyer, **Georgina Long**, Angela Hong, Modality of detection of nodal recurrence in sentinel node positive patients, in whom completion lymph node dissection was omitted Mar 2023
2. Ruth O Allen, Angela L Ferguson, Ellis Patrick, John F Thompson, Richard A Scolyer, **Georgina V Long**, Umaimainthan Palendira, Angela M Hong, Immune Mapping of radio-responsive tumours using Imaging Mass Cytometry – **oral presentation**
3. Caroline Gjorup , Ines Pires da Silva, Linda Martin, Jonathan Stretch, Richard Scolyer, Georgina Long, Angela Hong, Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose
4. Su Yin Lim, Yinxing Lin, Bernadette Pedersen, Ashleigh Stewart, Jean YH Yang, Jenny Lee, Richard A Scolyer, Georgina V Long, Helen Rizos, Single cell profiling of tumour biopsies reveals molecular heterogeneity of response – **oral presentation**
5. Aaron B Beasley, Tindaro Giardina, Anna L Reid, Luisa Pinnel, Ashleigh Stewart, Russell Diefenbach, Richard A Scolyer, Georgina V Long, Michael Millward, Benhur Amanuel, Elin S Gray, Helen Rizos, Blood tumour mutational burden as a predictor of response to immunotherapy in melanoma

Society of Surgical Oncology

1. Jason J. Luke; **Georgina V. Long**; Caroline Robert; Matteo S. Carlino; Toni K. Choueiri; Naomi B. Haas; Mary O'Brien; Luis Paz-Ares; Solange Peters; Thomas Powles; Melanie A. Leiby; Jianxin Lin; Yujie Zhao; Clemens Krepler; Rodolfo F. Perini; M. Catherine Pietanza; Ayman Samkari; Todd Mar 2023

Gruber; Nageatte Ibrahim; Alexander M. M. Eggermont, Safety of adjuvant pembrolizumab (pembro) in a pooled analysis of phase 3 clinical trials in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC)

2. Charles H. Yoon; Merrick I. Ross; Brian R. Gastman; Jason J. Luke; Paolo A. Ascierto; **Georgina V. Long**; Piotr Rutkowski; Muhammad Khattak; Michele Del Vecchio; Luis de la Cruz Merino; Jacek Mackiewicz; Vanna Chiarion-Sileni; Dirk Schadendorf; Matteo Carlino; Yujie Zhao; Mizuho Fukunaga-Kalabis; Clemens Krepler; Alexander M. M. Eggermont; Jeffrey E. Gershenwald; Vernon K. Sondak. Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study – **Oral presentation**

Melanoma Bridges

1. Alexander Menzies, **Georgina Long**, Aimee Kohn, Hussein Tawbi, Jeffery Weber, Keith Flaherty, Grant McArthur, Paolo A. Ascierto, Yanina Pfluger, Karl Lewis, Katy Tsai, Omid Hamid, Hans Prenen, Luis Fein, Erjian Wang, Carolin Guenzel, Fan Zhang, Joseph F Kleha, Alessandra Di Pietro, Michael Davies,, POLARIS: A randomized Phase 2 trial of encorafenib plus binimetinib (enco+bini) evaluating a high- and standard-dose regimen in patients with BRAFV600-mutant melanoma with brain metastasis (MBM) – **Oral presentation** Nov 2022

HDR Student Cancer Research Symposium

1. Alexander Siu, Georgina V. Long, Richard A. Scolyer, James S. Wilmott, Tuba N. Gide, Ines P. da Silva, Biomarkers of Response and Resistance to Lenvatinib plus Anti-PD-1 in Advanced Melanoma - **Oral presentation** Nov 2022
2. Michael Xie, T. N. Gide, C. Quek, G. H. Attrill, X. Bai, G. V. Long, R. A. Scolyer, J. S. Wilmott, Investigating predictive biomarkers in adjuvant immunotherapy for stage III melanoma patients – **Oral presentation**
3. Grace H. Attrill, Eva R. Shteinman, Xinyu Bai, Camelia Quek, Umaimainthan Palendira, Ismael A. Vergara, Georgina V. Long, Richard A. Scolyer, James S. Wilmott, Spatial characterisation of the tumour immune microenvironment in primary and metastatic melanoma – **Oral presentation**
4. Ella McCutcheon, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Ines P. da Silva, Tuba N. Gide, Identifying and Matching Novel Combination Immunotherapies to the Correct Patients in Advanced Melanoma – **Oral presentation**

American Rheumatology Conference

1. Alana Bruce, Georgina V. Long, Alexander M. Menzies, Brian Fernandes, Fredrick Joshua, Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions Nov 2022

SITC

1. **Georgina V. Long**, Tracy Tang, Abraham Apfel, David J. Paulucci, Scott D. Chasalow, Daniel J. Tenney, Gina Fusaro, Dirk Schadendorf, Hussein Tawbi, F. Stephen Hodi, Pratik K. Thakkar, James Larkin, Jedd D. Wolchok, Megan Wind-Rotolo, Shu-Pang Huang, Peter Mohr, Caroline Robert, Christoph Hoeller, Jean-Jacque Grob, Helen Gogas, Jeffrey S. Weber, Han Chang, Rebecca A. Moss, Charlotte Watson, Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) Nov 2022

2. Sonia Dolfi, Tracy Tang, **Georgina V. Long**, Paolo A. Ascierto, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, John Wojcik, Jennifer Postelnek, Yu Wang, Anne Marie Sobiesk, Kaushal Mishra, Sarah Keidel, Karen Miller-Moslin, Hussein A. Tawbi*, Charlie Garnett-Benson*, Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology
3. Celeste Lebbe, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Evan Muñoz Couselo, Caio Pereira, Shahneen Sandhu, Ming Zhuo, Brendan Curti, Nikhil Khushalani, Adi Diab, Matthew Taylor, Alfons Van Den Eertwegh, Gaele Quereux, Ute Hoch, **Georgina Long**, Yull Arriaga, Helen Gogas, Mechanism of action of bempegaldesleukin (BEMPEG) and nivolumab (NIVO) vs. NIVO monotherapy in patients with unresectable or metastatic melanoma from the phase 3 PIVOT IO 001 clinical trial
4. ILM Reijers, P Dimitriadis, J Traets, RPM Saw, JM Versluis, TE Pennington, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, W van Houdt, A Broeks, S Cornelissen, A Spillane, BA van de Wiel, RA Scolyer, AM Menzies, ACJ van Akkooi, **GV Long**, CU Blank, Response and survival data of the PRADO trial testing neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma stratified according to the interferon-gamma (IFN- γ) signature and tumor mutational burden (TMB)

Australian and New Zealand Society for Immunology (ASI)

1. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Ines P. Silva, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Robyn P. M. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Christian U. Blank, Richard A. Scolyer, Georgina V. Long, Longitudinal analysis of circulating immune cell subsets in melanoma patients treated with immune checkpoint inhibitor immunotherapy – **oral presentation** Nov 2022
2. Kazi J Nahar*, Felix Marsh-Wakefield*, Annie Tasker, Richard A Scolyer, **Georgina V Long**, Alexander M Menzies*, Umaimainthan Palendira*, Lessons from immunotherapy-induced immune related adverse events

ACR Convergence

1. Alana Bruce, Alexander M Menzies, Georgina V Long, Brian Fernandes, Fredrick Joshua, Rheumatic toxicities of Immune checkpoint inhibitors predict favourable tumour responses in patients with advanced melanoma – **Oral Presentation** Nov 2022
2. Alana Bruce, Alexander M Menzies, Georgina V Long, , Brian Fernandes, Fredrick Joshua, Rheumatic toxicities of immune checkpoint inhibitor therapy in patients with advanced melanoma and the effect of pre-existing autoimmune and non-immune mediated rheumatic conditions

Society for Melanoma Research (SMR)

1. Jean-Jacques Grob; Reinhard Dummer; Caroline Robert; Ronnie Shapira-Frommer; Hussein A. Tawbi; Celeste Lebbe; Paolo Ascierto; Stephane Dalle; Omid Hamid; Nicolas Meyer; Muhammad Khattak; Andrew Hill; Jonathan Cohen; Giuseppe Curigliano; Michele Maio; Michele Del Vecchio; Sekwon Jang; Rohini Singh; Xuan Peng; Scott J. Dieder; **Georgina V. Long**, KEYMAKER-U02 substudy 2A: pembrolizumab (pembro) plus quavonlimab (qmab) and vibostolimab (vibo) or Lenvatinib (len) in anti-PD-1/L1-refractory advanced melanoma Oct 2022
2. **Georgina V. Long**, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaele Quereux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo,

- Federico Campigotto, Brian Gastman, John M. Kirkwood, Adjuvant therapy of nivolumab versus placebo in patients with stage IIB/C melanoma (CheckMate 76K) – **oral presentation**
3. **Georgina V. Long**, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D. Lao, Iván Márquez-Rodas, John Wagstaff, Céleste Lebbé, Jacopo Pigozzo, Caroline Robert, Paolo A. Ascierto, Victoria Atkinson, Michael A Postow, Michael B. Atkins, Mario Sznol, Margaret K. Callahan, Suzanne L. Topalian, Jeffrey A. Sosman, Srividya Kotapati, Pratik Thakkar, Corey Ritchings, Melanie Pe Benito, Sandra Re, Samira Soleymani, F. Stephen Hodi, Pooled long-term outcomes with nivolumab plus ipilimumab (NIVO+IPI) and NIVO in advanced melanoma
 4. James S. Wilmott, Hussein Tawbi, Johnathan A Engh, Nduka Amankulor, Brindha Shivalingam,, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M Ferguson, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Lisa H. Butterfield, Richard A. Scolyer, John Kirkwood*, **Georgina V. Long***, Michael A. Davies*, Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases
 5. Xinyu Bai, Camelia Quek, Ines Silva, Alex Menzies, **Georgina V. Long**, Richard A. Scolyer and James S. Wilmott, Spatial analysis characterises cellular immunotypes of in-transit melanoma associated with response to checkpoint immunotherapy
 6. Mahrukh M. Syeda, Jennifer M. Wiggins, Saim Ali, **Georgina Long**, Victoria Atkinson, James Garrett, Sachin Bajirao Adnaik, Noelle Hanoteau, Jan C. Brase, Maya Dajee, David Polsky, Clinical validation of BRAF mutant ctDNA as a prognostic biomarker in patients with stage III melanoma
 7. Evan J. Lipson, Hussein A. Tawbi, F. Stephen Hodi, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Deepti Warad, Saima Rodriguez, Peter Wang, Sonia Dolfi, **Georgina V. Long**, Nivolumab (NIVO) + relatlimab (RELA) versus (vs) NIVO in previously untreated metastatic or unresectable melanoma: safety outcomes in RELATIVITY-047
 8. Caroline Robert, Dirk Schadendorf, Paul Nathan, Reinhard Dummer, Samyuctha Sudhir, Hiya Banerjee, Rohan Shah, **Georgina V. Long**, Evaluating melanoma-specific survival and associated clinical factors in COMBI-i study of spartalizumab or placebo plus dabrafenib and trametinib in patients with BRAF V600–mutant metastatic melanoma
 9. Paolo A. Ascierto, Ahmad Tarhini, Andreia C. de Melo, Eva Munoz, Hussein Tawbi, Jun Guo, Margaret Callahan, Sunandana Chandra, Deepti Warad, Karin Jonczak, Anne Maria Sobiesk, Sonia Dolfi, **Georgina V. Long**, RELATIVITY-098: a phase 3, randomized, double-blind trial of adjuvant nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus (vs) NIVO after complete resection of stage III or IV melanoma
 10. Su Yin Lim, Yinxing Lin, Bernadette Pedersen, Ashleigh Stewart, Jean YH Yang, Jenny Lee, Richard A Scolyer, **Georgina V Long**, Helen Rizos, Single cell profiling of tumor biopsies reveals molecular heterogeneity of response – **Oral presentation**
 11. T. N. Gide, E. Paver, Z. Yaseen, A. M. Menzies, J. S. Wilmott*, R. A. Scolyer*, and **G. V. Long***, LAG-3 Expression and Outcome of Metastatic Melanoma Patients Treated with Combination Anti-LAG-3 + Anti-PD-1 Immunotherapies
 12. Jordan W. Conway, Serigne N.Lo, Ismael A. Vergara, Tuba N. Gide, Jorja Braden, Matteo S.Carlino, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Brindha Shivalingam, Alexander M. Menzies, James S. Wilmott, **Georgina V. Long**, Richard A. Scolyer, Inês Pires da Silva, The hypoxic microenvironment at different sites of melanoma metastasis

13. Ines Pires da Silva, Ismael Vergara, Isabel Li, Serigne Lo, Matt Carlino, Alex Menzies, Richard Scolyer, **Georgina Long**, Time-dependent prediction of development of melanoma brain metastases (MBM) from the start of BRAF/MEK inhibitors (BRAF/MEKi) or anti-PD-1(PD1)-based immunotherapy (IO)
14. Caroline Robert, Jeeyun Lee, William Sharfman, James Larkin, Paolo A. Ascierto, Jeffrey Weber, **Georgina V. Long**, Maud Fromaget, Graeme Parr, Anna Koulai, Sonia Iyer, Jyoti Nehra, Bienvenu Loembé, Emma Dean, Antoni Ribas, MONETTE: Phase 2 study of ceralasertib (cerala) ± durvalumab (durva) in patients (pts) with advanced melanoma resistant to PD-(L)1 inhibition

World Congress of the
International Academy of
Pathology (IAP)

1. J. S. Wilmott, I. A. Vergara, T. N. Gide, P. Shang, J. F. Thompson, I. P. da Silva, M. S. Carlino, A. M. Menzies, S. N. Lo. A. J. Potter, G. V. Long, R. A. Scolyer, Accuracy of large tumour mutation burden panels in FFPE melanoma samples and associations with response to Immunotherapies – **Oral presentation** Oct 2022
2. J. Braden, A.J. Potter, E. Paver, A.M. Menzies, M.S. Carlino, G. Au-Yeung, R.P.M. Saw, A.J. Spillane, J.R. Stretch, K.F. Shannon, T. E. Pennington, S. Ch'ng, D. Gyorki, J. Howle, D. Daneshvar, I.P. Silva, R.A. Scolyer, J.S. Wilmott & G.V. Long, NeoTrio Trial; Optimal Neoadjuvant Sequencing of Anti-PD1 and BRAF targeting therapy in Resectable BRAF Mutant stage IIIB/C/D Melanoma: Results of Translational Investigations
3. T. N. Gide, E. Paver, Z. Yaseen, A. M. Menzies, M. S. Carlino, R. P.M. Saw, J. F. Thompson, J. S. Wilmott*, R. A. Scolyer*, and G. V. Long*, Analysis of LAG3 Expression In Metastatic Melanoma Patients Treated With Combination Anti-LAG3 + Anti-Pd-1-Based Immunotherapies – **Oral presentation**
4. E.R. Shteinman*, I.A. Vergara*, R.V. Rawson, S.N. Lo, N. Maeda, K. Koyama, I. Pires da Silva, G.V. Long, R.A. Scolyer, J.S. Wilmott+ and A.M. Menzies+, Molecular and Clinical Correlates of HER3 Expression In Melanoma

Chinese Society of Clinical
Oncology (CSCO)

1. Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman,* Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi, Relatlimab and nivolumab vs nivolumab in previously untreated metastatic or unresectable melanoma: overall survival and response rates from RELATIVITY-047 (CA224-047) Sept 2022

European Society of Medical
Oncology (ESMO)

1. Celeste Lebbe, **Georgina V. Long**, Caroline Robert, Omid Hamid, Victoria Atkinson, Alexander N. Shoushtari, Adil Daud, Oliver Becher, Dirk Schadendorf, Ryan J. Sullivan, Reinhard Dummer, Jean-Jacques Grob, Nancy Lewis, Liqiong Fan, Sumit Basu, Giordano Caponigro, Vesselina Cooke, Allen Lau, Rodabe N. Amaria, Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma – **LBA – Oral Presentation** Sept 2022
2. **Georgina V. Long**, Rodabe Amaria, Ahmad Tarhini, Paolo A. Ascierto, Ed Cha, Olivera Cirovic, Denise Cotting, Volker Teichgräber, Christian U. Blank, A Phase Ib/II Multicenter, Randomized Umbrella Study Evaluating

- the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (MORPHEUS-MELANOMA)
3. ILM Reijers, AM Menzies, JM Versluis, P Dimitriadis, MW Wouters, RPM Saw, WMC Klop, TE Pennington, WJ van Houdt, LJW Bosch, S Cornelissen, M Lopez-Yurda, LG Grijpink-Ongering, RV Rawson, AJ Spillane, RA Scolyer, BA van de Wiel, ACJ van Akkooi, **GV Long** and CU Blank, Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN- γ sign) algorithm
 5. Alexander HR Varey, Mary-Ann El-Sharouni, Julie Simon, Jeffrey E Gershenwald, **Georgina V Long**, Richard A Scolyer, John F Thompson, Serigne N Lo, Predicting recurrence free survival for stage II melanoma patients – a validated tool to guide adjuvant systemic therapy
 6. Amelia M Taylor, Claire Galea, Kerwin Shannon, Sydney Ch'ng, Robyn Saw, Thomas Pennington, Jonathan Stretch, Andrew Spillane, Alexander C J van Akkooi, Alexander HR Varey, Ines P da Silva, Matteo S Carlino, Richard A Scolyer, Georgina V Long, Serigne Lo, Alexander M Menzies, A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
 7. Julia Lai-Kwon, Brooke Kelly, Sarah Lane, Rebecca Biviano, Iris Bartula, Frank Brennan, Ingrid Kivikoski, Jake Thompson, Haryana Dhillon, Alexander Menzies, **Georgina V. Long**, Feasibility, acceptability and utility of a nurse-led survivorship program for people with metastatic melanoma
 8. F. Stephen Hodi, Hussein A. Tawbi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Saima Rodriguez, Peter Wang, Sonia Dolfi, **Georgina V. Long**, Nivolumab (NIVO) + Relatlimab (RELA) Vs NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Response Outcomes From RELATIVITY-047
 9. Dirk Schadendorf, Keith T. Flaherty, Hussein A. Tawbi, Caroline Robert, Paul D. Nathan, Reinhard Dummer, **Georgina V. Long**, Paolo A. Ascierto, Mario Mandalà, Axel Hauschild, Jean Jacques Grob, Rohan Shah, Braja Gopal Sahoo, Mike Lau, Antoni Ribas, Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post-hoc exploratory analysis from phase 3 COMBI-i trial
 10. Martin Gutierrez, Claire Friedman, **Georgina V. Long**, Paolo A. Ascierto, Ignacio Melero, Donald Richards, Bruno Bastos, Victor Moreno, Marc Uemura, Paul Conkling, Bradley R. Corr, Amy M. Kim, Li Zhu, Amy Hammell, Deepak Perumal, Armand Chouzy, Fernando Benavente, Ololade Awosemo, Dung T. Le, Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA 4) Probody BMS-986249 ± Nivolumab (NIVO) in Patients (pts) With Advanced Cancers: Updated Phase 1 Results
 11. Judith M. Versluis, Robert Elens, Irene L.M. Reijers, Alexander M. Menzies, Astrid A.M. van der Veldt, Ellen Kapiteijn, Elisa A. Rozeman, Martin C. Klop, Winan J. van Houdt, Robyn P.M. Saw, Charlotte L. Zuur, Thomas E. Pennington, Bart A. van de Wiel, Richard A. Scolyer, Annegien Broeks, Alexander van Akkooi, **Georgina V. Long**, Christian U. Blank, Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma – **Oral presentation**
 12. J. Mo, A.-S. Bohne, C. Gaudy Marqueste, N. Della Marta, L. Festino, C. Chen, S. Lo, J. Park, P. Ascierto, R. Ladwa, W. Xu, J.-J. Grob, A. Hauschild. A. Menzies, G. Long, M. Carlino, I. Pires da Silva, Patterns of response/progression and management following progression with anti-PD-(L)1 in patients (pts) with advanced Merkel Cell Carcinoma (MCC)

13. Paul D. Nathan, Jean-Jacques Grob, Reinhard Dummer, Paolo A. Ascierto, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Keith T. Flaherty, Hussein A. Tawbi, Axel Hauschild, Mario Mandalà, Rohan Shah, Hiya Banerjee, Mike Lau, **Georgina V. Long**, Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of Phase III COMBI-i trial
14. **Georgina V. Long**, Andrew Spillane, Thomas Pennington, Kerwin Shannon, Jonathan Stretch, Maria Gonzalez, Robyn P.M. Saw, Scrigne Lo, Richard A. Scolyer, Alexander M. Menzies, NeoPeLe: A Phase 2 Trial of Neoadjuvant (NAT) Pembrolizumab (Pembro) Combined with Lenvatinib (Lenva) In Resectable Stage III Melanoma
15. Diab A, Gogas H, Sandhu S, **Long GV**, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu T, Munoz Couselo E, Perfetti A, Lebbe C, Meier F, Curti B, Rojas C, Yang H, Zhou M, Ravimohan S, Tagliaferri M, Khushalani NI, PIVOT IO 001: first disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) in combination with nivolumab (NIVO) versus NIVO monotherapy in advanced melanoma (MEL) – **Oral presentation**
16. Rebecca C. Simpson, Marcel Batten, Erin R. Shanahan, Ines P. Silva, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Robyn P. M. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Christian U. Blank, Richard A. Scolyer, **Georgina V. Long**, Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo) – **Oral presentation**
17. Florentia Dimitriou, Jessica C. Hassel, Marlana M. Orloff, Isaac F. Hughes, Ellen Kapiteijn, Inderjit Mehmi, Kamaneh Montazeri, Douglas B. Johnson, Piyush Grover, Camille L. Gerard, Ester Simeone, Caroline Gaudy, Phil F. Cheng, **Georgina V. Long**, Richard D. Carvajal, Reinhard Dummer, Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in patients (pts) with metastatic uveal melanoma (mUM)
18. **Georgina V. Long**, Keyur Desai, Hao Tang, Jeff Weber, Sonia Dolfi, Corey Ritchings, Shu-Pang Huang, Mohan Bolisetty, Mark Sausen, Michele Del Vecchio, James Larkin, Jonathan Baden, David Balli, Han Chang, John Loffredo, Megan Wind-Rotolo, Daniel J. Tenney, Association of Pre-Treatment ctDNA with Disease Recurrence and Clinical and Translational Factors in Patients with Stage IIIB-D/IV Melanoma Treated with Adjuvant Immunotherapy (CheckMate 915) – **Oral presentation**
19. J. Braden, A. Potter, E. Paver, R Rawson, A. Menzies, M. Carlino, G. Au-Yeung, R. Saw, A. Spillane, J. Stretch, K. Shannon, T. Pennington, S. Ch'ng, D. Gyorki, J. Howle, D. Daneshvar, J. Wilmott, S. Lo, I. Silva, R. Scolyer, & **G. Long**, Neotrio Trial – Optimal Neoadjuvant Sequencing Of Anti-Pd1 And BRAF Targeting Therapy In Resectable BRAF Mutant Stage IIIB/C/D Melanoma: Results Of Histopathological Analysis
20. Alexander MM Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, **Georgina V Long**, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, Susana Puig, Paolo A Ascierto, Paul Lorigan, Dmitri Grebennik, Nageatte Ibrahim, Sandrine Marreaud, Stefan Suci, Caroline Robert, Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial
21. Xue Bai, Stefanie C. Gerstberger, Benjamin C. Park, Seungyeon Jung, Rebecca Johnson, Naoya Yamazaki, Dai Ogata, Yoshiyasu Umeda, Caili Li, Lu Si, Keith T. Flaherty#, Yasuhiro Nakamura#, Kenjiro Namikawa#, Georgina V. Long#, Alexander M. Menzies#, Douglas B. Johnson#, Ryan J. Sullivan#, Genevieve M. Boland#, Jun Guo#, Adjuvant anti-PD-1 monotherapy benefit varies across different ethnicities and melanoma subtypes

World Congress of the
International Academy of
Pathology

22. C. Quek*, A. Pratapa*, I. Silva*, G. Al-Eryani*, A. Mayer*, N. Bartonicek, K. Harvey, C. Buckley, O. Braubach, R. Saw, J. Stretch, K. Shannon, A. Menzies, R. Scolyer*, **G. Long***, A. Swarbrick*, J. Wilmott*, Spatially Resolved Single-Cell Features Reveal Distinct Cellular Maps In The Tumour Microenvironment Of Melanoma Patients With Primary And Acquired Resistance To Immunotherapies – **Oral presentation** Oct 2022

European League Against
Rheumatism ASM

1. Alana Bruce, Georgina V Long, Alexander M Menzies, Brian Fernandes, Fredrick Joshua, Predictors of rheumatic toxicities of immune checkpoint inhibitors and cancer outcomes in patients with advanced melanoma June 2022

American Society for Clinical
Oncology (ASCO)

1. Reinhard Dummer, **Georgina V. Long**, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Neha Pakhle, Sorcha Waters, Antoni Ribas, Dirk Schadendorf, Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: 3-year overall survival (OS) data from the randomized part 3 of the Phase III COMBI-i trial June 2022
2. Ines Esteves Domingues Pires Da Silva, Serigne N. Lo, Jordan W. Conway, Richard A. Scolyer, Matteo S. Carlino, Alexander M. Menzies, **Georgina V. Long**, VEGF inhibitors in liver metastases in any cancer type: meta-analysis and systematic review
3. J.M. Versluis, K. Sikorska, E.A. Rozeman, A.M. Menzies, H. Eriksson, W.M.C. Klop, R.P.M. Saw, B.A. van de Wiel, R.A. Scolyer, J.V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L.G. Grippink-Ongering, A. van der Wal, J.B.A.G. Haanen, A.C.J. van Akkooi, **G.V. Long**, C.U. Blank, Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma – the OpACIN and OpACIN-neo trials
4. **Georgina V. Long**, Jason Luke, Muhammad A. Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S. Carlino, Larry Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. M. Eggermont, Paolo A. Ascierto, : Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study, LBA – **oral presentation**
5. **Georgina V. Long**, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi, Relatlimab and Nivolumab Versus Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma: Overall Survival and Response Rate From RELATIVITY-047 (CA224-047), - Plenary – **oral presentation**
6. Michael G. White, Christopher P. Vellano, Miles C. Andrews, Russell G. Witt, Manoj Chelvanambi, Jennifer McQuade, Elizabeth M. Burton, Yanshuo Chu, Matthew J. Lastrapes, Michael Lau, Hiya Banerjee, Alexander J. Lazar, Michael A. Davies, Scott E. Woodman, Linghua Wang, Amy Moran, **Georgina Long**, Timothy Heffernan#, Joseph Marszalek#,

- Jennifer A. Wargo#, Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
7. Alexander M Menzies, Robyn P M Saw, Serigne Lo, Maria Gonzalez, Sydney Ch'ng, Omgo E Nieweg, Kerwin F Shannon, Peter M Ferguson, Jenny Lee, Helen Rizos, Robert V Rawson, Jonathan R Stretch, John F Thompson, Louise Emmett, Rony Kapoor, Andrew J Spillane, Richard A Scolyer, **Georgina V Long**, Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma – long-term results from the NeoCombi trial
 8. Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Laetitia Da Meda, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Florentia Dimitriou, Andrew Haydon, Serigne Lo, Alexander M. Menzies, **Georgina V. Long**, Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab
 9. **Georgina V. Long**, Kerwin Shannon, Sydney Ch'ng, Jonathan Stretch, Maria Gonzalez, Matteo Carlino, Julie Howle, David Gyorki, George Au-Yeung, Dariush Daneshvar, Robyn Saw, Thomas Pennington, Andrew Spillane, Richard A. Scolyer, Alexander M. Menzies, NeoTrio: A Randomized Trial of Neoadjuvant (NAT) Pembrolizumab (Pembro) ALONE, in Sequence (SEQ) Or Concurrent (CON) With Dabrafenib + Trametinib (D+T) In Resectable BRAF-Mutant Stage III Melanoma To Determine Optimal Combination of Therapy – **oral presentation**
 10. Roger Olofsson Bagge, Carl Jacob Holmberg, Tina J. Hieken, Jonathan S. Zager, **Georgina V. Long**, Alexander Christopher Jonathan Van Akkooi, Giorgos Karakousis, Lalit Pallan, John T. Vetto, David E. Gyorki, Paulo A Ascierto, Reinhard Dummer, Jane Yuet Ching Hui, Jacob Schachter, Hildur Helgadóttir, Hidde Kroon, Luke Daniel Rothermel, Matteo S. Carlino, Kristy Kummerow Broman, Lars Ny, The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study
 11. Amelia M Taylor, Claire Galea, Serigne Lo, Florentia Dimitriou, Sarah Jacques, Clara Allayous, Hui-Ling Yeoh, Julia Ressler, Katharina Kahler, Lucia Festino, Julia Schwarze, Alexandre Wicky, Joanna Placzke, Douglas B Johnson, Lisa Zimmer, Celeste Lebbe, Reinhard Dummer, Matteo S Carlino, **Georgina V Long**, Alexander M Menzies, Efficacy and Safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1 based immunotherapy
 12. Amelia M Taylor, Claire Galea, Kerwin Shannon, Sydney Ch'ng, Robyn Saw, Thomas Pennington, Jonathan Stretch, Andrew Spillane, Alexander C J van Akkooi, Alex Varey, Ines P da Silva, Matteo S Carlino, Richard Scolyer, **Georgina V Long**, Serigne Lo, Alexander M Menzies, A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
 13. Ines Esteves Domingues Pires Da Silva, Serigne N. Lo, Jordan W. Conway, Richard A. Scolyer, Matteo S. Carlino, Alexander M. Menzies, **Georgina V. Long**, VEGF inhibitors in liver metastases in any cancer type: meta-analysis and systematic review
 14. Serigne N. Lo, Tuba N. Gide, Maria Gonzalez, Ines P. da Silva, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Stephane Heritier, James S. Wilmott, **Georgina V. Long**, A biomarker guided Bayesian response-adaptive phase II platform trial for metastatic melanoma: the PIP-Trial design
 15. CU Blank1, ILM Reijers, T Pennington, JM Versluis, RPM Saw, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, W van Houdt, WMC Klop, K Sikorska, JA van der Hage, DJ Grünhagen, A Spillane, RV Rawson, BA van de Wiel, AM Menzies, ACJ van Akkooi and **GV Long**, Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma – **oral presentation**

16. ILM Reijers, P Dimitriadis, EA Rozeman, O Krijgsman, S Cornelissen, IJW Bosch, A Broeks, BA van de Wiel, AM Menzies, RA Scolyer, **GV Long** and CU Blank, The interferon-gamma (IFN- γ) signature from baseline tumor material predicts pathological response after neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in stage III melanoma
17. Brian Gastman*, Caroline Robert*, Helen Gogas, Piotr Rutkowski, **Georgina Long**, Marya F. Chaney, Harshada Joshi, Yu-Lin Lin, Wendy Snyder, Jason A. Chesney, Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti-PD-1 therapy: MASTERKEY-115
18. Dirk Schadendorf, Axel Hauschild, Mario Mandalà, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Paul D. Nathan, Michael A. Davies, Hiya Banerjee, Rohan Shah, Mike R. Lau, Reinhard Dummer, **Georgina V. Long**, Adjuvant dabrafenib + trametinib (D + T) vs placebo in patients with resected stage III BRAFV600-mutant melanoma: updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD
19. Harvey, C; Nahar, K; Lo, S; Ahmed, T; Taylor, A; Farag, S; Yousaf, N; Young, K; Tas, L; Eggink, A; Blank, C; Wang Y; McQuade, J; Schilling, B; Johnston, DB; Robert, M; Arance, A; Lee, J; Zimmer, L; **Long, GV**; Menzies, AM, Management of Infliximab-Refractory Immune Checkpoint Inhibitor Luminal Gastrointestinal toxicity: A multi-centre case series
20. Hussein A. Tawbi, Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman*, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Karin Jonczak, Anne Marie Sobiesk, Sonia Dolfi, **Georgina V. Long**, Nivolumab (NIVO) + relatimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047 – **oral presentation**
21. Muhammad Khattak; Jason Luke; Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study; Paolo A. Ascierto; Piotr Rutkowski; Dirk Schadendorf; Caroline Robert; Jean-Jacques Grob; Luis De La Cruz Merino; Michele Del Vecchio; Francesco Spagnolo; Jacek Mackiewicz; Vanna Chiarion-Sileni; Matteo S. Carlino; Peter Mohr; Ruixuan Jiang; Mizuho Fukunaga-Kalabis; Clemens Krepler; Alexander Eggermont; John Kirkwood, Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study
22. Antoni Ribas; Pier Francesco Ferrucci; Victoria Atkinson; Rosalie Fisher; **Georgina V. Long**; Donald Lawrence; Michele Del Vecchio; Omid Hamid; Henrik Schmidt; Jacob Schachter; Paola Queirolo; Sachin Agarwal; Wilson H. Miller, Jr.; Matteo S. Carlino; Anna Maria Di Giacomo; Inge Marie Svane; Razi Ghorji; Rohini Singh; Scott Dieder; Paolo A Ascierto, Pembrolizumab (pembro) plus dabrafenib and trametinib in BRAFV600E/K-mutant melanoma: long-term follow up of KEYNOTE-022 parts 1, 2 and 3
23. M.W.Lucas, J.M. Lijnsvelt, S.M. Pulleman, A.C.J. van Akkooi, W.J. van Houdt, K.P.M. Suijkerbuijk, E.W. Kapiteijn, A.A.M. van der Veldt, M.S. Carlino, S. Sandhu, A.M. Stevense, M.J.B. Aarts, G.A.P. Hospers, C.L. Zuur, W.M.C. Klop, **G.V. Long** and C.U. Blank, The NADINA trial: A multicenter, randomised phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma – **oral presentation**
24. Alexander H.R. Varey, **Georgina V. Long**, Richard A. Scolyer, Jeffrey E. Gershenwald, Julie Simon, John F. Thompson, Serigne N. Lo, A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma

25. M.W. Lucas, J. Lijnsvelt, S. Pulleman, R.A. Scolyer, A.M. Menzies, A.C.J. van Akkooi, W.J. van Houdt, K. Shannon, T.E. Pennington, E.W. Kapiteijn, K.P.M. Suijkerbuijk, S. Sandhu, G.A.P. Hospers, A.A.M. van der Veldt, M. Stevense, M.S. Carlino, J.W.B. de Groot, P. Rutkowski, G.V. Long and C.U. Blank, The NADINA trial: A multicenter, randomised phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma

Australian Rheumatology Association National ASM

- Alana Bruce, **Georgina V Long**, Alexander M Menzies, Brian Fernandes, Fredrick Joshua, Rheumatic toxicities of immune checkpoint inhibitors in an Australian melanoma cohort May 2022

18th EADO Congress

1. Alexander C. J. van Akkooi*, Axel Hauschild*, **Georgina V. Long***, Mario Mandala*, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul C. Lorigan, Alexander M. M. Eggermont, Phase III Study of Adjuvant Encorafenib Plus Binimetinib Versus Placebo In Fully Resected Stage Iib/C BRAFV600-Mutated Melanoma: COLUMBUS-AD Study Design April 2022

American Association for Cancer Research (AACR)

1. Grace H. Attrill, Teresa A. Bailey, Trina Lum, Jordan W. Conway, **Georgina V. Long**, James S. Wilmott, Richard A. Scolyer, Molecular analysis finds excision margin width predictive of recurrence in acral melanoma April 2022
2. Aung Naing, Margaret Callahan, Brian A. Costello, Brendan Curti, Evan Hall, Aaron Hansen, **Georgina V. Long**, Anthony M. Joshua, Cynthia Wetmore, Andrew Weickhardt, A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer

Melanoma Research Alliance (MRA)

1. Jason J. Luke, **Georgina V. Long**, Muhammad A. Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. Kirkwood, Caroline Robert, Jean Jacques Grob, Federica De Galitiis, Piotr Rutkowski, Dirk Schadendorf, Matteo Carlino, Peter Mohr, Reinhard Dummer, Andrew Poklepovic, Jeffrey E Gershenwald, Rachel Kloss Silverman, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Paolo Ascierto, Updated Results From the Phase 3 KEYNOTE-716 Study: Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage II Melanoma – **oral presentation** March 2022

Victorian Survivorship Conference

1. Julia Lai-Kwon, Sarah Lane, Brooke Kelly, Rebecca Biviano, Iris Bartula, Frank Brennan, Ingrid Kivikoski, Haryana Dhillon, Alexander Menzies, **Georgina V. Long**, Pilot study of a nurse-led survivorship program for people with metastatic melanoma (MELCARE)- baseline characteristics and preliminary feasibility and acceptability results March 2022

COSA

1. Victoria Atkinson, Alexander MM Eggermont, Andrey Meshcheryakov, Christian U Blank, Mario Mandala, **Georgina V Long**, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Fisher, Shahneen Sandhu, Ragini Kudchadkar, Pablo Luis Ortiz Romero, Inge Marie Svane, Alexander van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected Nov 2021

high-risk stage III melanoma: pembrolizumab crossover and rechallenge following recurrence

SITC

- 1 Aung Naing, Margaret Callahan, Brian Costello, Brendan Curti, Evan Hall, Aaron Hansen, **Georgina Long**, Anthony Joshua, Brooke Shankles, Umut Ulge, Andrew Weickhardt, A First-in-Human Phase 1 Study of NL-201 in Patients with Relapsed or Refractory Cancer Nov 2021

Australasian Melanoma Conference

1. A Potter, E Paver, A Colebatch, P Ferguson, R Rawson, S Ch'ng, R Saw, K Shannon, T Pennington, J Stretch, O Nieweg, A Spillane, M Carlino, A Menzies, **G Long**, & R Scolyer, Pathologist-initiated "reflex" BRAF mutation testing in metastatic melanoma at a tertiary referral centre – **Oral presentation** Nov 2021
2. Ismael A. Vergara, Serigne Lo, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, **Georgina V. Long** and Inês Pires da Silva, A graph-based approach to unveiling patterns of melanoma distant metastases – **Oral presentation**
3. Ismael A. Vergara*, Karina Aivazian*, Ping Shang, Matteo S. Carlino, Alexander D. Guminski, **Georgina V. Long**, James S. Wilmott, Richard A. Scolyer, Molecular features of metastatic basal cell carcinoma
4. Zarwa Yaseen, Tuba N. Gide, Jordan W. Conway, **Georgina V. Long**, Richard A. Scolyer, and James S. Wilmott, Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immunoprofiling Melanoma
5. Xu W, Atkinson V, **Long GV**, Guminski A, Sandhu S, Eastage M, Veness M, Chilkuri M, Lyle M, Nordman I, Yap M, Tothill R, Scolyer R, Poulson M, A randomized placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel Cell Carcinoma
6. Livingstone A, Dempsey K, Stockler MR, Howard K, **Long GV**, Carlino MS, Menzies AM, Morton RL. Whom should I recommend for adjuvant immunotherapy? An interview study
7. Jorja Braden, Richard Scolyer, James Wilmott, Alex Menzies, Andrew Spillane, Robyn Saw, Kerwin Shannon, Tom Pennington, Sydney Chng, Jonathan Stretch, Elizabeth Paver, Alison Potter and **Georgina Long**, Translational Investigation into the Optimal Neoadjuvant Sequencing of Anti-PD1 and BRAF targeting therapy in Resectable BRAF Mutant stage IIIB/C/D Melanoma
8. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Irene L. M. Reijers, Mark Read, Ines P. Silva, Judith Versluis, Rosilene Ribeiro, Alexandra S. Angelatos, Jian Tan, Chandra Adhikari, Alexander M. Menzies, Robyn P. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Rebecca Velickovic, Laurence Macia, Andrew J. Holmes, James S. Wilmott, Christian U. Blank, Richard A. Scolyer, **Georgina V. Long**, Enterotypes underlie gut microbial associations with clinical outcomes during anti-PD1/anti-CTLA4 immunotherapy – **Oral presentation**
9. Julia Lai-Kwon, Sarah Lane, Brooke Kelly, Iris Bartula, Frank Brennan, Haryana Dhillon, **Georgina Long**, Assessing the feasibility, acceptability and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE)- protocol for a pilot study
10. Tuba N. Gide, Serigne Lo, Camelia Quek, Ismael Vergara, Ines P. da Silva, Ping Shang, Eva Shteinman, Zarwa Yaseen, Elizabeth Paver, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Richard A. Scolyer*, **Georgina V. Long***, and James S. Wilmott*, PIP: Personalised

Immunotherapy Platform as a Predictive Tool for Immunotherapy Response in a Prospective Cohort of Patients with Metastatic Melanoma

11. Genevieve Ho; Rodrigo Jorge Schwartz Aldea; Amanda Regio Pereira; Florentia Dimitrou; Catriona McKenzie, **Georgina V Long**, Pascale Guitera, Reflectance confocal microscopy for assessment of treatment response to immunotherapy in unresectable scalp melanoma
12. Jake R. Thompson, Serigne Lo, Rachael L. Morton, Iris Bartula, Alexander M Menzies, Victoria Atkinson, Shahneen Sandhu, Michael Brown, Grant McArthur, **Georgina V. Long**, Health-Related Quality of Life of Patients with Melanoma Brain Metastases Treated with Immunotherapy: Findings from the ABC Trial – **Oral presentation**
13. Rodrigo J. Schwartz, Genevieve Ho, Annika Smith, Helena Collgros, Amanda Regio Pereira, **Georgina V. Long**, Alexander M. Menzies, Alison J. Potter, Elizabeth Paver, Richard A. Scolyer, Linda K. Martin, Successful treatment of Eruptive Keratoacanthomas with actitrein for patients on Checkpoint Inhibitor Immunotherapy
14. Grace H. Attrill, Hansol Lee, Annie T. Tasker, Eva Shteinman, Angela L. Ferguson, Ismael A. Vergara, Umaimainthan Palendira, **Georgina V. Long**, James S. Wilmott, Peter M. Ferguson, Richard A. Scolyer, Immunophenotyping of primary melanoma to predict patient outcomes
15. Grace H. Attrill*, Carina Owen, Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W. Conway, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Mainthan Palendira, Richard A. Scolyer, **Georgina V. Long**, James S. Wilmott, Tumour-specific, tumour-resident, cytotoxic T cells are associated with reduced recurrence in adjuvant PD-1 treated stage III melanoma – **Oral presentation**
16. Colebatch AJ*, Paver EC*, Vergara I, John F. Thompson, **Georgina V. Long**, Wilmott JS, Scolyer RA, Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma
17. Jen G. Cheung, Helen Rizos, Helmut Schaidler, Michael Brown, Nick Hayward, **Georgina Long**, Richard A Scolyer, Graham Mann, Mark Shackleton, AXMAP – the Australian pdX Melanoma Project

NSW Health Pathology Research Forum

1. AJ Potter, AT Li, JF Thompson, **GV Long**, S Ch'ng, RA Scolyer, Driver mutation status of cutaneous scalp melanoma – **Oral presentation** Nov 2021
2. A J Potter, E Paver, P Ferguson, R Rawson, A Colebatch, R Gupta, S O'Toole, W Cooper, **G V Long** & R A Scolyer, Pathologist-initiated “reflex” BRAF mutation testing in metastatic melanoma at a tertiary referral centre

COSA

1. **Georgina V. Long**, Reinhard Dummer, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Diede, Hussein Abdul-Hassan Tawbi, KEYMAKER-U02: Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Melanoma Nov 2021
2. **Georgina V. Long**, Luis de la Cruz-Merino, Teresa M Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Marquez Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Andrew Mant, Alan D. Smith, Ke Chen, Scott J. Diede, Klemens Krepler, Ana Arance, LEAP-004: updated data for lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progressive disease on a prior PD-(L)1 inhibitor – **oral presentation**

American Society for Dermatopathology Conference

1. AJ Potter, AT Li, JF Thompson, **GV Long**, S Ch'ng, RA Scolyer, Driver mutation status of cutaneous scalp melanoma Oct 2021

Society for Melanoma Research

- 1 Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher Lao, Jean-Jacques Grob, Engels Chou, Julia Braverman, Melissa Hamilton, Rachael Lawrance, Laurence Toms, **Georgina V. Long**, Health-related quality of life (HRQoL) with relatlimab plus nivolumab (RELA+NIVO) vs NIVO in patients (pts) with previously untreated metastatic or unresectable melanoma: RELATIVITY-047 Oct 2021
2. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Irene L. M. Reijers, Mark Read, Ines P. Silva, Judith Versluis, Rosilene Ribeiro, Alexandra S. Angelatos, Jian Tan, Chandra Adhikari, Alexander M. Menzies, Robyn P. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Rebecca Velickovic, Laurence Macia, Andrew J. Holmes, James S. Wilmott, Christian U. Blank, Richard A. Scolyer, **Georgina V. Long**, Enterotypes underlie gut microbial associations with response and toxicity from neo-adjuvant immunotherapy
3. **G. V. Long**; V. Atkinson; J. S. Cebon; A. M. Menzies; A. Diab; A. G. Hill; C. Robert; M. Butler; F. Courture; M. B. Jameson; B. M. Fitzharris; M. Brown; C. M. McNeil; S. Dalle; A. Ribas; M. B. Atkins; X. T. Li; S. J. Diede; D. Grebennik; M.S. Carlino, Long-term follow-up of KEYNOTE-029 1B and 1C: standard-dose pembrolizumab (pembro) + alternate-dose ipilimumab (ipi) in advanced melanoma
4. Grace H. Attrill, Hansol Lee, Annie T. Tasker, Eva Shteinman, Angela L. Ferguson, Ismael A. Vergara, Umaimainthan Palendira, **Georgina V. Long**, James S. Wilmott, Peter M. Ferguson, Richard A. Scolyer James S. Wilmott, Immunophenotyping of primary melanoma to predict patient outcomes – **Oral presentation**
5. Camelia Quek*, Xinyu Bai*, Ping Shang, Grace H. Attrill, Tuba Nur Gide, Peter M. Ferguson, Kazi Nahar, Umaimainthan Palendira, **Georgina V. Long***, Richard A. Scolyer* James S. Wilmott*, Identifying and targeting novel immunosuppressive driver mechanisms in adolescent and young adult (AYA) melanoma patients - **Oral presentation**
6. Caroline Robert, **Georgina V. Long**, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Dirk Schadendorf, Paul Nathan, Antoni Ribas, Piotr Rutkowski, Paul Lorigan, Pier F. Ferrucci, Hiya Banerjee, Tonatiuh Romero Salas, Rohan Shah, Mike Lau, Reinhard Dummer, Evaluating patients (pts) with a complete response (CR) in the Phase III COMBI-i study of spartalizumab (sparta) or placebo (pbo) plus dabrafenib and trametinib (DabTram) in pts with unresectable or metastatic cutaneous BRAF V600-mutant melanoma
7. Ismael A. Vergara, Serigne Lo, Alexander M. Menzies, Matteo S. Carlino Richard A. Scolyer, **Georgina V. Long**, Inês Pires da Silva, A graph-based approach unveils complex patterns of melanoma distant metastases
8. Zarwa Yaseen, Tuba N. Gide, Jordan W. Conway, **Georgina V. Long**, Richard A. Scolyer, and James S. Wilmott, Validation Of An Accurate Immunoprofiling Melanoma Method Using Automated Multiplex Immunofluorescence
9. Joanna Lee, Andrea Maurichi, Lorenza Alessi Di Guardo, Anna Maria Stagno, Lydia Warburton, Amelia Taylor, Elisabeth Livingstone, Saba Rehman, Adnan Khattak, Katharina Kahler, Vito Vanella, Victoria Atkinson, Michael Millward, Dirk Shadendorf, Douglas Johnson, Paolo

Ascierto, Serigne Lo, **Georgina V Long**, Alexander Menzies, Matteo Carlino, Cessation of BRAF+/-MEK inhibitor therapy without progression in advanced BRAF mutant melanoma

10. Russell J. Diefenbach, Jenny H. Lee, Ashleigh Stewart, Alexander M. Menzies, Matteo S. Carlino, **Georgina V. Long**, Robyn P. M. Saw, Jonathan R. Stretch, Richard A. Scolyer, and Helen Rizos, Anchored multiplex PCR custom melanoma next generation sequencing panel for analysis of circulating tumor DNA
11. Tuba N. Gide, Serigne Lo, Camelia Quek, Ismael A. Vergara, Ines P. da Silva, Ping Shang, Eva Shteinman, Zarwa Yaseen, Elizabeth Paver, Andrew J. Spillane, Jonathan R. Stretch, Kerwin F. Shannon, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Richard A. Scolyer*, **Georgina V. Long***, and James S. Wilmott*, Implementation of the Personalised Immunotherapy Platform in a Pilot Study to Predict Immunotherapy Response in Metastatic Melanoma
12. Caroline Robert, **Georgina Long**, Hussein Tawbi, Keith Flaherty, Paolo Ascierto, Dirk Schadendorf, Paul Nathan, Antonio Ribas, Piotr Rutkowski, Paul Lorigan, Pier F Ferrucci, Hiya Banerjee, Tonatiuh Romero Salas, Rohan Shah, Mike Lau, Reinhard Dummer, Characteristics of patients (pts) with a complete response (CR) in the Phase III COMBI-i study of spartalizumab (sparta) or placebo (pbo) plus dabrafenib and trametinib (DabTram) in pts with BRAF V600–mutant metastatic melanoma
13. C. Robert; M. S. Carlino; C. McNeil; A. Ribas; J. J. Grob; J. Schachter; M Nyakas; D. Kee; T. Petrella; A. Blaustein; M. Lotem; A. Arance Fernandez; A. I. Daud; O. Hamid; J. Larkin; J. Anderson; C Krepler; D Grebennik; **G. V. Long**, 7-year follow-up of KEYNOTE-006: pembrolizumab (pembro) versus ipilimumab (ipi) in advanced melanoma
14. Elizabeth Paver, Tuba N. Gide, Ismael A. Vergara, Ping Shang, Eva Shteinman, Zarwa Yaseen, Alexander M. Menzies, Richard A. Scolyer, **Georgina V. Long**, and James S. Wilmott, Carbonic Anhydrase IX expression as a predictor of resistance to immune checkpoint inhibition in melanoma
15. AJ Potter, I Vergara, A Colebatch, J Wilmott, J Thompson, **GV Long**, & RA Scolyer, In search of a primary: defining the molecular signature of isolated pulmonary melanoma
16. Jason Luke, **Georgina Long**, Muhammad A. Khattak, Luis de la Cruz Merino, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. Kirkwood, Caroline Robert, Michele Del Vecchio, Jean-Jacques Grob, Federica De Galitiis, Piotr Rutkowski, Dirk Schadendorf, Matteo Carlino, Peter Mohr, Reinhard Dummer, Andrew Poklepovic, Jeff Gershenwald, Rachel Kloss Silverman, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Paolo Ascierto, Pembrolizumab (Pembro) versus Placebo (PBO) after Complete Resection of High-Risk Stage II Melanoma: Updated results from KEYNOTE-716 - **Late Breaking Abstract, accepted as oral presentation**

American Society of Human Genetics Conference

1. Mathias Seviiri, Richard A. Scolyer, **Georgina V. Long**, Stuart MacGregor, Matthew H. Law, A large genome-wide association study for melanoma-specific survival reveals two novel loci linked to PSEN2, and ADCK3 genes Oct 2021

EMCR Symposium

1. Livingstone A, Dempsey K, Stockler MR, Howard K, **Long GV**, Carlino MS, Menzies AM, Morton RL. Whom should I recommend for adjuvant immunotherapy? An interview study – **Oral presentation** Sept 2021

European Society for Medical
Oncology (ESMO)

1. Florentia Dimitriou, Pawel Teterycz, Irene Reijers, Elizabeth I. Buchbinder, Jennifer A. Soon, Lisa Zimmer, Meghan J. Mooradian, Maria Grazia Vitale, Emma Armstrong, Douglas B. Johnson, Xue Bai, Clara Allayous, Caroline Robert, Mario Mandala, Prachi Bhave, Mohamad Farid, Katharina C. Kähler, Inderjit Mehmi, Serigne N. Lo, **Georgina V. Long**, Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (PD1+IPI) Sept 2021
2. F. Dimitriou, S. N. Lo, A.C. Tan, L. Emmett, R. Kapoor, M. S. Carlino, **G. V. Long**, A. M. Menzies, FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma
3. Antoni Ribas, Jason Chesney, **Georgina Long**, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Scott Diede, James Anderson, Sheryl Treichel, Ed Chan, Frank Stephen Hodi, Helen Gogas, MASTERKEY-265: Efficacy and safety of a phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) – **oral presentation**
4. Inês Pires da Silva, Danny Zakria, Tasnia Ahmed, Claudia Trojaniello, Florentia Dimitriou, Clara Allayous, Camille L Gerard, Lisa Zimmer, Serigne N Lo, Olivier Michielin, Celeste Lebbe, Joanna Mangana, Paolo A Ascierto, Douglas B Johnson, Matteo S Carlino, Alexander M Menzies, **Georgina V Long**, Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
5. Reinhard Dummer, **Georgina V. Long**, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Diede, Hussein Abdul-Hassan Tawbi, Investigational (Inv) Agents With or Without Pembrolizumab (pembro) or Pembro Alone in Melanoma (mel): KEYMAKER-U02
6. F. Stephen Hodi, Hussein A. Tawbi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Laurence Toms, Karin Jonczak, Anne Marie Sobiesk, **Georgina V. Long**, Relatlimab (RELA) + Nivolumab (NIVO) Vs. NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Efficacy in RELATIVITY-047 (127) – **oral presentation**
7. Caroline Robert; Dirk Schadendorf; **Georgina V. Long**; Paolo Ascierto; Salvatore Intagliata; Friedegund Meier; Astrid A.M. van der Veldt; Antoni Ribas; Jeffrey Weber; Laura Stenson; Nadia Solovieff; Anne-Laure Louveau; Aislyn Boran; Jean Jacques Grob; Reinhard Dummer, PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
8. Noëlle M.J. van den Heuvel, Irene L.M. Reijers, Judith M. Versluis, Elisa A. Rozeman, Robyn P.M. Saw, Karlijn H. Blommers, Katarzyna Józwiak, Karlijn P.M. Suijkerbuijk, Ellen W. Kapiteijn, Astrid van der Veldt, Geke A.P. Hospers, Andrew Spillane, Thomas E. Pennington, Michel W.J.M. Wouters, Alexander M. Menzies, Alexander C.J. van Akkooi, Lonneke V. van de Poll-Franse, **Georgina V. Long**, Christian U. Blank, *Annelies H. Boekhout, Health-Related Quality of Life in Stage III Melanoma Patients Treated with Neoadjuvant Ipilimumab and Nivolumab: week 60 update of the PRADO trial

9. Caroline Robert, Michael A. Davies, Reinhard Dummer, Jean Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Mario Mandalà, Paul D. Nathan, Hiya Banerjee, Braja Gopal Sahoo, Mike Lau, Kelly Biette, Aislyn Boran, Dirk Schadendorf, Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma
10. ILM Reijers, JM Versluis, AM Menzies, P Dimitriadis, M Wouters, RPM Saw, WMC Klop, T Pennington, A Broeks, L JW Bosch, LG Grijpink-Ongering, MJ Gregorio, K Sikorska, A Colebatch, AJ Spillane, BA van de Wiel, RA Scolyer, ACJ van Akkooi, **GV Long** and CU Blank, Personalized combination of neoadjuvant domatinostat (DOM), nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature (IFN- γ sign): first results of the DONIMI study – **Oral presentation**
11. Jason J. Luke; Piotr Rutkowski; Paola Queirolo; Michele Del Vecchio; Jacek Mackiewicz; Vanna Chiarion-Sileni; Luis de la Cruz Merino; Muhammad A Khattak; Dirk Schadendorf; Georgina V. Long, Paolo A Ascierto; Mario Mandalà; Federica De Galitiis; Vernon Sondak; Richard A. Scolyer; John M. Kirkwood; Ke Chen; Nageatte Ibrahim; Sama Ahsan; Alexander M. M. Eggermont, Pembrolizumab Versus Placebo After Complete Resection of High-risk Stage II Melanoma: Efficacy and Safety Results From the KEYNOTE-716 Double-blind Phase 3 Trial – **Late breaking abstract**

Sydney Cancer Conference

1. Kazi J Nahar*, Felix Marsh-Wakefield*, Robert V Rawson, Tuba N Gide, Angela Ferguson, Ruth Olivia, Camelia Quek, Stephen Tattersal, Christopher J Kiely, Neomal Sandanayake, Matteo S Carlino, James Wilmott, Richard A Scolyer, **Georgina V Long***, Alexander M Menzies*, Umaimainthan Palendira, Systemic myeloid cells and local T cells propel immunotherapy induced colitis – **Oral presentation** Sept 2021
2. Camelia Quek, Xinyu Bai, Ping Shang, Grace H. Attrill, Tuba Nur Gide, Peter M. Ferguson, Kazi Nahar, Umaimainthan Palendira, **Georgina V. Long**, Richard A. Scolyer and James S. Wilmott, Immunosuppressive features in young melanoma patients treated with checkpoint-based immunotherapies – **oral presentation**
3. Zarwa Yaseen, Tuba N. Gide, James S. Wilmott, **Georgina V. Long**, Richard A. Scolyer, Validation Of An Accurate Automated Multiplex Immunofluorescence Method For Immunoprofiling Melanoma – **oral presentation**

Genemappers

1. Ong J-S, Seviiri M, Dusingize JC, Gharahkhani P, Han X, Neale RE, Olsen CM, Landi MT, Iles MM on behalf of GenoMEL, Scolyer RA, Long GV on behalf of MIA, Whiteman DE, MacGregor S, Law MH, Evaluating the complex relationship between balding and skin cancer in men through multivariable Mendelian randomization analyses June 2021

Sydney Catalyst

1. Camelia Quek, Catherine Bai, Ping Shang, Grace Attrill, Tuba Nur Gide, Peter M. Ferguson, Kazi Nahar, Umaimainthan Palendira, **Georgina V. Long**, **Richard A. Scolyer**, and James S. Wilmott, Immunosuppressive-driven mechanisms impede response to checkpoint-based immunotherapies in adolescent and young adult melanoma patients – **oral presentation** June 2021

American Society of Clinical Oncology (ASCO)

1. Paolo A. Ascierto, Caroline Robert, Paul D. Nathan, Reinhard Dummer, Hussein A. Tawbi, Keith T. Flaherty, Antoni Ribas, Dirk Schadendorf, Steven Green, Lali Sandalic, Mike Lau, Tonatiuh Romero, **Georgina V.** June 2021

- Long**, Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients with BRAF V600–mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib in the COMBI-i trial
2. Ines Pires Da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas Buckner Johnson, Jennifer Soon, Clara Allayous, Camille L. Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen K. Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, **Georgina V. Long**, Patterns and management of progression to 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients
 3. Ana Arance, Luis de la Cruz Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Márquez-Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Andrew Mant, Alan D. Smith, Ke Chen, Scott J. Diede, Clemens Krepler, **Georgina V. Long**, Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004 – **oral presentation**
 4. Evan J. Lipson, Hussein A. Tawbi, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Katy L. Simonsen, Bin Li, **Georgina V. Long**, F. Stephen Hodi, Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: first phase 3 results from the RELATIVITY-047 study – **oral presentation**
 5. James Larkin, Helen Gogas, Michele Del Vecchio, Michele Maio, Petr Arenberger, Ana M. Arance, Jean-Jacques Grob, Vanna Chiarion-Sileni, Karl Lewis, Laurent Mortier, Patrick A. Ott, **Georgina V. Long**, Alfonsus van den Eertwegh, Lance Cowey, Michael Schenker, Marcus Butler, Shailender Bhatia, Rutger Koornstra, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, Jeffrey Weber, Analysis of patients with in-transit metastases treated with nivolumab or ipilimumab in CheckMate 238
 6. **Georgina V. Long**, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael Brown, Maria Gonzalez, Richard Scolyer, Louise Emmett, Alexander M. Menzies, Grant A. McArthur, Five-Year Overall Survival from the Anti-PD1 Brain Collaboration (ABC Study); Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets) – **oral presentation**
 7. Jason J. Luke, Piotr Rutkowski, Paolo Pronzato, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis De La Cruz Merino Sr., Muhammad Adnan Khattak, Dirk Schadendorf, **Georgina V. Long**, Paolo Antonio Ascierto, Mario Mandalà, Federica De Galitiis, Vernon K. Sondak, Richard A. Scolyer, John M. Kirkwood, Ke Chen, Nageatte Ibrahim, Sama Ahsan, Alexander M. Eggermont, Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial
 8. Xue Bai, Alexander Noor Shoushtari, Allison Betof Warner, Henry Quach, Christopher G Cann, Michael Zhang, Lalit Pallan, Catriona Harvey, Lu Si, Bixia Tang, Chuanliang Cui, Michelle S. Kim, Tatyana Sharova, Keith Flaherty, **Georgina V. Long**, Alexander M. Menzies, Ryan J. Sullivan, Genevieve Marie Boland, Douglas Buckner Johnson, Jun Guo, Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced non-acral cutaneous melanoma (NACM)
 9. Rebecca Johnson, Victoria Atkinson, Prachi Bhawe, Alison Weppeler, Geoffrey David Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Mark Haydon, Matteo S. Carlino, Shahneen Kaur Sandhu,

Georgina V. Long, Alexander M. Menzies, Management of resected stage III/IV melanoma with the introduction of adjuvant immunotherapy

10. Alexander M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandalà, **Georgina V. Long**, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Stephens, Shahneen Kaur Sandhu, Ragini Reiney Kudchadkar, Pablo L. Ortiz-Romero, Inge Marie Svane, Alexander Christopher Jonathan Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
11. Alison Margaret Weppler, Laetitia Da Meda, Ines Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, **Georgina V. Long**, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo Antonio Ascierto, Celeste Lebbe, Shahneen Sandhu, Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation
12. Hussein Tawbi, **Georgina Long**, Nicolas Meyer, Boris Breznen, Charmy Vyas, Lisa Leung, Andriy Moshyk, Divya Pushkarna, Pratik Thakkar, Mir Sohail Fazeli, Srividya Kotapati, Dirk Schadendorf, Treatment outcomes in patients with melanoma brain metastases: A systematic literature review (SLR) and meta-analysis
13. Florentia Dimitriou, Sabrina A Hogan, Phil F Cheng, Reinhard Dummer, Alexander M. Menzies, **Georgina V. Long**, IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy

EACR Bioinformatics in Cancer

1. Camelia Quek*, Ines P Silva*, Ghamdan Al-Eryani*, Aron Mayer8*, Nenad Bartonicek, Kate Harvey, Chi Buckley, Oliver Braubach, Robyn P M Saw, Jonathan Stretch, Kerwin Shannon, Alex M Menzies, Richard A Scolyer*, **Georgina V Long***, Alexander Swarbrick*, James Wilmott*, Spatially resolved single-cell sequencing reveals unfavourable immune diversity and intratumoural vessels in resistance melanoma patients treated with checkpoint inhibitor immunotherapy – **Oral presentation**

May
2021

Australian Rheumatology Association National Conference

1. Alana Bruce, **Georgina V Long**, Alexander M Menzies, Brian Fernandes, Fredrick Joshua, Epidemiology and risk factors for the development of rheumatic toxicities in patients with advanced melanoma treated with immune checkpoint inhibitors

May
2021

10th World Congress of Melanoma & EADO

1. Reinhard Dummer, **Georgina V. Long**, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Diede, Hussein Abdul-Hassan Tawbi, KEYMAKER-U02: Phase I/II study of investigational agents with or without pembrolizumab or pembrolizumab alone in patients with melanoma – **poster presentation**
2. Alexander Eggermont*, Paolo Ascierto, Nikhil Khushalani, Dirk Schadendorf, Genevieve Boland, Adi Diab, Jeffrey Weber, Karl D. Lewis, Daniel Johnson, **Georgina V Long**, Sue Currie, Mann Muhsin, Mary A. Tagliaferri, Matteo Carlino, PIVOT-12: A phase 3 randomized study of adjuvant bempedaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO alone in patients with completely resected cutaneous melanoma at high risk for recurrence – **poster presentation**

- Australian Polygenic Risk Symposium
1. Mathias Seviiri*, **Georgina V. Long**, Catherine M. Olsen, David C. Whiteman, Richard A. Scolyer, Stuart MacGregor, and Matthew H. Law – **oral presentation** April 2021
- American Association for Cancer Research (AACR)
1. **Georgina Long**, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo Carlino, Anna Maria Di Giacomo, Marcus Butler, Eva Muñoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Alexander Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Daniel Tenney, Hao Tang, Jeffrey Weber, Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with stage IIIB–D/IV melanoma (CheckMate 915) - **oral presentation**
 2. Camelia Quek*, Ines P Silva*, Ghamdan Al-Eryani*, Aron Mayer*, Nenad Bartonicek, Kate Harvey, Chi Buckley, Oliver Braubach, Robyn P M Saw, Jonathan Stretch, Kerwin Shannon, Alex M Menzies, Richard A Scolyer*, **Georgina V Long***, Alexander Swarbrick*, James Wilmott, CODEX highly multiplex image mapping to CITE-seq datasets reveal the spatial dynamics of the TME during the development of acquired resistant in anti-PD-1 and CTLA-4 treated melanoma
- Melanoma Research Alliance
1. Ana Arance, Steven J. O'Day, Luis de la Cruz Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Márquez-Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Alan D. Smith, Ke Chen, Scott J. Diede, Clemens Krepler, **Georgina V. Long**, Initial results of lenvatinib plus pembrolizumab for advanced melanoma that progressed following anti-PD-1/PD-L1 in LEAP-004 – **poster presentation** Feb 2021
 2. Reinhard Dummer, **Georgina V. Long**, Anna Pavlick, Michael Postow, Antoni Ribas, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Sama Ahsan, Scott J. Diede, Hussein A. Tawbi, Investigational agents with or without pembrolizumab versus pembrolizumab alone in patients with melanoma: the phase 1/2 MK-3475-U02 study – **poster presentation**
- Australian Rheumatology Association NSW Branch Annual Scientific Meeting
1. Alana Bruce, **Georgina Long**, Alexander Menzies, Brian Fernandes, Fredrick Joshua Epidemiology and risk factors for the development of rheumatic toxicities in patients with advanced melanoma treated with immune checkpoint inhibitors – **oral presentation** Dec 2020
- Cancer Research Network (CRN)
1. Jordan W. Conway, Robert V. Rawson, James S. Wilmott, **Georgina V. Long**, Richard A. Scolyer, Ines Pires da Silva, The tumour immune microenvironment (TIME) at different sites of melanoma metastases – **oral presentation** Nov 2020
 2. Grace H. Attrill, Carina Owen, Tasnia Ahmed, Serigne Lo, Andrew Colbatch, Jordan W. Conway, Ines Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Mainthain Palendira, Richard A. Scolyer, **Georgina V. Long**, James S. Wilmott, Tumour specific, tumour resident, cytotoxic T cells are associated with reduced recurrence in adjuvant PD-1 treatment stage III melanoma. Cancer Research Network (CRN) Postgraduate and Early career Researcher Symposium 2020 – **oral presentation**

Sydney Catalyst PG ECR Symposium

1. T. N. Gide*, I. P. Silva*, C. Quek, P. M. Ferguson, M. Batten, P. Shang, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P.M. Saw, J. F. Thompson, J. S. Wilmott*, R. A. Scolyer*, and **G. V. Long***, Genomic and Clinical Profiles of Patients with Innate Resistance to Anti-PD-1-Based Immunotherapies in Melanoma – **oral presentation** Nov 2020
2. Grace H. Attrill1*, Carina Owen*, Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W. Conway, Kazi Nahar, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Mainthan Palendira, Richard A. Scolyer, **Georgina V. Long**, James S. Wilmott, Tumour specific, tumour resident, cytotoxic CD8+ T cells are associated with reduced recurrence in adjuvant PD-1 treated melanoma
3. 1.Rebecca Simpson, Marcel Batten, Erin Shanahan, Mark Read, Ines Silva, Alexandra Aangelatos, Jian Tan, Rosilene Ribeiro, Chandra Adhikari, Jordan Conway, Alex Menzies, Robin Saw, Jonathan Stretch, Omgo Nieweg, Andrew Spillane, Laurence Macia, Maria Gonzales, Kerwin Shannon, Rebecca Velickovic, Christian Blank, Andrew Holmes, James Wilmott, Richard A. Scolyer, **Georgina V. Long**. Gut microbiota predicts response and adverse events during anti-PD1/anti-CTLA4 neoadjuvant immunotherapy

Society for Immunotherapy of Cancer (SITC)

1. **Georgina V. Long**, Reinhard Dummer, Douglas B Johnson, Olivier Michielin, Salvador Martin-Algarra, Sheryl A. Treichel, Edward Lau-Yue Chan, Scott J Diede, Antoni Ribas, Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma Nov 2020
2. R. Dummer, **G.V. Long**, A. Pavlick, M. Postow, A.Ribas, C. Robert. R.A. Scolyer, J.M. Taube, M. Tetzlaff, S.C. Su, S. Ahsan, S.J Diede, H.A. Tawbi, KEYMAKER-U02: Phase 1/2 Study of Investigational Agents with or without Pembrolizumab or Pembrolizumab Monotherapy in Melanoma
3. Matthias Braun, Indrajit Das, Amelia Roman Aguilera, Ashmitha Sundarajan, Dillon Corvino, Gabrielle Kelly, Frank Vari, Ailin Lepetier, Sally Pearson, Jason Madore, Sophie Krumeich, Sebastien Jacquelin, Maïke Effern, Mika Casey, Kyohei Nakamura, Eun Y. Seo, Andre Veillette, Michael Hoelzel, Touraj Taheri, **Georgina V. Long**, Richard Scolyer, Martin D. Batstone, William C. Dougall, Robert J. Johnston Ludovic Martinet, Mark J. Smyth,* and Tobias Bald, CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells
4. Patrinely J, Johnson R, Lawless A, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Davis EJ, Rapisuwon S, **Long GV**, Haydon A, Osman I, Mehnert JM, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB, A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma

Chinese Society of Clinical Oncology (CSCO)

1. **G. V. Long**, J. Schachter, A. Arance, J.-J. Grob, L. Mortier, A. Daud, M. S. Carlino, A. Ribas, C. M. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. U. Blank, T. M. Petrella, O. Hamid, C. Krepler, S. J. Diede, E. Jensen, C. Robert, Long-Term Survival with Pembrolizumab Completion and Retreatment in Patients With Advanced Melanoma: KEYNOTE-006 Sept 2020

European Society for Medical Oncology (ESMO)

1. Ana Arance, Steven J. O'Day, Luis de la Cruz Merino, Teresa Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Marquez-Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Alan D. Smith, Ke Chan, Scott J. Diede, Clemens Krepler, **Georgina V. Long**, Lenvatinin (len) plus pembrolizumab (pembro) for advanced melanoma Sept 2020

(Mel) that progressed on PD-1 or Pd-L1 inhibitor: initial results of LEAP-004 – oral presentation

2. Caroline Robert, **Georgina V. Long**, James Larkin, Jedd Wolchock, Jessica C Hassel, Dirk Schadendorf, F, Stephen Hodi, Celeste Lebbe, Jean-Jacques Grob, Kenneth Grossman, John Wagstaff, Jason Chesney, Marcus O. Butler, Oliver Bechter, Ivan Marquez-Rodas, Anna C. Paclick, Sandra Re, Wim van Dijck, Michael Postow, Paolo A. Ascierto, 5-year characterization of complete responses (CRs) in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
3. Paul D. Nathan, Reinhard Dummer, **Georgina V. Long**, Paolo A. Ascierto, Hussein A. Tawbi, Caroline Robert, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Keith T. Flaherty, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf, Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-i trial
4. John M. Kirkwood, Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Vanna Chiarion Sileni, James Larkin, Marta Nyakas, Andrew Haydon, Caroline Dutriaux, Jacob Schachter, Caroline Robert, Laurent Mortier, Hiya Banerjee, Tomas Haas, Monique Tan, Mike Lau, Dirk Schadendorf, **Georgina V. Long**, Mario Mandalá, Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma
5. O. Hamid, A Joshua, W.J.Hwu, A. Ribas, J.S. Weber, A.I. Daud, F.S. Hodi, J.D. Wolchok, T.C. Mitchell, P. Hersey, R. Dronca, R.W. Joseph, C. Boutros, L. Min, **G.V. Long**, J. Schachter, J. Lin, N. Ibrahim, M.S. Carlino, C. Robert, Long-Term Safety Profile of Pembrolizumab Monotherapy and Relationship with Clinical Outcome : A Pooled Analysis of patients with Advanced Melanoma
6. Paul D. Nathan, Reinhard Dummer, **Georgina V. Long**, Paolo A. Ascierto, Hussein A. Tawbi, Caroline Robert, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Keith T. Flaherty, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf, Spartalizumab plus dabrafenib plus trametinib in patients with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-i trial,

American Society of Clinical
Oncology (ASCO)

1. Victoria Atkinson, Kathleen Batty, **Georgina V. Long**, Matteo S. Carlino, Geoffrey David Peters, Prachi Bhave, Maggie A. Moore, Wen Xu, Lauren Julia Brown, Melissa Arneil, Megan Lyle, Alexander M. Menzies Activity and safety of 3rd-line BRAF targeted therapy (TT) following 1st line TT and 2nd line immunotherapy (IT) in advanced melanoma
2. EA Rozeman, ILM Reijers, EP Hoefsmit, K Sikorska, O Krijgsman, BA van de Wiel, P Dimitriadis, H Eriksson, M Gonzalez, LG Grijpink-Ongering, R Kerkhoven, A Broeks, WM Klop, AJ Spillane, RPM Saw, ACJ van Akkooi, RA Scolyer, AM Menzies, **GV Long** and CU Blank, 24-months RFS and updated toxicity data from OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO) in stage III melanoma
3. Maria Gonzalez, Alexander M. Menzies, Thomas Pennington, Robyn Saw, Andrew J. Spillane, Jonathan Stretch, Kerwin F. Shannon, Sydney Ch'ng, Omgo E. Nieweg, Maria Cruzado, Monica Osorio, Robert Rawson, Peter Ferguson, Helen Rizos, Serigne Lo, Richard A. Scolyer, **Georgina V. Long**, A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma – the NeoPeLe study

June
2020

4. Martin Gutierrez, **Georgina Long**, Claire Friedman, Donald Richards, Brad Corr, Bruno Bastos, Marc Uemura, Paul Conkling, Victor Garcia Moreno, William Edenfield, Carols Becerra, Sarina Piha-Paul, Michelle Brown, Lee James, Ming Zheng, Jieying Jiang, Georgia Kollia, Ailsa Swijter, Paolo Ascierto, Anti-CTLA-4 Probody Tx BMS-986249 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results (BMS020)
5. Reinhard Dummer, Kelly Biette, Daniel Gusenleitner, Radha Ramesh, Celeste Lebbe, Victoria Atkinson, Mario Mandala, Paul Nathan, Ana Arance, Erika Richtig, Naoya Yamazaki, Caroline Robert, Dirk Schadendorf, Hussein Tawbi, Paolo A. Ascierto, Antoni Ribas, Keith Flaherty, Eduard Gasal, Jan C. Brase, **Georgina V. Long**, Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma
6. Jenny H Lee, Matteo S Carlino, Alexander M Menzies, Richard A Scolyer, **Georgina V Long**, Helen Rizos, Circulating tumor DNA (ctDNA) using GUARDANT360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI)
7. John J. Park, Russell Diefenbach, Natalie Byrne, Richard F. Kefford, **Georgina V. Long**, Richard Scolyer, Matteo S. Carlino, Helen Rizos, Circulating tumour DNA (ctDNA) in patients with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi)
8. Lauren J Brown, Alison Weppler, Prachi Brave, Clara Allayous, Randall Patrinely, Patrick Ott, Shahneen Sandhu, Andrew Haydon, Celeste Lebbe, Douglas Johnson, **Georgina Long**, Alexander Menzies, Matteo S. Carlino, Combination Anti-PD1 and Ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD)
9. CU Blank, ILM Reijers, JM Versluis, EA Rozeman, K Sikorska, L Grijpink, M Gonzalez, R Zucker, A Spillane, JA van der Hage, DJ Grünhagen, R Scolyer, B van de Wiel, AM Menzies, ACJ van Akkooi, GAP Hospers, KPM Suijkerbuijk, AM van der Veldt, HW Kapiteijn and **GV Long**, First safety and efficacy results from the PRADO trial: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in high risk resectable stage III melanoma – **Oral Presentation**
10. *Noëlle M.J. van den Heuvel, *Elisa A. Rozeman, *Irene Reijers, *Judith Versluis, *Katarzyna Józwiak *Alexander C.J. van Akkooi, *Lonneke V. van de Poll-Franse, **Andrew J. Spillane, **Richard Scolyer, **Thomas Pennington, **Robyn P.M. Saw, **Maria Gonzalez **Alexander M. Menzies,*Winan J. Van Houdt, *Willem M. C. Klop, *Michel Wouters, ****Georgina V. Long** *Christian U. Blank, *Annelies H. Boekhout, Health-Related Quality of Life in Melanoma Patients treated with Neoadjuvant Ipilimumab and Nivolumab undergoing Index Lymph Node Dissection (ILND) only compared with Therapeutic LND: (TLND) first results from the PRADO trial
11. Ines Pires Da Silva, Tasnia Ahmed, Serigne Lo, Irene L.M. Reijers, Alison Weppler, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Celeste Lebbe, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Paolo Antonio Ascierto, Dan Stout, Megan Lyle, Oliver Klein, Camille Lea Gerard, Christian U. Blank, Alexander M. Menzies, **Georgina V. Long**, Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. – **Oral Abstract**
12. **Georgina V. Long**, Jacob Schachter, Ana Arance Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Antoni Ribas, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns Christian U. Blank, Teresa M. Petrella, Omid Hamid, Erin Jensen, Clemens Krepler,

Scott J. Diede, Caroline Robert, Long-term Survival From Pembrolizumab (pembro) Completion and Pembro Retreatment: Phase 3 KEYNOTE-006 in advanced melanoma

13. ILM Reijers, P Dimitriadis, EA Rozeman, JM Versluis, LJW Bosch, J Bouwman, S Cornelissen, O Krijgsman, M Gonzalez, D Rao, L Grijpink, M van Dijk, AJ Spillane, RA Scolyer, BA van de Wiel, AM Menzies, ACJ van Akkooi, **GV Long** and CU Blank, Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to the interferon-gamma (IFN- γ) signature – the DONIMI study
14. **Georgina V. Long**, Celeste Lebbé, Victoria Atkinson, Mario Mandala, Paul Nathan, Ana Arance, Erika Richtig, Naoya Yamazaki, Caroline Robert, Dirk Schadendorf, Hussein Abdul-Hassan Tawbi, Paolo Antonio Ascierto, Antoni Ribas, Keith Flaherty, Neha Pakhle, Aisha Masood, Eduard Gasal, Reinhard Dummer, The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in advanced BRAF V600-mutant melanoma: updated efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial
15. Adriana Hepner, Judith M. Versluis, Camille Lea Gerard, Lauren Julia Brown, Roslyn Wallace, Prachi Bhav, Yanina Jansen, Oliver Klein, Allison Betof Warner, Joanna Mangana, Victoria Atkinson, Serigne Lo, **Georgina V. Long**, Douglas Buckner Johnson, Jennifer Leigh McQuade, Paolo Antonio Ascierto, Lisa Zimmer, Celeste Lebbe, Christian U. Blank, Alexander M. Menzies; The Nature and Management of Acquired Resistance to PD1-based therapy in Melanoma.
16. Axel Hauschild, Reinhard Dummer, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M. Kirkwood, Vanna Chiarion Sileni, James M. G. Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Mark Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, **Georgina V. Long**, Dirk Schadendorf, Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600-mutant melanoma: Five-year analysis of COMBI-AD
17. Alexander M. Eggermont, Christian U. Blank, Mario Mandalà, **Georgina V. Long**, Victoria Atkinson, Stéphane Dalle, Andrew Mark Haydon, Andrey Meshcheryakov, Muhammad Khattak, Matteo S. Carlino, Shahneen Kaur Sandhu, Susana Puig, Paolo Antonio Ascierto, Alexander Christopher Jonathan Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suci, Caroline Robert, Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up

American Association for Cancer Research (AACR)

1. Christian U. Blank, Judith M. Versluis, Elisa A. Rozeman, Alexander M. Menzies, Irene L.M. Reijers, Oscar Krijgsman, Esmée P. Hoefsmid, Bart A. van de Wiel, Karolina Sikorska, Carolien Bierman, Petros Dimitriadis, Maria Gonzalez, Annegien Broeks, Ron M. Kerkhoven, Andrew J. Spillane, John B.A.G. Haanen, Winan J. van Houdt, Robyn P.M. Saw, Hanna Eriksson, Alexander C.J. van Akkooi, Richard A. Scolyer, Ton N. Schumacher and **Georgina V. Long**, 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients – update of the OpACIN and OpACIN-neo trials
2. Christian U Blank, Judith M Versluis, Elisa A Rozeman, Alexander M Menzies, Irene LM Reijers, Oscar Krijgsman, Esmée P Hoefsmid, Bart A van de Wiel, Karolina Sikorska, Carolien Bierman, Petros Dimitriadis, Maria Gonzalez, Annegien Broeks, Ron Kerkhoven, Andrew J Spillane, John Haanen, Winan J. van Houdt, Robyn PM Saw, Hanna Eriksson, Alexander CJ van Akkooi, Richard A Scolyer, Ton NM Schumacher and **Georgina V**

April
2020

Long, 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients – update of the OpACIN and OpACIN-neo trials

3. Jarem Edwards*, Inês Pires da Silva*, Angela Ferguson, Jordan Conway, Grace Attrill, Robyn P. M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira* and James S. Wilmott*, **Georgina V. Long***, Richard A. Scolyer* and James S. Wilmott, Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy
4. M. Batten, ER Simpson, R. Read, M. Silva, A Angelatos, J Tan, C. Adhikari, AM Menzies, RPM Saw, J. Stretch, O. Nieweg, AJ. Spillane, L. Marcia, M. Gonzales, KF. Shannon, R. Velickovic, I. Riegers, CU. Blank, AJ. Holmes, JS. Wilmott, RA. Scolyer, **GV. Long**, Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy – **Oral Presentation**
5. Adil Daud, Matteo S. Carlino, Antoni Ribas, Ana Arance, Jean-Jacques Grob, James Larkin, **Georgina V. Long**, Jacob Schachter, Andrea L. Webber, Clemens Krepler, Chunsheng Zhang, Jared Lunceford, Razvan Cristescu, Qing Zhao, Junshui Ma, Caroline Robert, Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naïve patients (pts) with melanoma

INVITED SPEAKER ENGAGEMENTS

Title	Conference/Event	Location	Date
Neoadjuvant Therapy. Where we have come from and where to next?	Keystone Symposia	Whistler/ Canada	March 2024
Panel Discussion on Failed Trials Panel Member	Keystone Symposia	Whistler/ Canada	March 2024
Keynote Address by Prof Long	75 th Anniversary Fulbright Gala Presentation Dinner	Canberra/ Sydney	Feb 2024
Skin Cancer in Australia: A Medical Update	Australian National High Performance Sport CMO Meeting 2023 – Australian Institute of Sport	Canberra/ Australia	Dec 2023
Skin Cancers Melanoma	Immunotherapy Bridge	Naples/ Italy	Dec 2023
Evolution of Melanoma Therapy in the last 20 years – Keynote speaker	Society for Melanoma Research	Philadelphia/ USA	Nov 2023
All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy – Controversy Session	ESMO	Madrid/ Spain	October 2023
Breaking Ground in 2023	ESMO	Madrid/ Spain	October 2023
Big Questions with Adam Spencer – Guest Speaker	SXSW 2023 inaugural event	Sydney/ Australia	October 2023
Journey of a GBM Diagnosis: Treatment and Translational Results (presented with Prof R Scolyer & Prof H Rizos)	15 th COGNO Annual Scientific Meeting: Bridge to the Future: Biomarkers in Brain Tumour Care	Sydney/ Australia	October 2023

Towards Zero Deaths from Melanoma: Progress to date, prospects for the future, drug therapies and beyond	Queens Club – morning tea, guest speaker	Sydney/ Australia	Sept 2023
How to treat and manage high-risk stage IIB/IIC and stage III melanoma patients Chair & speaker	Merck Sharp & Dohme Education dinner	Sydney/ Australia	August 2023
Dual Immunotherapy in advanced melanoma: Evolving the Treatment Paradigm	Bristol Myers Squibb Australia Meeting	Sydney (Chair) & Melbourne (Speaker)	August 2023
Impact of microbiome on Cancer Care	ASCO Breakthrough	Yokohama / Japan	August 2023
Systemic Drug Therapy in Melanoma: An Overview and the Increasing Role of the Dermatologist	World Congress of Dermatology	Singapore	July 2023
A new standard of care in melanoma: Neoadjuvant immunotherapy	CTIO	Sydney/ Australia	May 2023
Neoadjuvant therapy in melanoma – Keynote Lecture	19 th EADO Congress	Rome/Italy	April 2023
Has PD/LAG3 systemic therapies reached prime time for advanced disease? Industry session – Issues in managing advanced melanoma at unusual sites	Australasian Melanoma Conference	Brisbane / Australia	March 2023
A new standard of care in melanoma: neoadjuvant immunotherapy Plenary 2 – Neoadjuvant immunotherapy: a gamechanger for melanoma patients	Australasian Melanoma Conference	Brisbane / Australia	March 2023
Optimising care and treatment for BRAF-mut melanoma patients	Australasian Melanoma Conference	Brisbane / Australia	March 2023
Focus on targeted therapies and immune-oncology in melanoma	Melanoma Research Alliance	Washington America	March 2023
Systemic Therapy in Early Melanoma	Melanoma Institute Australia – GP Education Evening	Sydney / Virtual	March 2023
Achieving ‘Zero Deaths from Melanoma’ Research to Translation	Sydney Health Partners – EMCR Research Translation	Sydney Australia	Dec 2022
Neoadjuvant immunotherapy, the gut microbiome and circulating immune subsets: implications for efficacy and toxicity	The Genomic Cancer Clinical Trials Initiative – Microbiome and outcomes of cancer immunotherapy	Sydney Australia	Nov 2022
The NKI-MIA Nexus: A successful collaboration	Oration of Christian Blank	Leiden Netherlands	Oct 2022
AntiPD1 alone vs Ipi/Nivo vs Relatlimab/Nivo for metastatic melanoma without brain metastasis. How to choose?	Oncology Information – Virtual Master Class in Melanoma	Brazil / Virtual	Oct 2022

mRNA – the messenger of change for personalized cancer vaccines	McKinsey & Company Symposium	Paris	Sept 2022
Roundtable Discussion – Postmortem of Nektar Trial: Why Did it Fail?	International Melanoma Working Group (IMWG) - Fall Meeting	Paris	Sept 2022
Cancer Immunotherapy for Basic Physician Trainees	Royal North Shore Hospital – teaching/education	Sydney/ Virtual	Aug 2022
Best of ASCO – melanoma	MEDLA	Sydney	July 2022
My personal highlights at ASCO 2022	12 th European Post-Chicago Melanoma/Skin Cancer Meeting	Munich/ Virtual	June 2022
Future perspective for advanced BRAF-mutant melanoma	12 th European Post Chicago Melanoma/Skin Cancer Meeting	Munich/ Virtual	June 2022
ASCO 2022 Update: Melanoma & Complex Skin Cancer	The Limbic	Sydney / Australia	June 2022
Exploring the use of approved doublets in melanoma: which patients need them and how could they be sequenced?	ASCO - Education Session: Double Trouble: Immunotherapy Doublets	Chicago	June 2022
Achieving Zero Deaths from Melanoma	NeuRA Seminar	Randwick, Australia	May 2022
Could corticosteroids used for the management of side effects have an impact on the outcome of melanoma patients: Yes or No?	Melanoma Bridge Congress	Virtual	Dec 2021
Update on treatments of advanced Melanoma	Australasian Melanoma Conference	Virtual	Nov 2021
Neoadjuvant therapy in Melanoma - Chair & presented	Australasian Melanoma Conference	Virtual	Nov 2021
Neoadjuvant in Melanoma: The Perfect Model	Society for Immunotherapy of Cancer	Virtual	Nov 2021
Management of patients with BRAF-Mutant Melanoma	Meet the Professor: BRAF Mutant Melanoma webinar – Dr Neil Love	Virtual	Nov 2021
Neoadjuvant therapy in Melanoma – the perfect platform	Portuguese Melanoma Meeting	Virtual	Oct 2021
Towards Zero Deaths from Melanoma	The Professor Martin Gore CBE Memorial Prize Lecture – Focus on Melanoma Meeting	Virtual	Oct 2021
ESMO 2021: Highlights in Melanoma	The Limbic – ESMO 2021 Game Changers Part 2	Virtual	Oct 2021
Clinical Perspectives on the promise of LAG3 based combinations	IMWG Fall Meeting	Virtual	Oct 2021
The future of drug therapy in melanoma	EORTC Fall Meeting	Virtual	Oct 2021

Shaping tomorrow today: What does the future hold for Melanoma	BMS Satellite Symposium ESMO 2021	Virtual	Sept 2021
Approaches and early results tackling microenvironment structures and conclusions and perspectives	ESMO – Special Symposium Strategies to table resistance to checkpoint blockade – Chair & Speaker	Virtual	Sept 2021
Life as a Clinician Scientist Symposium – panel member	NSW Australian Academy of Health and Medical Sciences	Virtual	Sept 2021
The road to zero deaths from melanoma	The Garvan Institute	Virtual	Sept 2021
Basics on Immunotherapy MOA	Royal North Shore Hospital – teaching/education	Virtual	Aug 2021
Drug Therapy in Melanoma: Neoadjuvant/Adjuvant and Metastatic Disease	Royal North Shore Hospital – teaching/education	Virtual	Aug 2021
Long term outcomes in advanced melanoma	How to achieve long term outcomes for patients with advanced BRAF-mutant melanoma	Virtual	July 2021
My visions on melanoma treatment 2025	11 th European Post-Chicago Melanoma/Skin Cancer Meeting	Virtual	July 2021
Best of ASCO 2021: Melanoma	The Best of ASCO Australia	Virtual	June 2021
Making progress against Melanoma: Historical Perspective	ASCO Annual Meeting Education Session	Virtual	June 2021
Neoadjuvant therapy in Melanoma; so much more than meets the eye	USCF Melanoma Conference	Virtual	April 2021
All BRAF mutated patients should be primarily treated with BRAF/MEK inhibitors – Yes	10 th World Congress on Melanoma	Virtual	April 2021
Cure of metastatic melanoma on the horizon	10 th World Congress on Melanoma	Virtual	April 2021
Adjuvant targeted therapy	10 th World Congress on Melanoma	Virtual	April 2021
The MAPK Pathway, Molecular Testing, and Use of BRAF Inhibitor Therapies	Medscape Oncology	Virtual	Feb 2021
Neoadjuvant/Adjuvant Systemic Therapy in Early Melanoma; Is it worth it?	Clinical Oncology Society of Australia – Melanoma/Non-melanoma Skin Cancer Masterclass	Virtual	Dec 2020
Adjuvant Immunotherapy in Melanoma, Current Practice and Future	Melanoma Bridge Congress	Virtual	Dec 2020
The art and science of patient management in BRAF-mutant metastatic melanoma	Pierre Fabre Oncology Webinar	Virtual	Nov 2020

What does the latest data mean for Treatment Selection and Sequencing	Vindico Medical Education – CME Certified Virtual Expert Panel Discussion	Virtual	Nov 2020
Neoadjuvant therapies for stage III patients	Melanoma Education Day – Liverpool Hospital	Virtual	Nov 2020
Immunotherapy: Where are we now and where to next?	Society for Melanoma Research	Virtual	Oct 2020
Current Immunotherapies and Neo-Adjuvant	Melanoma Patient Association	Virtual	Oct 2020
Melanoma Round Table Hot Topics in Melanoma Neoadjuvant Therapy and Brain Metastases – Chair and Speaker	The Limbic	Virtual	Oct 2020
Where does adjuvant Keytruda fit in Australian clinical practice?	Chair for “the evolving treatment landscape in melanoma: special focus on adjuvant treatment plus updated in the advanced setting”	Virtual	Sept 2020
Game Changers –ESMO Highlight 2020	The Limbic	Virtual	Sept 2020
Adjuvant and neo-adjuvant therapy	ESMO – Educational Session Adjuvant and neo-adjuvant therapy for stage III melanoma: Who, what and when?	Virtual	Sept 2020
Zero Deaths from Melanoma; will systemic therapy get us there?	Alan Houghton Lecture – Memorial Sloane Kettering Grand Rounds	Virtual	Sept 2020
The future of neoadjuvant treatment – Key Note Lecture	10 th European Post-Chicago Melanoma/Skin Cancer Meeting	Virtual	July 2020
My personal highlight at ASCO 2020 in melanoma	10 th European Post-Chicago Melanoma/Skin Cancer Meeting	Virtual	July 2020
Improving melanoma patients’ care through digital solutions – Living with Melanoma: Capturing patient expectations	10 th European Post-Chicago Melanoma/Skin Cancer Meeting	Virtual	July 2020
Recent Advances in Medical Oncology	Faculty RTP	Virtual	July 2020
Evolving Treatment Approaches in Melanoma	Faculty RTP	Virtual	July 2020
Melanoma Round Table – Chair & Speaker	The Limbic	Virtual	July 2020
Game Changers - Melanoma Highlights from ASCO 2020	The Limbic	Virtual	June 2020
Patients with Melanoma Brain Metastases	Canadian Melanoma Conference	Canada	Feb 2020

Neoadjuvant Therapy – The Medical Oncologist Approach and Surgeon Point of View	Canadian Conference	Melanoma	Canada	Feb 2020
Emergent Strategies	Melanoma Bridge Congress		Naples, Italy	Dec 2019
Advances in Melanoma Management – Focus on Adjuvant Treatment in Recurring Disease	Society for Melanoma Research – CME certified symposium		Salt Lake City, USA	Nov 2019
Adjuvant Treatment in Melanoma, at look at the latest evidence	Society for Melanoma Research – CME certified symposium		Salt Lake City, USA	Nov 2019
Updates in Newly Diagnosed Melanoma – Focus on Long-term Outcomes and Emerging Combinations	Society for Melanoma Research – CME certified symposium		Salt Lake City, USA	Nov 2019
Characteristics of Long-Term Survivors and Subgroup Analyses with Combination Nivolumab plus Ipilimumab (NIVO+IPI) for Advanced Melanoma (Checkmate 067)	Society for Melanoma Research – CME certified symposium		Salt Lake City, USA	Nov 2019
Examining response and resistance in melanoma drug therapies	Huntsman Cancer Institute		Salt Lake City, USA	Nov 2019
Long-term Outcomes from the Randomized Ph 2 Study of Nivolumab or Nivo+Ipilimumab in Patients with Melanoma Brain Metastases: Anti-PD1 Brain Collaboration (ABC)	European Society for Medical Oncology		Barcelona, Spain	Sept 2019
Melanoma and other skin tumours Multidisciplinary Session: Perioperative therapy in melanoma - Neoadjuvant treatment	European Society for Medical Oncology		Barcelona, Spain	Sept 2019
Invited Chair	Pierre Fabre Satellite Symposium, European Society for Medical Oncology		Barcelona, Spain	Sept 2019
Redefining Survival – Latest advances in treatment of Melanoma: Translating Adjuvant Melanoma Data into Clinical Practice	MSD Symposium, European Society for Medical Oncology		Barcelona, Spain	Sept 2019
Zero deaths from Melanoma; latest data from early diagnosis and advanced disease	University Hospital, Vienna		Vienna	Sept 2019
Zero deaths from Melanoma; latest data from early diagnosis and advanced disease	University Hospital, Zurich		Zurich	Sept 2019
Distinguished Clinicians in Oncology Talk: Everything you need to know to manage patients and drug therapies in melanoma	Agora Research Centre, University Hospital Lausanne		Lausanne, Switzerland	Aug 2019

The Alan Cooper Epiderm Lecture 2019	The University of Queensland, Dimantina Institute	Brisbane, Australia	Aug 2019
Management of Melanoma. Hosted by CME of Northern America.	Research to Practice. Stand alone at American Society of Clinical Oncology	Chicago, USA	Jun 2019
Keynote	Cancer Institute NSW Fellows' Forum	Sydney, Australia	Jun 2019
Address at Women's Leadership Breakfast	Sydney Local Health District	Sydney, Australia	Jun 2019
Keynote	Annual Sydney Catalyst Postgraduate & Early Career Researcher Symposium	Sydney, Australia	Jun 2019
Overview of ongoing study landscape in neo-adjuvant melanoma	Novartis Advisory Board	Frankfurt	Feb 2019
How to combine target and immunotherapy?	European Association of Dermato Oncology	Barcelona, Spain	Nov 2018
Tumour board commission: how to manage it?	European Association of Dermato Oncology	Barcelona, Spain	Nov 2018
Issues in targeted therapy in BRAF mutant melanoma: Adjuvant therapy & which BRAF/MEK\ combination in the metastatic setting?	European Association of Dermato Oncology	Barcelona, Spain	Nov 2018
Evolving Role of Immunotherapy Across the Melanoma Landscape - The pursuit of survival in advanced melanoma	European Association of Dermato Oncology	Barcelona, Spain	Nov 2018
Therapy Resistance in the Clinic and in the Laboratory	The Society for Melanoma Research	Manchester, UK	Oct 2018
Congress "Melanoma" Highlights	European Society for Medical Oncology	Munich, Germany	Oct 2018
How do we improve treatment outcomes of patients with braf-positive metastatic melanoma - BRAF-positive melanoma: Case illustration	Pierre Fabre Satellite Symposium, European Society for Medical Oncology	Munich, Germany	Oct 2018
Melanoma Targeted Therapies - The Next Wave - Where to next with targeted therapies?	Australasian Melanoma Conference	Melbourne, Australia	Oct 2018
Melanoma Centre, trials team and database at Melanoma Institute Australia	Nordic Melanoma Meeting	Copenhagen	Sept 2018
Adjuvant and neo-adjuvant immunotherapy Management of Stage III Melanoma	Nordic Melanoma Meeting	Copenhagen	Sept 2018
Immunotherapy, Management of Stage IV Melanoma.	Nordic Melanoma Meeting	Copenhagen	Sept 2018
State of the art treatments for melanoma – what is the current situation?	CSCO 4th Beijing International Melanoma Congress, Beijing	Beijing, China	Aug 2018

A step forward in Melanoma Treatment with pembrolizumab. MSD Oncology Satellite Symposium	CSCO 4th Beijing International Melanoma Congress, Beijing	Beijing, China	Aug 2018
Management of Early Stage Melanoma – Neo Adjuvant	17th World Congress on Cancers of the Skin	Sydney, Australia	Aug 2018
Currently Melanoma Standard of Care.	17th World Congress on Cancers of the Skin	Sydney, Australia	Aug 2018
Resistance in immunotherapy: Why and can we overcome it. Where is Immunotherapy going next?	Immuno-Oncology Forum	Adelaide, Australia	Aug 2018
Melanoma, Drug Therapy, Surgery and Analyses: Rapid Translation from the Laboratory that Impact Patient Outcomes,	Charles Perkins Centre Bio-domain seminar	Sydney, Australia	Jul 2018
Melanoma Institute Australia: A Flagship for clinical and translational research, and improving patient outcomes	Sydney Innovation and Research Symposium,	Sydney, Australia	Jun 2018
Assessing Immunotherapy Response and Progression - Education Session - Treatment Beyond Progression: Current Understanding and Implications	American Society for Clinical Oncology	Chicago, USA	Jun 2018
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study, compelling Combinations: Raising the Bar with Immunotherapy	American Society for Clinical Oncology	Chicago, USA	Jun 2018
What Is the Rationale for (Neo-)Adjuvant Therapy in Stage III Melanoma? Adjuvant/Neoadjuvant Treatment in Melanoma: Where Surgery Meets Medical Oncology	American Society for Clinical Oncology	Chicago, USA	Jun 2018
Systemic drug therapy update and the critical role of sentinel node biopsy, The Critical Trinity: Primary diagnosis, Sentinel node biopsy and Drug therapy	Australasian Skin Cancer Congress	Gold Coast, Australia	May 2018
Melanoma Surgery in the Era of Effective Systemic Therapies	Royal Australasian College of Surgeons Annual Scientific Congress	Sydney, Australia	May 2018
Neoadjuvant treatment of resectable stage III disease, Current Trends in Immuno-Oncology		Sydney, Australia	May 2018
'Omics in cancer clinical practice,	The University of Sydney Cancer Research Networks	Sydney, Australia	Apr 2018

New Strategies in Preventing and Treating Melanoma - Adjuvant therapy for Melanoma	MRA 10 TH Annual Scientific	Washington DC, USA	Mar 2018
Optimization of Melanoma Treatment - Neo-adjuvant drug therapy: What, when, in who and what for?	European Society for Medical Oncology - Asia	Singapore	Nov 2017
Patient selection and biomarkers - Predicating response and resistance in drug therapy for advanced melanoma	COSA ASM	Sydney, Australia	Nov 2017
Future Perspectives and Highlights - Highlights in Melanoma	9 th World Congress of Melanoma	Brisbane, Australia	Oct 2017
Melanoma Centre Sessions - Conducting an efficient and effective melanoma tumour board / multi-disciplinary meeting	9 th World Congress of Melanoma	Brisbane, Australia	Oct 2017
A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases' with a presentation of the interim analysis and trial results (ANZMTG 01.14 ABC trial).	9 th World Congress of Melanoma	Brisbane, Australia	Oct 2017
Melanoma: Future Approaches to Therapy and Trials - State of the art treatments for melanoma – what is the current situation?	9 th World Congress of Melanoma	Brisbane, Australia	Oct 2017
The I-O-Approach in Advanced Melanoma – From an Innovation to a Standard Therapy: Clinical factors, biomarkers, guidelines – and how they contribute to an individual therapy decision	7 th European Post-Chicago Melanoma and Skin Cancer		Jun 2017
My Personal Highlights at ASCO 2017 in combined / sequential schedules	7 th European Post-Chicago Melanoma and Skin Cancer		Jun 2017
Clinical Problems in Oncology Session- in the Immunotherapy, Surgery, and Radiation Therapy of Melanoma – Monitoring for and Management of Immune-Related Adverse Events Resulting from Checkpoint Blockade.	American Society of Clinical Oncology	Chicago, USA	Jun 2017
Neoadjuvant Therapy of High-risk Melanoma: MIA Progress	International Melanoma Working Group	Athens, Greece	May 2017
Treatment of metastatic melanoma: Shaping the future together. Achieving the best outcomes in metastatic melanoma today: The experts experience	European Association of Dermato Oncology	Athens, Greece	May 2017

The evolving therapeutic landscape of advanced melanoma	European Association of Dermato Oncology	Athens, Greece	May 2017
Choice of immunotherapy versus targeted therapy in first line treatment for BRAF-mutant melanoma	European Association of Dermato Oncology	Athens, Greece	May 2017
Update on systemic therapies for pathologists	International Melanoma Pathology Course	Paris, France	Apr 2017
Cutaneous Melanoma / Ocular Melanoma: Systemic drug therapy in melanoma: does subtype matter?	International Society of Ocular Oncology and The Royal Australian and New Zealand College Biennial Conference	Sydney, Australia	Mar 2017
Melanoma: BRAF mutated metastatic melanoma: patient-centric management	Harnessing Targeted Oncology Therapies Symposium, Sydney	Sydney, Australia	Mar 2017
Neoadjuvant therapy in bulky stage III melanoma: Are we there yet?	European Cancer Organisation,	Amsterdam	Jan 2017
Debate: This house believes that high-risk stage III melanoma should NOT be treated with adjuvant ipilimumab after complete resection – Contra, Speaker against	European Cancer Organisation	Amsterdam	Jan 2017
Challenge Your Expert session: All patients should receive immune- based therapy for advanced melanoma in the first line	European Society for Medical Oncology Asia Congress	Singapore	Dec 2016
Clinical predictors of prolonged response and survival,	European Society for Medical Oncology Asia Congress	Singapore	Dec 2016
Translational Research Infrastructure	Sydney Vital, Sydney		Nov 2016
Neoadjuvant Therapy in Melanoma,	Australasian Melanoma Conference	Sydney, Australia	Oct 2016
Translational Research in Melanoma, Plenary Oral	Australasian Melanoma Conference	Sydney, Australia	Oct 2016
The Melanoma Treatment Landscape and Lessons from the Lab,	Beijing International Melanoma Congress	Beijing, China	Oct 2016
Immunotherapy for Mucosal Melanoma	Beijing International Melanoma Congress	Beijing, China	Oct 2016
Anti-PD1 Therapy in Melanoma	Beijing International Melanoma Congress	Beijing, China	Oct 2016
Melanoma Treatment Landscape,	European Society for Medical Oncology Congress, Roche Symposium	Copenhagen	Oct 2016

Management of Immunotherapy Side Effects	European Society for Medical Oncology Congress	Copenhagen	Oct 2016
The Role of Systemic Treatments for Metastatic Melanoma Brain Metastases,	Neurosurgical Society of Australasia Annual Scientific Meeting	Sydney, Australia	Sept 2016
Adjuvant systemic therapy update, Multidisciplinary management of locoregionally advanced melanoma – from surgery to immunotherapy	Peter MacCallum Cancer Centre	Melbourne, Australia	Aug 2016.
Melanoma drug therapies: Lessons from the clinic and results from the lab,	Kinghorn Cancer Centre	Sydney, Australia	Aug 2016
Immunotherapies in Melanoma: Results and Lessons from the Clinic, A Workshop on Immunotherapy: from bench to bedside	Centenary Institute	Sydney, Australia	Aug 2016
Melanoma: immuno-oncology treatment landscape	BMS Immuno-Oncology Conference	Sydney, Australia	Jul 2016
Melanoma drug therapies: where to next?, Kidson Lecture,	Annual Cancer Immunotherapy Highlight Talk Brisbane QIMR	Brisbane, Australia	Jun 2016
Highlights of the day for Melanoma Oral sessions	American Society for Clinical Oncology AGM	Chicago, USA	Jun 2016
Clinically Approaching Metastatic Melanoma in 2016: Overview of Data and Options, Education Session	American Society for Clinical Oncology AGM	Chicago	Jun 2016
Immunotherapy in Practice: Experiences in Melanoma	ANZGOG Annual Scientific Meeting,		Apr 2016
Current Trends in Immuno-Oncology: Emerging clinical IO data in Advanced Melanoma	MSD Stand Alone Scientific Symposium	Madrid	Mar 2016
Current Trends in Immuno-Oncology: Emerging clinical IO data in Advanced Melanoma	MSD Stand Alone Scientific Symposium	Rome	Feb 2016
Immunotherapy In Melanoma	First International Immunotherapy Conference	Brisbane	Nov 2015
Cancer Research: Melanoma, Cancer Research Uncovered Talks for the Community	The University of Sydney	Sydney	Nov 2015
Critical analysis of targeted therapy and immunotherapy outcome, Chair and Speaker	Novartis Oncology Region Europe Investigator Meeting	Marseille, France	Oct 2015
New Drug and New Trials; Dabrafenib Plus Trametinib	11 th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers	Marseille, France	Oct 2015

Melanoma Immunology; Response and Long Responders	Long	11 th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers	Marseille, France	Oct 2015
Progress in targeted therapy of Melanoma; Monitoring drug response and therapeutic escape,		11 th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers	Marseille, France	Oct 2015
Melanoma Management Matters: Optimising treatment for BRAF positive Metastatic Melanoma, Chair and Speaker		Novartis Symposium	Sydney	Oct 2015
Immunotherapy, Melanoma and the Future		BMS Melanoma symposium at ECCO-40 th ESMO European Cancer Congress	Vienna, Austria	Sept 2015
Mechanisms of Resistance to Targeted Therapies		18 th ECCO-40 th ESMO European Cancer Congress	Vienna, Austria	Sept 2015
Sequencing and Combining Immunotherapies and Targeted Therapies		18 th ECCO-40 th ESMO European Cancer Congress	Vienna, Austria	Sept 2015
Immunotherapy and The Treatment Landscape in Melanoma,		BMS Immuno-Oncology Symposium	Sweden	Sept 2015
Drug Therapies in Melanoma Brain Metastases, Advances in Treatment of Melanoma Brain Metastases		Melanoma Institute Australia, Education Event	Sydney	Aug 2015
Drug Therapies in Melanoma, Faculty of Pharmacy		University of Sydney	Sydney	Aug 2015
Clinical trial results on targeted drugs in metastatic melanoma, and plans for future research Melanoma & Skin Cancer Special Interest Group (MELSIG)		Mini-Symposium, University of Sydney	Sydney	Jul 2015
The Melanoma Treatment Landscape		AIM Patient Advocate Forum	Munich, Germany	Jun 2015
My personal highlights in ASCO 2015 in targeted therapies		5th European Post-Chicago Melanoma/Skin Cancer Meeting	Munich, Germany	Jun 2015
New drugs and trials II: An update on targeted agents and combo treatments – Dabrafenib and Trametinib		5th European Post-Chicago Melanoma/Skin Cancer Meeting	Munich, Germany	Jun 2015
Immunotherapies in the modern era of melanoma management		5th European Post-Chicago Melanoma/Skin Cancer Meeting	Munich, Germany	Jun 2015
Targeted therapies in the modern era of melanoma management		5th European Post-Chicago Melanoma/Skin Cancer Meeting	Munich, Germany	Jun 2015

The Evolving Landscape, Management of Advanced Melanoma,	Merck (MSD) Symposium Immuno-Oncology	Chicago, USA	Jun 2015
Emerging Data in Immuno-Oncology in Advanced Melanoma	Merck (MSD) Symposium Immuno-Oncology	Sydney, Australia	Jun 2015
Immunotherapy side effects, Discussant	American Society for Clinical Oncology AGM	Chicago, USA	May-Jun 2015
The Molecular Multi-disciplinary Team Meeting	International Melanoma Working Group	Krakow, Poland	Mar 2015
Melanoma systemic drug therapies	Skin and Cancer Foundation Scientific Meeting,	Leura, Sydney	Mar 2015
Checkpoint Inhibitors in Melanoma,	Merck (MSD) Immuno- Oncology Symposium	Hong Kong,	Mar 2015
Drug Therapies in Melanoma – where to next?	Lorne Cancer Conference	Melbourne	Feb 2015
Melanoma – Australian Epidemiology,	Merck (MSD), Melanoma Expert Input Forum	Taipei, Taiwan	Jan 2015
Combination Therapies; Where to next?	Society for Melanoma Research Annual Meeting	Zurich, Switzerland	Nov 2014
Brain metastases: how to integrate and optimize medical treatments,	Italian Melanoma Intergroup Meeting	Venice, Italy	Oct 2014
Organising melanoma care, conducting clinical and translational research and monitoring quality of melanoma treatment: the experience of the Melanoma Institute Australia	Italian Melanoma Intergroup Meeting	Venice, Italy	Oct 2014
Principles of novel therapeutics in combinations: Combined targeted immune therapy	American Association for Cancer Research, Melanoma Meeting	Philadelphia, USA	Sept 2014
Management challenges: brain metastases and progressive disease	GSK Melanoma Masterclass	Melbourne	Jul 2014
Immune effects MAPK inhibitor treatment, GSK Advisory Board Key Presentation	GSK Melanoma Masterclass	Melbourne	Jul 2014
Immuno-oncology therapies in melanoma	Paris Symposium	Paris	Jul 2014
Brain metastases: Targeted therapy or immunotherapy?	Paris Symposium	Paris	Jul 2014
Optimizing the Use of New Targeted Therapies in the Face of Toxicity	Education Session American Society for Clinical Oncology AGM	Chicago, USA	Jun 2014
Metastatic disease – Is it time to change our approach?	Merck Sharp and Dohme Melanoma Stand Alone Satellite Symposium, American Society for Clinical Oncology AGM	Chicago, USA	Jun 2014

GlaxoSmithKline Melanoma Launch of Dabrafenib and Trametinib,		Sydney	Apr 2014
Brain Metastases Protocol Activation,	International Melanoma Working Group	Budapest, Hungary	Mar 2014
Systemic Therapy in Melanoma. Insights	Perspectives and Future Directions, Cancer Institute NSW	Sydney	Mar 2014
Beyond the Target. Why we have to get personal	Haematology and Oncology Targeted Therapies Conference	Melbourne	Mar 2014
The Melanoma Treatment Landscape	Haematology and Oncology Targeted Therapies Conference	Melbourne	Mar 2014
Systemic Therapies in Melanoma, Royal Prince Alfred Hospital	Combined Immunology and Rheumatology Department Meeting	Sydney	Feb 2014
Management of BRAF-mutant melanoma	Journées Dermatologiques de Paris	Paris	Dec 2013
Kinase Inhibitors in Melanoma, Plenary Session	Society for Melanoma Research	Philadelphia, USA	Nov 2013
Systemic Therapies in Metastatic Melanoma: Insights and Perspectives	GlaxoSmithKline	Philadelphia, USA	Nov 2013
Treatment options of patients with advanced melanoma and the latest research	An interactive seminar for General Practitioners, Northern Sydney General Practice Network	Sydney	Oct 2013
Beating Melanoma; Targeting Genes, 21 st Century Medicine	The University of Sydney	Sydney	Oct 2013
Dabrafenib in Clinical Practice	GlaxoSmithKline Satellite Symposium, European Cancer Organisation Conference	Amsterdam	Sept 2013
Combination modality treatment for brain metastases	European Cancer Organisation Conference	Amsterdam	Sept 2013
Systemic Treatment of Metastatic Melanoma. Current status and perspectives	Plenary Session German Skin Cancer Meeting	Essen Germany	Sept 2013
Systemic Therapy in Melanoma, Melanoma education evening	Australasian Foundation for Plastic Surgery and Melanoma Institute Australia		Sept 2013
Melanoma: Beyond the Response to BRAF Inhibitors	Medical Oncology Group of Australia	Melbourne	Aug 2013
Highlights from ASCO 2013: Kinase Inhibitors	8 th World Congress for Melanoma	Hamburg Germany	Jul 2013
New Drugs and Trials: Dabrafenib plus Trametinib	8 th World Congress for Melanoma	Hamburg Germany	Jul 2013

Management of Brain Metastases: Targeted Therapy	8 th World Congress for Melanoma	Hamburg Germany	Jul 2013
Dabrafenib Toxicities	GlaxoSmithKline Dabrafenib Advisory Board Presentation	Chicago	Jun 2013
Management of Melanoma Brain Metastases	American Society for Clinical Oncology, Melanoma Education Session	Chicago, USA	Jun 2013
Systemic Therapies for Melanoma; a rapidly changing landscape, and a poster-child for targeted therapies and immunotherapy	Annual Scientific Meeting of the Australasian College of Dermatologist	Sydney	May 2013
Melanoma Heterogeneity, Resistance and Implications for Systemic Therapy	Meeting for the Asian Society for Pigment Cell Research (ASPCR) and the Australasian Society for Dermatology Research (ASDR)	Sydney	May 2013
BRIM3 and BRIM7 update	Skin Cancer Summit	Cancun, Mexico	Mar 2013
The Evolution of Targeted Therapy in Melanoma	Skin Cancer Summit	Cancun, Mexico	Mar 2013
Highlights from the Society for Melanoma Research	ReachMD XM 167, Medical Education Radio Station	USA	Jan 2013
New Treatments in Melanoma,	Melanoma Institute Australia, Community & Volunteers Seminar	Sydney	Dec 2012
Melanoma; Australias Cancer, Australias Progress	Parliamentarians supporting cancer causes breakfast event to mark National Skin Cancer Action Week	Canberra	Nov 2012
Discussant for Late Breaking Clinical Trials	Society for Melanoma Research Conference	Hollywood, CA USA	Nov 2012
Innovation and Translation in Clinical Practice: Lessons from Melanoma and Targeted Therapies	The Power of Innovation, NSW Health Symposium	Sydney	Oct 2012
Randomised Phase II study of BRAF inhibitor dabrafenib vs combination with MEK inhibitor trametinib in BRAF V600 mutant metastatic melanoma	GlaxoSmithKline Combination Dabrafenib and Trametinib Advisory Board Presentation	Vienna	Sept 2012
Personalising Therapy in Metastatic Melanoma	Roche Satellite Symposium, European Society for Medical Oncology Conference	Vienna	Sept 2012
Update on prognostic significant of tumor BRAF and other mutations	Perspectives in Melanoma XVI	Valencia, Spain	Sept 2012
Combination of BRAF and MEK inhibitors for BRAF mutant metastatic melanoma	Perspectives in Melanoma XVI	Valencia, Spain	Sept 2012

Targeting Oncogenic Pathways in Melanoma; Progress to Date, Melanoma now & into the future, Symposia	Olivia Newton-John Cancer and Wellness Centre	Melbourne	Aug 2012
Adjuvant Therapy in Melanoma	Melanoma Institute Australia's World Round-Up Symposia. The latest in melanoma from recent international meetings	Sydney	Jul 2012
Inhibiting mutant-BRAF in metastatic melanoma. Vemurafenib in clinical practice	Vemurafenib Launch Meeting, web meeting	Brazil, Sao Paulo	Jun 2012
Patient Cases and Discussion,	Vemurafenib Launch Meeting Australia	Sydney	Jun 2012
Targeted Therapies in Melanoma, MAP Kinase Pathway Inhibitors	GlaxoSmithKline Investigators Meeting for Phase 3 Studies of dabrafenib combined with trametinib versus single agent BRAF inhibitor	Sydney	Apr 2012
Building translation into clinical practice: Lessons from melanoma and targeted therapies	American Association for Cancer Research	Chicago, USA	Apr 2012
Managing metastatic melanoma, now and in the future,	Vemurafenib External Global Launch Meeting	Paris	Apr 2012
Targeted therapies, what lessons have we learnt	Haematology and Oncology Therapeutic Treatments (HOTI) conference	Melbourne	Mar 2012
The BRAF story – from Target to Treatment and Beyond	7 th Annual University of North Carolina Conference on Melanoma	Chapel Hill, North Carolina	Feb 2012
The BRAF story – from Target to Treatment and Beyond, Patient Symposium	7 th Annual University of North Carolina Conference on Melanoma	Chapel Hill, North Carolina	Feb 2012
The BRAF Story: Managing Metastatic Melanoma	Roche Education Day	Sydney	Dec 2011
Case-based discussion: How do you treat metastatic melanoma today?	Society for Melanoma Research	Tampa	Nov 2011
The BRAF Story-Managing Metastatic Melanoma	Prince of Wales Hospital	Sydney	Oct 2011
Vemurafenib in the Management of Metastatic Melanoma	Roche Internal Global Launch of Vemurafenib	Rome	Oct 2011
BRAF in metastatic melanoma. Prognostic significance, age and other associations	Perspectives in Melanoma XV	New York	Sept 2011
Management of Melanoma Brain Metastases	Roche Investigators Meeting for Phase 2 Study Vemurafenib in Brain metastases	London,	Jul 2011

Targeted Therapies in Melanoma – a New Approach to Systemic Therapies in Cancer	Plenary Session Cancer Nurses Society of Australia Congress	Sydney	Jul 2011
Systemic Therapies on Melanoma: Immunotherapy, BRAF inhibitors and Beyond	Merck Sharp Dome Educational Evening	Sydney	Jun 2011
BRAF mutant metastatic melanoma - clinical and translational research	University of California	LA, USA	Jun 2011
BRAF mutant metastatic melanoma – clinical and translational research	University of Pennsylvania	Philadelphia	May 2011
Advances in the Treatment of Melanoma	Westmead Medical Research Foundation Community Seminars		Jun 2011
Clinical Research in identified targets; The BRAF story in melanoma	Pfizer Oncology Forum Meeting	Melbourne	May 2011
GSK2118436 (Dabrafenib) Laboratory Correlates,	International Melanoma Working Group		Apr 2011
Management of Melanoma	Lecture for Advanced Training Oncology Meeting	Sydney	Feb 2011
Management of Patients with Brain Metastases	Roche Melanoma Advisory Board Presentation	Melbourne	Dec 2010
Systemic Therapies in Melanoma	Australian & New Zealand Head & Neck Cancer Society, Annual Scientific Meeting	Sydney	Sept 2010
Targeted therapies - Trials and the TEAM Study	Melanoma Institute Australia Science Symposium	Sydney	Mar 2010
Targeted Therapies in melanoma	Melanoma Update for Radiation and Medical Oncologists	Sydney	Mar 2010
BRAF Inhibitors and Other Targeted Therapies in melanoma	Sydney Head & Neck Cancer Institute	Sydney	Mar 2010
BRAF Inhibitors and Other Targeted Therapies in melanoma, Radiation Oncology Chapter Meeting		Sydney	Mar 2010
Research and Clinical Trials, Advances in Melanoma Care Symposium	Melanoma Network and Melanoma Institute	Australia,	Aug 2009

TEACHING, MENTORSHIP AND SUPERVISION

Post-Graduate Degree Supervision, University of Sydney **From 2011**

University of Sydney, co-supervision of post-graduate students
 Primary supervisor for four PhD students and co-supervisor of seven PhD students

Name	Year completed /Awarded PhD	Thesis Title	Primary/ Co-supervisor
------	-----------------------------	--------------	------------------------

Dr James Wilmott	2013	Biomarkers and biology of BRAF inhibitor treated metastatic melanoma	Co-supervisor
Dr Alexander Menzies	2015	Determining the Molecular mechanisms of BRAF/MEK inhibitor resistance in Melanoma	Primary
Dr Matteo Carlino	2015	Determining the Molecular mechanisms of BRAF/MEK inhibitor resistance in Melanoma	Co-supervisor
Mr Hansol Lee	2021	NK cells in the microenvironment of anti-PD1 treated melanoma	Co-supervisor
Dr Hojabr Kakavand	2017	Molecular determinants of melanoma progression and susceptibility to current treatment strategies	Co-supervisor
Dr Louise Jackett	Current commenced 2017	Clinical and histopathological associations of melanocytic lesions in the molecular era	Co-supervisor
Dr Jarem Edwards	Current commenced 2018	Improving immunotherapy in the clinic: The cells underlying response and resistance to drug immunotherapy	Co-supervisor
Ms Tuba Nur Gide	2019	Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma	Primary
Dr Jordan Conway	Current commenced 2019	Mechanisms of resistance to PD-1 based immunotherapy in melanoma liver metastases	Co-supervisor
Rebecca Simpson	Current commenced 2020	Assessing the mechanistic links between the intestinal microbiota and the immune system during cancer immunotherapy	Co-supervisor
Dr Jorja Braden	Current commenced 2021	Determining optimal neoadjuvant sequencing of anti-PD1 and BRAF – targeting therapy in resectable BRAF mutant stage IIIB/C/D melanoma	Primary
Dr Kazi Nahar	2021	Mechanisms of immune checkpoint inhibitor-induced gastrointestinal toxicities	Mentor – Lab PI
Xinyu Catherine Bai	2020	Immunogenomic features of adolescent and young adult melanoma and their implications for response to checkpoint inhibitor immunotherapy	Mentor – Lab PI
Eva Shteinman	Current commenced 2022	Characterising the Genomic and Immune Landscape of Melanoma Subtypes	Mentor – Lab PI
Grace Attril	Current comments 2019	Assessing the function of tumour specific and bystander T-cells in relation to clinical outcomes of melanoma patients	Mentor – Lab PI

Advanced and Basic Trainee Education and Supervision

I have mentored and trained more than 20 Advanced Trainees in medical oncology since 2009 at Westmead Hospital, Melanoma Institute Australia and Royal North Shore Hospital. Additionally, they have completed a research project, published and presented it, and many have pursued a higher post-graduate degree as a direct result of my mentorship. I lecture to basic and advanced physician trainees in formal hospital-based training programs.

Medical Oncology Fellow

The medical oncology unit at Melanoma Institute Australia has offered competitive 12-month clinical fellowships since 2013. As their primary supervisor, I:

- Oversee clinical commitments and duties; weekly 1:1 meetings for review of progress
- Educate regarding the management of patients with melanoma, and the conduct of clinical trials and research

- Provide support and mentorship for research projects (to be completed within 12 months)
- Provide guidance for writing successful publications and grant applications
- Support conference attendance
- Ensure my qualifications are sufficient for supervision e.g. completed Royal Australasian College Supervisors Training, completed University of Sydney post-graduate degree supervisor training

Fellows have published in high-impact journals as first authors (Journal of Clinical Oncology IF 44.54 CCR), presented original research at international conferences (including the prestigious American Society for Clinical Oncology, European Clinical Cancer Organisation, European Society for Medical Oncology, Clinical Oncology Society of Australia and Society for Melanoma Research).

The following Fellows have worked under my supervision since 2013

2013	Megan Lyle		
2014	Elizabeth Liniker		
2015	Sangeetha Ramanuja		
2016	Rajat Rai	Kazi Nahar	Ines Da Silva
2017	Helen Dearden	Elizabeth Liniker	
2018	Martin Tio	Carina Owen	
2019	Lalit Pallan	Adriana Hepner	
2020	Aljosja Rogiers	Florentia Dimitriou	Kay Xu
	Sarah Maloney	Tam Bui	
2021	Amelia Taylor	Julia Lai-Kwon	
2022	Rachel Woodford	Piyush Grover	
2023	Ivo Julio	Anne Zaremba	Thomas Bennett
2024	Andrea Boutros	Rebecca Symons	Yo-Ju (Ruby) Kuo

All of the above Fellows have gone on to prestigious careers.

Supervisor Training

Royal Australasian College of Physicians, training for supervisors of advanced trainees	2013
University of Sydney, training for supervisors of USYD post-graduate students	2011
Teaching on the run, training for teaching and mentorship in clinical settings	2005

Financial Support for Teaching and Supervision

Organised PhD top-up scholarship via Melanoma Institute Australia for PhD students

Obtained Educational Grants and Sponsorship for conference travel for Advanced Trainees and Post-graduate Students

Medical Student Teaching and Supervision

University of Sydney, supervision of Graduate Medical Program Honours Students	2009-2010
University of Sydney, Graduate Medical Program;	
<ul style="list-style-type: none"> • Communication Skills Tutorials, Central Clinical School 	2004-2006
<ul style="list-style-type: none"> • SCORPIO Procedural & Examination Skills Tutorials, Central Clinical School 	2004,2005
<ul style="list-style-type: none"> • Integrated Clinical Attachments, Central Clinical School 	2003-2005
<ul style="list-style-type: none"> • Integrated Clinical Attachments, Western Clinical School 	2011

Observerships/Sabbaticals

- I host colleagues for sabbaticals (6weeks-6months) and teach international and local medical students and trainees at Melanoma Institute Australia

Other Teaching

Intern lecture series, Royal Prince Alfred Hospital, regular invited speaker	2003-2006
University of Sydney	
• Careers Evening, final year MBBS. Physician Training, whats involved	2004
• Chemistry I laboratory Demonstrator and Tutor	1992-1995
• Chemistry III Laboratory Demonstrator	1992-1995
• High School Chemistry Workshops	1997, 1998
• Workshop for the Research and Scholarships Office Grants and Scholarships – how to apply	1996
• Mathematics and Chemistry Private Tuition, HSC and University level	1989-2002

Curriculum Development and Training Review

Member of The Royal Australasian College of Physicians Trainee Committee	2005
Basic Physician Trainee Representative, Network Governance Committee, RPAH Network	2005
RMO Representative, Clinical Training Committee, Royal Prince Alfred Hospital	2002
Student member - Yrs 3 & 4 Curriculum Committee, Sydney University Medical Program	1997, 1998
University of Sydney, Chemistry III laboratory curriculum development	1998

CLINICAL LEADERSHIP AND COMMITTEE MEMBERSHIP

Academic and Strategic Committees

• Chair CINSW Clinical Engagement on Melanoma	2021
• NSW Ministry of Health, Invitation to pitch for Moderna factory in NSW	2021
• NSW Ministry of Health, Teletrials	2019
• Expert Panel Committee Member for AJCC Cancer Staging System (Melanoma), 8 th Ed'n	2014-2016
• Committee Member International Scientific Reference Group (ISRG) – Global Advances and Controversies in Skin Cancer	2015
• Melanoma Research Foundation State of Melanoma Strategic Committee	2015
• NSW Health Government Consultant Workshop on Early Phase Clinical Trials Framework	2016
• International Melanoma Working Group Member	From 2011
• Australian Genomic Cancer Clinical Trials Initiative	2013-2015
• NHMRC Australian Biospecimen Banking Review	2012

Advisory/Advisor Board Membership

• Iovance Biotherapeutic's TIL Cell Therapy Developmental ("Developmental") Scientific Advisory Board (SAB)	From 2023
• Evaxion Biotech A/S	From 2021
• Aduro Biotech	From 2020
• Highlight Therapeutics	From 2020
• Q'Biotics Australia	From 2020
• Regeneron	From 2020

- SkylineDX B.V. **From 2020**
- Sandoz Global **From 2019**
- OncoSec Global **From 2017**
- Pierre Fabre Australia & Global **From 2017**
- Array BioPharma **2016**
- BMS Oncology Tumour Advisory Council Member (OTAC) **From 2015**
- Amgen, Australian and Global **From 2013**
- BMS, Australian and Global (Including role as Chair of the Advisory Board) **From 2011**
- GSK, Australian and Global **2009-2014**
- Merck (MSD), Australian and Global **From 2014**
- Novartis, Australian and Global **From 2012**
- Roche, Australian and Global **From 2010**
- Provectus, Global **2014**

Trial Steering Committees/Trial Design

- Regeneron; R3767-ONC-2011 **From 2021**
- Roche; Morpheus **From 2021**
- Pierre Febre; EORTC-1902-MG COLUMBUS-AD Study **From 2021**
- Amgen; TVEC Steering Committee Member **From 2015**
- MERCK MSD steering committees; KN716, LEAP 003, KN 964, MK3475-U02, MK 7902 **From 2018**
- BMS Steering committees; CA-047, CA-76K, CA-045, CA209-7UA, RELATIVITY-098 **From 2018**
- Glaxo Smith Kline Steering Committees; MEK115306 and MEK116513 **2012 - 2015**
- Novartis Steering Committee Studies; Platform, Combi-i, COMBI-d and v, CLXH254C12201 **From 2012**
- Array Biopharmaceuticals Steering Committee; CMEK162A2301 **From 2015**
- EORTC; Stage II adjuvant **From 2015**

CONFERENCE AND SYMPOSIA ORGANISATION

Title	Organisation	Date
Scientific Co-Chair	ESMO Asia	2024
Education Committee – Member	American Society of Clinical Oncology	2022-2025
Intratumoral Immunotherapy Clinical Trials Consensus Statement manuscript development group	Society of Immunotherapy of Cancer (SITC)	From 2022
Conference Committee/Conference Convenor	Australasian Melanoma Conference	2021
ASCO Plenary Series Scientific Review Committee – Member	American Society of Clinical Oncology	From 2021
Melanoma and other Skin Tumors Faculty Group – Faculty Member	European Society for Medical Oncology	2021-2025
Scientific Committee (Member)	European Society for Medical Oncology	2024-2027

Scientific Committee (Chair)		2017-2020 2019-2020
Melanoma/Skin Cancer Track Education and Scientific Committees – Chair Member	American Society of Clinical Oncology	2016 2014-2017
Steering Committee Member	International Society for Melanoma Research	From 2014
Scientific Committee (Member) Scientific Committee (Chair)	European Society for Medical Oncology - Asia	2015-2020 2016, 2019
Immuno-oncology Symposium Organising Committee (Member)	Medical Oncology Group of Australia	2018
Immuno-oncology Symposium Organising Committee (Chair)		2015
Conference Co-Chair	3 rd Australasian Melanoma Conference	2015-2016
Committee Member of the Australian Steering Committee	World Congress of Melanoma	2015-2017
Steering Committee Member	Immuno-Oncology Symposia Sydney July	2016
Organiser, Advances in Treatment of Melanoma Brain Metastases; A New Era	A Melanoma Institute Australia Education Event	2015
Member of Steering Organising Committee	Australian Melanoma Master Class	2014
Member of the Organising Committee	Haematology and Oncology Therapeutic Treatments Conference	2014
Member of the Organising Committee	University of Sydney Cancer Conference	2012
Melanoma Institute Australia, Annual Symposia Post-ASCO and other Highlights of Melanoma Research		From 2010

Note – Professor Long is regularly invited Faculty member for conferences (see invited speaker events)

CLINICAL PRACTICE GUIDELINES AND PATIENT INFORMATION RESOURCE DEVELOPMENT

Electronic Clinical Trial Resource Development For Physicians; ClinTrial Refer, Melanoma Lead Clinician - A free downloadable Application for iPhone/Android of clinical trials across Australia for patients with melanoma	From 2014
Australian Melanoma Management Guidelines Committee, Medical Oncology Section Leader	From 2014
Cancer Institute NSW Reviewer of Evi-Q – on-line evidence-based guidelines for clinicians using melanoma systemic treatments	From 2013
American Society for Clinical Oncology Editorial board member for Cancer.net patient information website for melanoma. Responsibilities: regular review of the website and its content.	2013-2016
Melanoma Institute Australia Patient Information Package Design & Review, including patient information for stage 3 and 4 melanoma	From 2013

MANAGING EDITOR AND EDITORIAL BOARD MEMBERSHIP

New England Journal of Medicine	Guest	From 2019
Lancet	Guest	From 2019
Nature	Guest	From 2019
Nature Medicine	Guest	From 2019
Cancer Cell	Guest + Advisory Board	From 2019
Cell	Guest	From 2019
Lancet Oncology	Guest	From 2019
Journal of Clinical Oncology	Guest + Editorial Board Member	From 2012
Clinical Cancer Research	Guest	From 2019
European Journal of Cancer	Guest	From 2019
Cancer	Guest	From 2019
Proceedings of the National Academy of Science	Guest	From 2019
Oncogene	Guest	From 2019
Melanoma Research	Guest	From 2019
Nature Review Clinical Oncology	Guest + Advisory Board	From 2018
Pigment Cell Melanoma Research	Guest Reviewer + Managing Editor for all clinical manuscripts, review process and final decisions	2015-2017
Annals of Oncology	Guest Editor + Guest Reviewer + Managing Editor for all melanoma related manuscripts, review process and final revisions	2016 - 2023
American Society for Clinical Oncology, Cancer.net	Guest	2013-2016

GRANT AND SCIENTIFIC JOURNAL REVIEWER COMMITMENTS

Regular reviewer for peer-reviewed scientific journals, including the New England Journal of Medicine (IF 91.24), Lancet (IF 79.32), Lancet Oncology (IF 54.43), Journal of Clinical Oncology (IF 44.54), Cancer Cell (IF 31.74), Nature Review Clinical Oncology (IF 66.68), PNAS (IF 11.2), Annals of Oncology (IF 51.76), Clinical Cancer Research (IF 13.8).

Regular reviewer of grants submitted to international and Australian funding organizations, including NHMRC program and project grant reviews.

NHMRC review committees

- Research Fellow 2018

- Clinical trials 2019

Session Chair for multiple conferences including (not limited to):

- American Society of Clinical Oncology Annual Meeting **From 2011**
- European Society for Medical Oncology Annual Meeting **From 2016**
- World Congress for Melanoma (4 yearly) **From 2013**
- International Society for Melanoma Research Annual Congress **From 2011**
- Multiple Australian and International Symposia **From 2012**
- Melanoma Institute Australia Symposia and Educations Events **From 2014**

WORKING GROUPS AND OTHER COMMITTEES

Executive Producer of Conquering Skin Cancer (jointly with Co-Medical Director Richard Scolyer)	2023 to 2024
Guest Professor of Xiangya Hospital of Central South University	2019 to 2024
Honorary Member Societe Francaise De Dermatology	2018
Member of The Royal Australasian College of Physicians Trainee Committee	2005
Basic Physician Trainee Representative, Network Governance Committee, RPAH Network	2005
President of RMOs Association, Royal Prince Alfred Hospital	2003
RMOs Association Member, Royal Prince Alfred Hospital	2002-2006
RMO Representative, Clinical Training Committee, Royal Prince Alfred Hospital	2002
Student member - Yrs 3 & 4 Curriculum Committee, Sydney University Medical Program	1997, 1998
Postgraduate student member, Chemistry School Board, University of Sydney	1995
Postgraduate student rep, School of Chemistry Staff/Student Liaison Committee, University of Sydney	1995

IMPLEMENTATION, QUALITY ASSURANCE AND AUDITS

Clinical Morbidity and Mortality Review **From 2013**

I developed and continue to evolve the Medical Oncology Morbidity and Mortality Reporting Template for Melanoma Institute Australia.

Database Review and Stage B and 4 Data Implementation **From 2010**

I conducted a review of the Melanoma Research Database Stage 4 data fields (44,000 patient entry database), and have instituted an interim database for stage 4 patients with relevant data fields in an era of effective stage 4 therapies. Under my supervision, the medical oncology fellows at Westmead and Melanoma Institute Australia were responsible for data entry. This database is planned for integration into the Melanoma Research Database, the largest clinical database of melanoma patients in the world.

Review of Melanoma Institute Australia Biospecimen Banking Protocols **From 2010**

Implementation of Trial-Patient Safety Measures **From 2010**

Implementations of weekly trial meeting, regular review and bench marking of the staffing levels and patient enrolment rates for phase 1, 2 & 3 studies.

Implementation of institution-wide tumour mutation testing for stage 4 melanoma patients **2009**

CLINICAL TRIALS

Investigator-led Clinical Trials

I am principal investigator for the following trials. I designed and wrote the protocols, and successfully sourced the funding for four studies. I have submitted additional investigator study proposals to gain access to experimental therapies, and am currently sourcing funding and drug.

- TEAM (Treat Excise Analyse Melanoma)
- Australian Brain Collaboration (ABC) Trial – A Phase 2 study of nivolumab +/- ipilimumab in patients with active melanoma brain metastases
- Phase 2 - Neoadjuvant dabrafenib in patients with resectable melanoma brain metastases, followed by combined dabrafenib+trametinib after brain metastasis resection
- Phase 2 – Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation - NeoCombi (NCT02231775)
- Molecular profiling and matched targeted therapy for patients with metastatic melanoma – MatchMel (NCT02645149)
- Phase 2 –A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma - NeoPele (NCT04207086)
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension – ABC-X (NCT03340129)
- Phase 2 - Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab – OPACIN-neo (NCT02977052)
- Phase 2 - Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma – PRADO (NCT02977052)
- Phase 2 –Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Dabrafenib, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma - DOMNIMI (NCT04133948)
- Phase 2 - Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma – NeoTrio (NCT02858921)

Sponsored Clinical Trials

I am Principal investigator for

- 33 trials in advanced stage melanoma, 13 currently open
- 11 trials in early stage melanoma, 4 currently open

I have been international key principal investigator and led the development for the following PBS listed drug therapies, available now for all Australians:

- Dabrafenib
- Dabrafenib + Trametinib
- Pembrolizumab
- Intralesional TVEC (*TVEC approved, not PBS listed*)
- Nivolumab + Ipilimumab
- Nivolumab
- Vemurafenib + Cobimetinib
- Vemurafenib

Cooperative Clinical Trials Groups

Member of the Melanoma and Skin Cancer Trials Group (MASC)
Advisor for medical oncology subgroup

From 2019

Member of the Australia and New Zealand Melanoma Trials Group (ANZMTG)	From 2010-2019
Member of the ANZ Breast Cancer Trials Group Limited (ANZ BCTG)	From 2010
Genomic Cancer Clinical Trials – ANZMTG member representative for this initiative	From 2013
Member of the International Melanoma Working Group	From 2011

Clinical Trials Training

Good Clinical Practice Training	Annual
Electronic Data Capture Training (System dependent)	Annual
Adverse Event and Serious Adverse Event Reporting	Annual
Attendance at Multiple International Investigators Meetings	From 2009

OTHER TRAINING

Introduction to Biostatistics, University of Sydney, Semester 1 (awarded High Distinction)	2009
--	-------------

COMMUNITY AND MEDIA**Community and Patient Speaking Engagements**

- General address to Pymble Ladies College (years 7 to 12) **March 2024**
- Bio accelerator presentation for The University of Sydney **Feb 2024**
- Cancer Research: Melanoma Cancer Research Uncovered Talks for the Community, The University of Sydney, Australia **Nov 2015**
- The Melanoma Treatment Landscape AIM Patient Advocate Forum, Munich, Germany **June 2015**
- Multiple Media Interviews for Community Awareness of Melanoma **From 2013**
 - Beating Melanoma; Targeting Genes. 21st Century Medicine, The University of Sydney, Sydney, Australia **Oct 2013**
 - The BRAF story – from Target to Treatment and Beyond. Patient Symposium, 7th Annual University of North Carolina Conference on Melanoma, Chapel Hill, North Carolina, USA **Feb 2012**
 - New Treatments in Melanoma. Melanoma Institute Australia, Community and Volunteers Seminar, Sydney, Australia **Dec 2012**
 - Advances in the Treatment of Melanoma. Westmead Medical Research Foundation Community Seminars, Sydney, Australia **June 2011**
- Research and Clinical Trials. Advances in Melanoma Care Symposium, Melanoma Network and Melanoma Institute Australia, Sydney, Australia **Aug 2009**

Television

Show	Channel	Date	Story
A Current Affair	9	01.03.2024	Australian of the Year warns against dangerous social media tanning trend putting lives at risk https://9now.nine.com.au/a-current-affair/australian-of-the-year-warns-against-dangerous-social-media-tanning-trend-putting-lives-at-risk/4571736e-ed47-4c12-95c4-42cd04f00a4e

Sky News Breakfast UK	Sky	08.02.2024	Australia's Tanning Culture (<i>link unavailable in Australia</i>)
BTN	ABC	07.02.2024	Breaking Australia's Tanning Culture https://www.abc.net.au/btn/high/breaking-australias-tanning-culture/103432442
A Current Affair	9	30.01.2024	'We have to stop glamourising tanning': Skin cancer experts' important message after Australian of the Year honour https://9now.nine.com.au/a-current-affair/australian-of-the-year-professor-richard-scolyer-professor-georgina-long-cancer-research-melanoma/e78f4291-7fee-4906-9673-a878097e5123
The Project	10	27.01.2024	Georgina Long and Richard Scolyer named Australians of the Year https://www.youtube.com/watch?v=gaMEoR9aVC4
SBS News	SBS	26.01.2024	"I don't want to die": How the professional became personal for this Australian of the Year https://www.sbs.com.au/news/article/i-dont-want-to-die-how-the-professional-became-personal-for-this-australian-of-the-year/dk772qx8w
Sky News	Sky	26.01.2024	"Incredibly humbled": Rare dual-winners awarded 2024 Australians of the Year https://www.skynews.com.au/australia-news/incredibly-humbled-rare-dualwinners-awarded-2024-australians-of-the-year/video/cd76146f938fe3c4eb39d036715c7f3d
ABC News	ABC	25.01.2024	Meet the change makers in the running to be named Australian of the Year 2024 https://www.abc.net.au/news/2024-01-25/meet-the-2024-nominees-for-australian-of-the-year/103375594
ABC	ABC	11.01.2024	Meet your 2024 Australians of the Year https://www.youtube.com/watch?v=dVVkTu8_8l8
ABC News	ABC	05.01.2024	Pioneering melanoma treatment https://www.youtube.com/watch?v=ZT95tyell.fI
Australian Story	ABC	04.12.2023	An open mind https://www.abc.net.au/news/2023-12-05/an-open-mind-richard-scolyer-australian-story-full-episode/103191502
A Current Affair	9	14.11.2023	Leading melanoma experts Richard Scolyer and Georgina Long awarded 2024 NSW Australians of the Year https://9now.nine.com.au/a-current-affair/2024-nsw-australian-of-the-year-cancer-researcher-professor-richard-scolyer-professor-georgina-long-melanoma-combination-immunotherapy/c4af9cac-9149-422a-9bd4-e1be4cc2d587
ABC	ABC	20.09.2023	Melanoma Science in the race against brain cancer. Using a terminal diagnosis as a path for good https://iview.abc.net.au/show/national-press-club-address/series/0/video/NC2311C034S00
A Current Affair	9	17.07.2023	"It could actually make me die:: Doctor's ultimate sacrifice amid cancer battle https://9now.nine.com.au/a-current-affair/aussie-doctor-professor-richard-scolyer-makes-sacrifice-after-brain-cancer-diagnosis/0e5f58e8-24bd-4dfe-b95f-186cc783a33c
7 News	7	26.06.2023	How more Australians can combat cancer https://www.youtube.com/watch?v=ZT3To-yhOO4
Landline	ABC	18.06.2023	Dangerous Rays https://iview.abc.net.au/video/RF2304Q019S00
7 News	7	01.03.2023	Immunotherapy PBS

			Coast/Townsville/Coffs Harbour/Gold Coast/Gosford/Lismore/Newcastle/ Port Macquarie/ Tamworth/Cairns/
7.30 Report	ABC	14.12.2020	Stuart Taylor story https://iview.abc.net.au/show/7-30/series/0/video/NC2001H197S00
7News	7	28.08.2020	MIA Calculator for skin cancer risk https://7news.com.au/lifestyle/health-wellbeing/melanoma-calculator-for-skin-cancer-risk-c-1271736
9 News	9	28.08.2020	MIA Calculator for skin cancer risk
10 News First	10	28.08.2020	MIA Calculator for skin cancer risk
Sunrise	7	08.06.2020	Queen's Birthday Honors List 2020 https://7news.com.au/sunrise/on-the-show/queens-birthday-honours-list-2020-tony-abbott-michael-clarke-among-australians-honoured-c-1084267
7 News	7	22.07.2019	Breast cancer drug may be key to beating the most deadly type of melanoma https://7news.com.au/lifestyle/health-wellbeing/breast-cancer-drug-may-be-key-to-beating-the-most-deadly-type-of-melanoma-c-359083
7.30 Report	ABC	14.02.2019	Research breakthrough to help melanoma treatment https://www.abc.net.au/7.30/research-breakthrough-to-help-melanoma-treatment/10813786
60 Minutes	9	2018	Australian mother's fight to beat incurable cancer https://9now.nine.com.au/60-minutes/allison-langdon-patient-71/e8a3fb4f-b072-4d29-9c77-41bb9115fa1b
ABC News	ABC	18.05.2012	New drug that shrinks brain tumours in melanoma patients https://www.youtube.com/watch?v=IHaGyyIeI4Q
Sunrise	7	19.07.2011	Skin cancer breakthrough – Melanoma injection gets the nod https://www.youtube.com/watch?v=S0xPkz-hQ7U

Print/online publications (including but not limited to)

Publication	Date	Story
Times Higher Education	20.02.2024	'Certain death' diagnosis 'unique opportunity to drive research' https://www.timeshighereducation.com/news/certain-death-diagnosis-unique-opportunity-drive-research
BNN	08.02.2024	Melanoma Institute Australia's Directors discuss melanoma on breakfast TV https://bnnbreaking.com/world/australia/melanoma-institute-australias-directors-discuss-melanoma-on-breakfast-tv
Brand Australia	06.02.2024	World leading melanoma researchers embody the brand of Australia https://www.brandaustralia.com/en/news-views/world-leading-melanoma-researchers-embody-brand-australia
RNZ	03.02.2024	Australian of the Year: Melanoma researcher Georgina Long https://www.rnz.co.nz/national/programmes/saturday/audio/2018924632/australian-of-the-year-melanoma-researcher-georgina-long
The Australian	26.01.2024	Our bronzed Aussie culture is actually killing us https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a_GGL&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fnation%2Fscientists-on-a-mission-to-cure-cancer-richard-scolyer-and-georgina-long-named-2024-australians-of-the-year%2Fnews-story%2F31b39254fcf2652a8ab9796c09203ee&memtype=anonymous&mode=premium&v21=GROUPA-Segment-1-NOSCORE&V21spcbehaviour=append
News.com.au	26.01.2024	Australian of the Year 2024 won by pioneering cancer researchers https://www.youtube.com/watch?v=I2NFX27F2fc

The Canberra Times	25.01.2024	2024 Australian of the Year recipients Professor Georgina Long and Professor Richard Scolyer https://www.canberratimes.com.au/video/breaking/x8rrxy3/2024-australian-of-the-year-recipients-professor-georgina-long-and-professor-richard-scolyer/
Daily Mail	25.01.2024	Australian of the Year awards 2024: Sad truth behind the inspiring cancer research duo awarded the nation's highest honour after making major breakthrough that will save millions of people around of the world https://www.dailymail.co.uk/news/breaking_news/article-13004723/Australian-Year-awards-2024-winners-revealed.html
9 News	25.01.2024	Australians of the Year Georgina Long and Richard Scolyer call for tanning and melanoma overhaul https://www.9news.com.au/national/australian-of-the-year-2024-full-winners-list/6acc4f16-f766-4b74-88b4-cad5d1ee8777
Sydney Morning Herald	25.01.2024	Pioneering doctors Richard Scolyer and Georgina Long named as Australians of the Year https://www.smh.com.au/politics/federal/pioneering-doctors-richard-scolyer-and-georgina-long-named-australians-of-the-year-20240124-p5ezo0.html
Sky News.com.au	25.01.2024	Melanoma researchers Georgina Long and Richard Scolyer named as 2024's Australians of the Year https://www.skynews.com.au/australia-news/melanoma-researchers-georgina-long-and-richard-scolyer-named-as-2024s-australians-of-the-year-in-historic-duelwin/news-story/81fd8dd29205194f33e958d8fabcf1fa
AAP	24.01.2024	Inspiring Australians gather as they vie for top honour https://www.msn.com/en-au/news/australia/inspiring-australians-gather-as-they-vie-for-top-honour/ar-BB1h8JHy published under licence with Canberra City News, Canberra Times, Yahooo
Nine News	24.01.2024	Meet the nominees for Australian of the Year https://www.9news.com.au/national/australian-of-the-year-awards-2024-meet-the-state-and-territory-finalists/922c4955-d0b1-4ac9-becc-0f292caed5ff
ABC News	23.01.2024	Hope for Richard Scolyer eight months into risky brain cancer treatment https://www.msn.com/en-au/health/other/hope-for-richard-scolyer-eight-months-into-risky-brain-cancer-treatment/ar-BB1h3C5Z
SBS News	16.01.2024	Who are the finalists for the 2024 Australian of the Year awards? https://www.sbs.com.au/news/article/who-are-the-finalists-for-the-2024-australian-of-the-year-awards/081zqajd3
Central Western Daily	05.01.2024	A son slain, a cancer diagnosis: nine inspiring lives shared https://ausprint.meltwater.com/print_clip_previewer/468290295?text=on&keyword=on&pdf=new Published under licence by The Age, Brisbane Times, The Sydney Morning Herald
Kalgoorlie Miner	20.12.2023	Artefacts an insight into exemplary national stories https://ausprint.meltwater.com/print_clip_previewer/466997583?text=on&keyword=on&pdf=new
Velvet Classic	15.12.2023	Experimental vaccine shows benefits against melanoma in trial https://www.velvetclassic.net/experimental-vaccine-shows-benefits-against-melanoma-in-trial/
Sydney Morning Herald	09.12.2023	52 News Makers of 2023 Meltwater Outside Insight
Narooma News	14.11.2023	Cancer Research pioneers names NSW Australians of the Year for 2024 https://www.naroomanewsonline.com.au/story/8421348/meet-the-melanoma-fighters-named-2024-australians-of-the-year-for-nsw/?cs=1489 published under licence by Daily Liberal, Jimboomba Times, Cowra Guardian, Singleton Argus, The Northern Daily Leader, Nyngan Observer, Tenterfield Star, Mussellbrook Chronicle, Hunter Valley News, Newcastle Herald, Armidale Express, The Standard, Augusta-Margaret River Mail, Illawarra Mercury, Parkes

		Champion Post, Mandurah Mail, Eden Magnet, Namoi Valley Independent, The North West Star, Milton Ulladulla Times
AAP	13.11.2023	Melanoma researchers NSW Australians of the Year Melanoma researchers NSW Australians of the Year (msn.com)
ABC News	13.11.2023	Cancer Experts Richard Scolyer , who has an incurable brain tumour, and Georgina Long named joint NSW Australians of the Year https://www.msn.com/en-au/health/other/cancer-experts-richard-scolyer-who-has-an-incurable-brain-tumour-and-georgina-long-named-joint-nsw-australians-of-the-year/ar-AA1jPzII?ocid=entnewsntp&cvid=91a48407ee414244ad7404b3addb02b5&ei=10
The Narooma News	06.11.2023	Doing us proud: NSW 2024 Australian of the Year Award Nominees https://www.naroomanewsonline.com.au/story/8410490/meet-the-inspiring-nsw-nominees-for-2024-australian-of-the-year/ published under licence by Jimboomba Times, Mandurah Mail, Hawkesbury Gazette, Daily Liberal, Coly Point Observer, Oberon Review, Western Advocate, Merimbula News Weekly, Nyngan Observer, Central Western Daily, Gloucester Advocate, Goulburn Post, The Stawell Times-News, Harden Murrumburrah Express, The Border Mail, Southern Highlands News, The Lithgow Mercury, Wellington Times, The Forbes Advocate, Milton Ulladulla Times.
Gloucester Advocate	08.11.2023	Community advocates, achievers who are doing us proud https://ausprint.meltwater.com/print_clip_previewer/461322231?text=on&keyword=on&pdf=new published under licence by Western Advocate, Goulburn Post, Bay Post/ Moruya Examiner, South Coast Register, Merimbula News Weekly, Narooma News, The Daily Advertiser, Daily Liberal, Central Western Daily, The Border Mail
Daily Mail	21.09.2023	Ally Langdon breaks down in tears during emotional interview with cancer expert Dr Richard Scolyer who was diagnosed with an incurable form of brain cancer https://www.dailymail.co.uk/news/article-12540267/Ally-Langdon-tears.html
MSN.com	20.09.2023	Melanoma expert 'patient zero' in brain cancer fight https://www.msn.com/en-au/health/medical/melanoma-expert-patient-zero-in-brain-cancer-fight/ar-AA1gYsC4?ocid=entnewsntp&cvid=ebc342b3c5e44a35a2039a424fac8dd9&ei=38
Good Weekend	16.09.2023	Eyes on the Prize https://www.smh.com.au/national/the-september-16-edition-20230803-p5dtor.html
Head Topics	17.07.2023	Doctor's ultimate sacrifice after incurable brain cancer diagnosis https://headtopics.com/au/doctor-s-ultimate-sacrifice-after-incurable-brain-cancer-diagnosis-41280595
HemOnc Today	05.06.2023	Biomarkers predict benefit of adjuvant nivolumab in resected melanoma https://www.healio.com/news/hematology-oncology/20230605/biomarkers-predict-benefit-of-adjuvant-nivolumab-in-resected-melanoma
Medical Forum	09.03.2023	Cheaper melanoma treatments https://mforum.com.au/cheaper-melanoma-treatments/
Australian Seniors News	02.03.2023	Treatment for recurrent melanoma to be subsidized https://australianseniorsnews.com.au/featured/treatment-for-recurrent-melanoma-to-be-subsidised/
The National Tribune	02.03.2023	Affordable treatment for recurrent melanoma https://www.nationaltribune.com.au/affordable-treatment-for-recurrent-melanoma/
Formulary Watch	01.03.2023	FDA sets action date for Opdivo for melanoma indication https://www.formularywatch.com/view/fda-sets-action-date-for-opdivo-for-melanoma-indication
Drug Topics	01.03.2023	FDA accepts supplemental BLA for nivolumab for melanoma https://www.drugtopics.com/view/fda-accepts-supplemental-bla-for-nivolumab-for-melanoma

SBS News	12.02.2023	Australia has the world's highest melanoma rate. What are tanning products still being advertised? https://www.sbs.com.au/news/article/australia-has-the-worlds-highest-melanoma-rate-why-are-tanning-products-still-being-advertised/2oczxzmut
Your Life Choices	16.12.2022	Vaccine may be 'the penicillin moment' for cancer, says researchers https://www.yourlifechoices.com.au/health/melanoma-vaccine-may-be-the-penicillin-moment-in-cancer-treatment-say-researchers/
Beauresert Times	15.12.2022	Melanoma vaccine using mRNA technology on the horizon https://www.beaureserttimes.com.au/story/8019810/another-leap-forward-recurring-melanoma-vaccine-on-horizon-after-breakthrough-trial/
Internewscast	15.12.2022	Melanoma vaccine could be 'penicillin moment' for cancer treatment https://internewscast.com/news/au/melanoma-vaccine-could-be-penicillin-moment-for-cancer-treatment/
Starts at 60	15.12.2022	Melanoma vaccine trial shows 'highly encouraging' results in improving patient outcomes https://starts60.com/media/health/melanoma-vaccine-trial-shows-highly-encouraging-results-in-improving-patient-outcomes
Port Lincoln Times	15.12.2022	Melanoma vaccine using mRNA technology on the horizon https://www.portlincolntimes.com.au/story/8019810/another-leap-forward-recurring-melanoma-vaccine-on-horizon-after-breakthrough-trial/ The article was also published in - The Muswellbrook Chronicle, Goulburn Post, The Daily Advertiser, The Transcontinental, The Murray Valley Standard, Merimbula News Weekly, Harden Express, The Queanbeyan Age, The Scone Advocate, Blue Mountains Gazette, The Flinders News, The Standard, The Narooma News, The Jimboomba Times, Namoi Valley Independent, Cootamundra Herald, The Braidwood Times
The Daily Telegraph	14.12.2022	Vaccine nearly halves melanoma deaths https://ausprint.meltwater.com/print_clip_previewer/420427371?text=on&keyword=on&pdf=new
The Australian	14.12.2022	Vaccine cuts risk of new melanomas https://ausprint.meltwater.com/print_clip_previewer/420416555?text=on&keyword=on&pdf=new
Head Topics Australia	14.12.2022	Moderna develops melanoma vaccine https://headtopics.com/au/moderna-develops-melanoma-vaccine-32843677
Head Topics Australia	14.12.2022	Major breakthrough in skin cancer treatment https://headtopics.com/au/major-breakthrough-in-skin-cancer-treatment-32848044
Daily Telegraph	14.12.2022	Latest Aussie science victory is great for us https://ausprint.meltwater.com/print_clip_previewer/420416445?text=on&keyword=on&pdf=new
The Advertiser	14.12.2022	Hope for new skin cancer 'vaccine' https://ausprint.meltwater.com/print_clip_previewer/420415845?text=on&keyword=on&pdf=new
Daily Telegraph	14.12.2022	Drug busts melanoma https://ausprint.meltwater.com/print_clip_previewer/420419683?text=on&keyword=on&pdf=new
The Herald Sun	14.12.2022	Cancer vaccine win https://ausprint.meltwater.com/print_clip_previewer/420426269?text=on&keyword=on&pdf=new
Geelong Advertiser	14.12.2022	Cancer vaccine breakthrough https://ausprint.meltwater.com/print_clip_previewer/420436477?text=on&keyword=on&pdf=new
Brisbane Times	01.12.2022	"Australians are obsessed" : TikTok announces ban on tanning videos

		https://www.brisbanetimes.com.au/culture/celebrity/australians-are-obsessed-tiktok-announces-ban-on-tanning-videos-20221129-p5c28l.html
Sydney Morning Herald	01.12.2022	TikTok slaps prohibition on tanning videos https://ausprint.meltwater.com/print_clip_previewer/418721305?text=on&keyword=on&pdf=new
Canada Today	01.12.2022	TikTok bans videos promoting sunburn and tanning after alarm from medical experts https://canadatoday.news/ca/tiktok-bans-videos-promoting-sunburn-and-tanning-after-alarm-from-medical-experts-169402/
Indian Express	01.12.2022	As TikTok bans videos encouraging sunburn and tanning, experts share how they damage the skin https://indianexpress.com/article/lifestyle/life-style/tiktok-bans-videos-encouraging-sunburn-tanning-8300012/
The Australian	28.09.2022	Olympic star Cate Campbell reveals melanoma found after chat at brunch https://www.theaustralian.com.au/breaking-news/olympic-star-cate-campbell-reveals-devastating-diagnosis/news-story/32aff36e380b066f60d3755ed67ef5ec?btr=becc3dc7b2854e55622783a1584b101a This article was also published in – News.com.au, Bunbury Herald, North West Telegraph, PerthNow, The Herald Sun, The Courier Mail, Cairns Post, Townsville Bulletin, The Mercury
WA Today	23.09.2022	Melanoma Patients; diet patterns ‘linked to success of treatment’ https://www.watoday.com.au/lifestyle/health-and-wellness/melanoma-patients-diet-patterns-linked-to-success-of-treatment-20220923-p5bkma.html
9News	23.09.2022	Diet Patterns linked to success in immunotherapy for melanoma, research finds https://www.9news.com.au/national/australia-research-links-diet-patterns-gut-flora-to-how-patient-responds-to-immunotherapy-for-melanoma/b3c350d4-ccac-4cd2-be30-1b0ffd589c6d
The Sydney Morning Herald	22.09.2022	Sport has skin in the game: cancer experts https://ausprint.meltwater.com/print_clip_previewer/409397560?text=on&keyword=on&pdf=new
180gadgets	22.09.2022	Melanoma Prevention: calls for influencers to promote sun safety https://180gadgets.com/melanoma-prevention-calls-for-influencers-to-promote-sun-safety-sbs-news/
The Toys Matrix	21.09.2022	Olympic Star Cate Campbell reveals devastating diagnosis https://toysmatrix.com/olympic-star-cate-campbell-reveals-devastating-diagnosis/ The article was also published in – Broome Advertiser, Great Southern Herald, The West Australian, The Advertiser, Gold Coast Bulletin, The Daily Telegraph, The weekly Times, Geelong Advertiser, The Toowoomba Chronicle
The West Australian	21.09.2022	Olympic star calls for melanoma campaign https://thewest.com.au/news/health/olympic-star-calls-for-melanoma-campaign This article was also published in – Great Southern Herald, Bunbury Herald, Kimberley Echo, North West Telegraph, Daily Mail, Perth Now, The Daily Advertiser, The Cessnock Advertiser, The Northern Daily Leader, Yass Tribune, The Singleton Argus, The Inverell Times, Port Lincoln Times, Hawkesbury Gazette, Border Chronicle, Busselton-Dunsborough Mail, Milton Ulladulla Times, Namoi Valley Independent, Goulburn Post, Harden Murrumburrah Express
The Australian	21.09.2022	Melanoma Institute urges influences to stop glamorizing tanning https://www.theaustralian.com.au/the-oz/news/influencers-urged-to-stop-glamorising-sunburn/news-story/d3f721cd36f47f665b3894bbbecc64cb?btr=eaf8b13f054ea10ba6d09e0ccaf038c7
WA Today	21.09.2022	Medical Experts call on sports to reduce melanoma risks

News Azi		https://www.watoday.com.au/lifestyle/health-and-wellness/medical-experts-call-on-sports-to-reduce-melanoma-risks-20220919-p5bj9d.html https://newsazi.com/medical-experts-call-on-sports-to-reduce-melanoma-risks/
Sanidad	23.06.2022	Pembrolizumab yields positive results in patients with stage IIB melanoma and IIC avoiding recurrences and distant metastases https://isanidad.com/219225/pembrolizumab-arroja-resultados-positivos-pacientes-melanoma-estadio-iib-iic-evitando-recurrencias-metastasis-distancia/
Nine News	23.06.2022	“Check your skin” 2GB radio personality Ray Hadley opens up about recent cancer scare https://www.9news.com.au/national/2gb-radio-personality-ray-hadley-opens-up-about-recent-cancer-scare/2b612569-d3bb-4917-af99-24bd5028017b
Health Industry Hub	08.06.2022	Australian dermatologists reveal new frontier in melanoma treatment https://www.healthindustryhub.com.au/pharmaceutical-news-trends/australian-dermatologists-reveal-new-frontier-in-melanoma-treatment/
Healio	06.07.2022	Adjuvant pembrolizumab shows benefit in patients with resected stage IIB, IIC melanoma https://www.healio.com/news/hematology-oncology/20220606/adjuvant-pembrolizumab-shows-benefit-in-patients-with-resected-stage-iib-iic-melanoma
Doctors Lounge	21.03.2022	Update shows Relatlimab+Nivolumab slows advanced Melanoma https://www.doctorslounge.com/index.php/news/pb/108133
Medical Xpress		https://medicalxpress.com/news/2022-03-relatlimab-nivolumab-advanced-melanoma.html
Cure 20	20.03.2022	FDA approves Opdualag, a new fixed-dose combination treatment, for certain patients with skin cancer https://www.curetoday.com/view/fda-approves-opdualog-a-new-fixed-dose-combination-treatment-for-certain-patients-with-skin-cancer
Globe World News Echo	17.03.2022	The minor body changes that led an Aussie mum to discover cancer diagnosis https://globeecho.com/news/australia/the-minor-body-changes-that-led-an-aussie-mum-to-discover-cancer-diagnosis/
Cure 20	17.03.2022	Opdivo-based combo continues to improve survival outcomes in previously untreated patients with metastatic or unresectable melanoma https://www.curetoday.com/view/opdivo-based-combo-continues-to-improve-survival-outcomes-in-previously-untreated-patients-with-metastatic-or-unresectable-melanoma
My Weekly Preview	03.03.2022	Melanoma March Meltwater Outside Insight
9 News	09.02.2022	Melanoma to cost Australia \$8.7 billion without “critical action” https://www.9news.com.au/national/new-report-calls-for-urgent-government-action-to-tackle-the-growing-impact-of-melanoma/a1060b3e-c468-45fb-8cbb-666630c42a1d
Franklin Women	31.01.2022	Career Blog – Georgina Long https://franklinwomen.com.au/georgina-long/
The Courier-Mail	17.12.2021	Sprint on to beat cancer Meltwater Outside Insight
My Weekly Preview	05.11.2021	Pandemic melanoma crisis https://www.myweeklypreview.com.au/news/pandemic-melanoma-crisis/
SBS News	31.10.2021	Fears of post-pandemic skin cancer crisis in Australia https://www.sbs.com.au/news/fears-of-post-pandemic-skin-cancer-crisis/aadafab-9970-4486-a85f-583a6d3de25e
The News Network		https://timesnewsnetwork.com/news/world/australia/fears-of-post-pandemic-skin-cancer-crisis-in-australia/

Times News Express		https://timesnewsexpress.com/news/world/australia/fears-of-post-pandemic-skin-cancer-crisis-in-australia/
Australian Online News		https://australianonlinenews.com.au/2021/10/31/fears-of-post-pandemic-skin-cancer-crisis-in-australia/
Head topics		https://headtopics.com/au/fears-of-post-pandemic-skin-cancer-crisis-in-australia-22340551
7News	31.10.2021	Fears of post-pandemic melanoma crisis https://7news.com.au/lifestyle/health-wellbeing/fears-of-post-pandemic-melanoma-crisis-c-4376850
Jimboomba Times		https://www.jimboombatimes.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Sound Telegraph		https://www.soundtelegraph.com.au/news/health/fears-of-post-pandemic-melanoma
Northern Rivers Review		https://www.northernriversreview.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/?cs=9676
Blue Mountains Gazette		https://www.bluemountaingazette.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
The Young Witness		https://www.youngwitness.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Wellington Times		https://www.wellingtontimes.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Goondwindi Argus		https://www.goondwindiargus.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Newcastle Herald		https://www.newcastleherald.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Canberra Times		https://www.canberratimes.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
		This article was also published with the following papers under copyright The Northern Daily Leader, St George & Sutherland Shire Leader, Gloucester Advocate, Whyalla News, Liverpool City Champion, SBS, Seymour Telegraph, The Corowa Free Press, Redland City Bulletin, Daily Mail, The West Australian, Perth Now, Moree Champion, Port Lincoln Times, The Islander, Bay Post, Camden Haven Courier, Bendigo Advertiser, Tenterfield Star, Southern Cross, Inverell Times, The Advocate, Bunbury Mail, Blayney Chronicle, The Macleay Argus and Coastal Leader
Sydney News Today	31.10.2021	Fear of melanoma crisis after pandemic https://sydneynewstoday.com/fear-of-melanoma-crisis-after-pandemic/405455/
Medical Republic	11.10.2021	Treatment shift for Stage II Melanoma https://medicalrepublic.com.au/treatment-shift-for-stage-ii-melanoma/55424
Nine.com.au	26.09.2021	Terminally ill man's plea for Australians to get their skin checked https://honey.nine.com.au/latest/skin-cancer-signs-and-symptoms-terminally-ill-man-advice/e42ed2a4-bcb2-423e-b973-8bba579331ea
Shepparton News	20.09.2021	Hope for melanoma patients https://ausprint.meltwater.com/print_clip_previewer/348632261

The Singapore Time	19.09.2021	Australian researchers breakthrough in melanoma treatment https://www.thesingaporetime.com/australian-researchers-breakthrough-in-melanoma-treatment/
Sydney News Today	19.09.2021	New Hope for Early Melanoma Patients https://sydneynewstoday.com/new-hope-for-early-melanoma-patients/352908/
From Press		https://pressfrom.info/au/lifestyle/health/-442795-new-hope-for-early-stage-melanoma-patients.html
Seymour Telegraph	20.09.2021	https://www.seymourtelegraph.com.au/national/2021/09/19/5206844/new-hope-for-early-stage-melanoma-patients
McIvor Times		http://www.mcivortimes.com.au/national/2021/09/19/5206800/new-hope-for-early-stage-melanoma-patients
Cowra Free Press		https://www.corowafreepress.com.au/national/2021/09/19/5206795/new-hope-for-early-stage-melanoma-patients
Daily Mail		https://www.dailymail.co.uk/wires/aap/article-10005721/New-hope-early-stage-melanoma-patients.html
Sound Telegraph		https://www.soundtelegraph.com.au/news/health/new-hope-for-early-stage-melanoma-patients-c-4005937
The West Australian		https://thewest.com.au/news/health/new-hope-for-early-stage-melanoma-patients-c-4005937
Perth Now		https://www.perthnow.com.au/news/health/new-hope-for-early-stage-melanoma-patients-c-4005934
Forbes Alert	19.09.2021	Australian researchers make melanoma treatment breakthrough https://forbesalert.com/news/world/australia/australian-researchers-make-melanoma-treatment-breakthrough/
Scienmag	18.09.2021	Immunotherapy drug benefits patients with high-risk local melanomas https://scienmag.com/immunotherapy-drug-benefits-patients-with-high-risk-local-melanomas/
Newsfallout.com	18.09.2021	New hope for early-stage melanoma sufferers https://newsfallout.com/country-news/australia/new-hope-for-early-stage-melanoma-sufferers/
Bioengineer.org	18.09.2021	Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma https://bioengineer.org/adjuvant-immunotherapy-prolongs-recurrence-free-survival-in-resected-stage-ii-b-c-melanoma/
Campus Morning Mail	17.09.2021	Georgina Long wins the Australian Academy of Health and Medical Sciences Outstanding Female Researcher Medal https://campusmorningmail.com.au/news/appointments-achievements-339/
The National Tribune	14.09.2021	Sydney awarded \$61 million for health research https://www.nationaltribune.com.au/sydney-awarded-61-million-for-health-research/
Health Industry Hub	07.06.2021	Australian researchers lead world in trial of novel melanoma treatment https://www.healthindustryhub.com.au/pharmaceutical-news-trends/australian-researchers-lead-world-in-trial-of-novel-melanoma-treatment/
Infosurhoy		https://infosurhoy.com/health/new-immunotherapy-drug-effective-for-melanoma-other-cancers.html
Medical Xpress	03.06.2021	New Immunotherapy drug effective for melanoma, other cancers

		https://medicalxpress.com/news/2021-06-immunotherapy-drug-effective-melanoma-cancers.html
InQueensland	03.06.2021	Melanoma “miracle” might pave the way for more cancer breakthroughs https://inql.com.au/news/2021/06/03/melanoma-miracle-might-pave-the-way-for-more-cancer-breakthroughs/
Health Times	03.06.2021	Australian researchers discovered a miracle drug for melanoma https://healthtimes.com.au/hub/oncology/4/news/aap/australian-researchers-discovered-a-miracle-drug-for-melanoma/5898/
Oncology News	03.06.2021	ASCO 2021: Australian researchers and patients lead world in successful new melanoma trial https://oncologynews.com.au/asco-2021-australian-researchers-and-patients-lead-world-in-successful-new-melanoma-trial/
Seymour Telegraph	03.06.2021	“Miracle” drug for melanoma identified https://www.seymourtelegraph.com.au/national/2021/06/03/4368027/miracle-drug-for-melanoma-identified
Jimbooma Times		https://www.jimboomatimes.com.au/story/7281734/miracle-drug-for-melanoma-identified/
The McIvor Times		http://www.mciwortimes.com.au/national/2021/06/03/4368012/miracle-drug-for-melanoma-identified
Daily Mail		https://www.dailymail.co.uk/wires/aap/article-9646577/Miracle-drug-melanoma-identified.html
This is money.co.uk		https://www.thisismoney.co.uk/wires/aap/article-9646577/Miracle-drug-melanoma-identified.html
MSN		https://www.msn.com/en-au/health/medical/miracle-drug-for-melanoma-identified/ar-AAKEdU9
7News.com		https://7news.com.au/lifestyle/health-wellbeing/miracle-drug-for-melanoma-identified-c-3003352
Perth Now		https://www.perthnow.com.au/news/health/miracle-drug-for-melanoma-identified-c-3003349
The Standard		https://www.standard.net.au/story/7281734/miracle-drug-for-melanoma-identified/
Liverpool City Champion		https://www.liverpoolchampion.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Fairfield City Champion		https://www.fairfieldchampion.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Cootamundra Herald		https://www.cootamundraherald.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Yass Tribune		https://www.yasstribune.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Coly Point Observer		https://www.colypointobserver.com.au/story/7281734/miracle-drug-for-melanoma-identified/
PressFrom		https://pressfrom.info/au/lifestyle/health/-394450-miracle-drug-for-melanoma-identified.html

Medical Republic	07.04.2021	New treatment regime saving lives in melanoma https://medicalrepublic.com.au/new-treatment-regime-saving-lives-in-melanoma/42972?utm_source=TMR%20List&utm_campaign=c1a164e14e-Newsletter April 07 04 21&utm_medium=email&utm_cid=c1a164e14e&utm_cid=73f9c29fe4
Port News	11.02.2021	Ryan Channells now working with Melanoma Institute Australia to raise awareness about melanoma after overcoming stage four https://www.portnews.com.au/story/7121586/ground-breaking-treatment-saves-channels-life-in-battle-with-cancer/?cs=12
Redland City Bulletin	14.02.2021	https://www.redlandcitybulletin.com.au/story/7123755/ground-breaking-treatment-saves-fires-life-in-battle-with-cancer/
Beaudesert Times		https://www.beaudeserttimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Jimboomba Times		https://www.jimboombatimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Hunter Valley News		https://www.huntervalleynews.net.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
The Canberra Times		https://www.canberratimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Western Magazine		https://www.westernmagazine.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9397
The Advocate – Hepburn		https://www.hepburnadvocate.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
The Young Witness		https://www.youngwitness.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Liverpool City Champion		https://www.liverpoolchampion.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Manning River Times		https://www.manningrivertimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9397
Gloucester Advocate		https://www.gloucesteradvocate.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Moree Champion		https://www.moreechampion.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Goulburn Post		https://www.goulburnpost.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Blue Mountains Gazette		https://www.bluemountainsgazette.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Forbes Advocate		
The Northern Daily Leader		https://www.forbesadvocate.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676

The Advertiser Lake Times		https://www.northerndailyleader.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Barossa Herald		https://www.advertiserlaketimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Grenfell Record		https://www.barossaheald.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Illawarra Mercury		https://www.grenfellrecord.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
		https://www.illawarramercury.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Archyde.com	10.02.2021	Immunotherapy before surgery limits the risk of relapse https://www.archyde.com/immunotherapy-before-surgery-limits-the-risk-of-relapse/
My Healthy Click	09.02.2021	New treatment found effective in preventing spread of Melanoma, Study https://www.myhealthyclick.com/new-treatment-found-effective-in-preventing-spread-of-melanoma-study/
Your Life Choices	09.02.2021	New melanoma treatment a game-changer in cancer therapy https://www.yourlifechoices.com.au/health/news-health/new-melanoma-treatment-a-game-changer-in-cancer-therapy/
Yerepouni News	09.02.2021	Melanoma breakthrough: New treatment saving lives https://www.yerepouni-news.com/2021/02/09/melanoma-breakthrough-new-treatment-saving-lives/
ABC Diseases	09.02.2021	Melanoma, the order of the factors does alter survival https://www.abc.es/salud/enfermedades/abci-melanoma-orden-factores-si-altera-supervivencia-202102091157_noticia.html
Nine News	09.02.2021	Revolutionary melanoma treatment offers new lease on life https://www.9news.com.au/national/melanoma-treatment-huge-advance-australia/88d16605-6f6c-4644-8a78-a2b33f482de1
Up News Info		https://upnewsinfo.com/2021/02/09/revolutionary-melanoma-treatment-offers-new-lease-on-life/
Sydney Morning Herald	09.02.2021	Feeling “So lucky” to be alive after melanoma game-changer https://www.smh.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html
The Age		https://www.theage.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html
Brisbane Times		https://www.brisbanetimes.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html
WA Today		https://www.watoday.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html
Internews Cast		https://internewscast.com/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment/
EXBulletin	08.02.2021	Breakthrough in Melanoma: A new Life-Saving treatment https://exbulletin.com/world/health/726474/
ABC News	15.12.2020	Melanoma patient Stuart Taylor told he is unlikely to live until Christmas

		https://www.abc.net.au/news/2020-12-15/melanoma-patient-told-he-is-unlikely-to-live-until-christmas/12985378
Surf Coast Times	15.12.2020	Major award for melanoma researchers https://timesnewsgroup.com.au/surfcoasttimes/living/major-award-for-melanoma-researchers/
Financial Review	21.12.2019	How the decade's biggest health breakthrough saved a US President https://www.afr.com/life-and-luxury/health-and-wellness/how-the-decade-s-biggest-health-breakthrough-saved-a-us-president-20191216-p53kkf
Cure Today	10.12.2019	The Future of Novel Immunotherapy Combinations in Melanoma https://www.curetoday.com/view/the-future-of-novel-immunotherapy-combinations-in-melanoma
Northshore Living	01.10.2019	On the Medical Frontier https://www.thinklocal.com.au/thmagazines/north-shore-living-october-2019 (page 32 & 33)
Retail Pharmacy	30.08.2019	Australia risks falling behind in melanoma prevention https://retailpharmacymagazine.com.au/australia-risks-falling-behind-in-melanoma-prevention/
Medical Journal of Australia	08.06.2020	Happy Birthday Honours List https://www.mja.com.au/journal/2020/213/1/happy-birthday-honours-list
Illawarra Mercury	23.02.2019	Picton mother Melissa Tague shares story of melanoma battle https://www.illawarramercury.com.au/story/5920408/melissas-shock-diagnosis-after-she-found-a-strange-lump-in-her-groin/
Women Love Tech	04.01.2019	One Generation Away from Zero Melanoma Deaths https://womenlovetech.com/one-generation-away-from-zero-melanoma-deaths/
Daily Telegraph	26.12.2018	All Aussies should have access to this life saver https://www.melanoma.org.au/news-events/news/all-aussies-should-have-access-to-this-lifesaver/
Sutherland Shire	14.11.2018	Sutherland Shire melanoma patient undergoing clinical trial for innovative treatment https://www.theleader.com.au/story/5757259/working-towards-zero-deaths-by-exposing-innovative-treatments-into-melanoma/
Sydney Morning Herald	03.11.2018	How Georgina is driving down one cancer's death rate down to zero https://www.smh.com.au/national/nsw/how-georgina-is-driving-one-cancer-s-death-rate-down-to-zero-20181102-p50dmc.html
SBS News	14.03.2018	Marching towards zero deaths from melanoma https://www.sbs.com.au/news/marching-towards-zero-deaths-from-melanoma
Victor Harbor Times		https://www.victorharbortimes.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9397
Bega District News		https://www.begadistrictnews.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/
The Examiner		https://www.examiner.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=7
Mandurah Mail		https://www.mandurahmail.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9676
The Standard		https://www.standard.net.au/story/5284068/marching-towards-zero-deaths-from-melanoma/
Bunbury Mail		https://www.bunburymail.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=27

The Advocate Wollondilly Advertiser Northwest Star Bendigo Advertiser Campbelltown Macarthur Advertiser		https://www.theadvocate.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9397 https://www.wollondillyadvertiser.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9676 https://www.northweststar.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/ https://www.bendigoadvertiser.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=27 https://www.macarthuradvertiser.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9676
9News Health Financial Review	11.09.2017	New therapies stop melanoma from spreading https://www.9news.com.au/health/melanoma-stopped-from-spreading-in-trials/4dd30d82-c1d8-41ff-a508-66230ee27814 https://afr.com/companies/healthcare-and-fitness/new-therapies-stop-melanoma-spreading-20170911-gyfai6
Daily Telegraph	17.06.2015	Women warriors fighting a deadly disease nominate for Pride of Australia https://www.dailytelegraph.com.au/news/pride-of-australia/women-warriors-fighting-a-deadly-disease-nominated-for-pride-of-australia/news-story/09e1694a3b579e66eb92bf1903c3c7e5
Herald Sun	04.02.2015	New drug to be trialled on melanoma patients in world first https://www.heraldsun.com.au/news/victoria/new-drug-to-be-trialled-on-melanoma-patients-in-world-first/news-story/b6a91faeac34da6477b3403b52f21281
Medical Xpress	08.10.2012	New drug shrinks brain tumours in melanoma patients https://medicalxpress.com/news/2012-10-drug-brain-tumours-melanoma-patients.html
The Health Safari	20.07.2012	Extending survival: powerful late-stage melanoma treatment to be considered for PBS http://www.thehealthsafari.com/blog2012july-extending-survival.html
AFR Boss (Financial Review)	June 2012	The scientific researcher: a team effort

Radio (including but not limited to)

Radio Show	Date	Link (if available)
2GB	26.01.2024	Australian of the Year This was used under licence by numerous outlets in Australia and worldwide
2GB	06.11.2023	Who is nominated for Australian of the Year This was also used under licence with 2CC, 2GB Ben Fordham, 2GB Drive with Chris O'Keefe, 2GO, 2WEB, 990AM, 4RO, Afternoons with Deborah Knight, Breakfast with James Valentine, Chanel 7 Adelaide, Cairns, Central Queensland, Darwin, Mackay, Perth, Sunshine Coast, Toowoomba, Townsville, Wide Bay
ABC	06.11.2023	Meet Georgina Long – nominated for Australian of the Year

		https://www.abc.net.au/listen/programs/sydney-mornings/georgina-long-australian-of-the-year-nomination/103068584
2GB	18.07.2023	<p>Cancer diagnosis inspires doctor to test his treatment research https://www.2gb.com/cancer-diagnosis-inspires-doctor-to-test-his-treatment-research/</p> <p>This was also used under licence with 2CC, 4BC, 990, 2GN, Imparja Bull, NBN Coffs Harbour, Gosford, Lismore, Newcastle, Port Macquarie, Nine Adelaide, Cairns, Central Queensland, Mackay, Mount Gambier, Perth, Renmark, Sunshine Coast, Toowoomba, Townsville, Wide Bay, Triple M Riverina, Darling Downs,</p>
2CC Talking Canberra	14.12.2022	<p>Moderna melanoma vaccine</p> <p>This was also used under licence with 2GB, 2PM, 2SM, 666 ABC, 720 ABC Perth, 891 ABC Adelaide, 4RO, ABC Alice Springs, ABC Broken Hill, ABC Capricornia FM, ABC Esperance, ABC Far North Queensland, ABC Goldfields, ABC Great Southern WA, ANC Kimberley, ABC Late News, ABC National News, ABC New England, ABC Darwin, ABC Hobart, ABC Melbourne, ABC North and West SA, ABC North Queensland, ABC North West WA, ABC Riverland, ABC South East SA, ABC Southern Queensland, ABC Sunshine Coast, ABC Tropical North, ABC West Coast, ABC Western Queensland, ABC Wide Bay, ABC New England, 2HD, GIVEaa, 10 Brisbane</p>
ABC Melbourne	14.12.2022	<p>Personalised vaccine trial for melanomas hailed a breakthrough https://www.abc.net.au/melbourne/programs/mornings/melanoma-vaccine/101770552</p>
6PR	14.12.2022	<p>New melanoma vaccine hailed as cancer's penicillin moment https://www.6pr.com.au/new-melanoma-vaccine-hailed-as-cancers-penicillin-moment/</p>
Mike & Emma	30.09.2022	https://omny.fm/shows/mike-e-emma/m-e-professor-long-melanoma-institute
2GB	23.06.2022	<p>Ray Hadley reveals recent melanoma scare as new cancer tech emerges https://www.2gb.com/ray-hadley-reveals-recent-melanoma-scare-as-new-cancer-tech-emerges/</p>
2GB, 2CC, 4BC, 990, ABC, 2GN, 1152	01.03.2022	Melanoma March
1053	09.02.2022	<p>State of the Nation media release</p> <p>This was also used under licence with following stations: 2CA Canberra, 1233 ABC Newcastle, 2BS, 2CC, 2EC, 2GB, 2UE, 3AW, 4MK, 612 ABC, 666, 702, 91.7, 981, ABC 24m ABC Centre Coast, ABC Far North Queensland, ABC Illawarra, ABC North West Queensland, ABC Radio National, ABC Southern Queensland, ABC Sunshine Coast, ABC Upper Hunter, ABC Western Queensland, ABC Wide Bay, Eagle FM, Forever Classic, Gold Central Victoria, Hot 100Fm, Mix 104.9, Power FM Bega, Power FM Nowra, Radio 2ST, River 1467, Southern Cross Port Lincoln,</p>
WSFM,	11.11.2021	<p>COVID restrictions deterred people from seeking treatment</p> <p>This was also used under licence with following stations: ABC Newcastle, 4KQ, 612 ABC Brisbane, 666 ABC Canberra, 702 ABC</p>

		Sydney, 891 ABC Adelaide, 91.7 ABC Coast FM, 936 ABC Hobart, 97.3FM, ABC Alice Springs, ABC Ballarat, ABC Broken Hill, ABC Capricornia FM, ABC Central Victoria, ABC Great Southern WA, ABC Illawarra, ABC Kimberley, ABC Mid West and Wheatbelt, ABC Mildura, ABC New England, ABC North and West SA, ABC North Coast NSW, ABC Northern Tasmania, ABC North Queensland, ABC South East NSW, ABC Sunshine Coast, ABC Tropical North, ABC Upper Hunter, ABC West Coast SA, ABC Western Plains, ABC West Victoria, ABC Wife Bay, Cruise 1323, Gold 104.3, Mix 102.3
ABC Radio National Drive	10.11.2021	When was the last time you got a skin check? https://www.abc.net.au/radionational/programs/drive/when-was-the-last-time-you-got-a-skin-check/13625474
2CC Talking Canberra	20.09.2021	Breakthrough in melanoma treatment
2CA Canberra,	03.06.2021	Australian researchers discovered a miracle drug for melanoma This was also used under licence with following stations: 2BS, 2CC, 2GB, 2SM, 2UE, 3AW, 4BC, 4BU, 4CA, 4MK, 5AU, 5CC, 5CS, 5RM, 6PR, 981, 990, ABC, Forever Classic, Gold Central, Imparja Bull, NBN Coffs Harbour, Newcastle, Port Macquarie, Nine Adelaide, Cairns, Canberra, Central Queensland, Darwin, Mackay, Perth, Riverina, Sunshine Coast, Sydney, Toowoomba, Townsville, Sunshine Coast, WideBay, 2ST
ABC Radio National	09.02.2021	https://www.abc.net.au/radionational/programs/breakfast/new-study-drug-therapy-melanoma/13134858
Alan Jones Breakfast Show	03.04.2019	https://omny.fm/shows/the-alan-jones-breakfast-show/professor-georgina-long-co-medical-director-melano
Triple MMM	11.09.2019	Huge Melanoma Breakthrough Could Save Lives https://www.triplem.com.au/story/huge-melanoma-breakthrough-will-save-lives-56618
Other interviews (but not limited to) BBC, ABC, 2GB,		

Oncology education programs and interviews (regular invitee) & Podcasts

Channel	Date	Story/Link
Melanoma Institute Australia	03.04.2024	Spotlight on mucosal melanoma: Head & Neck https://melanomaeducation.org.au/courses/melanoma214/
The Daily Aus	01.03.2024	Will Australia's tanning culture ever change? https://thedailyaus.com.au/podcast/will-australias-tanning-culture-ever-change/
The ASCO Post	03.06.2023	Resected Melanoma: Biomarkers for and efficacy of adjuvant nivolumab vs placebo https://ascopost.com/videos/2023-asco-annual-meeting/georgina-long-on-resected-melanoma-biomarkers-for-and-efficacy-of-adjuvant-nivolumab-vs-placebo/
Melanoma Institute Australia	13.04.2023	WA Update – The Game Changer, Neoadjuvant Therapy & Early Melanoma
Melanoma Institute Australia	14.03.2023	Neoadjuvant immunotherapy: Revolutionising melanoma treatment https://melanomaeducation.org.au/courses/melanoma183/
Melanoma Institute Australia	04.11.2022	Diagnosis and management of uveal melanoma https://melanomaeducation.org.au/courses/melanoma176/

OncoLive	21.10.2022	Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma https://www.onclive.com/view/adjuvant-nivolumab-reduces-risk-of-recurrence-or-death-by-58-in-select-stage-iib-or-iic-melanoma
Cancer Network	22.10.2022	Adjuvant Nivolumab demonstrates reduced risk of death or recurrence vs placebo in stage IIB/C Melanoma https://www.cancernetwork.com/view/adjuvant-nivolumab-demonstrates-reduced-risk-of-death-or-recurrence-vs-placebo-in-stage-iib-c-melanoma
The ASCO Post	13.09.2022	Findings on circulating tumor DNA, disease recurrence, and immunotherapy https://ascopost.com/videos/esmo-congress-2022/georgina-long-on-melanoma-findings-on-circulating-tumor-dna-disease-recurrence-and-immunotherapy/
Touch Oncology	13.09.2022	CheckMate 915 study – the use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma https://touchoncology.com/melanoma/conference-hub/georgina-long-esmo-2022-checkmate-915-study-the-use-of-ctdna-as-a-biomarker-for-predicting-outcomes-for-adjuvant-melanoma/
Touch Oncology	13.09.2022	Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma https://touchoncology.com/melanoma/conference-hub/prof-georgina-long-esmo-2022-highlights-in-melanoma-swog-s1801-trial-investigating-neoadjuvant-versus-adjuvant-pembrolizumab-for-resected-stage-iii-iv-melanoma/
VJ Oncology	10.09.2022	Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma https://www.vjoncology.com/video/_qc4quh1lc0-pre-treatment-ctdna-linked-to-increased-risk-of-early-recurrence-in-io-treated-melanoma/
OncoLive	20.08.2022	Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma https://www.onclive.com/view/dr-long-on-evaluating-adjuvant-pembrolizumab-vs-placebo-in-melanoma
The ASCO Post	17.06.2022	Distant Metastasis-Free Survival With Adjuvant Pembrolizumab https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-distant-metastasis-free-survival-with-adjuvant-pembrolizumab/
The ASCO Post	17.06.2022	Melanoma: New Data on Pembrolizumab, Dabrafenib, and Trametinib https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-new-data-on-pembrolizumab-dabrafenib-and-trametinib/
Oncology Tube	17.06.2022	ASCO 2022: Phase 3 KEYNOTE-716 study https://oncologytube.com/video/41070/podcast-prof-georgina-long-proflongmia-melanoma-us-sydcancernetwork-nthsydhealth-asco22-oncotwitter-oncoalert-phase-3-keynote-716-study?channelName=AnnualCancerMeeting#gsc.tab=0
OncoLive	07.06.2022	Nivolumab plus relatlimab demonstrates sustained PFS benefit in advanced melanoma https://www.onclive.com/view/nivolumab-plus-relatlimab-demonstrates-sustained-pfs-benefit-in-advanced-melanoma

OncoLive	06.06.2022	Adjuvant pembrolizumab results in significant DMFS improvement over placebo in Stage II melanoma https://www.onclive.com/view/adjuvant-pembrolizumab-results-in-significant-dmfs-improvement-over-placebo-in-stage-ii-melanoma
The ASCO Post	04.06.2022	New data on pembrolizumab, dabrafenib and trametinib https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-new-data-on-pembrolizumab-dabrafenib-and-trametinib/
The ASCO Post	04.06.2022	Distant metastasis-free survival with adjuvant pembrolizumab https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-distant-metastasis-free-survival-with-adjuvant-pembrolizumab/
Melanoma Institute Australia	13.05.2022	Melanoma Insights for Professionals https://melanomaeducation.org.au/courses/melanoma149/
OncoLive	17.03.2022	Relatlimab/Nivolumab Combo Continues to Impress in Previously Untreated Metastatic or Unresectable Melanoma https://www.onclive.com/view/relatlimab-nivolumab-combo-continues-to-impress-in-previously-untreated-metastatic-or-unresectable-melanoma
ASCO Post	16.03.2022	Immunotherapy Duo Delays Disease Progression in Previously Untreated Patients With Melanoma: RELATIVITY-047 https://ascopost.com/news/march-2022/immunotherapy-duo-delays-disease-progression-in-previously-untreated-patients-with-melanoma-relativity-047/
Melanoma Institute Australia Education portal	04.02.2022	The evolving paradigm shift in melanoma https://melanomaeducation.org.au/courses/melanoma133/
Melanoma & Skin Cancer Advocacy Network	17.12.2021	Patient stories: Diagnosed with advanced melanoma https://mscan.org.au/learning-hub/podcasts/series-2-the-patient-story/8-patient-stories-diagnosed-with-advanced-melanoma/
High5oncology	22.09.2021	MASTERKEY-265 Pembrolizumab +/- T-VEC My ESMO highlights https://high5oncology.tv/en/esmo-2021/?al=1/#c2543
Melanoma Institute Australia	12.08.2021	Early Stage Melanoma; Your questions answered https://www.youtube.com/watch?v=SaaF1Nxa2gU
Oncology News (Podcast)	30.07.2021	Melanoma update with Georgina Long https://oncologynews.com.au/the-ojc-episode-44/
ASCO Post	June 2021	ASCO annual meeting – Virtual Abstract presentation Nivolumab plus ipilimumab vs nivolumab alone https://ascopost.com/videos/aacr-annual-meeting-2021/georgina-long-on-melanoma-nivolumab-plus-ipilimumab-vs-nivolumab-alone/
Oncology News	16.04.2021	Neoadjuvant Therapy in Melanoma – podcast https://oncologynews.com.au/the-ojc-29/
Ecancer	13.04.2021	Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma https://ecancer.org/en/video/9680-adjuvant-therapy-with-nivolumab-combined-with-ipilimumab-vs-nivolumab-alone-in-patients-with-resected-stage-iiib-d-iv-melanoma
MIA & MPA Melanoma Symposium Series	21.10.2020	Melanoma treatments and clinical trials https://melanomapatients.org.au/resource/melanoma-treatments-and-clinical-trials/
The Doctor's Channel	28.07.2020	Patients in CheckMate 067 Demonstrate Durable Complete Responses

		https://www.thedoctorschannel.com/view/patients-in-checkmate-067-demonstrate-durable-complete-responses/
Targeted Oncology	20.05.2020	Patients in CheckMate 067 demonstrate durable complete responses https://www.youtube.com/watch?v=POBHLcPEess
MIA & MPA Patient Information Evening	01.12.2019	Updates on drug treatments in melanoma https://www.youtube.com/watch?v=YPVxf2Dn0_M
OncLive	14.11.2019	Rationale for Nivolumab/Ipilimumab in patients with melanoma who have brain mets https://www.onclive.com/view/dr-long-on-rationale-for-nivolumabipilimumab-in-patients-with-melanoma-who-have-brain-mets
OncLive	05.11.2019	Including patients with melanoma who have brain mets on clinical trials https://www.onclive.com/view/dr-long-on-including-patients-with-melanoma-who-have-brain-mets-on-clinical-trials
OncLive	22.10.2019	Sequencing local therapy patients with melanoma who have brain mets https://www.onclive.com/view/dr-long-on-sequencing-local-therapy-in-patients-with-melanoma-who-have-brain-mets
VJOncology	29.09.2019	Long-term outcomes of nivo vs nivo/ipi in melanoma brain metastases: ABC trial data https://www.youtube.com/watch?v=ujXRRV8uRD8
OncLive	12.10.2019	Nivolumab/Ipilimumab in patients with melanoma who have brain mets https://www.onclive.com/view/dr-long-on-nivolumabipilimumab-in-patients-with-melanoma-who-have-brain-mets
OncLive	28.08.2019	Results of the pooled analysis of the COMBI-I trial in melanoma https://www.onclive.com/view/dr-long-on-the-results-of-the-pooled-analysis-of-the-combii-trial-in-melanoma
OncLive	26.07.2019	Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma https://www.onclive.com/view/dr-long-on-dabrafenibtrametinib-in-braf-v600emutant-melanoma
VJOncology	25.06.2019	KEYNOTE-029: pembrolizumab with ipilimumab for melanoma https://www.youtube.com/watch?v=aSeET16TTaQ
CancerNSW	05.11.2018	The most exciting development happening in melanoma research https://www.youtube.com/watch?v=zPSWqUak9e0
CancerNSW	05.11.2018	The most exciting thing I have learnt this year https://www.youtube.com/watch?v=llJIfXgpOII
OncLive	08.08.2017	IDO inhibitors in metastatic melanoma https://www.youtube.com/watch?v=i-1mcPMuySM
OncLive	08.08.2017	Metastatic Melanoma: Clinical pearls from the experts https://www.youtube.com/watch?v=T03TS75iUyk
OncLive	08.08.2017	Novel targeted therapies for metastatic melanoma https://www.youtube.com/watch?v=XGDNbJXBtX0
Sydney LHD	31.07.2018	Melanoma Institute Australia: A flagship for clinical translational research https://www.youtube.com/watch?v=qZX2NgwFI5E
OncLive	27.07.2017	Novel combinations for metastatic melanoma https://www.youtube.com/watch?v=CWXz5E9oV1U
OncLive	26.07.2017	Optimal Treatment of Melanoma at Progression https://www.youtube.com/watch?v=t_bFid7Tx7s

OncLive	14.07.2017	How are you using PD-1 testing in melanoma? https://www.youtube.com/watch?v=HvB8cZj_qeI
OncLive	14.07.2017	Options for NRAS-mutant melanoma https://www.youtube.com/watch?v=6MPeLFlqcY
OncLive	14.07.2017	New data for immunotherapy in melanoma brain metastases https://www.youtube.com/watch?v=X5xGQpdp9OA
OncLive	14.07.2017	Long-term results for immunotherapy in melanoma https://www.youtube.com/watch?v=zaq1oMnY6sE
OncLive	06.07.2017	Emerging adjuvant and neoadjuvant options for melanoma https://www.youtube.com/watch?v=oZSdAf_u6dY
OncLive	06.07.2017	Dual targeted or immunotherapy for BRAF-Mutant Melanoma https://www.youtube.com/watch?v=KhV1Zyi6r8E
OncLive	06.07.2017	Adjuvant therapy for patients with melanoma https://www.youtube.com/watch?v=7BIXL2A1EKc
OncLive	05.07.2017	Recommendations for resectability in melanoma https://www.youtube.com/watch?v=q_GtNxxdXdU
Targeted Oncology	20.06.2017	Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain Metastases https://www.youtube.com/watch?v=D5dzJgK_Ck0
VJOncology	09.06.2017	Immunotherapy updates for melanoma from ASCO 2017 https://www.youtube.com/watch?v=BwfO_hg1H14
Targeted Oncology	05.06.2017	Five-Year OS data for Dabrafenib/Trametinib Combo in Melanoma https://www.youtube.com/watch?v=CkC4a1KhDr0
OncLive	04.02.2017	The future management of melanoma https://www.youtube.com/watch?v=6Ng8qGe-y3I
OncLive	31.01.2017	Neoadjuvant trials in high-risk melanoma https://www.youtube.com/watch?v=qIInN7vweOw
OncLive	31.01.2017	T-VEC data in the neoadjuvant setting in melanoma https://www.youtube.com/watch?v=bvgEN-Jxnmw
OncLive	17.01.2017	Melanoma: Nuances of BRAF/MEK Combinations in the front line https://www.youtube.com/watch?v=4nBOF6xHzc4
OncLive	16.01.2017	Post-Surgical Recurrent Melanoma https://www.youtube.com/watch?v=9cE5AuAONDM
OncLive	04.01.2017	Frontline decisions in Stage IV BRAF-mutant melanoma https://www.youtube.com/watch?v=IaIItGM4k80
OncLive	04.01.2017	Sequencing decisions and multidisciplinary care in metastatic melanoma https://www.youtube.com/watch?v=jKNESs-s_4k
OncLive	12.12.2016	Melanoma: Helping patients understand immunotherapy https://www.youtube.com/watch?v=YUjGbVJhkjc
OncLive	13.12.2016	Immunotherapy in melanoma: Managing toxicities https://www.youtube.com/watch?v=FJzuOENBpS0
OncLive	09.12.2016	The current understanding of biomarkers in melanoma https://www.youtube.com/watch?v=F1YBlp3u6NI
OncLive	16.11.2016	Treating Melanoma with Dabrafenib plus Trametinib https://www.youtube.com/watch?v=BeKQeMGgEzC
OncLive	31.08.2016	Multi-Modality Treatment in Basal Cell Carcinoma https://www.youtube.com/watch?v=jlRynjSv8G4
OncLive	25.08.2016	Managing brain metastases and side effects in melanoma https://www.youtube.com/watch?v=gzzbAgECwOQ
OncLive	18.08.2016	Melanoma: BRAF/MEK targeted therapy https://www.youtube.com/watch?v=K-Ivcf_YnNQ
OncLive	05.08.2016	Disease burden and first-line melanoma treatment https://www.youtube.com/watch?v=oLHhaQCdEzo

OncLive	26.07.2016	Immunotherapy in advanced melanoma https://www.youtube.com/watch?v=iJP2ztMQjHk
OncLive	15.07.2016	Validity of PD-L1 testing in melanoma https://www.youtube.com/watch?v=fq3rGrFuTqM
OncLive	21.11.2015	Dabrafenib and Trametinib in BRAF-Mutated Melanoma https://www.youtube.com/watch?v=vsOwsM5v-vw
EMG-Health	16.11.2015	MASTERKEY-265: Phase 1B/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma https://www.youtube.com/watch?v=29O515klBtE
ecancer	28.10.2015	Long response and long responders in melanoma immunology https://ecancer.org/en/video/4203-long-response-and-long-responders-in-melanoma-immunology
EMG Health	03.07.2015	COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma https://www.youtube.com/watch?v=3Z1hSxl9NHo
Targeted Oncology	17.12.2013	Treatment of Melanoma with emerging targeting therapies https://www.youtube.com/watch?v=zJU-waby6rI
The Westmead Medical Institute for Medical Research	23.08.2011	New ways to target melanoma https://www.youtube.com/watch?v=vmkjLOCp6ok

PROFESSIONAL AFFILIATIONS

ASCO Melanoma/Skin Cancers (Plenary Series Scientific Review Committee) Member	Jun 2021-Jun 2024
Scientific Board Member Melanoma World Society	From 2021
European Academy for Tumour Immunology (EATI)	From 2016
Medical Board of Australia, Registered Medical Practitioner (MED 0001186892)	From 2010
New South Wales Medical Board, Registered Medical Practitioner, MPO 338589	2002-2009
Member of the Australia and New Zealand Melanoma Trials Group (ANZMTG)	From 2010
Member of the ANZ Breast Cancer Trials Group Limited (ANZ BCTG)	From 2010
Member of the ANZ Gynaecology Oncology Group	From 2007
Society for Melanoma Research (Nominated for Steering Committee Member for 2014) (President 2018-2020)	From 2009
American Society of Clinical Oncology	From 2006
Medical Oncology Group of Australia	From 2006
European Society of Medical Oncology	From 2010
The Royal Australasian College of Physicians Trainee Committee	From 2005
Royal Prince Alfred Hospital Resident Medical Officers Association (President 2003)	2002-2006
Australian Medical Association	From 1997
Australian Fulbright Association	From 1996
United Kingdom General Medical Council, Registered Medical Practitioner	From 2004
Sydney University Medical Society	1997-2000
Royal Australian Chemical Institute (MRACI)	1992-2005
Sydney University Chemical Society	1992-1996
Sydney University Law Society	1989-1990

PAST EMPLOYMENT

President for the International Society for Melanoma Research	2018-2020
Associate Professor of Melanoma Biology and Translational Research Melanoma Institute Australia, The University of Sydney, and Mater Hospital	2013-2016
NSW Cancer Institute Clinical Fellow; Medical Oncologist and Clinical Researcher Melanoma Institute Australia, Royal Prince Alfred Hospital and Westmead Hospital Clinical, Research and Teaching responsibilities. Mentor; Professor Richard Kefford Professor of Cancer Medicine Head, Department of Clinical Medicine, Macquarie University Co-Director of Research, Melanoma Institute Australia	2009-2011
Locum Medical Oncologist, Macarthur Cancer Centre Clinical Responsibilities Once weekly clinic, (@ rate of 1150 patient encounters per annum) Tumour Areas = Breast (60%), GU (20%), Gynae-oncology (20%) Weekly Departmental meeting Monthly Morbidity and Mortality meeting Teaching and Supervision Supervision of Advanced Trainees ALJESAL Basic Physician Lecture Series	2008-2009
Medical Oncology Advanced Trainee Royal Prince Alfred, Concord, Liverpool and Campbelltown Hospitals	2006-2008
Basic Physician Medical Training, Residency and Internship Royal Prince Alfred, Bathurst and Dubbo Hospitals	2001-2005
Fullbright Postdoctoral Fellow Scripps Research Institute, La Julia, CA, USA	1996-1997

CAREER INTERRUPTIONS

Maternity Leave	2003, 2005, 2007
Interruption to Research Publications Completion of MB BS (commenced 1997) and medical training after PhD and post-doctoral studies (completed 1997)	1997-2011